0000819050-19-000030.txt : 20191114 0000819050-19-000030.hdr.sgml : 20191114 20191113174035 ACCESSION NUMBER: 0000819050-19-000030 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 64 CONFORMED PERIOD OF REPORT: 20190930 FILED AS OF DATE: 20191114 DATE AS OF CHANGE: 20191113 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Brickell Biotech, Inc. CENTRAL INDEX KEY: 0000819050 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 930948554 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-21088 FILM NUMBER: 191215518 BUSINESS ADDRESS: STREET 1: 5777 CENTRAL AVENUE STREET 2: SUITE 102 CITY: BOULDER STATE: CO ZIP: 80301 BUSINESS PHONE: (720) 505-4755 MAIL ADDRESS: STREET 1: 5777 CENTRAL AVENUE STREET 2: SUITE 102 CITY: BOULDER STATE: CO ZIP: 80301 FORMER COMPANY: FORMER CONFORMED NAME: VICAL INC DATE OF NAME CHANGE: 19940211 10-Q 1 a20190930-10q.htm 10-Q Document
0.015false--12-31Q320190000819050000.010.018000000500000005890017810680781068058900178106807810680110000022000100000P5Y000018225000110009227600078000741180000.142904698500000.010.01500000001256466312423401309286151256583001256466312423401309286151256583 0000819050 2019-01-01 2019-09-30 0000819050 2019-11-07 0000819050 2018-12-31 0000819050 2019-09-30 0000819050 2018-01-01 2018-09-30 0000819050 2018-07-01 2018-09-30 0000819050 2019-07-01 2019-09-30 0000819050 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0000819050 us-gaap:CommonStockMember 2018-07-01 2018-09-30 0000819050 us-gaap:RedeemableConvertiblePreferredStockMember 2018-03-31 0000819050 us-gaap:RedeemableConvertiblePreferredStockMember 2018-07-01 2018-09-30 0000819050 us-gaap:CommonStockMember 2018-01-01 2018-03-31 0000819050 us-gaap:CommonStockMember 2018-09-30 0000819050 us-gaap:AdditionalPaidInCapitalMember 2018-04-01 2018-06-30 0000819050 2018-01-01 2018-03-31 0000819050 us-gaap:AdditionalPaidInCapitalMember 2018-06-30 0000819050 us-gaap:AdditionalPaidInCapitalMember 2018-03-31 0000819050 us-gaap:AccountingStandardsUpdate201409Member 2018-01-01 0000819050 us-gaap:RetainedEarningsMember 2018-03-31 0000819050 us-gaap:RedeemableConvertiblePreferredStockMember 2017-12-31 0000819050 us-gaap:RetainedEarningsMember 2018-06-30 0000819050 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-09-30 0000819050 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-06-30 0000819050 2018-04-01 2018-06-30 0000819050 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-03-31 0000819050 us-gaap:CommonStockMember 2018-03-31 0000819050 us-gaap:CommonStockMember 2017-12-31 0000819050 us-gaap:AdditionalPaidInCapitalMember 2018-09-30 0000819050 us-gaap:RetainedEarningsMember 2018-04-01 2018-06-30 0000819050 us-gaap:CommonStockMember 2018-06-30 0000819050 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0000819050 us-gaap:AccountingStandardsUpdate201409Member us-gaap:RetainedEarningsMember 2018-01-01 0000819050 us-gaap:RetainedEarningsMember 2018-01-01 2018-03-31 0000819050 us-gaap:RetainedEarningsMember 2018-07-01 2018-09-30 0000819050 us-gaap:AdditionalPaidInCapitalMember 2018-07-01 2018-09-30 0000819050 us-gaap:RedeemableConvertiblePreferredStockMember 2018-09-30 0000819050 2018-06-30 0000819050 us-gaap:RedeemableConvertiblePreferredStockMember 2018-04-01 2018-06-30 0000819050 us-gaap:RetainedEarningsMember 2018-09-30 0000819050 us-gaap:RedeemableConvertiblePreferredStockMember 2018-06-30 0000819050 2018-03-31 0000819050 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-03-31 0000819050 2017-12-31 0000819050 2018-09-30 0000819050 us-gaap:RetainedEarningsMember 2017-12-31 0000819050 us-gaap:RedeemableConvertiblePreferredStockMember 2018-01-01 2018-03-31 0000819050 2019-01-01 2019-03-31 0000819050 2019-03-31 0000819050 us-gaap:RetainedEarningsMember 2019-03-31 0000819050 us-gaap:AdditionalPaidInCapitalMember 2019-09-30 0000819050 us-gaap:RedeemableConvertiblePreferredStockMember 2019-01-01 2019-03-31 0000819050 us-gaap:RetainedEarningsMember 2018-12-31 0000819050 2019-04-01 2019-06-30 0000819050 bbi:RedeemableConvertiblePreferredStockAndPreferredStockDividendsToCommonStockMember us-gaap:CommonStockMember 2019-07-01 2019-09-30 0000819050 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0000819050 us-gaap:CommonStockMember 2019-07-01 2019-09-30 0000819050 us-gaap:CommonStockMember 2019-09-30 0000819050 us-gaap:AdditionalPaidInCapitalMember 2019-07-01 2019-09-30 0000819050 us-gaap:RedeemableConvertiblePreferredStockMember 2018-12-31 0000819050 us-gaap:CommonStockMember 2019-03-31 0000819050 us-gaap:CommonStockMember 2019-06-30 0000819050 us-gaap:RedeemableConvertiblePreferredStockMember 2019-04-01 2019-06-30 0000819050 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-06-30 0000819050 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0000819050 us-gaap:RetainedEarningsMember 2019-06-30 0000819050 bbi:ConvertibleNotesPayableAndAccruedInterestToCommonStockMember us-gaap:AdditionalPaidInCapitalMember 2019-07-01 2019-09-30 0000819050 us-gaap:RedeemableConvertiblePreferredStockMember 2019-03-31 0000819050 us-gaap:CommonStockMember 2018-12-31 0000819050 bbi:RedeemableConvertiblePreferredStockAndPreferredStockDividendsToCommonStockMember us-gaap:RedeemableConvertiblePreferredStockMember 2019-07-01 2019-09-30 0000819050 us-gaap:RedeemableConvertiblePreferredStockMember 2019-06-30 0000819050 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0000819050 us-gaap:RedeemableConvertiblePreferredStockMember 2019-09-30 0000819050 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-03-31 0000819050 us-gaap:RetainedEarningsMember 2019-04-01 2019-06-30 0000819050 us-gaap:RetainedEarningsMember 2019-09-30 0000819050 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-07-01 2019-09-30 0000819050 us-gaap:RetainedEarningsMember 2019-07-01 2019-09-30 0000819050 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0000819050 us-gaap:RedeemableConvertiblePreferredStockMember 2019-07-01 2019-09-30 0000819050 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-09-30 0000819050 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0000819050 2019-06-30 0000819050 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0000819050 us-gaap:AdditionalPaidInCapitalMember 2019-04-01 2019-06-30 0000819050 bbi:ConvertibleNotesPayableAndAccruedInterestToCommonStockMember 2019-07-01 2019-09-30 0000819050 bbi:RedeemableConvertiblePreferredStockAndPreferredStockDividendsToCommonStockMember 2019-07-01 2019-09-30 0000819050 bbi:ConvertibleNotesPayableAndAccruedInterestToCommonStockMember us-gaap:CommonStockMember 2019-07-01 2019-09-30 0000819050 bbi:RedeemableConvertiblePreferredStockAndPreferredStockDividendsToCommonStockMember us-gaap:AdditionalPaidInCapitalMember 2019-07-01 2019-09-30 0000819050 bbi:VicalFormerSecurityholdersMember 2019-08-31 0000819050 bbi:BrickellFormerSecurityholdersMember 2019-08-31 0000819050 bbi:VicalMember 2019-08-31 0000819050 bbi:NovaQuestCapitalManagementLLCMember 2018-09-30 0000819050 2019-08-31 0000819050 us-gaap:CommonStockMember 2019-09-30 0000819050 us-gaap:RedeemableConvertiblePreferredStockMember 2019-08-31 0000819050 bbi:NovaQuestCapitalManagementLLCMember 2019-09-30 0000819050 bbi:VicalMember 2019-08-31 2019-08-31 0000819050 us-gaap:WarrantMember 2018-01-01 2018-09-30 0000819050 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-09-30 0000819050 us-gaap:ConvertibleDebtSecuritiesMember 2019-01-01 2019-09-30 0000819050 us-gaap:RedeemableConvertiblePreferredStockMember 2019-01-01 2019-09-30 0000819050 us-gaap:ConvertibleDebtSecuritiesMember 2018-01-01 2018-09-30 0000819050 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-09-30 0000819050 us-gaap:WarrantMember 2019-01-01 2019-09-30 0000819050 us-gaap:RedeemableConvertiblePreferredStockMember 2018-01-01 2018-09-30 0000819050 bbi:VicalMember 2019-08-31 2019-08-31 0000819050 us-gaap:CollaborativeArrangementMember 2018-05-01 2018-05-31 0000819050 us-gaap:CollaborativeArrangementMember 2015-03-01 2015-03-31 0000819050 us-gaap:CollaborativeArrangementMember 2015-03-31 0000819050 us-gaap:CollaborativeArrangementMember 2018-01-01 2018-03-31 0000819050 srt:MinimumMember us-gaap:MeasurementInputDiscountRateMember 2019-09-30 0000819050 bbi:SublicensingCostsMember us-gaap:CollaborativeArrangementMember 2017-10-01 2017-10-31 0000819050 bbi:VicalMember 2019-08-31 0000819050 bbi:VicalWarrantsMember 2018-06-02 0000819050 us-gaap:CollaborativeArrangementMember 2017-12-01 2017-12-31 0000819050 us-gaap:RedeemableConvertiblePreferredStockMember 2019-01-01 2019-09-30 0000819050 us-gaap:CollaborativeArrangementMember 2019-01-01 2019-09-30 0000819050 us-gaap:CollaborativeArrangementMember 2019-07-01 2019-09-30 0000819050 bbi:SublicensingCostsMember us-gaap:CollaborativeArrangementMember 2018-01-01 2018-03-31 0000819050 bbi:VicalWarrantsMember 2018-06-02 2018-06-02 0000819050 us-gaap:CollaborativeArrangementMember 2017-10-01 2017-10-31 0000819050 us-gaap:RedeemableConvertiblePreferredStockMember 2018-01-01 2018-09-30 0000819050 srt:MaximumMember bbi:MeasurementInputIndividualCumulativeAchievementProbabilitiesMember 2019-09-30 0000819050 srt:MaximumMember us-gaap:MeasurementInputDiscountRateMember 2019-09-30 0000819050 srt:MinimumMember bbi:MeasurementInputIndividualCumulativeAchievementProbabilitiesMember 2019-09-30 0000819050 us-gaap:CollaborativeArrangementMember 2019-09-30 0000819050 us-gaap:CollaborativeArrangementMember 2018-03-01 2018-03-31 0000819050 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-09-30 0000819050 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-09-30 0000819050 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-09-30 0000819050 us-gaap:MeasurementInputExpectedDividendRateMember 2018-12-31 0000819050 us-gaap:MeasurementInputPriceVolatilityMember 2018-12-31 0000819050 us-gaap:MeasurementInputRiskFreeInterestRateMember 2018-12-31 0000819050 us-gaap:MeasurementInputExpectedTermMember 2018-12-31 0000819050 bbi:RedeemableConvertiblePreferredStockWarrantLiabilityMember 2018-12-31 0000819050 bbi:CommonStockWarrantLiabilityMember 2018-12-31 0000819050 us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember 2019-01-01 2019-09-30 0000819050 bbi:RedeemableConvertiblePreferredStockWarrantLiabilityMember 2019-09-30 0000819050 us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember 2019-09-30 0000819050 bbi:ContingentConsiderationLiabilityMember 2019-01-01 2019-09-30 0000819050 bbi:RedeemableConvertiblePreferredStockWarrantLiabilityMember 2019-01-01 2019-09-30 0000819050 bbi:CommonStockWarrantLiabilityMember 2019-01-01 2019-09-30 0000819050 bbi:CommonStockWarrantLiabilityMember 2019-09-30 0000819050 us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember 2018-12-31 0000819050 bbi:ContingentConsiderationLiabilityMember 2018-12-31 0000819050 bbi:ContingentConsiderationLiabilityMember 2019-09-30 0000819050 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000819050 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000819050 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000819050 us-gaap:AccountingStandardsUpdate201602Member 2019-01-01 0000819050 us-gaap:NewAccountingPronouncementMember 2019-01-01 0000819050 2019-01-01 0000819050 us-gaap:MeasurementInputRiskFreeInterestRateMember 2019-09-30 0000819050 us-gaap:MeasurementInputPriceVolatilityMember 2019-09-30 0000819050 us-gaap:MeasurementInputExpectedTermMember 2019-09-30 0000819050 srt:MaximumMember 2019-01-01 2019-09-30 0000819050 2019-09-03 2019-09-03 0000819050 bbi:NovaQuestWarrantsMember 2019-09-03 2019-09-03 0000819050 srt:MinimumMember 2019-01-01 2019-09-30 0000819050 us-gaap:MeasurementInputExpectedDividendRateMember 2019-09-30 0000819050 us-gaap:ConvertibleNotesPayableMember 2019-07-01 2019-09-30 0000819050 us-gaap:ConvertibleNotesPayableMember 2019-03-31 0000819050 us-gaap:ConvertibleNotesPayableMember 2019-09-30 0000819050 us-gaap:ConvertibleNotesPayableMember 2019-03-01 2019-03-31 0000819050 us-gaap:ConvertibleNotesPayableMember 2019-03-01 2019-08-31 0000819050 us-gaap:ConvertibleNotesPayableMember us-gaap:CommonStockMember 2019-08-31 2019-08-31 0000819050 us-gaap:ConvertibleNotesPayableMember 2019-08-31 2019-08-31 0000819050 us-gaap:ConvertibleNotesPayableMember 2019-08-31 0000819050 us-gaap:ConvertibleNotesPayableMember 2019-01-01 2019-09-30 0000819050 bbi:InterestRateOptionTwoMember us-gaap:NotesPayableOtherPayablesMember us-gaap:PrimeRateMember 2016-02-18 2016-02-18 0000819050 us-gaap:NotesPayableOtherPayablesMember 2016-02-18 0000819050 us-gaap:NotesPayableOtherPayablesMember 2016-02-18 2018-07-31 0000819050 us-gaap:NotesPayableOtherPayablesMember 2017-12-01 2018-07-31 0000819050 bbi:InterestRateOptionOneMember us-gaap:NotesPayableOtherPayablesMember 2016-02-18 0000819050 bbi:InterestRateOptionTwoMember us-gaap:NotesPayableOtherPayablesMember 2016-02-18 0000819050 bbi:HerculesCapitalWarrantsMember 2018-06-02 0000819050 bbi:HerculesCapitalWarrantsMember 2018-06-02 2018-06-02 0000819050 bbi:SharebasedPaymentArrangementOptionOutstandingMember 2019-09-30 0000819050 bbi:SharebasedPaymentArrangementOptionAvailableForGrantMember bbi:EquityIncentivePlan2009Member 2019-09-30 0000819050 bbi:SharebasedPaymentArrangementOptionAvailableForGrantMember bbi:VicalStockIncentivePlanMember 2019-09-30 0000819050 bbi:CommonStockWarrantsMember 2019-09-30 0000819050 bbi:SeriesC1PreferredStockMember 2018-12-31 0000819050 us-gaap:SeriesCPreferredStockMember 2018-12-31 0000819050 us-gaap:SeriesAPreferredStockMember 2018-12-31 0000819050 bbi:SeriesC1PreferredStockMember 2018-12-31 2018-12-31 0000819050 us-gaap:SeriesBPreferredStockMember 2018-12-31 0000819050 us-gaap:SeriesCPreferredStockMember 2018-12-31 2018-12-31 0000819050 2018-12-31 2018-12-31 0000819050 us-gaap:SeriesAPreferredStockMember 2018-12-31 2018-12-31 0000819050 us-gaap:SeriesBPreferredStockMember 2018-12-31 2018-12-31 0000819050 us-gaap:SeriesCPreferredStockMember 2019-08-31 0000819050 bbi:SeriesC1PreferredStockMember 2019-08-31 0000819050 us-gaap:SeriesAPreferredStockMember 2019-08-31 2019-08-31 0000819050 us-gaap:SeriesAPreferredStockMember 2019-08-31 0000819050 us-gaap:SeriesBPreferredStockMember 2019-08-31 0000819050 2019-08-31 2019-08-31 0000819050 us-gaap:SeriesBPreferredStockMember 2019-08-31 2019-08-31 0000819050 bbi:SeriesC1PreferredStockMember 2019-08-31 2019-08-31 0000819050 us-gaap:SeriesCPreferredStockMember 2019-08-31 2019-08-31 0000819050 us-gaap:EmployeeStockOptionMember bbi:EquityIncentivePlan2009Member 2019-09-30 0000819050 us-gaap:EmployeeStockOptionMember bbi:VicalStockIncentivePlanMember 2019-09-30 0000819050 bbi:VicalStockIncentivePlanMember 2019-01-01 2019-09-30 0000819050 bbi:VicalStockIncentivePlanMember 2019-09-30 0000819050 us-gaap:GeneralAndAdministrativeExpenseMember 2019-01-01 2019-09-30 0000819050 us-gaap:ResearchAndDevelopmentExpenseMember 2018-07-01 2018-09-30 0000819050 us-gaap:GeneralAndAdministrativeExpenseMember 2018-07-01 2018-09-30 0000819050 us-gaap:GeneralAndAdministrativeExpenseMember 2019-07-01 2019-09-30 0000819050 us-gaap:ResearchAndDevelopmentExpenseMember 2018-01-01 2018-09-30 0000819050 us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-09-30 0000819050 us-gaap:GeneralAndAdministrativeExpenseMember 2018-01-01 2018-09-30 0000819050 us-gaap:ResearchAndDevelopmentExpenseMember 2019-07-01 2019-09-30 xbrli:pure xbrli:shares iso4217:USD xbrli:shares iso4217:USD utreg:sqft bbi:renewal_term


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2019
Or
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from to
Commission File Number: 000-21088
BRICKELL BIOTECH, INC.
(Exact name of registrant as specified in its charter)
Delaware
 
93-0948554
 
(State or other jurisdiction of incorporation or organization)
 
(I.R.S. Employer Identification No.)
 
 
 
 
 
 
 
 
 
 
5777 Central Avenue,
 Boulder,
CO
 
 
80301
 
(Address of principal executive offices)
 
(Zip Code)
 
(720) 505-4755
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Securities Act:
Title of each class
Trading symbol(s)
Name of each exchange on which registered
Common stock, $0.01 par value per share
BBI
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes No
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of ‘‘large accelerated filer,’’ ‘‘accelerated filer,’’ ‘‘smaller reporting company,’’ and ‘‘emerging growth company’’ in Rule 12b-2 of the Exchange Act.
Large accelerated filer
Accelerated filer
Non-accelerated filer
Smaller reporting company
Emerging growth company
 
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.




Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No
As of November 7, 2019, there were 7,810,680 shares of the registrant’s common stock outstanding.





BRICKELL BIOTECH, INC.
FORM 10-Q
INDEX

PART I. FINANCIAL INFORMATION
 
 
ITEM 1. Financial Statements (Unaudited)
 
 
Condensed Consolidated Balance Sheets as of September 30, 2019 and December 31, 2018
 
Condensed Consolidated Statements of Operations for the Three and Nine Months Ended September 30, 2019 and 2018
 
Condensed Consolidated Statements of Comprehensive Loss for the Three and Nine Months Ended September 30, 2019 and 2018
 
Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders’ Equity (Deficit) for the Three and Nine Months Ended September 30, 2019 and 2018
 
Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2019 and 2018
 
Notes to Condensed Consolidated Financial Statements for the Nine Months Ended June 30, 2019 and 2018
 
ITEM 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
 
ITEM 3. Quantitative and Qualitative Disclosures About Market Risk
 
ITEM 4. Controls and Procedures
PART II. OTHER INFORMATION
 
 
ITEM 1. Legal Proceedings
 
ITEM 1A. Risk Factors
 
ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds
 
ITEM 3. Defaults Upon Senior Securities
 
ITEM 4. Mine Safety Disclosures
 
ITEM 5. Other Information
 
ITEM 6. Exhibits
SIGNATURES

3



PART I. FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

BRICKELL BIOTECH, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands, except share and per share data)
(unaudited)
 
September 30,
2019
 
December 31,
2018
Assets
 
 
 
Current assets:
 
 
 
Cash and cash equivalents
$
7,225

 
$
8,067

Marketable securities, available-for-sale
18,473

 

Prepaid expenses and other current assets
5,034

 
204

Total current assets
30,732

 
8,271

Property and equipment, net
20

 
37

Operating lease right-of-use asset
176

 

Intangible assets
441

 
441

Total assets
$
31,369

 
$
8,749

Liabilities, redeemable convertible preferred stock, and stockholders’ equity (deficit)
 
 
 
Current liabilities:
 
 
 
Accounts payable
$
1,291

 
$
4,067

Accrued liabilities
3,475

 
3,272

Lease liability, current portion
75

 

Deferred revenue, current portion
2,464

 
8,117

Note payable

 
4,639

Total current liabilities
7,305

 
20,095

Contingent consideration
145

 
145

Lease liability, net of current portion
94

 

Warrant liability

 
242

Deferred revenue, net of current portion

 
1,595

Research and development funding liability
5,600

 

Total liabilities
13,144

 
22,077

Redeemable convertible preferred stock (Series A, B, C and C-1), $0.01 par value, 5,000,000 and 4,182,943 shares authorized at September 30, 2019 and December 31, 2018, respectively; 0 and 1,256,466 shares issued and outstanding at September 30, 2019 and December 31, 2018, respectively; aggregate liquidation preference of $0 and $46,985 at September 30, 2019 and December 31, 2018, respectively

 
58,290

Commitments and contingencies (Note 8)


 


Stockholders’ equity (deficit):
 
 
 
Common stock, $0.01 par value, 50,000,000 and 8,000,000 shares authorized at September 30, 2019 and December 31, 2018, respectively; 7,810,680 and 589,001 issued and outstanding at September 30, 2019 and December 31, 2018, respectively
78

 
6

Additional paid-in capital
92,276

 

Accumulated other comprehensive loss
(11
)
 

Accumulated deficit
(74,118
)
 
(71,624
)
Total stockholders’ equity (deficit)
18,225

 
(71,618
)
Total liabilities, redeemable convertible preferred stock, and stockholders’ equity (deficit)
$
31,369

 
$
8,749


See accompanying notes to these condensed consolidated financial statements.

4



BRICKELL BIOTECH, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except share and per share data)
(unaudited)
 
 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
 
2019
 
2018
 
2019
 
2018
Collaboration revenue
$
1,183

 
$
3,042

 
$
7,248

 
$
8,415

 
 
 
 
 
 
 
 
Operating expenses:
 
 
 
 
 
 
 
Research and development
3,337

 
4,135

 
13,585

 
8,571

General and administrative
3,901

 
1,206

 
7,290

 
4,694

Total operating expenses
7,238

 
5,341

 
20,875

 
13,265

Loss from operations
(6,055
)
 
(2,299
)
 
(13,627
)
 
(4,850
)
Investment and other income, net
54

 
23

 
64

 
45

Gain on extinguishment
2,318

 

 
2,318

 

Interest expense
(1,098
)
 
(267
)
 
(1,982
)
 
(769
)
Change in fair value of derivative liability

 

 
(11
)
 

Change in fair value of warrant liability

 
2

 
223

 
8

Net loss
(4,781
)
 
(2,541
)
 
(13,015
)
 
(5,566
)
Reduction (accretion) of redeemable convertible preferred stock to redemption value
(82
)
 
(966
)
 
10,274

 
(5,071
)
Net loss attributable to common stockholders
$
(4,863
)
 
$
(3,507
)
 
$
(2,741
)
 
$
(10,637
)
Net loss per share attributable to common stockholders, basic and diluted
$
(1.65
)
 
$
(5.98
)
 
$
(1.98
)
 
$
(18.13
)
Weighted-average shares used to compute net loss per share attributable to common stockholders, basic and diluted
2,943,896

 
586,738

 
1,382,592

 
586,701



























See accompanying notes to these condensed consolidated financial statements.

5



BRICKELL BIOTECH, INC.
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
(in thousands)
(unaudited)

 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
 
2019
 
2018
 
2019
 
2018
Net loss
$
(4,781
)
 
$
(2,541
)
 
$
(13,015
)
 
$
(5,566
)
Other comprehensive loss:
 
 
 
 
 
 
 
Unrealized loss on available-for-sale marketable securities arising during holding period, net of tax benefit of $0
(11
)
 

 
(11
)
 

Total comprehensive loss
$
(4,792
)
 
$
(2,541
)
 
$
(13,026
)
 
$
(5,566
)








































See accompanying notes to these condensed consolidated financial statements.

6



BRICKELL BIOTECH, INC.
CONDENSED CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY (DEFICIT)
(in thousands, except share and per share data)
(unaudited)
 
Series A, B, C & C-1 Redeemable
Convertible Preferred Stock
 
Common Stock
 
Additional
Paid-In Capital
 
Accumulated Other Comprehensive Loss
 
Accumulated
Deficit
 
Total
Stockholders’
Equity (Deficit)
 
Shares
 
Carrying Value
 
Shares
 
Par Value
 
Balance, December 31, 2018
1,256,466

 
$
58,290

 
589,001

 
$
6

 
$

 
$

 
$
(71,624
)
 
$
(71,618
)
Stock based compensation

 

 

 

 
384

 

 

 
384

Reduction of redeemable convertible preferred stock to redemption value

 
(10,521
)
 

 

 

 

 
10,521

 
10,521

Net loss

 

 

 

 

 

 
(4,580
)
 
(4,580
)
Balance, March 31, 2019 (unaudited)
1,256,466

 
47,769

 
589,001

 
6

 
384

 

 
(65,683
)
 
(65,293
)
Stock based compensation

 

 

 

 
299

 

 

 
299

Accretion of redeemable convertible preferred stock to redemption value

 
165

 

 

 
(165
)
 

 

 
(165
)
Net loss

 

 

 

 

 

 
(3,654
)
 
(3,654
)
Balance, June 30, 2019 (unaudited)
1,256,466

 
47,934

 
589,001

 
6

 
518

 

 
(69,337
)
 
(68,813
)
Accretion of redeemable convertible preferred stock to redemption value

 
82

 

 

 
(82
)
 

 

 
(82
)
Conversion of redeemable convertible preferred stock and preferred stock dividends to common stock
(1,256,466
)
 
(48,016
)
 
2,783,951

 
28

 
47,988

 

 

 
48,016

Common stock issued in recapitalization

 

 
3,367,988

 
34

 
36,059

 

 

 
36,093

Conversion of convertible notes payable and accrued interest to common stock

 

 
1,069,740

 
10

 
5,082

 

 

 
5,092

Reclassification of warrant liability to equity

 

 

 

 
1,511

 

 

 
1,511

Common stock warrants issued in connection with the research and development funding liability

 

 

 

 
876

 

 

 
876

Stock based compensation

 

 

 

 
324

 

 

 
324

Unrealized loss on available-for-sale marketable securities

 

 

 

 

 
(11
)
 

 
(11
)
Net loss

 

 

 

 

 

 
(4,781
)
 
(4,781
)
Balance, September 30, 2019 (unaudited)

 
$

 
7,810,680

 
$
78

 
$
92,276

 
$
(11
)
 
$
(74,118
)
 
$
18,225



7



BRICKELL BIOTECH, INC.
CONDENSED CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY (DEFICIT)
(in thousands, except share and per share data)
(unaudited)
 
Series A, B, C & C-1 Redeemable
Convertible Preferred Stock
 
Common Stock
 
Additional
Paid-In Capital
 
Accumulated Other Comprehensive Loss
 
Accumulated
Deficit
 
Total
Stockholders’
Deficit
 
Shares
 
Carrying Value
 
Shares
 
Par Value
 
Balance, December 31, 2017
1,256,466

 
$
52,354

 
585,262

 
6

 

 
$

 
(59,942
)
 
(59,936
)
Effect of adoption of Topic 606

 

 

 

 

 

 
2,734

 
2,734

Stock based compensation

 

 

 

 
190

 

 

 
190

Issuance of common stock through exercise of stock option

 

 
1,438

 

 
17

 

 

 
17

Accretion of redeemable convertible preferred stock to redemption value

 
3,240

 

 

 
(207
)
 

 
(3,033
)
 
(3,240
)
Net income

 

 

 

 

 

 
527

 
527

Balance, March 31, 2018 (unaudited)
1,256,466

 
55,594

 
586,700

 
6

 

 

 
(59,714
)
 
(59,708
)
Stock based compensation

 

 

 

 
175

 

 

 
175

Accretion of redeemable convertible preferred stock to redemption value

 
865

 

 

 
(175
)
 

 
(690
)
 
(865
)
Net loss

 

 

 

 

 

 
(3,552
)
 
(3,552
)
Balance, June 30, 2018 (unaudited)
1,256,466

 
56,459

 
586,700

 
6

 

 

 
(63,956
)
 
(63,950
)
Stock based compensation

 

 

 

 
151

 

 

 
151

Issuance of common stock through exercise of stock option

 

 
863

 

 
10

 

 

 
10

Accretion of redeemable convertible preferred stock to redemption value

 
966

 

 

 
(161
)
 

 
(805
)
 
(966
)
Net loss

 

 

 

 

 

 
(2,541
)
 
(2,541
)
Balance, September 30, 2018 (unaudited)
1,256,466

 
$
57,425

 
587,563

 
$
6

 
$

 
$

 
$
(67,302
)
 
$
(67,296
)












See accompanying notes to these condensed consolidated financial statements.

8



BRICKELL BIOTECH, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(unaudited, in thousands)
 
Nine Months Ended
September 30,
 
2019
 
2018
CASH FLOWS FROM OPERATING ACTIVITIES:
 
 
 
Net loss
$
(13,015
)
 
$
(5,566
)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
 
 
 
Depreciation
25

 
37

Accretion of discount on marketable securities
(25
)
 

Non-cash interest expense
666

 

Change in fair value of derivative liability
11

 

Change in fair value of warrant liability
(223
)
 
(8
)
Gain on extinguishment
(2,318
)
 

Amortization of operating lease right-of-use assets
50

 

Amortization of convertible promissory notes discount
828

 

Amortization of debt discounts and financing costs
215

 
310

Stock-based compensation
1,007

 
516

Changes in operating assets and liabilities:
 
 
 
Prepaid expenses and other current assets
(2,480
)
 
14

Accounts payable
(2,776
)
 
473

Accrued liabilities
(2,207
)
 
(343
)
Lease liability
(50
)
 

Research and development funding liability
5,600

 

Deferred revenue
(7,248
)
 
12,188

Net cash provided by (used in) operating activities
(21,940
)
 
7,621

CASH FLOWS FROM INVESTING ACTIVITIES:
 
 
 
Cash and cash equivalents acquired in recapitalization
13,017

 

Maturities of marketable securities
5,500

 

Capital expenditures
(8
)
 
(8
)
Net cash provided by (used in) investing activities
18,509

 
(8
)
CASH FLOWS FROM FINANCING ACTIVITIES:
 
 
 
Payments of principal of note payable
(4,808
)
 
(509
)
Proceeds from issuance of convertible promissory notes
7,397

 

Proceeds from the exercise of stock options

 
27

Net cash provided by (used in) financing activities
2,589

 
(482
)
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS   
(842
)
 
7,131

CASH AND CASH EQUIVALENTS—BEGINNING   
8,067

 
5,399

CASH AND CASH EQUIVALENTS—ENDING   
$
7,225

 
$
12,530

Supplement Disclosure of Cash Flow Information:
 
 
 
Interest paid
$
319

 
$
310

Supplement Disclosure of Non-Cash Investing and Financing Activities:
 
 
 
Conversion of redeemable convertible preferred stock and preferred stock dividends to common stock
$
48,016

 
$

Accretion (reduction) of redeemable convertible preferred stock to redemption value
$
(10,377
)
 
$
5,041

Shares issued in recapitalization
$
23,076

 
$

Accretion of redeemable convertible preferred stock issuance costs
$
103

 
$
30

Derivative liability issued with convertible promissory notes
$
1,442

 
$

Warrants to purchase common stock issued with funding agreement
$
876

 
$

Warrants to purchase common stock issued with convertible promissory notes
$
1,492

 
$

Change in unrealized loss on available-for-sale marketable securities
$
(11
)
 
$

See accompanying notes to these condensed consolidated financial statements.

9



BRICKELL BIOTECH, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(unaudited)

NOTE 1. ORGANIZATION AND NATURE OF OPERATIONS

Brickell Biotech, Inc. (the “Company” or “Brickell”) is a clinical-stage pharmaceutical company focused on the development of innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases. The Company’s pipeline consists of potential novel therapeutics for hyperhidrosis, cutaneous T-cell lymphoma, psoriasis, and other prevalent dermatological conditions. Its pivotal Phase 3-ready clinical-stage product candidate, sofpironium bromide, is a proprietary new molecular entity that belongs to a class of medications called anticholinergics. The Company is developing sofpironium bromide as a potential best-in-class, self-administered, once daily, topical therapy for the treatment of primary axillary hyperhidrosis. The Company’s operations to date have been limited to business planning, raising capital, developing its pipeline assets (in particular sofpironium bromide), identifying product candidates, and other research and development.

On August 31, 2019, the Company, then known as Vical Incorporated (“Vical”), and Brickell Biotech, Inc., a then privately-held Delaware corporation that began activities in September 2009 (“Private Brickell”), completed a recapitalization in accordance with the terms of the Agreement and Plan of Merger and Reorganization, dated June 2, 2019, as further amended on August 20, 2019 and on August 30, 2019 (the “Merger Agreement”), by and among Vical, Vical Subsidiary, Inc., a wholly owned subsidiary of Vical (“Merger Sub”), and Private Brickell. Pursuant to the Merger Agreement, Merger Sub merged with and into Private Brickell, with Private Brickell surviving as a wholly-owned subsidiary of Vical (the “Merger”). Additionally, on August 31, 2019, immediately after the completion of the Merger, the Company changed its name from “Vical Incorporated” to “Brickell Biotech, Inc.” and Private Brickell changed its name from "Brickell Biotech, Inc." to "Brickell Subsidiary, Inc."

The accompanying condensed consolidated financial statements and related notes reflect the historical results of Private Brickell prior to the Merger and of the combined company following the Merger, and do not include the historical results of Vical prior to the completion of the Merger. These financial statements and related notes should be read in conjunction with the audited financial statements of Private Brickell for the year ended December 31, 2018, included in the Company’s Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on September 3, 2019.

On August 31, 2019, in connection with, and prior to the consummation of the Merger, Vical effected a reverse stock split of its common stock, par value $0.01 per share, at a ratio of 1-for-7 (the “Reverse Stock Split”). Unless otherwise noted herein, references to share and per-share amounts give retroactive effect to the Reverse Stock Split.

On August 31, 2019, all shares of preferred stock of Private Brickell converted into shares of common stock of Private Brickell on a one-for-one basis.

At the effective date of the Merger, the Company issued shares of its common stock to Private Brickell stockholders, at an exchange rate of approximately 2.4165 shares of common stock in exchange for each share of Private Brickell common stock outstanding immediately prior to the Merger (the “Exchange Ratio”). The exchange rate was calculated by a formula that was determined through arms-length negotiations between the Vical and Private Brickell. Unless otherwise noted herein, references to share and per-share amounts give retroactive effect to the Reverse Stock Split and the Exchange Ratio, which was effected upon the Merger.

Immediately following the consummation of the Merger, there were 7,810,680 shares of common stock issued and outstanding, with Private Brickell’s former securityholders beneficially owning approximately 57% of the outstanding shares of common stock and Vical’s former securityholders beneficially owning approximately 43% of the outstanding shares of common stock.

Funding Agreement with NovaQuest

On August 31, 2019, concurrent with the Merger Agreement, the Company entered into a research and development arrangement with NovaQuest Capital Management, LLC (“NovaQuest”) pursuant to which NovaQuest committed up to $25.0 million in research and development funding to the Company following the closing of the Merger (the “Funding Agreement”). These proceeds will partially fund the Company's Phase 3 clinical trials in the United States for sofpironium bromide. The Company issued a warrant to NovaQuest to purchase 241,225 shares of common stock. Additional details of this agreement are described in Note 4. In October 2019, additional funding was temporarily suspended. Refer to Note 11 for additional details.


10



Liquidity and Capital Resources

The accompanying condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. The condensed consolidated financial statements do not reflect any adjustments relating to the recoverability and reclassification of assets and liabilities that might be necessary if the Company is unable to continue as a going concern. The Company has incurred significant operating losses and has an accumulated deficit as a result of ongoing efforts to develop product candidates, including conducting preclinical and clinical trials and providing general and administrative support for these operations. For the nine months ended September 30, 2019, the Company had a net loss of $13.0 million and net cash used in operating activities of $21.9 million. As of September 30, 2019, the Company had cash, cash equivalents, and marketable securities of $25.7 million, and an accumulated deficit of $74.1 million.

Pending resolution of the contentious matter discussed further in Note 11 and NovaQuest resuming additional funding, the Company intends to conserve its resources. The advancement of the Phase 3 clinical trials for sofpironium bromide may be negatively impacted by these developments. The Company may take actions to reduce its cash spend, including delaying the start of the clinical trials or staff reductions. Taking these measures into account, the Company believes that its cash, cash equivalents, and marketable securities as of September 30, 2019 would be sufficient to fund its operations for at least the next 12 months from the issuance of these condensed consolidated financial statements.

The Company expects to continue to incur additional substantial losses in the foreseeable future as a result of the Company’s research and development activities. Additional funding will be required in the future to maintain the Company’s current and proposed research activities. There can be no assurance that additional equity or debt financing will be available on acceptable terms, if at all. If the Company is unable to raise additional funding to meet its working capital needs in the future, it will be forced to delay or reduce the scope of its research programs and/or limit or cease its operations.

NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The accompanying condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, Brickell Subsidiary, Inc., are presented in U.S. dollars and have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”) and applicable rules and regulations of the SEC for interim reporting. As permitted under those rules and regulations, certain footnotes or other financial information normally included in financial statements prepared in accordance with US GAAP have been condensed or omitted. These condensed consolidated financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments, consisting only of normal recurring adjustments, which are necessary for a fair presentation of the Company’s financial information. The results of operations for the three and nine months ended September 30, 2019 are not necessarily indicative of the results to be expected for the full year ending December 31, 2019, for any other interim period, or for any other future period. The condensed consolidated balance sheet as of December 31, 2018 has been derived from audited financial statements at that date but does not include all of the information required by US GAAP for complete financial statements. All intercompany balances and transactions have been eliminated in consolidation.

The Merger has been accounted for as a recapitalization. Prior to the Merger, Vical wound down its pre-merger business assets and liabilities. The owners and management of Private Brickell have actual and effective voting and operating control of the combined company. In the Merger transaction, Vical is the accounting acquiree and Private Brickell is the accounting acquirer. A recapitalization is equivalent to the issuance of stock by the private operating company for the net monetary assets of the accounting acquiree accompanied by a recapitalization with accounting similar to that resulting from a reverse acquisition, except that no goodwill or intangible assets are recorded. 


11



In connection with the Merger, 3,367,988 shares of common stock were transferred to the existing Vical stockholders and the Company assumed approximately $36.1 million in net tangible assets from Vical, which were recorded as charges against additional paid-in capital. The following table summarizes the net assets acquired based on their estimated fair values immediately prior to the Merger (in thousands):
Cash and cash equivalents
$
13,017

Marketable securities
23,959

Prepaid expenses and other current assets
1,474

Accrued liabilities
(2,357
)
Net acquired tangible assets
$
36,093



In connection with the Merger, the Company assumed warrants previously held by Vical, which provide the warrantholder the right to purchase 891,582 shares of common stock at an exercise price of $0.07 (the “Vical Warrants”). The Vical Warrants were classified as equity.

The combined company assumed all the outstanding options, under Vical’s equity incentive plan (the "Vical Plan") with such options representing the right to purchase a number of shares of Brickell common stock previously represented by such options, as adjusted for the recapitalization.
 
Use of Estimates

The Company’s condensed consolidated financial statements are prepared in accordance with US GAAP, which requires it to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Although these estimates are based on the Company’s knowledge of current events and actions it may take in the future, actual results may ultimately differ from these estimates and assumptions.

Risks and Uncertainties

The Company’s business is subject to significant risks common to early-stage companies in the pharmaceutical industry including, but not limited to, the ability to develop appropriate formulations, scale up and production of the compounds, dependence on collaborative parties, uncertainties associated with obtaining and enforcing patents and other intellectual property rights, clinical implementation and success, the lengthy and expensive regulatory approval process, compliance with regulatory and other legal requirements, competition from other products; uncertainty of broad adoption of its approved products, if any, by physicians and patients; significant competition; ability to manage third-party manufacturers, suppliers, contract research organizations, business partners and other alliance management, and obtaining additional financing to fund the Company’s efforts.

The product candidates developed by the Company require approvals from the U.S. Food and Drug Administration (“FDA”) and foreign regulatory agencies prior to commercial sales in the United States or foreign jurisdictions, respectively. There can be no assurance that the Company’s current and future product candidates will receive the necessary approvals. If the Company is denied approval or approval is delayed, it may have a material adverse impact on the Company’s business and its financial condition.

The Company expects to incur substantial operating losses for the next several years and will need to obtain additional financing in order to complete clinical studies and launch and commercialize any product candidates for which it receives regulatory approval. There can be no assurance that such financing will be available or will be at terms acceptable by the Company.

Fair Value Measurements

Fair value is the price that the Company would receive to sell an asset or pay to transfer a liability in a timely transaction with an independent counterparty in the principal market or in the absence of a principal market, the most advantageous market for the asset or liability. A three-tier hierarchy is established to distinguish between (1) inputs that reflect the assumptions market participants would use in pricing an asset or liability developed based on market data obtained from sources independent of the reporting entity (observable inputs) and (2) inputs that reflect the reporting entity’s own assumptions about the assumptions market participants would use in pricing an asset or liability developed based on the best information available in the circumstances (unobservable inputs), and establishes a classification of fair value measurements for disclosure purposes.

12




The hierarchy is summarized in the three broad levels listed below:
 
Level 1—quoted prices in active markets for identical assets and liabilities
Level 2—other significant observable inputs (including quoted prices for similar assets and liabilities, interest rates, credit risk, etc.)
Level 3—significant unobservable inputs (including the Company’s own assumptions in determining the fair value of assets and liabilities)

The following tables set forth the fair value of the Company’s financial assets and liabilities measured at fair value on a recurring basis based on the three-tier fair value hierarchy as of September 30, 2019 and December 31, 2018 (in thousands):
 
September 30, 2019
 
Level 1 
 
Level 2 
 
Level 3 
Assets:
 
 
 
 
 
Money market funds
$
7,225

 
$

 
$

U.S. treasuries
18,473

 

 

Total
$
25,698

 
$

 
$

Liabilities:
 
 
 
 
 
Contingent consideration
$

 
$

 
$
145

 
December 31, 2018
 
Level 1
 
Level 2
 
Level 3
Assets:
 
 
 
 
 
Money market funds
$
8,067

 
$

 
$

Liabilities:
 
 
 
 
 
Redeemable convertible preferred stock warrant liability
$

 
$

 
$
242

Contingent consideration

 

 
145

Total
$

 
$

 
$
387



Fair Value of Financial Instruments

The following methods and assumptions were used by the Company in estimating the fair values of each class of financial instrument disclosed herein:

Money Market Funds—The carrying amounts reported as cash and cash equivalents in the condensed consolidated balance sheets approximate their fair values due to their short-term nature and/or market rates of interest (Level 1 of the fair value hierarchy).

U.S. Treasuries—The Company has designated its investments in U.S. treasury securities as available-for-sale securities and accounts for them at their respective fair values. The securities are classified as short-term or long-term based on the nature of the securities and their availability to meet current operating requirements. Securities that are readily available for use in current operations are classified as short-term available-for-sale marketable securities and are reported as a component of current assets in the condensed consolidated balance sheets (Level 1 of the fair value hierarchy).

Securities that are classified as available-for-sale are measured at fair value, including accrued interest, with temporary unrealized gains and losses reported as a component of stockholders’ equity until their disposition. The Company reviews available-for-sale securities at the end of each period to determine whether they remain available-for-sale based on its then current intent. The cost of securities sold is based on the specific identification method. The securities are subject to a periodic impairment review. An impairment charge would occur when a decline in the fair value of the investments below the cost basis is judged to be other-than-temporary.


13



As of September 30, 2019, the Company’s available-for-sale securities had an amortized cost of $18.5 million, fair value of $18.5 million, and an unrealized gain of $20 thousand. Because the securities were acquired in August 2019 in connection to the Merger, there were no related balances as of December 31, 2018.

Contingent Consideration—These amounts represent future payments in conjunction with various business combinations related to the acquisition of certain early-stage pipeline assets. The ultimate amount of future payments is based on specified future criteria, such as the achievement of certain future development and regulatory milestones. The Company evaluates its estimates of the fair value of contingent consideration on a quarterly basis. The fair value of the contingent consideration was determined with the assistance of a third-party valuation firm applying the income approach. This approach estimates the fair value of the contingent consideration related to the achievement of future development and regulatory milestones by assigning an achievement probability and date of expected completion to each potential milestone and discounting the associated cash payment to its present value using a risk-adjusted rate of return. The probability of success of each milestone assumes that the prerequisite developmental milestones are successfully completed and is based on the asset’s current stage of development and anticipated regulatory requirements. The probability of success for each milestone is determined by multiplying the preceding probabilities of success. The unobservable inputs (Level 3 of the fair value hierarchy) to the valuation models that have the most significant effect on the fair value of the Company’s contingent consideration are the probabilities that certain in-process development projects will meet specified development milestones, including ultimate approval by the FDA, with individual cumulative probabilities ranging from 2.1% to 20.9%. Other unobservable inputs used in this approach include risk-adjusted discount rates ranging from 15.5% to 27.1% and estimates of the timing of the achievement of the various product development, regulatory approval, and sales milestones.

Redeemable Convertible Preferred Stock Warrant Liability—These amounts represented potential future obligations to transfer assets to the holders at a future date. The Company remeasured these warrants to current fair value at each balance sheet date, and any change in fair value was recognized as a change in fair value of warrant liability in the condensed consolidated statements of operations. The Company estimated the fair value of these warrants at December 31, 2018 using the Black-Scholes option-pricing model (Level 3 of the fair value hierarchy table). These warrants converted from warrants exercisable for redeemable convertible preferred stock to common stock in August 2019 in connection to the Merger (see further discussion in Note 7).

Inputs used to determine estimated fair value of the warrant liabilities included the estimated fair value of the underlying stock at the valuation date, the estimated term of the warrants, risk-free interest rates, expected dividends, and the expected volatility of the underlying stock. The most significant unobservable inputs used in the fair value measurement of the convertible preferred stock warrant liability were the fair value of the underlying stock at the valuation date and the estimated term of the warrants. Generally, increases (decreases) in the fair value of the underlying stock and estimated term resulted in a directionally similar impact to the fair value measurement.

The fair value of the outstanding warrants was remeasured as of each period end using the Black-Scholes option-pricing model with the following assumptions:
 
2018
Expected term (in years)
7.1

Expected volatility
30.00
%
Risk free interest rate
2.59
%
Expected dividend yield
%


The fair value of the shares of the convertible preferred stock underlying the preferred stock warrants was historically determined with the assistance of a third-party valuation firm. Because there had been no public market for the Company’s convertible preferred stock, the third-party valuation firm determined fair value of the convertible preferred stock at each balance sheet date by considering a number of objective and subjective factors, including valuation of comparable companies, sales of convertible preferred stock to unrelated third parties, operating and financial performance, the lack of liquidity of capital stock, and general and industry specific economic outlook, among other factors.

Remaining Term. The Company derived the expected term based on the time from the balance sheet date until the preferred stock warrant’s expiration date.


14



Expected Volatility. Since the Company was a private entity with no historical data regarding the volatility of its preferred stock, the expected volatility used was based on volatility of a group of similar entities. In evaluating similarity, the Company considered factors such as industry, stage of life cycle, and size.

Risk-free Interest Rate. The risk-free interest rate was based on U.S. Treasury zero-coupon issues with remaining terms similar to the expected term of the warrants.

Expected Dividend Rate. The Company has never paid any dividends and does not plan to pay dividends in the foreseeable future and, therefore, used an expected dividend rate of zero in the valuation model.

Derivative Liability—These amounts represented potential future obligations to transfer assets to the holders at a future date. The fair value of the derivative liability has historically been determined with the assistance of a third-party valuation firm (Level 3 of the fair value hierarchy table) (see further discussion in Note 6). At the inception of the liability, there was no public market for the Company’s common stock, and a third-party valuation firm determined fair value of the stock by considering a number of objective and subjective factors, including valuation of comparable companies, sales of common stock to unrelated third parties, operating and financial performance, the lack of liquidity of capital stock, and general and industry specific economic outlook, among other factors. The derivative liability was marked-to-market each measurement period and any change in fair value was recorded in the condensed consolidated statements of operations. In August 2019, in connection to the Merger, the derivative liability was reclassified to equity in the condensed consolidated balance sheet (see further discussion in Note 6).

Common Stock Warrant Liability—These amounts represented potential future obligations to transfer assets to the holders at a future date. The fair value of the warrants was historically determined with the assistance of a third-party valuation firm (Level 3 of the fair value hierarchy table) (see further discussion in Note 6). At the inception of the liability, there was no public market for the Company’s common stock, and a third-party valuation firm determined fair value of the stock by considering a number of objective and subjective factors, including valuation of comparable companies, sales of common stock to unrelated third parties, operating and financial performance, the lack of liquidity of capital stock, and general and industry specific economic outlook, among other factors. The warrant liability was remeasured to fair value at each balance sheet date, and any change in fair value was recognized as a change in fair value of warrant liability in the condensed consolidated statements of operations. The Company estimated the fair value of these warrants using the Black-Scholes option-pricing model. In August 2019, in connection to the Merger, the warrant liability was reclassified to equity in the condensed consolidated balance sheet (see further discussion in Note 6).

Inputs used to determine estimated fair value of the warrant liabilities included the estimated fair value of the underlying stock at the valuation date, the estimated term of the warrants, risk-free interest rates, expected dividends, and the expected volatility of the underlying stock. The most significant unobservable inputs used in the fair value measurement of the warrant liability were the fair value of the underlying stock at the valuation date and the estimated term of the warrants. Generally, increases (decreases) in the fair value of the underlying stock and estimated term resulted in a directionally similar impact to the fair value measurement.

The following table sets forth a summary of the changes in the fair value of the Company’s Level 3 financial instruments as follows (in thousands):
 
Derivative
Liability
 
Common
Stock
Warrant
Liability
 
Redeemable
Convertible
Preferred
Stock Warrant
Liability
 
Contingent
Consideration
Liabilities
Fair value as of December 31, 2018
$

 
$

 
$
242

 
$
145

Fair value of financial instruments issued
1,442

 
1,492

 

 

Change in fair value
11

 
17

 
(240
)
 

Reclassification to equity
(1,453
)
 
(1,509
)
 
(2
)
 

Fair value as of September 30, 2019
$

 
$

 
$

 
$
145



Leases

On January 1, 2019, the Company adopted Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 842, Leases (“ASC 842”), using the modified retrospective method for all lease arrangements at the beginning of the

15



period of adoption. Results for reporting periods beginning January 1, 2019 are presented under ASC 842, while prior period amounts were not adjusted and continue to be presented in accordance with the Company’s historical accounting under ASC Topic 840, Leases. ASC 842 had an impact on the Company’s condensed consolidated balance sheets but did not have a significant impact on the Company’s net loss.

Under ASC 842, the Company determines if an arrangement is a lease at inception. Leases with a term greater than one year are recognized on the balance sheet as right-of-use assets, lease liabilities and, if applicable, long-term lease liabilities. The Company has elected the practical expedient not to recognize on the balance sheet leases with terms of one-year or less and not to separate lease components and non-lease components for long-term real-estate leases. Lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company estimates the incremental borrowing rate based on industry peers in determining the present value of lease payments. The Company’s facility operating lease has one single component. The lease component results in a right-of-use asset being recorded on the balance sheet, which is amortized as lease expense on a straight-line basis in the Company’s condensed consolidated statements of operations.

Redeemable Convertible Preferred Stock

Redeemable convertible preferred stock was classified as a mezzanine instrument outside of the Company’s capital accounts. Accretion of redeemable convertible preferred stock included the greater of an adjustment to fair market value or the accrual of dividends on and accretion of issuance costs of the Company’s redeemable convertible preferred stock. The carrying values of the redeemable convertible preferred stock were increased or reduced by periodic accretion or reduction to their respective redemption values from the date of issuance to August 31, 2019, the date that all outstanding shares of redeemable convertible preferred stock converted into shares of common stock. The carrying value adjustments were recorded as charges against additional paid-in capital balance.

Preferred stock issuance costs represent costs related to the Company’s issuance of redeemable convertible preferred stock. These amounts were included as a reduction of redeemable convertible preferred stock and were amortized over the estimated redemption period until its conversion to common stock in August 2019. For the nine months ended September 30, 2019 and 2018, amortization of preferred stock issuance costs amounted to approximately $0.1 million and $30 thousand, respectively.
 
Redeemable Convertible Preferred Stock Warrants

The Company accounted for warrants to purchase shares of its redeemable convertible preferred stock as liabilities at their estimated fair value because the underlying shares were redeemable, which obligated the Company to transfer assets to the holders at a future date. The warrants were subject to remeasurement to fair value at each balance sheet date, and any fair value adjustments were recognized as change in fair value of redeemable convertible preferred stock warrant liability in the condensed consolidated statements of operations. The Company continued to adjust the liability for changes in fair value until the conversion of the redeemable convertible preferred stock into common stock in August 2019. At that time, the redeemable convertible preferred stock warrant liability was adjusted to fair value in the condensed consolidated statements of operations with the final fair value reclassified to equity.

Revenue Recognition

The Company recognizes revenue upon the transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies the performance obligations. At contract inception, the Company assesses the goods or services promised within each contract and assesses whether each promised good or service is distinct and determines those that are performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.

To date, the Company’s drug candidates have not been approved for sale by the FDA or any other country’s regulatory authority, and the Company has not generated or recognized any revenue from the sale of products.


16



In March 2015, the Company entered into a license and collaboration agreement with Kaken Pharmaceutical, Co., Ltd. (“Kaken”), which is referred to as the “Collaboration Agreement.” Under the Collaboration Agreement, the Company granted to Kaken an exclusive right to develop, manufacture, and commercialize the Company’s sofpironium bromide compound (formerly BBI-4000), a topical anticholinergic, in Japan and certain other Asian countries (the “Territory”). In exchange, Kaken paid the Company an upfront, non-refundable payment of $11.0 million (the “upfront fee”). In addition, the Company is entitled to receive aggregate payments of up to $10.0 million upon the achievement of specified development milestones, and $30.0 million upon the achievement of commercial milestones, as well as tiered royalties based on a percentage of net sales of licensed products in the Territory. The Collaboration Agreement further provides that Kaken will be responsible for funding all development and commercial costs for the program in the Territory and, until such time, if any, as Kaken elects to establish its own source of supply of drug product, Kaken can purchase product supply from the Company to perform all non-clinical studies, and Phase 1 and Phase 2 clinical trials in Japan at cost. Kaken is also required to enter into negotiations with the Company, to supply the Company, at cost, with clinical supplies to perform Phase 3 clinical trials in the United States.

Collaboration Arrangement Subsequent to Adoption of Topic 606

The Company evaluates collaboration arrangements to determine whether units of account within the collaboration arrangement exhibit the characteristics of a vendor and customer relationship. The Company determined that the licenses transferred to Kaken in exchange for the upfront fees were representative of this type of a relationship. If a license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from non-refundable, upfront fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other performance obligations, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition on a prospective basis.

Under Topic 606, the Company evaluated the terms of the Collaboration Agreement and the transfer of intellectual property and manufacturing rights (the “license”) was identified as the only performance obligation as of the inception of the agreement. The Company concluded that the license for the intellectual property was distinct from its ongoing supply obligations. The Company further determined that the transaction price under the arrangement was comprised of the $11.0 million upfront payment. The future potential milestone amounts were not included in the transaction price, as they were all determined to be fully constrained. As part of its evaluation of the development and regulatory milestones constraint, the Company determined that the achievement of such milestones is contingent upon success in future clinical trials and regulatory approvals, each of which is uncertain at this time. The Company will re-evaluate the transaction price each quarter and as uncertain events are resolved or other changes in circumstances occur. Future potential milestone amounts would be recognized as revenue from collaboration arrangements, if unconstrained. The remainder of the arrangement, which largely consisted of both parties incurring costs in their respective territories, provides for the reimbursement of the ongoing supply costs. These costs were representative of a collaboration arrangement outside of the scope of Topic 606 as it does not have the characteristics of a vendor and customer relationship. Reimbursable program costs are recognized proportionately with the delivery of drug substance and are accounted for as reductions to research and development expense and are excluded from the transaction price.

Under Topic 606, the entire transaction price of $11.0 million was allocated to the license performance obligation. The license was deemed to be delivered in 2015 in connection with the execution of the Collaboration Agreement and upon transfer of the underlying intellectual property the performance obligation was fully satisfied. As a result, a cumulative adjustment to reduce deferred revenue and the corresponding sublicensing costs of $2.7 million was recorded upon the adoption of Topic 606 on January 1, 2018. As of September 30, 2019, the Company does not have a deferred revenue or deferred sublicensing costs balance related to the upfront fee on the condensed consolidated balance sheet.

In May 2018, the Company entered into an amendment to the Collaboration Agreement (as further amended, “Collaboration Agreement”), pursuant to which, the Company received an upfront non-refundable fee of $15.6 million (the “Collaboration R&D Payment”), which was initially recorded as deferred revenue, to provide the Company with research and development funds for the sole purpose of conducting certain clinical trials and other such research and development activities required to support the submission of a NDA for sofpironium bromide. These clinical trials have a benefit to Kaken and have the characteristics of a vendor and customer relationship. The Company has accounted for these under the provisions of Topic 606. This Collaboration R&D Payment will be initially recognized using an input method over the average estimated performance period of 1.45 years in proportion to the cost incurred. Upon receipt of the Collaboration R&D Payment, on May 31, 2018, a milestone payment

17



originally due upon the first commercial sale in Japan was removed from the Collaboration Agreement and all future royalties to the Company under the Collaboration Agreement were reduced 150 basis points.

Consequently, during the three and nine months ended September 30, 2019, the Company recognized revenue of $1.2 million and $7.2 million, respectively related to the Collaboration R&D Payment. As of September 30, 2019, the Company has a deferred revenue balance related to the Collaboration R&D Payment of $2.5 million, which is recorded in deferred revenue, current portion on the accompanying condensed consolidated balance sheets.

Milestones

At the inception of each arrangement that includes milestone payments (variable consideration), the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company or the Company’s collaboration partner’s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such milestones and any related constraint, and if necessary, adjust the Company’s estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration or other revenues and earnings in the period of adjustment.

In October 2017, the Company entered into an amendment to the Collaboration Agreement, pursuant to which, the Company granted Kaken a prepayment option (the “Kaken Option”) on 50% of the Initiation of Phase 3 milestone (the “Phase 3 Milestone”). The Kaken Option was exercisable by Kaken within 25 business days of receipt of the BBI-4000-CL-203 study topline results. In December 2017, Kaken exercised the Kaken Option and paid the Company $5.0 million (the “Kaken Option Payment”). Upon receipt of the non-refundable Kaken Option Payment, the Company provided Kaken the right to negotiate an exclusive license to develop, manufacture and commercialize each of the Company’s other product candidates in Japan (“ROFN Agreement”). Under the ROFN Agreement, following the completion of any Initial Proof of Concept Clinical Trial (“Initial POC”) for the Company’s other product candidates, the Company must provide Kaken with certain information relating to the results of the clinical trial (“Initial POC Package”). The ROFN Agreement is exercisable by Kaken within 30 days of receipt of the Initial POC Package. In December 2017, the Company recognized collaboration revenue related to the Collaboration Agreement of $5.0 million, in connection with the Kaken Option. Additionally, the Company recognized sublicensing costs of $1.0 million, which are included in general and administrative expenses.

The Collaboration Agreement was further amended in March 2018 to accelerate payment of the Phase 3 Milestone. The Phase 3 Milestone was modified to be due upon the successful completion of the End of Phase 2 Meeting with the PMDA by Kaken on March 8, 2018, as determined by Kaken in its reasonable discretion (the “Third Milestone”). In March 2018, Kaken triggered the Third Milestone and paid the Company $5.0 million (the “Third Milestone Payment”). Upon receipt of the non-refundable Third Milestone Payment, the ROFN Agreement was amended (the “Amended ROFN Agreement”) to grant an additional option to exercise upon completion of a Subsequent Clinical Trial (first clinical trial after the Initial POC) for the Company’s other product candidates. The Company has determined that the ROFN Agreement is not a material right and has not allocated transaction price to this provision. As of September 30, 2019, Kaken has not exercised the Amended ROFN Agreement. In March 2018, the Company recognized collaboration revenue related to the Collaboration Agreement of $5.0 million in connection with the Third Milestone. Additionally, the Company recognized sublicensing costs of $1.0 million, which are included in general and administrative expenses.

Royalties

For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognized revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue from any collaborative arrangement.

Under collaborative arrangements, the Company has been reimbursed for a portion of the Company’s research and development expenses, including costs of drug supplies. When the research and development services are performed under a reimbursement

18



or cost sharing model with a collaboration partner, the Company records these reimbursements as a reduction of research and development expense in the Company’s condensed consolidated statements of operations.
 
Net Loss per Common Share

Basic and diluted net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares outstanding. When the effects are not anti-dilutive, diluted earnings per share is computed by dividing the Company’s net earnings by the weighted average number of common shares outstanding and the impact of all dilutive potential common shares.

Diluted earnings per share gives effect to all dilutive potential common shares outstanding during the period, including stock options and warrants, using the treasury stock method, and redeemable convertible preferred stock, using the if-converted method. In computing diluted earnings per share, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants. Potentially dilutive common share equivalents are excluded from the diluted earnings per share computation in net loss periods because their effect would be anti-dilutive.

The following table sets forth the potential common shares excluded from the calculation of net loss per common share, because their inclusion would be anti-dilutive:
 
Three and Nine Months Ended
September 30,
 
2019
 
2018
Warrants to purchase common stock
1,632,495

 
55,360

Options to purchase common stock
1,802,895

 
1,347,500

Redeemable convertible preferred stock (as converted into common stock)

 
1,256,466

Warrants to purchase redeemable convertible preferred stock (as converted into common stock)

 
9,005

Total
3,435,390

 
2,668,331



NOTE 3. RECENT ACCOUNTING PRONOUNCEMENTS

In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement (“ASU 2018-13”), which amends certain disclosure requirements over Level 1, Level 2, and Level 3 fair value measurements. ASU 2018-13 is effective for fiscal years beginning after December 15, 2019 and interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the impact of adopting ASU 2018-13, but does not anticipate it will have a material impact on its disclosures.

In February 2016, the FASB issued ASU No. 2016-02, “Leases (Topic 842)” (“ASU 2016-02”). ASU 2016-02 is aimed at making leasing activities more transparent and comparable and requires substantially all leases be recognized by lessees on their balance sheets as a right-of-use asset and corresponding lease liability, including leases currently accounted for as operating leases. The Company adopted ASU 2016-02 on January 1, 2019 using the modified retrospective approach. The adoption did not have a material impact on the Company’s condensed consolidated statements of operations. The new standard has required the Company to establish liabilities and corresponding right-of-use assets on its condensed balance sheet for operating leases of $0.2 million that existed as of the January 1, 2019 adoption date. The impact on the condensed consolidated balance sheets as of January 1, 2019 was as follows (in thousands):
Balance Sheet
 
Topic 840
January 1, 2019
 
Topic 842
January 1, 2019
 
Impact of
Adoption
Operating lease right-of-use asset
 
$

 
$
219

 
$
219

Lease liability, current portion
 

 
(68
)
 
(68
)
Lease liability, net of current portion
 

 
(151
)
 
(151
)


NOTE 4. NOVAQUEST FUNDING ARRANGEMENT

On August 31, 2019, concurrent with the Merger Agreement, the Company entered into a research and development arrangement with NovaQuest pursuant to which NovaQuest committed up to $25.0 million in research and development funding to the

19



Company following the closing of the Merger. These proceeds will partially fund the Company’s Phase 3 clinical trials in the United States for its product candidate that contains sofpironium bromide, which treats hyperhidrosis of the skin. The Company is obligated to use commercially reasonable efforts to complete the clinical trials and file to obtain regulatory approval. The funding was projected to cover 67% of the product development costs up to $25.0 million.

As there is a substantive and genuine transfer of risk, the development funding is accounted for as an obligation to perform contractual services. However, given the potential obligation to repay the amounts received, the Company defer any funding received as a liability unless and until it becomes probable that the Company will not have to make a repayment of the received funding to NovaQuest. If the research and development is successful and the product candidate is ultimately approved by the FDA, NovaQuest will be entitled to a payment in the amount of $37.5 million, with $20.0 million due upon approval and the remainder due within two years of approval. Additionally, NovaQuest will be entitled to royalty payments based on annual net sales (except for Japan and certain other Asian countries) of the product candidate based on a sliding scale starting from the date that is two years after the first commercial sale. The portion of the approval payment, should it occur, that exceeds any liabilities recorded on the balance sheet, will be expensed immediately as interest expense. The royalties will be expensed as incurred and will also be included in cost of sales.

If the funding arrangement is terminated in certain circumstances, the Company will be required to pay NovaQuest $25.0 million plus interest, ranging from 8% to 12%. However, in the event that the Company terminates its development program for sofpironium bromide for other specified reasons, including serious safety issues, a failure of the product’s Phase 3 studies, or the FDA’s unwillingness to approve the product, the Company will not be obligated to make any payments to NovaQuest.

In conjunction with the transaction, the Company issued a fully vested warrant to NovaQuest providing it with the right to purchase 241,225 shares of common stock at an exercise price of $10.36 that is exercisable any time within ten years of the execution of the research and development arrangement (the “NovaQuest Warrant”). At issuance, the NovaQuest Warrant was classified as equity and recorded at fair value with no subsequent remeasurement. The fair value of the outstanding warrants was derived from the Black-Scholes option-pricing model using the following assumptions: expected volatility of 85.56%; risk free interest rate of 1.50%; expected term of 10 years; and expected dividend yield of 0.00%.

As of September 30, 2019, $5.6 million of funding had been received from NovaQuest, of which $0.9 million was allocated to the NovaQuest Warrant and deferred on the balance sheet within other current assets and will be recorded as interest expense over the term of the NovaQuest Warrant. In October 2019, NovaQuest notified the Company that additional funding was suspended temporarily based on a material adverse event. Refer to Note 11 for additional details.

NOTE 5. ACCRUED LIABILITIES

Accrued liabilities consisted of the following (in thousands):
 
September 30,
2019
 
December 31,
2018
Accrued contracted research and development services
$
1,715

 
$
847

Accrued professional fees
992

 
1,269

Accrued compensation
768

 
569

Accrued note issuance costs

 
587

Total
$
3,475

 
$
3,272



NOTE 6. CONVERTIBLE PROMISSORY NOTES

In March 2019, the Company initiated a convertible promissory notes offering pursuant to which the Company issued unsecured convertible promissory notes (the “Prom Notes”), bearing interest at 12.00% with a maturity of one year and convertible into shares of Series C-1 redeemable convertible preferred stock or the most senior preferred equity outstanding at the time of conversion at the option of the holder at a conversion price of $31.05 per share. In addition, the Prom Notes were automatically convertible upon closing of a qualified financing of at least $15.0 million before maturity at a conversion price equal to 80% of the effective price per share paid in the qualified financing, but not to exceed $38.82 per share. Through August 31, 2019, the Company had raised an aggregate principal amount of $7.4 million in Prom Notes. On August 31, 2019, prior to the Merger, the Prom Notes and related accrued interest converted into 1,069,740 shares of Private Brickell common stock at a conversion price of $7.54 per share (the “Conversion”).

20




The Prom Notes also provided for the issuance of warrants at 50% coverage, to acquire 490,683 shares of common stock. The warrants are exercisable for a term of five years at an exercise price of $10.36. Prior to the Merger, the warrants were exercisable at an exercise price of $42.70 or 10% premium to the effective price per share paid in a qualified financing. The Company evaluated the various financial instruments under ASC 480 and ASC 815 and determined the warrants required fair value accounting. The fair value of the warrants was recorded as a warrant liability upon issuance. The fair value of the warrants on the dates of issuance of $1.5 million was determined with the assistance of a third-party valuation firm. The fair value of the warrants was recorded as a debt discount upon issuance and was amortized to interest expense over the term of the Prom Notes based on the effective interest method.

At inception of the Prom Notes offering, the Company analyzed the conversion feature of the agreement for derivative accounting consideration under ASC 815 and determined that the embedded conversion features should be classified as a derivative because the exercise price of the Prom Notes are subject to a variable conversion rate. The Company determined that the variable conversion feature was a redemption feature that was not clearly and closely related to the Prom Notes and was therefore required to be bifurcated. In accordance with AC 815, the Company bifurcated the conversion feature of the Prom Notes and recorded a derivative liability.

The embedded derivative for the Prom Notes was carried on the Company’s condensed consolidated balance sheet at fair value. The derivative liability was marked-to-market each measurement period and any change in fair value was recorded as a component of the statements of operations. The fair value of the derivative liabilities on the date of issuance of $1.4 million was determined with the assistance of a third-party valuation firm. The fair value of the conversion feature was recorded as a debt discount upon issuance and was amortized to interest expense over the term of the Prom Notes based on the effective interest method.

The Company evaluated the conversion option to discern whether a beneficial conversion feature existed based upon comparing the effective exercise price of the convertible notes to the fair value of the shares they were convertible into. The Company concluded no beneficial conversion feature existed. During the three months ended September 30, 2019, the Company recognized $1.1 million of interest expense, including $0.4 million of accretion of discounts using an effective interest rate of 12.00%. During the nine months ended September 30, 2019, the Company recognized $2.0 million of interest expense, including $0.8 million of accretion of discounts using an effective interest rate of 12.00%.

As a result of the Conversion on August 31, 2019, the Prom Notes payable, warrant liability, and derivative liability balances were reclassified to equity in the condensed consolidated balance sheets. A gain of $2.3 million resulted from the Conversion of the Prom Notes, which is included in the gain on extinguishment line in the condensed consolidated statements of operations.

NOTE 7. NOTE PAYABLE

On February 18, 2016, the Company entered into a loan and security agreement (the “Loan Agreement”) with Hercules Capital, Inc. (the “Lender”) under which the Company borrowed $7.5 million upon the execution of the Loan Agreement on February 18, 2016. The interest rate applicable to each tranche was variable based upon the greater of either (i) 9.2% and (ii) the sum of (a) the Prime Rate as reported in The Wall Street Journal minus 3.5%, plus (b) 9.2%; notwithstanding the above, such rate could not exceed the permissible rates of interest on commercial loans under the laws of the State of California. Payments under the Loan Agreement were interest only until June 1, 2017, followed by equal monthly payments of principal and interest through the maturity date of September 1, 2019. The Company was required to make an end of term payment of 4.5% of the sum of (i) term loan advances, plus (ii) 50% of the aggregate unfunded term loan commitments. The Loan Agreement was further amended in December 2017, March 2018, and July 2018 (as further amended, “Loan Agreement”) to provide for an additional combined interest-only period of eight months, and the outstanding loan balance continued to be paid in equal monthly installments of principal and interest. As a result of the amendments, the Company was required to increase the end-of-term payment by $0.1 million. At the inception of the loan and the following amendment dates, the Company paid the Lender aggregate facility fees of $0.2 million in connection with the Loan Agreement.

In connection with the Loan Agreement, the Company issued warrants to the Lender, which are exercisable for 9,005 shares of common stock at a per share exercise price of $33.31 (the “Hercules Capital Warrants”). The Hercules Capital Warrants will terminate, if not earlier exercised, on February 18, 2026. The fair value of the Hercules Capital Warrants was recorded at inception as a redeemable convertible preferred stock warrant liability upon issuance. The fair value of the Hercules Capital Warrants on the date of issuance of $0.3 million was determined using the Black-Scholes option-pricing model and was recorded as a debt discount upon issuance and was amortized to interest expense over the term of the loan based on the effective interest method.


21



On September 3, 2019, the Company repaid the remaining outstanding loan balance of $2.6 million and an associated accrued interest and aggregate end-of-term payment of $0.6 million, and the Loan Agreement was terminated. At the effective time of the Merger, the warrant liability was reclassified to equity in the condensed consolidated balance sheet. As of September 30, 2019, there were no remaining unaccreted debt discounts and issuance costs.

NOTE 8. COMMITMENTS AND CONTINGENCIES

Operating Leases

In August 2016, the Company entered into a five-year lease for office space in Boulder, Colorado that expires on October 31, 2021 (the “Boulder Lease”) subject to the Company’s option to renew the Boulder Lease for two additional terms of three years each. Pursuant to the Boulder Lease, the Company leased 3,038 square feet of space in a multi-suite building. Rent payments under the Boulder Lease included base rent of $4,430 per month during the first year of the Boulder Lease with an annual increase of 3.5%, and additional monthly fees to cover the Company’s share of certain facility expenses, including utilities, property taxes, insurance, and maintenance, which were $2,160 per month during the first year of the Boulder Lease.

The Company recognized a right-of-use asset and corresponding lease liability on January 1, 2019, by calculating the present value of lease payments, discounted at 12.0%, the Company’s estimated incremental borrowing rate, over the 2.8 years expected remaining term. As the Company’s lease does not provide an implicit rate, the Company estimated the incremental borrowing rate based on industry peers. Industry peers consist of several public companies in the biotechnology industry with comparable characteristics, including clinical trials progress and therapeutic indications. Amortization of the operating lease right-of-use asset for the Boulder Lease amounted to $17 thousand and $50 thousand for the three and nine months ended September 30, 2019, respectively, and was included in operating expense. As of September 30, 2019, the remaining lease term was 2.1 years.

The terms of the Boulder Lease provide for rental payments on a monthly basis on a graduated scale. The Company recognizes rent expense on a straight-line basis over the lease period. Lease expense for the three and nine months ended September 30, 2019 and 2018 was $22 thousand and $0.1 million, respectively.

NOTE 9. CAPITAL STOCK

Common Stock

Each share of common stock is entitled to one vote, and the holders of common stock are entitled to receive dividends when and as declared or paid by its board of directors. At the effective date of the Merger, each outstanding share of the Company’s common stock was converted into the right to receive approximately 2.4165 shares of the Private Brickell’s common stock.

The Company has reserved authorized shares of common stock, on an as-converted basis, for future issuance at September 30, 2019 as follows:
 
September 30, 2019
Common stock options outstanding
1,802,895

Common stock warrants
1,632,495

Options available for grant under the Vical Plan
119,070

Options available for grant under the 2009 Plan
17,232

Total
3,571,692



Preferred Stock

In August 2019, in conjunction with the Merger, all outstanding shares of redeemable convertible preferred stock converted into shares of common stock at a ratio of 1:1 and were immediately exchanged for common stock at an Exchange Ratio of 2.4165 as a result of the Merger.  


22



Redeemable convertible preferred stock consisted of the following prior to the conversion on August 31, 2019 (in thousands, except share data):
 
Preferred
Shares
Authorized
 
Preferred
Shares
Issued and
Outstanding
 
Par
Value
 
Carrying
Value
 
Common
Stock Issued
Upon
Conversion
Series A
1,162,505

 
401,309

 
$
4

 
$
12,164

 
401,309

Series B
882,216

 
286,151

 
3

 
10,084

 
286,151

Series C
869,565

 
256,583

 
3

 
11,630

 
256,583

Series C-1
1,531,942

 
312,423

 
3

 
14,138

 
312,423

 
4,446,228

 
1,256,466

 
$
13

 
$
48,016

 
1,256,466


Redeemable convertible preferred stock consisted of the following as of December 31, 2018 (in thousands, except share data):
 
Preferred
Shares
Authorized
 
Preferred
Shares
Issued and
Outstanding
 
Par
Value
 
Carrying
Value
 
Common
Stock Issuable
Upon
Conversion
Series A
1,162,505

 
401,309

 
$
4

 
$
16,098

 
401,309

Series B
882,216

 
286,151

 
3

 
13,011

 
286,151

Series C
869,565

 
256,583

 
3

 
13,018

 
256,583

Series C-1
1,268,657

 
312,423

 
3

 
16,163

 
312,423

 
4,182,943

 
1,256,466

 
$
13

 
$
58,290

 
1,256,466



As of September 30, 2019, the Company had no outstanding shares of redeemable convertible preferred stock and had not designated the rights, preferences, or privileges of any class or series of preferred stock. Although, the Company’s board of directors has the authority, at its discretion, to issue preferred stock in one or more classes or series and to fix the designations, powers, preferences and rights, and the qualifications, limitations, or restrictions thereof, including dividend rights, conversion right, voting rights, terms of redemption, liquidation preferences, and the number of shares constituting any class or series of preferred stock, without further vote or action by the stockholders.

NOTE 10. STOCK-BASED COMPENSATION

Equity Incentive Plans

The Company’s 2009 Equity Incentive Plan, as amended and restated (the “2009 Plan”), provides for the Company to sell or issue common stock or restricted common stock, or to grant incentive stock options or nonqualified stock options for the purchase of common stock, to employees, members of the Board of Directors, and consultants of the Company. At September 30, 2019, the total shares authorized under the 2009 Plan were 1,634,655 shares. The Board of Directors or a designated Committee of the Board is responsible for the administration of the 2009 Plan and determines the term, exercise price, and vesting terms of each option. Options granted under the 2009 Plan have an exercise price equal to the market value of the common stock at the date of grant and expire ten years from the date of grant. At September 30, 2019, a total of 17,232 shares were available for grant under the 2009 Plan.

In connection with the Merger, the Company adopted Vical’s Equity Incentive Plan (the “Vical Plan”). At September 30, 2019, the total shares authorized under the Vical Plan were 413,710 shares The Vical Plan, as amended, provides for the Company to sell or issue common stock or restricted common stock, or to grant incentive stock options or nonqualified stock options for the purchase of common stock, to employees, members of the Board of Directors, and consultants of the Company. The plan provides for the grant of incentive and nonstatutory stock options and the direct award or sale of shares, including restricted stock. The exercise price of stock options must equal at least the fair market value of the underlying common stock on the date of grant. The maximum term of options granted under the plan is ten years. The Vical Plan also limits the number of options that may be granted to any plan participant in a single calendar year to 1,300,000 shares. At September 30, 2019, a total of 119,070 shares were available for grant under the Vical Plan.


23



Share-based Compensation Expense

Total stock-based compensation expense related to stock options granted under the 2009 Plan was allocated as follows (in thousands):
 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
 
2019
 
2018
 
2019
 
2018
Research and development
$
81

 
$
76

 
$
237

 
$
263

General and administrative
243

 
75

 
770

 
253

Total stock-based compensation expense
$
324

 
$
151

 
$
1,007

 
$
516



NOTE 11. SUBSEQUENT EVENTS

On October 23, 2019, Bodor Laboratories, Inc. (“Bodor”) notified the Company of its termination of the license agreement entered into between Bodor and the Company, dated December 15, 2012, as amended by Amendment No. 1 to License Agreement, effective as of October 21, 2013, and Amendment No. 2 to License Agreement, effective as of March 31, 2015 (the “License Agreement”). Bodor alleges that the Company materially breached the License Agreement resulting in its termination.

On October 23, 2019, Bodor and Nicholas S. Bodor (the “Plaintiffs”), filed a complaint (the “Bodor Complaint”) against the Company in the United States District Court for the Southern District of Florida. The complaint alleges damages incurred by the Plaintiffs in connection with the Company’s alleged breach of the License Agreement. The complaint seeks: (i) a declaratory judgment that the termination of the License Agreement by the Plaintiffs was valid and enforceable; (ii) an injunction requiring the Company to cease and desist use of the Plaintiffs’ intellectual property; and (iii) damages for breach of contract and breach of the covenant of good faith and fair dealing.

On October 25, 2019, NovaQuest provided written notice to the Company of its determination that a “Material Adverse Event” (as defined in Section 1.1 of the Funding Agreement) occurred as a result of the matters described above. As a result, NovaQuest exercised its right under Section 3.3(e) of the Funding Agreement to suspend further Development Payments (as defined in Section 3.1(a) of the Funding Agreement). Pursuant to the Funding Agreement, NovaQuest is obligated to resume Development Payments if the Material Adverse Event is resolved or cured by the Company to NovaQuest’s reasonable satisfaction by October 25, 2020. If the Material Adverse Event is not resolved or cured to NovaQuest’s reasonable satisfaction by such date, then NovaQuest may, in its sole discretion, terminate any future payment obligation under the Funding Agreement and Brickell may be obligated to make certain payments to NovaQuest.

On October 30, 2019, the Company initiated an arbitration proceeding pursuant to Article 9 of the License Agreement with the American Arbitration Association (“AAA”) in Florida against Bodor and Nicholas S. Bodor. This arbitration seeks a declaratory judgment that the purported termination of the License Agreement by Bodor and Nicholas S. Bodor was invalid and unenforceable and asserts (i) a claim for breach of the License Agreement against Bodor and Nicholas S. Bodor, in his individual capacity, and (ii) a claim against Bodor and Nicholas S. Bodor, in his individual capacity, for tortious interference with the Company’s business relations. The Company requested expedited treatment of the arbitration proceeding and concurrent mandatory mediation under the AAA rules. On October 30, 2019, the Company concurrently filed with the United States District Court for the Southern District of Florida a motion to dismiss the complaint brought against the Company by Bodor and Nicholas S. Bodor described above.

As a result of the matters described above, the timeline for the Company’s Phase 3 clinical trials in patients with primary axillary hyperhidrosis in the United States may be negatively impacted. Any potential impact to the financial statements with respect to loss contingencies for asserted legal and other claims is not estimable by the Company at this time.


24



FORWARD-LOOKING STATEMENTS
 
This quarterly report on Form 10-Q, or this Quarterly Report, contains forward-looking statements that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements contained in this Quarterly Report other than statements of historical fact, including statements regarding our strategy, future operations, future financial position, liquidity, future revenue, projected expenses, results of operations, expectations concerning the timing and our ability to report data from ongoing and planned non-clinical studies and clinical trials, prospects, plans and objectives of management are forward-looking statements. The words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “plan,” “expect,” “predict,” “potential,” “opportunity,” “goals,” or “should,” and similar expressions are intended to identify forward-looking statements. Such statements are based on management’s current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors. Unless otherwise mentioned or unless the context requires otherwise, all references in this Quarterly Report, to “Brickell,” “Brickell Subsidiary,” “company,” “we,” “us,” and “our,” or similar references, refer to Brickell Biotech, Inc., and our consolidated subsidiaries.
 
We based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, business strategy, short-term and long-term business operations and objectives, and financial needs. These forward-looking statements are subject to a number of risks, uncertainties, and assumptions, including those described in Part II, Item 1A, “Risk Factors” in this Quarterly Report, and under a similar heading in any other periodic or current report we may file with the Securities and Exchange Commission, or the SEC, in the future. Moreover, we operate in a very competitive and rapidly changing environment. New risks emerge quickly and from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the future events and trends discussed in this Quarterly Report, may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. We undertake no obligation to revise or publicly release the results of any revision to these forward-looking statements, except as required by law. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement.
 
You should also read carefully the factors described in the “Risk Factors” section of this Quarterly Report to better understand the risks and uncertainties inherent in our business and underlying any forward-looking statements. You are advised to consult any further disclosures we make on related subjects in our audited financial statements of for the year ended December 31, 2018, included in the Form 8-K filed with the SEC on September 3, 2019, Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and our website.



25



ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Overview

We are a clinical-stage pharmaceutical company focused on the development of innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases. Our pipeline consists of potential novel therapeutics for hyperhidrosis, cutaneous T-cell lymphoma, psoriasis, and other prevalent dermatological conditions. We believe that our portfolio of product candidates targets significant market opportunities where innovative therapies are needed. Our executive management team and board of directors bring extensive experience in product development and global commercialization, having served in leadership roles at large global pharmaceutical companies and biotechs that have developed and/or launched successful products, including several that were first-in-class and/or achieved iconic status, such as Cialis®, Taltz®, Gemzar®, Prozac®, Cymbalta® and Juvederm®. Our strategy is to leverage this experience to in-license, acquire, develop, and commercialize innovative products that we believe can be successful in the currently underserved dermatology global marketplace.

Our pivotal Phase 3-ready clinical-stage product candidate, sofpironium bromide, is a proprietary new molecular entity. It belongs to a class of medications called anticholinergics. Anticholinergics block the action of acetylcholine, a chemical that transmits signals within the nervous system that are responsible for a range of bodily functions, including activation of the sweat glands. Sofpironium bromide was retrometabolically designed. Retrometabolic drugs are designed to exert their action topically and are potentially rapidly metabolized once absorbed into the blood. This proposed mechanism of action may allow for highly effective doses to be used while limiting systemic side effects. We are developing sofpironium bromide as a potential best-in-class, self-administered, once-daily, topical therapy for the treatment of primary axillary hyperhidrosis. Hyperhidrosis is a life-altering condition of sweating beyond what is physiologically required to maintain normal thermal regulation. It is believed to be caused by an overactive cholinergic response of the sweat glands and affects an estimated 15.3 million, or 4.8%, of the U.S. population. According to a 2016 update on the prevalence and severity of hyperhidrosis in the United States by Doolittle et al., axillary (underarm) hyperhidrosis, which is the targeted first potential indication for sofpironium bromide, is the most common occurrence of hyperhidrosis, affecting approximately 65% of patients in the United States or an estimated 10 million individuals.

We and our development partner in Asia, Kaken, have conducted 19 clinical trials of sofpironium bromide gel that encompass over 1,200 subjects in the U.S. and Japan. These trials evaluated the potential safety, tolerability, pharmacokinetics, and efficacy of sofpironium bromide gel in adult and pediatric primary axillary hyperhidrosis patients and healthy adult subjects. In March 2019, Kaken completed a Phase 3 trial in patients with primary axillary hyperhidrosis in Japan, achieving statistical significance on all primary and secondary endpoints. Based on the positive results of these clinical trials, we intend to initiate two pivotal Phase 3 clinical trials in up to 450 subjects per trial with primary axillary hyperhidrosis in the United States, subject to resolution of matters currently in dispute with Bodor Laboratories, Inc. and Nicholas S. Bodor, or collectively, Bodor, and assuming the results of the Phase 3 clinical trials are favorable, we plan to submit a New Drug Application, or an NDA, to the U.S. Food and Drug Administration, or the FDA, for the treatment of primary axillary hyperhidrosis.

Our second product candidate, BBI-3000, is a selective, potentially highly tolerable and potent novel RXR agonist being developed for the oral treatment of CTCL. Retinoids are derivatives of vitamin A that play a pivotal role in a diverse group of biologic processes including, but not limited to, cellular proliferation, differentiation, apoptosis, and development. The biological activity and tolerability of retinoids depends in part on the binding availability to retinoic acid and RXR receptors. There are several topical and oral retinoids currently on the market that have shown efficacy in the treatment of several skin conditions, such as CTCL (e.g., bexarotene/Targretin®), acne and psoriasis (e.g., tazarotene, adapalene and tretinoin). BBI-3000 currently is being tested by the National Cancer Institute, or NCI, in two Phase 1 clinical studies as a chronic, orally-administered chemoprevention agent for breast cancer. The product candidate has been well tolerated in the NCI clinical investigations conducted to date, providing an encouraging signal of the potential overall favorable systemic safety profile of BBI-3000 for CTCL.

Our third product candidate, BBI-6000, is a novel RORg inhibitor that we are developing for the topical treatment of mild-to-moderate psoriasis. RORg inhibition targets the pathway of IL-17 that has been implicated in the pathogenesis of psoriasis. Monoclonal antibodies targeting IL‑17 recently have shown significant efficacy in the treatment of psoriasis, and we are planning to develop BBI‑6000 as a topically applied, potent and selective small-molecule therapeutic targeting this pathway. BBI-6000 is currently in the preclinical stages of development.


26



Recent Developments

On October 23, 2019, Bodor notified us of its purported termination of the license agreement entered into between Bodor and us, dated December 15, 2012, as amended by Amendment No. 1 to License Agreement, effective as of October 21, 2013, and Amendment No. 2 to License Agreement, effective as of March 31, 2015, or the License Agreement. Bodor alleges that we materially breached the License Agreement resulting in its termination. On October 23, 2019, Bodor and Nicholas S. Bodor, or the Plaintiffs, filed a complaint, or the Bodor Complaint, against us in the United States District Court for the Southern District of Florida. The Bodor Complaint alleges damages incurred by the Plaintiffs in connection with our alleged breach of the License Agreement. The Bodor Complaint seeks: (i) a declaratory judgment that the termination of the License Agreement by the Plaintiffs was valid and enforceable; (ii) an injunction requiring us to cease and desist use of the Plaintiffs’ intellectual property; and (iii) damages for breach of contract and breach of the covenant of good faith and fair dealing. We vigorously deny and dispute these allegations. In response, Brickell moved to dismiss the Bodor Complaint in the federal court and filed an arbitration demand as the License Agreement requires against Bodor, seeking a declaratory judgment that the license is not terminated, and that it is in fact Bodor who materially breached the License Agreement, and filing a claim against Bodor for tortious interference with our business relations. The timeline for our Phase 3 clinical trials in patients with primary axillary hyperhidrosis in the United States may be negatively impacted. Any potential impact to the financial statements with respect to loss contingencies for asserted legal and other claims is not estimable by us at this time.

Merger Agreement

On August 31, 2019, the company then known as Vical Incorporated, or Vical, and Brickell Biotech, Inc., a then privately-held Delaware corporation that began activities in September 2009, or Private Brickell, completed a recapitalization in accordance with the terms of the Agreement and Plan of Merger and Reorganization, dated June 2, 2019, as further amended on August 20, 2019 and August 30, 2019, or the Merger Agreement, by and among Vical, Vical Subsidiary, Inc., a wholly owned subsidiary of Vical, or Merger Sub, and Private Brickell. Pursuant to the Merger Agreement, Merger Sub merged with and into Private Brickell, with Private Brickell surviving as a wholly-owned subsidiary of Vical, or the Merger. Additionally, on August 31, 2019, immediately after the completion of the Merger, the Company changed its name from “Vical Incorporated” to “Brickell Biotech, Inc.”, or the Company, and Private Brickell changed its name from “Brickell Biotech, Inc.” to “Brickell Subsidiary, Inc.”

On August 31, 2019, in connection with, and prior to the consummation of the Merger, Vical effected a reverse stock split of its common stock, par value $0.01 per share at a ratio of 1-for-7, or the Reverse Stock Split. Unless otherwise noted herein, references to share and per-share amounts give retroactive effect to the Reverse Stock Split. On August 31, 2019, all shares of preferred stock of Private Brickell converted into shares of common stock of Private Brickell on a one-for-one basis.

At the effective date of the Merger, the Company issued shares of its common stock to Private Brickell stockholders, at an exchange rate of approximately 2.4165 shares of common stock in exchange for each share of Private Brickell common stock outstanding immediately prior to the Merger, or the Exchange Ratio. The exchange rate was calculated by a formula that was determined through arms-length negotiations between the Vical and Private Brickell. Unless otherwise noted herein, references to share and per-share amounts give retroactive effect to the Reverse Stock Split and the Exchange Ratio, which was effected upon the Merger.

Immediately following the consummation of the Merger, there were 7,810,680 shares of common stock issued and outstanding, with Brickell’s former securityholders beneficially owning approximately 57% of the outstanding shares of common stock and Vical’s former securityholders beneficially owning approximately 43% of the outstanding shares of common stock. The Company’s common stock is listed on The Nasdaq Capital Market, on a post-split basis (giving effect to the Reverse Stock Split) under the new name on September 3, 2019. The trading symbol also changed on that date from “VICL” to “BBI.” The common stock is represented by CUSIP number 10802T 105.

Funding Agreement

On August 31, 2019, concurrent with the Merger Agreement, we entered into a research and development arrangement with NovaQuest, or the Funding Agreement, pursuant to which NovaQuest committed to us up to $25.0 million in research and development funding to partially fund our Phase 3 clinical trials for sofpironium bromide in the United States, with $5.6 million of the commitment paid in September 2019. We are obligated to use commercially reasonable efforts to complete the clinical trials and file to obtain regulatory approval with the FDA. The funding will cover 67% of the product development costs up to $25.0 million, however, as of October 2019, additional funding has been suspended temporarily as described below.


27



If the research and development is successful and the product candidate is ultimately approved by the FDA, NovaQuest will be entitled to a payment in the amount of $37.5 million, with $20.0 million due upon approval and the remainder due within two years of approval. Additionally, NovaQuest will be entitled to royalty payments based on annual net sales (except for Japan and certain other Asian countries) of the product candidate based on a sliding scale starting from the date that is two years after the first commercial sale. If the funding arrangement is terminated in certain circumstances, we will be required to pay NovaQuest $25.0 million plus interest. However, in the event that we terminate our development program for sofpironium bromide for other specified reasons, including serious safety issues, a failure of the product’s Phase 3 studies, or the FDA’s unwillingness to approve the product, we will not be obligated to make any payments to NovaQuest.

Under the Funding Agreement, we make various representations and warranties and commit to comply with various covenants. NovaQuest may terminate the Funding Agreement and terminate its obligation to make payments in the event of our material uncured breach of a representation or covenant under the Funding Agreement. We also entered into a security agreement with NovaQuest, or the Security Agreement, immediately following consummation of the Merger. Under the Security Agreement, NovaQuest will be able to exercise certain rights in the event of an uncured default by us of the Funding Agreement. NovaQuest’s rights following an uncured event of default include, among other things, foreclosing on our assets in the United States relating to sofpironium bromide and, in certain circumstances, accelerating payment obligations under the Funding Agreement. NovaQuest also has the right to suspend its funding obligations owed to them by us under the Funding Agreement in the event of certain adverse developments relating to sofpironium bromide and in the event that certain of our senior executives leave the Company and we do not find replacements acceptable to NovaQuest.

On October 25, 2019, NovaQuest provided written notice to us of its determination that a “Material Adverse Event” (as defined in Section 1.1 of the Funding Agreement) occurred as a result of the matters under dispute with Bodor. As a result, NovaQuest exercised its right under Section 3.3(e) of the Funding Agreement to suspend further Development Payments (as defined in Section 3.1(a) of the Funding Agreement). Pursuant to the Funding Agreement, NovaQuest is obligated to resume Development Payments if the Material Adverse Event is resolved or cured by us to NovaQuest’s reasonable satisfaction by October 25, 2020. If the Material Adverse Event is not resolved or cured to NovaQuest’s reasonable satisfaction by such date, then NovaQuest may, in its sole discretion, terminate any future payment obligation under the Funding Agreement and Brickell may be obligated to make certain payments to NovaQuest.

Financial Overview

Our operations to date have been limited to business planning, raising capital, developing our pipeline assets (in particular sofpironium bromide), identifying product candidates, and other research and development. To date, we have financed operations primarily through private placements of convertible preferred stock, debt, funds received from license and collaboration agreements, the funds received in connection with the Merger, and funds received in connection with the NovaQuest Funding Agreement. We do not have any products approved for sale and have not generated any product sales. Since inception and through September 30, 2019, we have raised an aggregate of $130.8 million to fund our operations, of which $39.1 million was through license and collaboration agreements, $37.0 million was from cash and investments acquired in the Merger, $33.6 million was from the sale of convertible preferred stock, $7.5 million was from the sale of debt, and $7.4 million was from the sale of convertible notes, and $5.6 million was from research and development arrangements. As of September 30, 2019, we had cash and cash equivalents totaling $7.2 million and marketable securities of $18.5 million.

Since inception, we have incurred operating losses. We recorded a net loss of $13.0 million and $5.6 million for the nine months ended September 30, 2019 and 2018, respectively. As of September 30, 2019, we had an accumulated deficit of $74.1 million. We expect to continue incurring significant expenses and operating losses for at least the next several years as we:

pursue mediation, arbitration, and/or litigation in connection with the License Agreement;
initiate and complete our two pivotal Phase 3 clinical trials for sofpironium bromide;
contract to manufacture product candidates;
advance research and development-related activities to develop and expand our product pipeline;
maintain, expand, and protect our intellectual property portfolio;
hire additional staff, including clinical, scientific, and management personnel; and
add operational and finance personnel to support product development efforts and to support operating as a public company.


28



We do not expect to generate significant revenue unless and until we successfully complete development of, obtain marketing approval for, and commercialize product candidates, either alone or in collaboration with third parties. We expect these activities may take several years and our success in these efforts is subject to significant uncertainty, especially in light of the recently commenced litigation with Bodor. Accordingly, we expect we will need to raise additional capital prior to the regulatory approval and commercialization of any of our product candidates. Until such time, if ever, that we generate substantial product revenues, we expect to finance our operations through public or private equity or debt financings, collaborations or licenses, or other available financing transactions. However, we may be unable to raise additional funds through these or other means when needed.

Key Components of Operations

Collaboration Revenue

Collaboration revenues generally consist of revenues recognized under our strategic collaboration agreements for the development and commercialization of our product candidates. Our strategic collaboration agreements generally outline overall development plans and include payments we receive at signing, payments for the achievement of certain milestones, and royalties. For these activities and payments, we utilize judgment to assess the nature of the performance obligations to determine whether the performance obligations are satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. We have not recognized any royalty revenue to date. Other than the revenue we may generate in connection with these agreements, we do not expect to generate any revenue from any product candidates that we develop unless and until we obtain regulatory approval and commercialize our products or enter into other collaborative agreements with third parties.

Research and Development

Research and development expenses principally consist of payments to third parties known as Clinical Research Organizations, or CROs. These CROs help plan, organize, and conduct clinical and nonclinical studies under our direction. Personnel costs, including wages, benefits, and share-based compensation, related to our research and development staff in support of product development activities are also included, as well as costs incurred for supplies, preclinical studies and toxicology tests, consultants, and facility and related overhead costs.

Below is a summary of our research and development expenses related to sofpironium bromide by categories of costs for the periods presented. The other expenses category includes travel, lab and office supplies, clinical trial management software, license fees, and other miscellaneous expenses.
 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
 
2019
 
2018
 
2019
 
2018
 
 
 
 
 
 
 
 
 
(in thousands)
Direct program expenses related to sofpironium bromide
$
2,452

 
$
3,496

 
$
10,871

 
$
5,359

Personnel and other expenses
 
 
 
 
 
 
 
Salaries, benefits, and stock-based compensation
863

 
691

 
2,518

 
2,485

Regulatory and compliance
18

 
116

 
158

 
603

Other expenses
4

 
(168
)
 
38

 
124

Total research and development expenses
$
3,337

 
$
4,135

 
$
13,585

 
$
8,571


We intend to conserve our resources. The advancement of the clinical trials may be negatively impacted by recent developments discussed above. Once NovaQuest has resumed additional funding, we intend to increase our investments in research and development in order to advance our clinical trials.

General and Administrative

General and administrative expenses consist primarily of personnel costs, including wages, benefits, and share-based compensation, related to our executive, sales, marketing, finance, and human resources personnel, as well as professional fees, including legal and accounting fees, and sublicensing fees.


29



We expect our general and administrative expenses to increase in the near term, both in absolute dollars and as a percentage of revenue largely driven by legal expenses related to the Bodor Complaint. We also expect significant additional expenses associated with operating as a public company. Such increases may include increased insurance premiums, investor relations expenses, legal and accounting fees associated with the expansion of our business and corporate governance, financial reporting expenses, and expenses related to Sarbanes-Oxley and other regulatory compliance obligations.

Total Other Income (Expense)

Investment and Other Income, Net

Investment and other income, net consists primarily of interest earned on cash and cash equivalent and marketable securities balances. Our interest income will vary each reporting period depending on our average cash balances during the period and market interest rates. We expect interest income to fluctuate in the future with changes in average cash balances and market interest rates.

Gain on Extinguishment

Gain on extinguishment consists of the gain realized on the conversion of the convertible promissory notes to common stock in August 2019.

Interest Expense

Interest expense consists primarily of interest and amortization related to the issuance of $7.4 million of convertible promissory note principal in 2019 and principal borrowings of $7.5 million provided by the loan and security agreement entered into with Hercules Capital, Inc. on February 18, 2016, or the Loan Agreement.

Change in Fair Value of Warrant Liability

In connection with the Loan Agreement, we issued warrants to Hercules Capital, Inc., which are exercisable for 9,005 shares of common stock at a per share exercise price of $33.31. In connection with the convertible promissory notes, we issued warrants which are exercisable for 490,683 shares of common stock at a per share exercise price of $10.36.

We accounted for the warrants as liabilities at their estimated fair value. The warrants were subject to remeasurement to fair value at each balance sheet date, and any fair value adjustments were recognized as changes in fair value of warrant liability in the condensed consolidated statements of operations. The liability was adjusted for changes in fair value through August 31, 2019, and at that time the final warrant liability fair value was reclassified to equity in the condensed consolidated balance sheets.

Critical Accounting Policies and Estimates

We have prepared the condensed consolidated financial statements in accordance with accounting principles generally accepted in the United States of America, or US GAAP. The preparation of these condensed consolidated financial statements requires us to make estimates, assumptions, and judgments that affect the reported amounts of assets, liabilities, expenses, and related disclosures at the date of the condensed consolidated financial statements. On an ongoing basis, management evaluates its critical estimates, including those related to revenue recognition, accrued research and development expenses, convertible promissory notes, redeemable convertible preferred stock, warrants, and stock-based compensation. We base our estimates on our historical experience and on assumptions that we believe are reasonable; however, actual results differ materially from these estimates under different assumptions or conditions.

For information on our significant accounting policies, please refer Note 2 to our condensed consolidated financial statements.
 
Revenue Recognition

We currently recognize revenue generated primarily from licensing fees received under a license and collaboration agreement entered into in March 2015 with Kaken, which is referred to as the “Collaboration Agreement.” The terms of the agreements include non-refundable upfront fees, funding of research and development activities, payments based upon achievement of milestones, and royalties on net product sales.


30



Under Accounting Standards Update, or ASU, No. 2014-09, Revenue from Contracts with Customers, or Topic 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of Topic 606, the entity performs the following five steps: (i) identify the promised goods or services in the contract with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price, including the constraint on variable consideration; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when or as the entity satisfies a performance obligation.

At contract inception, we assess the goods or services promised within each contract, determine those that are performance obligations, and assess whether each promised good or service is distinct. We then recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when or as the performance obligation is satisfied. We utilize judgment to assess the nature of the performance obligation to determine whether the performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition.

Licenses of Intellectual Property

If a license to our intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, we recognize revenue from non-refundable, up-front fees allocated to the license when the license is transferred to the customer, and the customer can use and benefit from the license.

Milestone payments

At the inception of each arrangement that includes milestone payments, we evaluate whether the milestones are considered probable of being achieved and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the value of the associated milestone (such as a regulatory submission) is included in the transaction price, which is then allocated to each performance obligation. Milestone payments that are not within our control or the control of our partner, such as approvals from regulators, are not considered probable of being achieved until those approvals are received. At the end of each subsequent reporting period, we re-evaluate the probability of achievement of such development milestones and, if necessary, adjust our estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration, and other revenues and earnings in the period of adjustment and in future periods through the end of the performance obligation period.
 
Royalties

For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and where the license is deemed to be the predominant item to which the royalties relate, we recognize revenue at the later of (a) when the related sales occur, or (b) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, we have not recognized any royalty revenue resulting from any of our licensing arrangements.
 
For a complete discussion of accounting for collaborative licensing agreements, see Note 2, to our condensed consolidated financial statements. Our revenue to date has been generated primarily from collaboration and licensing fees received under our Collaboration Agreement with Kaken.

Research and Development

Research and development costs are charged to expense when incurred and consist of costs incurred for independent and collaborative research and development activities. The major components of research and development costs include formulation development, clinical studies, clinical manufacturing costs, salaries and employee benefits, toxicology studies, allocations of various overhead, and occupancy costs. Research costs typically consist of applied research, preclinical, and toxicology work. Pharmaceutical manufacturing development costs consist of product formulation, chemical analysis, and the transfer and scale up of manufacturing at contract manufacturers.


31



As part of the process of recording research and development costs, we are required to estimate and accrue expenses. This process involves the following:
communicating with appropriate internal personnel to identify services that have been performed on our behalf and estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of actual cost;
estimating and accruing expenses in our financial statements as of each balance sheet date based on facts and circumstances known to us at the time; and
periodically confirming the accuracy of our estimates with service providers and making adjustments, if necessary.

Examples of estimated research and development expenses that we accrue include:
payments to CROs in connection with preclinical and toxicology studies and clinical trials;
payments to investigative sites in connection with clinical trials;
payments to CMOs in connection with the production of clinical trial materials; and
professional service fees for consulting and related services.

We base our expense accruals related to clinical trials on our estimates of the services received and efforts expended pursuant to contracts with multiple research institutions and CROs that conduct and manage clinical trials on our behalf. The financial terms of these agreements vary from contract to contract and may result in uneven payment flows. Payments under some of these contracts depend on factors such as the successful enrollment of patients and the completion of clinical trial milestones. In accruing costs, we estimate the period over which services will be performed and the level of effort to be expended in each period. If we do not identify costs that we have begun to incur or if we underestimate or overestimate the level of services performed or the costs of these services, our actual expenses could differ from estimates.

To date, we have not experienced significant changes in our estimates of accrued research and development expenses after a reporting period. However, due to the nature of estimates, we cannot assure that we will not make changes to our estimates in the future as we become aware of additional information about the status or conduct of our clinical trials and other research activities.

Stock-Based Compensation

Stock options granted to employees and non-employees under our stock option plan are accounted for by using a fair value-based method. Stock-based payments to employees and non-employees are measured based on their fair values at the date of grant, net of forfeitures, and are recorded on a straight-line basis over the requisite employee service period. We use the Black-Scholes option-pricing model to estimate the fair value of stock options at the grant date. For performance-based awards where the vesting of the options may be accelerated upon the achievement of certain milestones, vesting and the related stock-based compensation is recognized as an expense when it is probable the milestone will be met.

When awards are modified, we compare the fair value of the affected award measured immediately prior to modification to its value after modification. To the extent that the fair value of the modified award exceeds the original award, the incremental fair value of the modified award is recognized as compensation on the date of modification for vested awards, and over the remaining vesting period for unvested awards.

One of the inputs in the Black-Scholes option-pricing model is the estimated fair value of common stock. After the date of the Merger, the estimated value of common stock is based on closing price of the common stock on The Nasdaq Capital Market at the date of grant. Prior to the Merger there had been no public market for the our common stock, and the fair value was determined with the assistance of a third-party valuation firm at each balance sheet date by considering a number of objective and subjective factors, including valuation of comparable companies, sales of capital stock to unrelated third parties, operating and financial performance, the lack of liquidity of capital stock, and general and industry specific economic outlook, among other factors. The valuations were prepared in accordance with methodologies outlined in the American Institute of Certified Public Accountants Practice Aid, Valuation of Privately-Held-Company Equity Securities Issued as Compensation.

There are significant judgments and estimates inherent in the determination of these valuations. These judgments and estimates include assumptions regarding our future performance, including the successful completion of future clinical trials and the time to liquidity, as well as the determination of the appropriate valuation methods at each valuation date. If different assumptions

32



were used, our valuation could have been different. The foregoing valuation methodologies are not the only methodologies available, and they are not be used to value the common stock after the date of the Merger. Accordingly, stockholders and investors should not place undue reliance on the foregoing valuation methodologies as an indicator of the Company’s future stock price.

Redeemable Convertible Preferred Stock

Redeemable convertible preferred stock was classified as a mezzanine instrument outside of our capital accounts prior to the Merger. Accretion of redeemable convertible preferred stock included the accrual of dividends on and accretion of issuance costs of our redeemable convertible preferred stock. The carrying values of the redeemable convertible preferred stock were increased or reduced by periodic accretion or reduction to their respective redemption values from the date of issuance to August 31, 2019, the date that all outstanding shares of redeemable convertible preferred stock converted into shares of common stock. At the date of conversion, the carrying value was reclassified to stockholders’ equity.

Convertible Promissory Notes

From time to time, in the past as a private company, we entered into debt financing transactions whereby such convertible debt contains conversion features into preferred or common shares. We account for such instruments under ASC, 470-20 “Debt with Conversion and Other Options” which requires companies to bifurcate conversion options from their host instruments and account for them as free standing derivative financial instruments according to certain criteria. We account for instruments issued with convertible debt that have been determined to be free standing derivative financial instruments or embedded derivatives in accordance with ASC 815 “Derivatives and Hedging”. Under ASC 815, a portion of the proceeds received upon the issuance of the convertible debt is allocated to the fair value of the derivative and a corresponding discount is recorded on the convertible debt. The derivative is subsequently marked to market at each reporting date based on current fair value, with the changes in fair value reported in the statements of operations.
 
During the nine months ended September 30, 2019, we issued an aggregate principal amount of $7.4 million of convertible debt to investors containing a redemption feature, which was deemed an embedded derivative and required us to bifurcate and separately account for the embedded derivative as a liability. The warrants also required fair value accounting and were accounted as a liability. The discount on the debt was amortized through interest expense based on the effective interest method. On August 31, 2019, the convertible promissory notes and related accrued interest converted into 1,069,740 shares of common stock, which resulted in a gain on extinguishment of $2.3 million.

Recent Accounting Pronouncements

For information on the recent accounting pronouncements which may impact our business, see Note 3 of the notes to the condensed consolidated financial statements included in this Quarterly Report.

Results of Operations

Comparison of the Three Months Ended September 30, 2019 and 2018
 
Three Months Ended
September 30,
 
2019
 
2018
 
(in thousands)
Collaboration revenue
$
1,183

 
$
3,042

Research and development expenses
(3,337
)
 
(4,135
)
General and administrative expenses
(3,901
)
 
(1,206
)
Total other income (expense), net
1,274

 
(242
)
Net loss
$
(4,781
)
 
$
(2,541
)


33



Collaboration Revenue

Collaboration revenue decreased by $1.9 million, or 61%, for the three months ended September 30, 2019 from the three months ended September 30, 2018. The decrease is due primarily to the completion of certain research and development activities during the three months ended September 30, 2019 related to the Collaboration Agreement for which Kaken provided funding.

Research and Development

Research and development expense decreased by $0.8 million, or 19%, for the three months ended September 30, 2019 from the three months ended September 30, 2018, primarily due to a decrease in clinical studies costs associated with sofpironium bromide, as we prepared to and began initiation of activities to start the Phase 3 clinical trials of sofpironium bromide.

General and Administrative Expenses

General and administrative expenses increased by $2.7 million, or 223%, for the three months ended September 30, 2019 from the three months ended September 30, 2018, primarily due to an increase of $1.8 million in professional fees for legal, accounting, and auditing services, including Merger-related costs, an increase of $0.5 million in payroll expenses due to increased headcount, and an increase of $0.2 million for insurance and travel costs.

Total Other Income (Expense), Net

Total other income, net increased to $1.3 million for the three months ended September 30, 2019, compared to total other expense, net of $0.2 million, for the three months ended September 30, 2018, primarily due to a gain of $2.3 million related to conversion of the convertible promissory notes in August 2019 and a decrease of $0.8 million in interest expense related to issuance of convertible promissory notes in 2019 and principal borrowings provided by the Loan Agreement.

Comparison of the Nine Months Ended September 30, 2019 and 2018
 
Nine Months Ended
September 30,
 
2019
 
2018
 
(in thousands)
Collaboration revenue
$
7,248

 
$
8,415

Research and development expenses
(13,585
)
 
(8,571
)
General and administrative expenses
(7,290
)
 
(4,694
)
Total other income (expense), net
612

 
(716
)
Net loss
$
(13,015
)
 
$
(5,566
)

Collaboration Revenue

Collaboration revenue decreased by $1.2 million, or 14%, for the nine months ended September 30, 2019 from the nine months ended September 30, 2018. The revenue recognized for the nine months ended September 30, 2019 was due to research and development activities related to the Collaboration Agreement for which Kaken provided funding. The revenue recognized for the nine months ended September 30, 2018 was primarily the result of a milestone payment in March 2018 from Kaken in the amount of $5.0 million for the achievement of a certain regulatory milestone and the remainder was due to research and development activities related to the Collaboration Agreement for which Kaken provided funding.

Research and Development

Research and development expenses increased by $5.0 million, or 58%, for the nine months ended September 30, 2019 from the nine months ended September 30, 2018, primarily due to an increase of $5.5 million in clinical studies costs associated with sofpironium bromide, an increase of $0.4 million in supply costs, a decrease of $0.4 million in regulatory and compliance costs, and a $0.1 million decrease in other costs.


34



General and Administrative Expenses

General and administrative expenses increased by $2.6 million, or 55%, for nine months ended September 30, 2019 from the nine months ended September 30, 2018, primarily due to increases of $2.3 million in fees for legal, accounting, and auditing services, including Merger-related costs, and $0.9 million in payroll expenses due to increased headcount, partially offset by a decrease of $1.0 million in sub-licensing fees.

Total Other Income (Expense), Net

Total other income, net increased by $1.3 million, or 185%, for the nine months ended September 30, 2019 from the nine months ended September 30, 2018, due to a gain of $2.3 million related to the conversion of the convertible promissory notes in August 2019, which was partially offset by a $1.2 million in interest expense related to issuance of convertible promissory notes in 2019 and principal borrowings provided by the Loan Agreement.

Liquidity and Capital Resources

We have incurred significant operating losses and have an accumulated deficit as a result of ongoing efforts to develop our product candidates, including conducting preclinical and clinical trials and providing general and administrative support for these operations. For the nine months ended September 30, 2019 and 2018, we had a net loss of $13.0 million and $5.6 million, respectively. As of September 30, 2019 and December 31, 2018, we had an accumulated deficit of $74.1 million and $71.6 million, respectively. As of September 30, 2019 and December 31, 2018, we had cash, cash equivalents, and marketable securities of $25.7 million and $8.1 million, respectively. Since inception, we have financed operations primarily through sales of equity securities, convertible promissory notes, and warrants, as well as payments received under strategic collaboration and licensing agreements.

On August 31, 2019, concurrent with the Merger Agreement, we entered into a research and development arrangement with NovaQuest pursuant to which NovaQuest committed to us up to $25.0 million in research and development funding to partially fund our Phase 3 clinical trials for sofpironium bromide, with $5.6 million of the commitment paid in September 2019. We are obligated to use commercially reasonable efforts to complete the clinical trials and file to obtain regulatory approval. The funding will cover 67% of the product development costs up to $25.0 million, however, as of October 2019, additional funding was temporarily suspended.

If the research and development is successful and the product candidate is approved ultimately by the FDA, NovaQuest will be entitled to a payment in the amount of $37.5 million, with $20.0 million due upon approval and the remainder due within two years of approval. Additionally, NovaQuest will be entitled to royalty payments based on annual net sales (except for Japan and certain other Asian countries) of the product candidate based on a sliding scale starting from the date that is two years after the first commercial sale. If the funding arrangement is terminated in certain circumstances, we will be required to pay NovaQuest $25.0 million plus interest. However, in the event that we terminate our development program for sofpironium bromide for other specified reasons, including serious safety issues, a failure of the product’s Phase 3 studies, or the FDA’s unwillingness to approve the product, we will not be obligated to make any payments to NovaQuest.

We expect to continue to incur additional substantial losses in the foreseeable future as a result of litigation or arbitration related expenses and our research and development activities. Pending resolution of the contentious matter discussed further in Note 11 and NovaQuest resuming additional funding, we intend to conserve our resources. The advancement of the Phase 3 clinical trials for sofpironium bromide may be negatively impacted by these developments. We may take actions to reduce our cash spend, including further delaying the start of the clinical trials or staff reductions. Taking these measures into account, we believe that our cash, cash equivalents, and marketable securities as of September 30, 2019 would be sufficient to fund our operations for at least the next 12 months from the issuance of this Quarterly Report.


35



Cash Flows

Since inception, we have primarily used our available cash to fund expenditures related to product discovery and development activities. The following table sets forth a summary of cash flows for the periods presented:
 
 
 
 
 
Nine Months Ended
September 30,
 
2019
 
2018
 
(in thousands)
Net cash provided by (used in) operating activities
$
(21,940
)
 
$
7,621

Net cash provided by (used in) investing activities
18,509

 
(8
)
Net cash provided by (used in) financing activities
2,589

 
(482
)
Net increase (decrease) in cash and cash equivalents
$
(842
)
 
$
7,131


Operating Activities

Net cash used in operating activities of $21.9 million during the nine months ended September 30, 2019 increased compared to cash provided by operating activities of $7.6 million during the same period in the prior year primarily due to $20.6 million milestone and research and development funding received from Kaken during the nine months ended September 30, 2018 as well as an increase in net loss of $7.4 million, a gain on extinguishment of the convertible promissory note of $2.3 million, and an increase in other changes in working capital of $0.9 million.

Investing Activities

Net cash provided by investing activities of $18.5 million during the nine months ended September 30, 2019 increased compared to cash used in investing activities of $8 thousand during the same period in the prior year. The $18.5 million increase was primarily the result of the cash acquired in the Merger and maturities of marketable securities in 2019.

Financing Activities

Net cash provided by financing activities of $2.6 million during the nine months ended September 30, 2019 increased compared to net cash used in financing activities of $0.5 million during the prior year. The increase was primarily related to proceeds of $7.4 million from the issuance of convertible promissory notes in 2019, partially offset by payments of $4.8 million in 2019 towards the note payable pursuant to the Loan Agreement.

Contractual Obligations and Commitments

The following is a summary of the contractual obligations related to operating lease commitments as of September 30, 2019 and the effect such obligations are expected to have on the liquidity and cash flows in future periods (in thousands):
Less than 1 year
 
$
83

1-3 years
 
124

3-5 years
 

More than 5 years
 

Total
 
$
207


Under various agreements, including the Funding Agreement and License Agreement, we will be required to make milestone or other payments and pay royalties and other amounts to third parties, including NovaQuest and Bodor. We have not included any contingent payment obligations, such as milestones or royalties, in the table above as the amount, timing, and likelihood of such payments are not known.

We enter into contracts in the normal course of business with CROs for clinical trials, preclinical research studies and testing, chemistry and manufacturing, and other services and products for operating purposes. These contracts generally provide for termination upon notice, and therefore we believe that the non-cancelable obligations under these agreements are not material.

36




Off-Balance Sheet Arrangements

As of September 30, 2019 and December 31, 2018, we had not been involved in any material off-balance sheet arrangements, as defined in the rules and regulations of the SEC.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We are subject to interest rate risk. Our investment portfolio is maintained in accordance with our investment policy which defines allowable investments, specifies credit quality standards, and limits the credit exposure of any single issuer. Our investment portfolio consists of cash equivalents and marketable securities, including government agency securities and money market funds, and are classified as available-for-sale securities. The average maturity of our investments is approximately three months. Because of the short-term nature of our investment portfolio, a hypothetical increase of 1% in interest rates would not be material.

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in the reports that we file under the Securities Exchange Act of 1934, as amended, or the Exchange Act, is recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the SEC, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosures. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

Conclusion Regarding the Effectiveness of Disclosure Controls and Procedures

Under the supervision and with the participation of our management, including our principal executive and financial officer, we conducted an evaluation of the design and operation of our disclosure controls and procedures, as such term is defined in Rule 13a-15(e) and 15d-15(e) promulgated under the Exchange Act as of the end of the period covered by this Quarterly Report. Based on this evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were effective and were operating at a reasonable assurance level as of September 30, 2019.

Changes in Internal Control over Financial Reporting

Management has determined that there were no significant changes in our internal control over financial reporting that occurred during the three months ended September 30, 2019 before or after the Merger that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. No processes or systems of Vical continued subsequent to the Merger.


37



PART II. OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

The Company is subject to certain legal proceedings and claims that could materially impact the company and which have not been fully resolved and that have arisen in the ordinary course of business. The nature of these material legal proceedings is described in Part I, Item 1 of this Form 10-Q in the Notes to Condensed Consolidated Financial Statements in Note 11, “Subsequent Events.” The Company is assessing the impact of these recently asserted legal claims. Any potential impact to the financial statements with respect to loss contingencies for asserted legal and other claims is not estimable by the Company at this time.

The outcome of arbitration or litigation is inherently uncertain. If one or more legal matters were resolved against the Company in a reporting period for amounts in excess of management’s expectations, the Company’s financial condition and operating results for that reporting period could be materially adversely affected. Refer to the risk factor “We are currently involved in litigation with Bodor relating to our right to continue to develop sofpironium bromide and NovaQuest has suspended product development payments to us as a result,” in Part II, Item 1A of this Form 10-Q under the heading “Risk Factors.”

ITEM 1A. RISK FACTORS

Our business, financial condition, and operating results may be affected by a number of factors, whether currently known or unknown, including but not limited to those described below. Any one or more of such factors could directly or indirectly cause our actual results of operations and financial condition to vary materially from past or anticipated future results of operations and financial condition. Any of these factors, in whole or in part, could materially and adversely affect our business, financial condition, results of operations, and stock price. The following information should be read in conjunction with Part I, Item 2, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and the condensed consolidated financial statements and related notes in Part I, Item 1, “Financial Statements” of this Quarterly Report.
Risks Related to the Development, Commercialization and Regulatory Approval of Our Investigational Drug, Sofpironium Bromide
We are currently involved in litigation with Bodor relating to our right to continue to develop sofpironium bromide and NovaQuest has suspended product development payments to us as a result.

On October 23, 2019, Bodor notified us of its termination of the License Agreement. Bodor alleges that we materially breached the License Agreement resulting in its termination. In connection with the termination, on October 23, 2019, the Plaintiffs filed the Bodor Complaint. The complaint alleges damages incurred by the Plaintiffs in connection with our alleged breach of the License Agreement. The complaint seeks: (i) a declaratory judgment that the termination of the License Agreement by the Plaintiffs was valid and enforceable; (ii) an injunction requiring us to cease and desist use of the Plaintiffs’ intellectual property; and (iii) damages for breach of contract and breach of the covenant of good faith and fair dealing.

On October 25, 2019, NovaQuest provided written notice to us of its determination that a “Material Adverse Event” (as defined in Section 1.1 of the Funding Agreement) occurred as a result of the matters described above. As a result, NovaQuest exercised its right under Section 3.3(e) of the Funding Agreement to suspend further Development Payments (as defined in Section 3.1(a) of the Funding Agreement). Pursuant to the Funding Agreement, NovaQuest is obligated only to resume Development Payments if the Material Adverse Event is resolved or cured by us to NovaQuest’s reasonable satisfaction by October 25, 2020. If the Material Adverse Event is not resolved or cured to NovaQuest’s reasonable satisfaction by such date, then NovaQuest may, in its sole discretion, terminate any future payment obligation under the Funding Agreement and we may be obligated to make certain payments to NovaQuest. See “Risks Related to Our Dependence on Third Parties” below for a further discussion of the Funding Agreement and related risks.

On October 30, 2019, we initiated an arbitration proceeding pursuant to Article 9 of the License Agreement with the American Arbitration Association, or AAA, in Florida against Bodor and Nicholas S. Bodor. This arbitration seeks a declaratory judgment that the purported termination of the License Agreement by Bodor and Nicholas S. Bodor was invalid and unenforceable and asserts (i) a claim for breach of the License Agreement against Bodor and Nicholas S. Bodor, in his individual capacity, and (ii) a claim against Bodor and Nicholas S. Bodor, in his individual capacity, for tortious interference with our business relations. We requested expedited treatment of the arbitration proceeding and concurrent mandatory mediation under the AAA rules. On October 30, 2019, we concurrently filed with the United States District Court for the Southern District of Florida a motion to dismiss the complaint brought against us by Bodor and Nicholas S. Bodor described above.

38




As a result of these matters, the timeline for the Company’s Phase 3 clinical trials in subjects with primary axillary hyperhidrosis in the United States may be negatively impacted. In addition, the Company will be required to devote substantial financial resources to address the Bodor Complaint. Mediation, arbitration, and litigation are expensive and may likely be time-consuming and divert management’s attention and the Company’s resources away from other clinical development activities.

The outcome of arbitration or litigation is inherently uncertain. If one or more of the legal claims made by Bodor were resolved against us, we may become subject to additional litigation claims, and our ability to continue to develop sofpironium bromide and our financial condition and operating results could be materially adversely affected.  While we maintain insurance coverage for certain types of claims, such insurance coverage may be insufficient to cover all losses or all types of claims that may arise.

Our business depends on the successful clinical development, regulatory approval, and commercialization of sofpironium bromide.

The success of our business, including our prospective ability to finance our operations and generate revenue, primarily depends on the successful development, regulatory approval, and commercialization of sofpironium bromide, at least in the United States. The clinical and commercial success of sofpironium bromide depends on a number of factors, including but not limited to the following:
timely and successful completion of Phase 3 clinical trials in the United States not yet initiated, which may be significantly slower, particularly in light of the Bodor Complaint, or costlier than we currently anticipate and/or produce results that do not achieve the endpoints of the trials or which are ultimately deemed not to be clinically meaningful;
whether we are required by the FDA or similar foreign regulatory agencies to conduct additional clinical trials beyond those currently planned to support the approval and commercialization of sofpironium bromide;
achieving and maintaining, and, where applicable, ensuring that our third-party contractors achieve and maintain, compliance with our and their contractual obligations and with all regulatory and legal requirements applicable to sofpironium bromide;
ability of third parties with which we contract to manufacture consistently adequate clinical trial and commercial supplies of sofpironium bromide, to remain in good standing with regulatory agencies and to develop, validate and maintain or supervise commercially viable manufacturing processes that are compliant with FDA-regulated Current Good Manufacturing Practices, or cGMPs, and the product’s package insert;
a continued acceptable safety profile during clinical development and following approval of sofpironium bromide;
ability to obtain favorable labeling for sofpironium bromide through regulators that allows for successful commercialization, given the drug may be marketed only to the extent approved by these regulatory authorities (unlike with most other industries);
ability to commercialize sofpironium bromide successfully in the United States and internationally, if approved for marketing, sale and distribution in such countries and territories, whether alone or in collaboration with Kaken or others;
acceptance by physicians, insurers and payors, and patients of the quality, benefits, safety, and efficacy of sofpironium bromide, if approved, including relative to alternative and competing treatments and the next best standard of care;
existence of a regulatory and legal environment conducive to the success of sofpironium bromide;
ability to price sofpironium bromide to recover our development costs and generate a satisfactory profit margin; and
our ability and our partners’ ability to establish and enforce intellectual property rights in and to sofpironium bromide, including but not limited to patents and licenses.
If we do not achieve one or more of these factors, many of which are beyond our reasonable control, in a timely manner or at all, and with adequate financing, we could experience significant delays or an inability to obtain regulatory approvals or commercialize sofpironium bromide. Even if regulatory approvals are obtained, we may never be able to successfully

39



commercialize sofpironium bromide. Accordingly, we cannot assure you that we will be able to generate sufficient revenue through the sale of sofpironium bromide, or any current primary asset, to continue our business.
We have never conducted a Phase 3 clinical trial ourselves and may be unable to successfully do so for sofpironium bromide.
The conduct of a Phase 3 clinical trial is a long, expensive, complicated, uncertain, and highly regulated process. Although our employees have conducted successful Phase 2 and Phase 3 clinical trials in the past across many therapeutic areas while employed at other companies, we as a company have not conducted a Phase 3 pivotal clinical trial, and as a result we may require more time and incur greater costs than we anticipate. We commenced a Phase 3 long-term safety study for sofpironium bromide gel in the third quarter of 2018 and intend to initiate two pivotal Phase 3 clinical trials in subjects with primary axillary hyperhidrosis in the United States, subject to resolution of matters currently in dispute with Bodor. Failure to commence or complete, or delays in, our planned clinical trials would prevent us from, or delay us in, obtaining regulatory approval of and commercializing sofpironium bromide and could prevent us from, or delay us in, receiving development- or regulatory-based milestone payments and commercializing sofpironium bromide gel for the treatment of hyperhidrosis, which would impact adversely our financial performance, as well as put us in potential breach of material contracts for the licensing and development of sofpironium bromide, subjecting us to significant contract liabilities, including but not limited to loss of rights in and to sofpironium bromide.
Clinical drug development for sofpironium bromide is very expensive, time-consuming, and uncertain.
Clinical development for sofpironium bromide is very expensive, time-consuming, difficult to design and implement, and its outcome is inherently uncertain. Most product candidates that commence clinical trials are never approved by regulatory authorities for commercialization and of those that are approved many do not cover their costs of development or ever generate a profit. In addition, we, any partner with which we currently or may in the future collaborate, the FDA, a local or central institutional review board, or IRB, or other regulatory authorities, including state and local agencies and counterpart agencies in foreign countries, may suspend, delay, extend, require modifications or add additional requirements to or terminate our clinical trials at any time.
In the case of sofpironium bromide, we are seeking to deliver sufficient concentrations of the active pharmaceutical ingredient, or API, absorbed from the skin surface through the skin barrier to the targeted dermal tissue to achieve the intended therapeutic effect, in this case treatment of hyperhidrosis. The topical route of administration may involve new dosage forms, which can be difficult to develop and manufacture and may raise novel regulatory issues and result in development or review delays or inability to get the investigational drug approved for use.
Use of patient-reported outcome assessments, PROs, in sofpironium bromide clinical trials may delay the development of sofpironium bromide gel or increase our development costs.
Due to the difficulty of objectively measuring the symptoms of hyperhidrosis in a clinical trial, which is the primary target of treatment for sofpironium bromide, PROs will have an important role in the development and regulatory approval of sofpironium bromide. PROs involve patients’ own subjective assessments of efficacy, and this subjectivity increases the uncertainty of determining and achieving clinical endpoints and obtaining regulatory approval. Such assessments can be influenced by factors outside of our reasonable control and can vary widely from day to day for a particular patient, and from patient to patient and site to site within a clinical trial, notwithstanding that regulators may or may not accept PROs as part of the drug approval process.
Sofpironium bromide may cause undesirable side effects or have other unexpected properties that could delay or prevent its regulatory approval, limit the commercial profile of an approved label, or result in post-approval regulatory action.
Unforeseen side effects from sofpironium bromide could arise either during clinical development or, if approved, after it has been marketed. Undesirable side effects caused by sofpironium bromide could cause us, any partners with which we may collaborate, or regulatory authorities to interrupt, extend, modify, delay, or halt clinical trials and could result in a more restrictive or narrower product label or the delay or denial of regulatory approval by the FDA or comparable foreign authorities.
Results of clinical trials could reveal a high and unacceptable severity and prevalence of side effects. In such an event, trials could be suspended or terminated, and the FDA or comparable foreign regulatory authorities could order us to cease further development of or deny approval of sofpironium bromide for any or all targeted indications. The drug-related side effects could affect patient recruitment or the ability of enrolled patients to complete the trial or result in product liability claims. Any of these occurrences may expose us to liability or harm our business, financial condition, operating results, and prospects.

40



Additionally, if we or others identify undesirable side effects, or other previously unknown problems, caused by sofpironium bromide after obtaining U.S. or foreign regulatory approval, a number of potentially negative consequences could result, which could prevent us or our potential partners from achieving or maintaining market acceptance of sofpironium bromide and could substantially increase the costs of commercializing sofpironium bromide, potentially even leading to recall of the drug.
Kaken substantially controls the development of sofpironium bromide in Japan and certain other Asian countries and may make decisions regarding product development, regulatory strategy and commercialization that may not be in our best interests. Kaken may be unable to obtain positive approval of the drug in Asian markets.
The license agreement we entered into with Kaken granted Kaken an exclusive Japan license and certain rights to additional Asian countries to develop and commercialize sofpironium bromide. Under the terms of the agreement, as amended, we received an up-front payment, development milestones and research and development payments and are eligible to receive future milestones and a royalty on net sales.
Kaken has final decision-making authority for the overall regulatory, development and commercialization strategy for sofpironium bromide, market access activities, pricing and reimbursement activities, promotion, distribution, packaging, sales and safety and pharmacovigilance in Japan and certain other Asian countries. In exercising its final decision-making authority in such territories, Kaken may make decisions regarding product development or regulatory strategy based on its determination of how best to preserve and extend regulatory approvals in these territories for sofpironium bromide, which may delay or prevent achieving regulatory approval for sofpironium bromide in Kaken’s territories, as well as by us in the United States and the other territories where we maintain exclusive rights. Additionally, Kaken is responsible for conducting certain nonclinical and API (chemistry, manufacturing, and controls)-related activities that will be required for FDA approval in the United States, and as a result, we are reliant on Kaken to execute successfully, in a timely and efficient manner, such activities on our behalf. To the extent Kaken experiences delays and/or difficulties in performing its development activities, this could prevent or cause substantial delays in our ability to seek approval for sofpironium bromide gel in the United States and other territories in which we maintain exclusive rights. We will not receive additional milestone or other payments from Kaken if Kaken is not successful in its development activities.
If we or any partners with which we may collaborate with to market and sell sofpironium bromide are unable to achieve and maintain insurance coverage and adequate levels of reimbursement for this compound following regulatory approval and usage by patients, our commercial success may be hindered severely.
If sofpironium bromide only becomes available by prescription, successful sales by us or by any partners with which we collaborate may depend on the availability of insurance coverage and adequate reimbursement from third-party payors as patients would then be forced to pay for the drug out-of-pocket if coverage and associated reimbursement is denied. Patients who are prescribed medicine for the treatment of their conditions generally rely on third-party payors to reimburse all or part of the costs associated with their prescription drugs. The availability of coverage and adequate reimbursement from governmental healthcare programs, such as Medicare and Medicaid in the United States, and private third-party payors is often critical to new product acceptance regardless of how well the product works. Coverage decisions may depend on clinical and economic standards that disfavor new drug products when more established or lower-cost therapeutic alternatives are already available or subsequently become available, even if these alternatives are not as safe and effective, or may be affected by the budgets and demands on the various entities responsible for providing health insurance to patients who will use sofpironium bromide. If insurers and payors decide that hyperhidrosis itself is not a disease they are willing to extend coverage to, which could happen if they only think the treatment improves quality of life, then coverage and reimbursement for sofpironium bromide may be denied, or at least severely restricted. In this case, patients would be forced to pay for sofpironium bromide out-of-pocket for cash, which they may not be willing (or able) to do. Even if we obtain coverage for sofpironium bromide, the resulting reimbursement payment rates might not be adequate or may require co-payments that patients find unacceptably high. Patients may not use sofpironium bromide unless coverage is provided and reimbursement is adequate to cover a significant portion of the cost of sofpironium bromide.
In addition, the market for sofpironium bromide will depend significantly on access to third-party payors’ drug formularies or lists of medications for which third-party payors provide coverage and reimbursement. The industry competition to be included in such formularies often leads to downward pricing pressures on pharmaceutical companies and there may be time limitations on when a new drug may even be eligible for formulary inclusion. Also, third-party payors may refuse to include sofpironium bromide in their formularies or otherwise restrict patient access to sofpironium bromide when a less costly generic equivalent or other treatment alternative is available in the discretion of the formulary.

41



Third-party payors, whether foreign or domestic, or governmental or commercial, are developing increasingly sophisticated methods of controlling healthcare costs. In addition, in the United States, although private third-party payors tend to follow Medicare and Medicaid practices, no uniform or consistent policy of coverage and reimbursement for drug products exists among third-party payors. Therefore, coverage and reimbursement for drug products can differ significantly from payor to payor as well as state to state. Consequently, the coverage determination process is often uncertain and a time-consuming and costly process that must be played out across many jurisdictions and different entities and which will require us to provide scientific, clinical and health economics support for the use of sofpironium bromide compared to current alternatives and do so to each payor separately, with no assurance that coverage and adequate reimbursement will be obtained and in what amount or time frame.
Further, we believe that future coverage and reimbursement likely will be subject to increased restrictions both in the United States and in international markets. Third-party coverage and reimbursement for sofpironium bromide may not be available or adequate in either the United States or international markets, which could harm our business, financial condition, operating results, and prospects.
Even if sofpironium bromide obtains regulatory approval, it may fail to achieve the broad degree of physician and patient adoption and use necessary for commercial success.
The commercial success of sofpironium bromide, if approved, will depend significantly on the broad adoption and use of it by physicians and patients for approved indications, and may not be commercially successful even though the drug is shown to be safe and effective. The degree and rate of physician and patient adoption of sofpironium bromide, if approved, especially in the United States, will depend on a number of factors, including but not limited to:
patient demand for approved products that treat hyperhidrosis;
our ability to market and sell the drug, including through direct-to-consumer advertising and non-traditional sales strategies;
the safety and effectiveness of sofpironium bromide, and ease of use, compared to other available hyperhidrosis therapies, whether approved or used by physicians off-label;
the availability of coverage and adequate reimbursement from managed care plans and other healthcare payors for sofpironium bromide;
the cost of treatment with sofpironium bromide in relation to alternative hyperhidrosis treatments and willingness to pay for sofpironium bromide, if approved, on the part of patients;
overcoming physician or patient biases toward particular therapies for the treatment of hyperhidrosis and achieving acceptance by physicians, major operators of clinics and patients of sofpironium bromide as a safe, effective, and economical hyperhidrosis treatment;
patients’ perception of hyperhidrosis as a disease and one for which medical treatment may be appropriate and a prescription therapy may be available;
insurers’ and physicians’ willingness to see hyperhidrosis as a disease worth treating and for which reimbursement will be made available for treatment;
proper administration of sofpironium bromide;
patient satisfaction with the results and administration of sofpironium bromide and overall treatment experience;
limitations or contraindications, warnings, precautions or approved indications for use different than those sought by us that are contained in any final FDA-approved labeling for sofpironium bromide;
any FDA requirement to undertake a risk evaluation and mitigation strategy;

42



the effectiveness of our sales, marketing, pricing, reimbursement and access, government affairs, legal, medical, and distribution efforts;
adverse publicity about sofpironium bromide or favorable publicity about competitive products;
new government regulations and programs, including price controls and/or public or private institutional limits or prohibitions on ways to commercialize drugs, such as increased scrutiny on direct-to-consumer advertising of pharmaceuticals or restrictions on sales representatives to market pharmaceuticals; and
potential product liability claims or other product-related litigation or litigation related to the licensing and or other commercial matters associated with sofpironium bromide.
If sofpironium bromide is approved for use but fails to achieve the broad degree of physician and patient adoption necessary for commercial success, our operating results and financial condition will be affected adversely, which may delay, prevent, or limit our ability to generate revenue and continue our business.
Sofpironium bromide, if approved, will face significant competition and its failure to compete effectively may prevent it from achieving significant market penetration.
The pharmaceutical industry is characterized by rapidly advancing technologies, intense competition, less effective patent terms, and a strong emphasis on developing newer, fast-to-market proprietary therapeutics. Numerous companies are engaged in the development, patenting, manufacturing, and marketing of healthcare products competitive with those that we are developing, including sofpironium bromide. We face competition from a number of sources, such as pharmaceutical companies, generic drug companies, biotechnology companies and academic and research institutions, many of which have greater financial resources, marketing capabilities, sales forces, manufacturing capabilities, research and development capabilities, regulatory expertise, clinical trial expertise, intellectual property portfolios, more international reach, experience in obtaining patents and regulatory approvals for product candidates and other resources than us. Some of the companies that offer competing products also have a broad range of other product offerings, large direct sales forces, and long-term customer relationships with our target physicians, which could inhibit our market penetration efforts. In addition, sofpironium bromide, if approved, may compete with other dermatological products, including over-the-counter treatments, for a share of some patients’, or payors’, discretionary budgets and for physicians’ attention within their clinical practices.
We anticipate that sofpironium bromide would compete with other therapies currently used for hyperhidrosis, including but not limited to:
Self-Administered Treatments. Self-administered treatments, such as OTC and prescription topical antiperspirants, and recently approved (June 2018) Qbrexza® (glycopyrronium) 2.4% topical cloths. Oral and compounded topical anticholinergics also may be used off-label.
Non-Surgical Office-Based Procedures. Office-based procedures have been approved by the FDA for certain uses and which may be used, on-or-off label, to treat hyperhidrosis, including intradermal injections of BOTOX®, marketed by Allergan plc., and MiraDry®, a microwave-based treatment marketed by Miramar Labs, Inc.
Surgical Treatments. Surgical treatments include techniques for the removal of sweat glands, such as excision, curettage, and liposuction. Surgical procedures, such as endoscopic thoracic sympathectomy, are also used to destroy nerves that transmit activating signals to sweat glands.
To compete successfully in this market, we will have to provide an attractive alternative to these existing and other new therapies. Such competition could lead to reduced market share for sofpironium bromide and contribute to downward pressure on the pricing of sofpironium bromide, which could harm our business, financial condition, operating results, and prospects.
Due to less stringent regulatory requirements in certain foreign countries, there are many more dermatological products and procedures available for use in those international markets than are approved for use in the United States. In certain international markets, there are also fewer limitations on the claims that our competitors can make about the effectiveness of their products and the manner in which they can market them. As a result, we expect to face more competition in these markets than in the United States.

43



We may in the future face generic competition for sofpironium bromide, which could expose us to liability or adversely affect our business, financial condition, operating results, and prospects.
Upon expiration of primary patent protection in 2031 in the United States for sofpironium bromide, and in the absence of receiving a pending composition of matter patent that would provide protection through 2040, we could lose a significant portion of then-existing sales of sofpironium bromide in a short period of time, which could expose us to liability and would adversely affect our business, financial condition, operating results, and prospects.
We have in the past relied, and expect to continue to rely, on third-party CROs and other third parties to conduct and oversee our sofpironium bromide clinical trials. If these third parties do not meet our requirements or otherwise conduct the trials as required, we may not be able to satisfy our contractual obligations or obtain regulatory approval for, or commercialize, sofpironium bromide.
We have in the past relied, and expect to continue to rely, on third-party CROs to conduct and oversee our sofpironium bromide clinical trials and other aspects of product development. We also rely on various medical institutions, clinical investigators and contract laboratories to conduct our trials in accordance with our clinical protocols and all applicable regulatory requirements, including the FDA’s regulations and good clinical practice, or GCP, requirements, which are an international standard meant to protect the rights and health of patients and to define the roles of clinical trial sponsors, administrators and monitors, and state regulations governing the handling, storage, security and recordkeeping for drug and biologic products. These CROs and other third parties play a significant role in the conduct of these trials and the subsequent collection and analysis of data from the clinical trials. We rely heavily on these parties for the execution of our clinical trials and preclinical studies, and control only certain aspects of their activities. We and our CROs and other third-party contractors are required to comply with GCP and good laboratory practice, or GLP, requirements, which are regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities for sofpironium bromide. Regulatory authorities enforce these GCP and GLP requirements through periodic inspections of trial sponsors, principal investigators, and trial sites. If we or any of these third parties fail to comply with applicable GCP and GLP requirements, or reveal noncompliance from an audit or inspection, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or other regulatory authorities may require us to perform additional clinical trials before approving our or our partners’ marketing applications. We cannot assure that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical or preclinical trials comply with applicable GCP and GLP requirements. In addition, our clinical trials generally must be conducted with product produced under cGMP regulations. Our failure to comply with these regulations and policies may require us to extend or repeat clinical trials, which would delay the regulatory approval process.
If any of our CROs or clinical trial sites terminate their involvement in one of our clinical trials for any reason, or are unable to continue to support us due to delay in implementation of the clinical trials due to the Bodor Complaint, we may not be able to enter into arrangements with alternative CROs or clinical trial sites, or do so on commercially reasonable terms, and in a satisfactory time frame. In addition, if our relationship with clinical trial sites is terminated, we may experience the loss of follow-up information on patients enrolled in our ongoing clinical trials unless we are able to transfer the care of those patients to another qualified clinical trial site. In addition, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and could receive cash or equity compensation in connection with such services. If these relationships and any related compensation result in perceived or actual conflicts of interest, the integrity of the data generated at the applicable clinical trial site may be questioned by the FDA.
We currently have limited marketing capabilities and no sales organization. If we are unable to establish sales and marketing capabilities on our own or through third parties, or are delayed in establishing these capabilities, we will be unable to successfully commercialize our product candidates, if approved, or generate product revenue.
We currently have limited marketing capabilities and no sales organization. To commercialize our product candidates, if approved, in the United States, Canada, the European Union, Latin America and other jurisdictions we seek to enter, we must build our marketing, sales, distribution, managerial and other non-technical capabilities or make arrangements with third parties to perform these services, and we may not be successful in doing so. Although our employees have experience in the marketing, sale and distribution of pharmaceutical products, and business development activities involving external alliances, from prior employment at other companies, we as a company have no prior experience in the commercial launch, marketing, sale and distribution of pharmaceutical products, and there are significant risks involved in building and managing a sales organization, including our ability to hire, retain and incentivize qualified individuals, generate sufficient sales leads, provide adequate training to sales and marketing personnel, and effectively manage a geographically dispersed sales and marketing team. Any failure or delay in the

44



development of our internal sales, marketing, distribution, and pricing/reimbursement/access capabilities would impact adversely the commercialization of these products.
To commercialize sofpironium bromide in Asia, we also intend to leverage the commercial infrastructure of our partner, Kaken, which will provide us with resources and expertise in certain areas that are greater than we could initially build ourselves. We may choose to collaborate with additional third parties in various countries that have direct sales forces and established distribution systems, either to augment our own sales force and distribution systems or in lieu of our own sales force and distribution systems. If we are unable to enter into such arrangements on acceptable terms or at all, we may not be able to successfully commercialize our product candidates, especially in other countries where we currently do not have a foreign legal presence. The inability to commercialize successfully our product candidates, either on our own or through collaborations with one or more third parties, would harm our business, financial condition, operating results, and prospects.
Risks Related to Our Business
We currently have no products approved for sale, and we may never obtain regulatory approval to commercialize any of our product candidates.
The research, testing, manufacturing, safety surveillance, efficacy, quality assurance and control, recordkeeping, labeling, packaging, storage, approval, sale, marketing, distribution, import, export and reporting of safety and other post-market information related to our drug products are subject to extensive regulation by the FDA and other regulatory authorities in the United States and in foreign countries, and such regulations differ from country to country and frequently are revised.
Even after we or our partners achieve U.S. regulatory approval for a product candidate, if any, we or our partners will be subject to continued regulatory review and compliance obligations, including on how the product is commercialized. For example, with respect to our product candidates, the FDA may impose significant restrictions on the approved indicated use(s) for which the product may be marketed or on the conditions of approval. A product candidate’s approval may contain requirements for potentially costly post-approval studies and surveillance, including Phase 4 clinical trials, to monitor the safety and efficacy of the product or include in the approved label restrictions on the product and how it may be used or sold. We also will be subject to ongoing FDA obligations and continued regulatory review with respect to, among other things, the manufacturing, processing, labeling, packaging, distribution, pharmacovigilance and adverse event reporting, storage, advertising, promotion, and recordkeeping for our product candidates. These requirements include submissions of safety and other post-marketing information and reports, registration, continued compliance with cGMP requirements and with the FDA’s GCP requirements and GLP requirements, which are regulations and guidelines enforced by the FDA for all of our product candidates in clinical and preclinical development, and for any clinical trials that we conduct post-approval, as well as continued compliance with the FDA’s laws governing commercialization of the approved product, including but not limited to the FDA’s Office of Prescription Drug Promotion, or OPDP, regulation of promotional activities, fraud and abuse, antikickback, product sampling, debarment, scientific speaker engagements and activities, formulary interactions as well as interactions with healthcare practitioners, including various conflict-of-interest reporting requirements for any healthcare practitioners we may use as consultants, and laws relating to the pricing of drug products, including federal “best price” regulations that if not met can prohibit the company from participating in federal reimbursement programs like Medicare or Medicaid. To the extent that a product candidate is approved for sale in other countries, we may be subject to similar or more onerous (i.e., prohibition on direct-to-consumer advertising that does not exist in the United States) restrictions and requirements imposed by laws and government regulators, and even private institutions, in those countries.
In addition, manufacturers of drug and biologic products and their facilities are subject to continual review and periodic inspections by the FDA and other regulatory authorities for compliance with cGMP regulations. If we or a regulatory agency discovers previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the manufacturing, processing, distribution or storage facility where, or processes by which, the product is made, a regulatory agency may impose restrictions on that product or us, including requesting that we initiate a product recall, or requiring notice to physicians or the public, withdrawal of the product from the market, or suspension of manufacturing.
If we, our partners, our product candidates, or the manufacturing facilities for our product candidates fail to comply with applicable regulatory requirements, a regulatory agency may:
impose restrictions on the sale, marketing, or manufacturing of the product, amend, suspend, or withdraw product approvals or revoke necessary licenses;

45



mandate modifications to or prohibit promotional and other product-specific materials or require us to provide corrective information to healthcare practitioners and other customers and/or patients, or in our advertising and promotion;
require us or our partners to enter into a consent decree, which can include imposition of various fines, reimbursements for inspection costs, required due dates for specific actions, penalties for noncompliance and, in extreme cases, require an independent compliance monitor to oversee our activities;
issue warning letters, bring enforcement actions, initiate surprise inspections, issue show cause notices or untitled letters describing alleged violations, which may be available publicly;
commence criminal investigations and prosecutions;
debar certain healthcare professionals;
exclude us from participating in or being eligible for government reimbursement and formulary inclusion;
initiate audits, inspections, accounting and civil investigations or litigation;
impose injunctions, suspensions or revocations of necessary approvals or other licenses;
impose other civil or criminal penalties;
suspend or cancel any ongoing clinical trials;
place restrictions on the kind of promotional activities that can be done;
delay or refuse to approve pending applications or supplements to approved applications filed by us or our potential partners;
refuse to permit drugs or precursor chemicals to be imported or exported to or from the United States;
suspend or impose restrictions on operations, including costly new manufacturing requirements; or
seize or detain products or require us or our partners to initiate a product recall.
The regulations, policies or guidance of the FDA and other applicable government agencies may change quickly, and new or additional statutes or government regulations may be enacted, including at the state and local levels, which can differ by geography and could prevent or delay regulatory approval of our product candidates or further restrict or regulate post-approval activities, including commercial efforts. We cannot predict the likelihood, nature or extent of adverse government regulations that may arise from future legislation or administrative action, either in the United States or abroad. If we are not able to achieve and maintain regulatory compliance, we may not be permitted to commercialize our product candidates, which would adversely affect our ability to generate revenue and achieve or maintain profitability.
We have sponsored or supported and may in the future sponsor or support clinical trials for our product candidates outside the United States, and the FDA and applicable foreign regulatory authorities may not accept data from such trials.
We have sponsored or supported and may in the future choose to sponsor or support one or more of our clinical trials outside of the United States. Although the FDA or applicable foreign regulatory authority may accept data from clinical trials conducted outside the United States or the applicable jurisdiction, acceptance of such study data by the FDA or applicable foreign regulatory authority may be subject to certain conditions or exclusion. Where data from foreign clinical trials are intended to serve as the basis for marketing approval in the United States, the FDA will not approve the application on the basis of foreign data alone unless such data are applicable to the U.S. population and U.S. medical practice; the studies were performed by clinical investigators of recognized competence; and the data are considered valid without the need for an on-site inspection by the FDA or, if the FDA considers such an inspection to be necessary, the FDA is able to validate the data through an on-site inspection or other appropriate means. Many foreign regulatory bodies have similar requirements. In addition, such foreign studies would be subject to the applicable local laws of the foreign jurisdictions where the studies are conducted. There can be no assurance the FDA or applicable foreign regulatory authority will accept data from trials conducted outside of the United States or the

46



applicable home country. If the FDA or applicable foreign regulatory authority does not accept such data, it would likely result in the need for additional trials, which would be costly and time-consuming and delay aspects of our business plan.
We may face product liability exposure, and if successful claims are brought against us, we may incur substantial liability if our insurance coverage for those claims is inadequate.
We face an inherent risk of product liability or similar causes of action as a result of the clinical testing of our product candidates and will face an even greater risk if we commercialize any products. This risk exists even if a product is approved for commercial sale by the FDA and is manufactured in facilities licensed and regulated by the FDA or an applicable foreign regulatory authority and notwithstanding that we comply with applicable laws on promotional activity. Our products and product candidates are designed to affect important bodily functions and processes. Any side effects, manufacturing defects, misuse or abuse associated with our product candidates could result in injury to a patient that may or may not be reversible or potentially even cause death. We cannot offer any assurance that we will not face product liability or other similar suits in the future or that we will be successful in defending them, nor can we assure that our insurance coverage will be sufficient to cover our liability under any such cases.
In addition, a liability claim may be brought against us even if our product candidates merely appear to have caused an injury. Product liability claims may be brought against us by consumers, healthcare providers, pharmaceutical companies or others selling or otherwise coming into contact with our product candidates, among others, and under some circumstances even government agencies. If we cannot successfully defend against product liability or similar claims, we will incur substantial liabilities, reputational harm and possibly injunctions and punitive actions. In addition, regardless of merit or eventual outcome, product liability claims may result in:
withdrawal or delay of recruitment or decreased enrollment rates of clinical trial participants;
termination or increased government regulation of clinical trial sites or entire trial programs;
the inability to commercialize our product candidates;
decreased demand for our product candidates;
impairment of our business reputation;
product recall or withdrawal from the market or labeling, marketing or promotional restrictions;
substantial costs of any related litigation or similar disputes;
distraction of management’s attention and other resources from our primary business;
significant delay in product launch;
debarment of our clinical trial investigators or other related healthcare practitioners working with our company;
substantial monetary awards to patients or other claimants against us that may not be covered by insurance;
withdrawal of reimbursement or formulary inclusion; or
loss of revenue.
We have obtained product liability insurance coverage for our clinical trials. Large judgments have been awarded in class action or individual lawsuits based on drugs that had unanticipated side effects. Our insurance coverage may not be sufficient to cover all of our product liability-related expenses or losses and may not cover us for any expenses or losses we may suffer. Moreover, insurance coverage is becoming increasingly expensive, restrictive, and narrow, and, in the future, we may not be able to maintain adequate insurance coverage at a reasonable cost, or through self-insurance, in sufficient amounts or upon adequate terms to protect us against losses due to product liability or other similar legal actions. We will need to increase our product liability coverage if any of our product candidates receive regulatory approval, which will be costly, and we may be unable to obtain this increased product liability insurance on commercially reasonable terms or at all and for all geographies in which we wish

47



to launch. A successful product liability claim or series of claims brought against us, if judgments exceed our insurance coverage, decrease our cash, expose us to liability and harm our business, financial condition, operating results, and prospects.
Our employees, independent contractors, principal investigators, other clinical trial staff, consultants, vendors, CROs and any partners with which we may collaborate may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.
We are exposed to the risk that our employees, independent contractors, principal investigators, other clinical trial staff, consultants, vendors, CROs and any partners with which we may collaborate may engage in fraudulent or other illegal or unethical activity. Misconduct by these persons could include intentional, reckless, gross or negligent misconduct or unauthorized activity that violates: laws or regulations, including those laws requiring the reporting of true, complete and accurate information to the FDA or foreign regulatory authorities; product sampling; manufacturing standards; federal, state and foreign healthcare fraud and abuse laws and data privacy; anticorruption laws, anti-kickback and Medicare/Medicaid rules, debarment laws, promotional laws, securities laws, and/or laws that require the true, complete and accurate reporting of financial information or data, books and records. If any such or similar actions are instituted against us and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of civil, criminal and administrative and punitive penalties, damages, monetary fines, possible exclusion from participation in Medicare, Medicaid, and other federal or state healthcare programs, debarments, contractual damages, reputational harm, diminished profits and future earnings, injunctions, and curtailment or cessation of our operations, any of which could expose us to liability and adversely affect our business, financial condition, operating results, and prospects.
We may be subject to risks related to pre-approval promotion or off-label use, or unauthorized direct-to-consumer advertising of our product candidates.
The FDA strictly regulates the advertising and promotion of drug products, and drug products may only be marketed or promoted for their FDA-approved uses, consistent with the product’s approved labeling and to appropriate patient populations. Advertising and promotion of any product candidate that obtains approval in the United States will be heavily scrutinized by the FDA, the Department of Justice, the Office of Inspector General of the Department of Health and Human Services, state attorneys general, members of Congress and the public and others. Violations, including promotion of our products for unapproved or off-label uses, are subject to enforcement letters, inquiries, and investigations, and civil, criminal, and/or administrative sanctions by the FDA and other government agencies or tribunals and lawsuits by competitors, healthcare practitioners, consumers, investors, or other plaintiffs. Additionally, advertising and promotion of any product candidate that obtains approval outside of the United States will be scrutinized heavily by relevant foreign regulatory authorities.
Even if we obtain regulatory approval for our product candidates, the FDA or comparable foreign regulatory authorities may require labeling changes or impose significant restrictions on a product’s indicated uses or marketing, or impose ongoing requirements for potentially costly post-approval studies or post-market surveillance.
In the United States, engaging in impermissible promotion of our product candidates for off-label uses, or engaging in pre-approval promotion of an unapproved drug candidate, also can subject us to false claims litigation under federal and state statutes, which can lead to civil, criminal and/or administrative penalties and fines and agreements, such as a corporate integrity agreement, that materially restrict the manner in which we promote or distribute our product candidates. If we do not lawfully promote our products once they have received regulatory approval, we may become subject to such litigation and, if we are not successful in defending against such actions, those actions could expose us to liability and could have a material adverse effect on our business, financial condition, operating results, and prospects and even result in having an independent compliance monitor assigned to audit our ongoing operations at our cost for a lengthy period of time.
Other than sofpironium bromide, our product candidates are at the early stages of clinical and regulatory development.
We are evaluating the next clinical development steps for BBI-3000 and BBI-6000 as each is in an early stage of clinical (prior to Phase 3) and preclinical development. The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time consuming, costly, and inherently unpredictable, especially for early-stage product candidates. The time required to obtain approval for early-stage product candidates from the FDA and comparable foreign authorities is unpredictable but typically takes many years, involves significant expenditures, and depends upon numerous factors, including the substantial discretion of the regulatory authorities. In addition, approval policies, regulations, or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate’s clinical development and may vary among jurisdictions. Our early-stage product candidates will require substantial additional preclinical and clinical development before

48



we will be able to submit an application to the FDA, if at all. Accordingly, we cannot assure you that we will be able to seek or obtain regulatory approval for any of our early-stage product candidates.
Our clinical trials may fail to demonstrate the safety and efficacy of our other investigational agents BBI-3000 or BBI-6000, or serious adverse or unacceptable side effects may be identified during their development, which could prevent or delay marketing approval and commercialization, increase our costs or necessitate the abandonment or limitation of the development of BBI-3000 or BBI-6000.
Before obtaining marketing approvals for the commercial sale of BBI-3000 and BBI-6000, we must demonstrate through lengthy, complex, uncertain, and expensive preclinical testing and clinical trials that BBI-3000 and BBI-6000 are both safe and effective for use in each targeted indication, and failures can occur at any stage of testing. Clinical trials often fail to demonstrate safety and are associated with side effects or have characteristics that are unexpected. Based on the safety profile seen in clinical testing, we may need to abandon development or limit development to more narrow uses in which the side effects or other characteristics are less prevalent, less severe, or more tolerable from a risk-benefit perspective. The FDA or an IRB also may require that we suspend, discontinue, or limit clinical trials based on safety information. Such findings could further result in regulatory authorities failing to provide marketing authorization for BBI-3000 or BBI-6000. Many drug candidates that initially showed promise in early-stage testing and which were efficacious have later been found to cause side effects that prevented further development of the drug candidate and, in extreme cases, the side effects were not seen until after the drug was marketed and exposed to large populations, causing regulators to remove the drug from the market post-approval.
We may choose not to continue developing or commercializing any of our early-stage product candidates at any time during development or after approval, which would reduce or eliminate our potential return on investment for those product candidates.
At any time, we may decide to discontinue the development of any of our early-stage product candidates for a variety of reasons, including the appearance of new technologies that make our product obsolete, competition from a competing product including entry of generics, supply chain considerations, intellectual property right impacts, ability to price or changes in or failure to comply with applicable regulatory requirements. If we terminate a program in which we have invested significant resources, we will not receive any return on our investment and we will have missed the opportunity to have allocated those resources to potentially more productive uses.
Healthcare reform measures could hinder or prevent the commercial success of our product candidates.
The current presidential administration and certain members of the majority of the U.S. Congress have sought to repeal all or part of the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively, the Affordable Care Act, and implement a replacement program. For example, the so-called “individual mandate” was repealed as part of tax reform legislation adopted in December 2017, such that the shared responsibility payment for individuals who fail to maintain minimum essential coverage under section 5000A of the Internal Revenue Code was eliminated beginning in 2019. In addition, litigation may prevent some or all of the Affordable Care Act legislation from taking effect. For example, on December 14, 2018, the U.S. District Court for the Northern District of Texas held that the individual mandate is a critical and inseverable feature of the Affordable Care Act, and therefore, because it was repealed as part of the tax reform legislation, the remaining provisions of the Affordable Care Act are invalid as well. The impact of this ruling is stayed as it was appealed to the Fifth Circuit Court of Appeals. While the ruling will have no immediate effect, it is unclear how this decision, and subsequent appeals, if any, will impact the law. In 2019 and beyond, we may face additional uncertainties as a result of likely federal and administrative efforts to repeal, substantially modify or invalidate some or all of the provisions of the Affordable Care Act. There is no assurance that the Affordable Care Act, as amended in the future, will not affect adversely our business and financial results.
Additionally, in October 2018, the U.S. President proposed to lower Medicare Part B drug prices, in addition to contemplating other measures to lower or prescribe certain mandatory prescription drug prices or drug substitution policies. While these proposals have not yet been enacted, we expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our product candidates if approved or additional pricing pressures.
There are also calls to severely curtail or ban all direct-to-consumer advertising of pharmaceuticals, which would limit our ability to market our product candidates. The United States is already in a minority of jurisdictions that allow this kind of advertising and its removal could limit the potential reach of a marketing campaign.

49



We also may be subject to stricter healthcare laws, regulation and enforcement, and our failure to comply with those laws could expose us to liability or adversely affect our business, financial condition, operating results, and prospects.
Certain federal and state healthcare laws and regulations pertaining to fraud and abuse and patients’ rights are and will be applicable to our business. We are subject to regulation by both the federal government and the states in which we or our partners conduct business. The healthcare laws and regulations that may affect our ability to operate include: the Federal Food, Drug and Cosmetic Act (FDCA), as amended; Title 21 of the Code of Federal Regulations Part 202 (21 CFR Part 202); the 21st Century Cures Act, the federal Anti-Kickback Statute; federal civil and criminal false claims laws and civil monetary penalty laws; the federal Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology for Economic and Clinical Health Act; the Prescription Drug Marketing Act (for sampling of drug product among other things); the federal Best Price Act and Medicaid drug rebate program; the federal physician sunshine reporting requirements under the Affordable Care Act and state disclosure laws; the Foreign Corrupt Practices Act as it applies to activities both inside and outside of the United States; the new federal Right-to-Try legislation; and state law equivalents of many of the above federal laws.
Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of our business activities could be subject to challenge under one or more of such laws. In addition, recent healthcare reform legislation has strengthened these laws. For example, the Affordable Care Act, among other things, amended the intent requirement of the federal Anti-Kickback Statute and certain criminal healthcare fraud statutes. A person or entity no longer needs to have actual knowledge of the statute or specific intent to violate it. In addition, the Affordable Care Act provides that the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act.
Achieving and sustaining compliance with these laws may prove costly. In addition, any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management’s attention from the operation of our business and result in reputational damage. If our operations are found to be in violation of any of the laws described above or any other governmental laws or regulations that apply to us, we may be subject to penalties, including administrative, civil and criminal penalties, damages, including punitive damages, fines, disgorgement, the exclusion from participation in federal and state healthcare programs, individual imprisonment or corporate criminal liability, or the curtailment or restructuring of our operations, and injunctions, any of which could expose us to liability and could adversely affect our business, financial condition, operating results, and prospects.
We intend to in-license and acquire product candidates and may engage in other strategic transactions, which could impact our liquidity, increase our expenses, and present significant distractions to our management.
One of our strategies is to in-license and acquire product candidates and we may engage in other strategic transactions. Additional potential transactions that we may consider include a variety of different business arrangements, including mergers and acquisitions, spin-offs, strategic partnerships, joint ventures, co-marketing, co-promotion, distributorships, development and co-development, restructurings, divestitures, business combinations and investments on a global basis. Any such transaction(s) may require us to incur non-recurring or other charges, may increase our near- and long-term expenditures and may pose significant integration challenges or disrupt our management or business, which could adversely affect our operations and financial results. Accordingly, there can be no assurance that we will undertake or successfully complete any transactions of the nature described above, and any transaction that we do complete could expose us to liability and could harm our business, financial condition, operating results, and prospects. We have no current plan, commitment, or obligation to enter into any transaction described above other than ones to which we are already committed.
Our failure to in-license, acquire, develop, and market successfully additional product candidates or approved products would impair our ability to grow our business.
We intend to in-license, acquire, develop, and market additional products and product candidates. Because our internal research and development capabilities are limited, we may be dependent on pharmaceutical or other companies, investment groups or funds, academic or government scientists and other researchers to sell or license products or technology to us. The success of this strategy depends partly on our ability to identify and select promising pharmaceutical product candidates and products, negotiate licensing or acquisition agreements with their current owners, and finance these arrangements.
The process of proposing, negotiating, and implementing a license or acquisition of a product candidate or approved product is lengthy and complex. Other companies, including some with substantially greater financial, marketing, sales, legal and other resources, may compete with us for the license or acquisition of product candidates and approved products. We have limited

50



resources to identify and execute the acquisition or in-licensing of third-party products, businesses and technologies and integrate them into our current infrastructure. Moreover, we may devote resources to potential acquisitions or licensing opportunities that are never completed, or we may fail to realize the anticipated benefits of such efforts. We may not be able to acquire the rights to additional product candidates on terms that we find acceptable or at all.
Further, any product candidate that we acquire may require additional development efforts prior to commercial sale, including preclinical or clinical testing and approval by the FDA and applicable foreign regulatory authorities for the targeted use(s). All product candidates are prone to significant risks of failure typical of pharmaceutical product development, including the possibility that a product candidate will not be shown to be sufficiently safe and effective for approval by regulatory authorities. In addition, we cannot provide assurance that any approved products that we acquire will be manufactured or sold profitably, obtain reimbursement, be subject to patents and other intellectual property rights that provide any form of market or regulatory exclusivity, or achieve market acceptance.
Risks Related to Our Dependence on Third Parties
Under the Funding Agreement with NovaQuest, NovaQuest has the right to suspend product development payments or take other actions adverse to Brickell’s interests in certain circumstances.
Concurrent with the execution of the Merger Agreement with Vical, on June 2, 2019, we entered into the Funding Agreement with NovaQuest pursuant to which NovaQuest committed to partially fund our expenses relating to product development activities in respect of sofpironium bromide, subject to the terms and conditions contained in the Funding Agreement. NovaQuest may suspend its payments under the Funding Agreement in certain limited circumstances, including: (i) adverse regulatory events relating to sofpironium bromide; (ii) termination of any material clinical study in respect of sofpironium bromide; (iii) an event reasonably expected to delay U.S. approval or launch of sofpironium bromide by 12 months or more; (iv) a material amendment of the study protocol for our U.S. Phase 3 clinical trials in respect of our sofpironium bromide product candidate without NovaQuest’s consent; (v) if we determine that sofpironium bromide is unsafe; (vi) the failure of sofpironium bromide to achieve the primary endpoints for our Phase 3 clinical trials; (vii) sofpironium bromide receiving a final non-approval letter from the FDA or European Medicines Agency; and/or (viii) if certain of our senior executives cease to work for us and we do not hire replacements reasonably acceptable to NovaQuest in a reasonable time. NovaQuest’s obligation to make the payments will resume upon NovaQuest’s notice to us that the condition allowing NovaQuest to suspend payments has been resolved or cured. NovaQuest may terminate its obligation to pay any further payments if such condition is not resolved or cured within 12 months. If NovaQuest’s payment obligations terminate in these circumstances, we will remain obligated to make the milestone payments contemplated in the Funding Agreement to NovaQuest in the event we nonetheless receive FDA approval for sofpironium bromide, and we will remain obligated to make revenue sharing payments in the territory covered by the Funding Agreement in the event we launch sofpironium bromide anywhere in that territory.
If we suspend or terminate the development program for sofpironium bromide under certain circumstances, we will be obligated to pay NovaQuest $25 million plus interest.
Under the Funding Agreement with NovaQuest, we are not permitted to suspend or discontinue the development program in respect of sofpironium bromide except in certain circumstances. If we suspend or terminate the development program following completion of U.S. Phase 3 clinical trials because the FDA requires an additional study or additional, unexpected development work, and we reasonably determine that the additional study or work would take longer than 18 months to complete or cost more than an established threshold, we are entitled to terminate the development program. In that case, we would be obligated to pay NovaQuest $25 million plus interest from the date of the Funding Agreement until the date on which the payment is made (however, in the event that we terminate our development program for sofpironium bromide for certain reasons, including serious safety issues, a failure of the product’s U.S. Phase 3 studies, or the failure of the FDA to approve the product, we will not be obligated to make any payments to NovaQuest). If we subsequently resume development of sofpironium bromide, we will remain obligated to make the milestone payments contemplated in the Funding Agreement to NovaQuest in the event we nonetheless receive FDA approval for sofpironium bromide, and we will remain obligated to make revenue sharing payments in the territory covered by the Funding Agreement in the event we launch sofpironium bromide anywhere in that territory, with any such payment made upon termination of the program credited against the milestone payment or revenue sharing payments.
If we breach the Funding Agreement, NovaQuest may terminate the agreement and exercise rights under a related Security Agreement, including foreclosing on our assets relating to sofpironium bromide in the United States and accelerating certain payments.

51



Under the Funding Agreement, we make various representations and warranties and commit to comply with various covenants. NovaQuest may terminate the Funding Agreement and terminate its obligation to make certain payments in the event of our material uncured breach of a representation or covenant under the Funding Agreement. We also entered into a Security Agreement with NovaQuest immediately following consummation of the Merger. Under the Security Agreement, NovaQuest is able to exercise certain rights in the event of default. An event of default would occur if (i) we fail to make payments due under the Funding Agreement, (ii) we terminate the Funding Agreement under circumstances giving rise to a payment obligation to NovaQuest and fail to make the required payment, as described above under “—If we suspend or terminate the development program for sofpironium bromide under certain circumstances, we will be obligated to pay NovaQuest $25 million plus interest,” (iii) if we fail to comply with a covenant to maintain certain minimum cash balances specified in the Funding Agreement, or (iv) the occurrence of certain insolvency events affecting us or other related entities that are, or become parties to, the Security Agreement. NovaQuest’s rights following an event of default include, among other things, foreclosing on our assets in the territory relating to sofpironium bromide and, in certain circumstances, accelerating payment obligations under the Funding Agreement.
We expect to rely on our collaboration with third-party out-license partners for the successful development and commercialization of our product candidates.
We expect to rely upon the efforts of third-party out-license partners for the successful development and commercialization of our current and future product candidates. The clinical and commercial success of our product candidates may depend upon maintaining successful relationships with third-party out-license partners which are subject to a number of significant risks, including the following:
our partners’ ability to execute their responsibilities in a timely, cost-efficient, and compliant manner;
reduced control over delivery and manufacturing schedules;
price increases and product reliability;
manufacturing deviations from internal or regulatory specifications;
quality incidents;
the failure of partners to perform their obligations for technical, market, legal or other reasons;
misappropriation of our current or future product candidates; and
other risks in potentially meeting our current and future product commercialization schedule or satisfying the requirements of our end-users.
We cannot assure you that we will be able to establish or maintain third-party out-license partner relationships in order to successfully develop and commercialize our product candidates.
We rely completely on third-party contractors to supply, manufacture and distribute clinical drug supplies for our product candidates, including certain sole-source suppliers and manufacturers; we intend to rely on third parties for commercial supply, manufacturing and distribution if any of our product candidates receive regulatory approval; and we expect to rely on third parties for supply, manufacturing and distribution of preclinical, clinical and commercial supplies of any future product candidates.
We do not currently have, nor do we plan to acquire, the infrastructure or internal capability to supply, store, manufacture or distribute preclinical, clinical, or commercial quantities of drug substances or products. Additionally, we have not entered into a long-term commercial supply agreement to provide us with such drug substances or products. As a result, our ability to develop our product candidates is dependent, and our ability to supply our products commercially will depend, in part, on our ability to obtain the APIs and other substances and materials used in our product candidates successfully from third parties and to have finished products manufactured by third parties in accordance with regulatory requirements and in sufficient quantities for preclinical and clinical testing and commercialization. If we fail to develop and maintain supply and other technical relationships with these third parties, we may be unable to continue to develop or commercialize our products and product candidates.

52



We do not have direct control over whether our contract suppliers and manufacturers will maintain current pricing terms, be willing to continue supplying us with APIs and finished products or maintain adequate capacity and capabilities to serve our needs, including quality control, quality assurance and qualified personnel. We are dependent on our contract suppliers and manufacturers for day-to-day compliance with applicable laws and cGMP regulations for production of both APIs and finished products. If the safety or quality of any product or product candidate or component is compromised due to a failure to adhere to applicable laws or for other reasons, we may not be able to commercialize or obtain regulatory approval for the affected product or product candidate successfully, and we may be held liable for injuries sustained as a result.
In order to conduct larger or late-stage clinical trials for our product candidates and supply sufficient commercial quantities of the resulting drug product and its components, if that product candidate is approved for sale, our contract manufacturers and suppliers will need to produce our drug substances and product candidates in larger quantities, more cost-effectively and, in certain cases, at higher yields than they currently achieve. If our third-party contractors are unable to scale up the manufacture of any of our product candidates successfully in sufficient quality and quantity and at commercially reasonable prices, or are shut down or put on clinical hold by government regulators, and we are unable to find one or more replacement suppliers or manufacturers capable of production at a substantially equivalent cost in substantially equivalent volumes and quality, and we are unable to transfer the processes successfully on a timely basis, the development of that product candidate and regulatory approval or commercial launch for any resulting products may be delayed, or there may be a shortage in supply, either of which could significantly harm our business, financial condition, operating results, and prospects.
We expect to continue to depend on third-party contract suppliers and manufacturers for the foreseeable future. Our supply and manufacturing agreements, if any, do not guarantee that a contract supplier or manufacturer will provide services adequate for our needs. Additionally, any damage to or destruction of our third-party manufacturers’ or suppliers’ facilities or equipment, even by force majeure, may significantly impair our ability to have our products and product candidates manufactured on a timely basis. Our reliance on contract manufacturers and suppliers further exposes us to the possibility that they, or third parties with access to their facilities, will have access to and may misappropriate our trade secrets or other proprietary information. In addition, the manufacturing facilities of certain of our suppliers may be located outside of the United States. This may give rise to difficulties in importing our products or product candidates or their components into the United States or other countries.
Manufacturing and supply of the APIs and other substances and materials used in our product candidates and finished drug products is a complex and technically challenging undertaking, and there is potential for failure at many points in the manufacturing, testing, quality control and assurance and distribution supply chain, as well as the potential for latent defects after products have been manufactured and distributed.
Manufacturing and supply of APIs, other substances and materials and finished drug products is technically challenging. Changes beyond our direct control can impact the quality, volume, price and successful delivery of our products and product candidates and can impede, delay, limit or prevent the successful development and commercialization of our products and product candidates. Mistakes and mishandling are not uncommon despite reasonable best efforts and can affect successful production and supply. Some of these risks include but are not limited to:
failure of our manufacturers to follow cGMP or other legal requirements or mishandling of or adulterating product while in production or in preparation for transit;
inability of our contract suppliers and manufacturers to efficiently and cost-effectively increase and maintain high yields and batch quality, consistency, and stability;
difficulty in establishing optimal drug delivery substances and techniques, production and storage methods and packaging and shipment processes;
challenges in designing effective drug delivery substances and techniques especially in light of competitor options;
transportation and import/export risk, particularly given the global nature of our supply chain;
delays in analytical results or failure of analytical techniques that we depend on for quality control/assurance and release of a product;

53



natural disasters, strikes and labor disputes, war and terrorism, financial distress, lack of raw material supply, issues with facilities and equipment or other forms of disruption to business operations of our contract manufacturers and suppliers; and
latent defects that may become apparent after a product has been released and even sold and used and that may result in recall and destruction of the product.
Any of these factors could result in delays or higher costs in connection with our clinical trials, regulatory submissions, required approvals or commercialization of our products, which could expose us to liability or harm our business, financial condition, operating results, and prospects.
Risks Related to Our Financial Operations
We will need to raise additional financing in the future to fund our operations, which may not be available to us on favorable terms or at all.
We will require substantial additional funds to conduct the costly and time-consuming clinical trials necessary to pursue regulatory approval of each potential product candidate and to continue the development of sofpironium bromide in new indications or uses. Our future capital requirements will depend upon a number of factors, including but not limited to: the number and timing of future product candidates in the pipeline; progress with and results from preclinical testing and clinical trials; the ability to manufacture sufficient drug supplies to complete preclinical and clinical trials; the costs involved in preparing, filing, acquiring, prosecuting, maintaining and enforcing patent and other intellectual property claims; compliance with our material contracts including the licensing agreement for sofpironium bromide and resolution of the Bodor Complaint; the time and costs involved in obtaining regulatory approvals and favorable reimbursement or formulary acceptance for such product candidates; and overall stock market conditions and trends. Raising additional capital may be costly or difficult to obtain and could significantly dilute stockholders’ ownership interests or inhibit our ability to achieve our business objectives. If we raise additional funds through public or private equity offerings, the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. Further, to the extent that we raise additional capital through the sale of common stock or securities convertible or exchangeable into common stock, our stockholders’ ownership interests in our company will be diluted. In addition, any debt financing may subject us to fixed payment obligations and covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, or declaring dividends. If we raise additional capital through marketing and distribution arrangements or other collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish certain valuable intellectual property or other rights to our product candidates, technologies, future revenue streams or research programs or grant licenses on terms that may not be favorable to us in one or more countries. Even if we were to obtain sufficient funding, there can be no assurance that it will be available on terms acceptable to us or our stockholders.
Our operating results and liquidity needs could be affected negatively by global market fluctuations and economic downturn.
Our operating results and liquidity could be affected negatively by global economic conditions generally, both in the United States and elsewhere around the world. The market for discretionary pharmaceutical products, medical devices and procedures may be particularly vulnerable to unfavorable economic conditions. Some patients may consider sofpironium bromide as discretionary, and if full reimbursement for the product is not available, demand for the product may be tied to the discretionary, out-of-pocket cash-spending levels of our targeted patient populations. Domestic and international equity and debt markets have experienced and may continue to experience heightened volatility and turmoil based on domestic and international economic conditions and concerns. In the event these economic conditions and concerns continue or worsen and the markets continue to remain volatile, or a bear market ensues in the U.S. stock market given the current bull market is the longest on record, our operating results and liquidity could be affected adversely by those factors in many ways, including weakening demand for sofpironium bromide, making it more difficult for us to raise funds if necessary, and our stock price may decline.
Our stock price has been and may continue to be highly volatile and illiquid.
The market price of our common stock following the Merger has been subject to significant fluctuations. Market prices for securities of biotechnology and other life sciences companies historically have been particularly volatile subject even to large daily price swings. In addition, there has been limited liquidity in the trading market for our securities, which may adversely affect stockholders. Some of the factors that may cause the market price of our common stock to continue to fluctuate include, but are not limited to:

54



material developments in, or the conclusion of, any litigation to enforce or defend any intellectual property rights or defend against the intellectual property rights of others;
the entry into, or termination of, or breach by us or our partners of material agreements, including key commercial partner or licensing agreements, including the License Agreement;
our ability to obtain timely regulatory approvals for sofpironium bromide or future product candidates, and delays or failures to obtain such approvals;
failure of sofpironium bromide, if approved, to achieve commercial success;
issues in manufacturing sofpironium bromide or future product candidates;
the results of current and any future clinical trials of sofpironium bromide;
failure of other product candidates, if approved, to achieve commercial success;
announcements of any dilutive equity financings;
announcements by commercial partners or competitors of new commercial products, clinical progress or the lack thereof, significant contracts, commercial relationships, or capital commitments;
the introduction of technological innovations or new therapies or formulations that compete with sofpironium bromide;
lack of commercial success of competitive products or products treating the same or similar indications;
failure to elicit meaningful stock analyst coverage and downgrades of our stock by analysts; and/or
the loss of key employees.
Moreover, the stock markets in general have experienced substantial volatility in our industry that has often been unrelated to the operating performance of individual companies or a certain industry segment. These broad market fluctuations may also adversely affect the trading price of our common stock.
In the past, following periods of volatility in the market price of a company’s securities, shareholders have often instituted class action securities litigation against those companies. Such litigation, if instituted, could result in substantial costs and diversion of management attention and resources, which could significantly harm our profitability and reputation. In addition, such securities litigation often has ensued after a reverse merger or other merger and acquisition activity of the type we recently completed. Such litigation if brought could expose us to liability or impact negatively our business, financial condition, operating results, and prospects.
Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations.
Our operations to date have been limited primarily to researching and developing sofpironium bromide and undertaking preclinical studies and clinical trials of sofpironium bromide. We (and our partners) have not yet obtained regulatory approvals for sofpironium bromide in any country. Consequently, any predictions you or we make about our future success or viability may not be as accurate as they could be if we had a longer operating history or approved products on the market. Our revenue and profitability will depend on development funding and the achievement of development and clinical milestones under an agreement with Kaken, as well as any potential future collaboration and license agreements and sales of sofpironium bromide or future products, if approved, and our ability to maintain the related license as part of the Bodor Complaint. These up-front and milestone payments may vary significantly from period to period, and country to country, and any such variance could cause a significant fluctuation in our operating results from one period to the next. In addition, we will measure compensation cost for stock-based awards made to employees at the grant date of the award, based on the fair value of the award as determined by our board of directors and recognize the cost as an expense over the employee’s requisite service period. As the variables that we use as a basis for valuing these awards change over time, including our underlying stock price and stock price volatility, the

55



magnitude of the expense that we must recognize may vary significantly. Furthermore, our operating results may fluctuate due to a variety of other factors, many of which are outside of our control and may be difficult to predict.
We incur costs and demands upon management as a result of complying with the laws and regulations affecting public companies.
We incur significant legal, accounting, and other expenses that Brickell did not incur as a private company prior to the Merger and operating as a public company, including costs associated with public company reporting and other SEC requirements. We also incur costs associated with newly applicable corporate governance requirements, including requirements under the Sarbanes-Oxley Act, as well as new rules implemented by the SEC and The Nasdaq Stock Market LLC. These rules and regulations are expected to increase our legal and financial compliance costs and to make some activities more time-consuming and costly. Our executive officers and other personnel will need to devote substantial time to gaining expertise regarding operations as a public company and compliance with applicable laws and regulations. These rules and regulations may also make it expensive for us to operate our business.
We are a “smaller reporting company” and the reduced disclosure and governance requirements applicable to smaller reporting companies may make our common stock less attractive to some investors.
We qualify as a “smaller reporting company” under Rule 12b-2 of the Exchange Act. As a smaller reporting company, we are entitled to rely on certain exemptions and reduced disclosure requirements, such as simplified executive compensation disclosures and reduced financial statement disclosure requirements, in our SEC filings. These exemptions and decreased disclosures in our SEC filings due to our status as a smaller reporting company may make it harder for investors to analyze our results of operations and financial prospects. We cannot predict if investors will find our common stock less attractive because we rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our common stock price may be more volatile. We will remain a “smaller reporting company” under Item 10(f)(1) of SEC Regulation S-K as long as we maintain a public float as defined by that regulation of less than $250 million; or we have less than $100 million in annual revenues and (i) either no public float, or (ii) a public float of less than $700 million.
Provisions of Delaware law and our amended certificate of incorporation and amended and restated bylaws may discourage another company from acquiring us and may prevent attempts by our stockholders to replace or remove our current management.
Provisions of Delaware law and our amended certificate of incorporation and amended and restated bylaws may discourage, delay, or prevent a merger or acquisition that our stockholders may consider favorable, including transactions in which you might otherwise receive a premium for your shares. In addition, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace or remove our board of directors. These provisions include, but are not limited to:
authorizing the issuance of “blank check” preferred stock without any need for action by stockholders;
providing for a classified board of directors with staggered terms;
requiring supermajority stockholder voting to effect certain amendments to our current certificate of incorporation and bylaws;
eliminating the ability of stockholders to call special meetings of stockholders; and
establishing advance notice requirements for nominations for election to our board of directors or for proposing matters that can be acted on by stockholders at stockholder meetings.
Although we believe these provisions collectively provide for an opportunity to receive higher bids by requiring potential acquirers to negotiate with our board of directors, they would apply even if an offer may be considered beneficial by some stockholders. In addition, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it difficult for stockholders to replace members of our board of directors, which is responsible for appointing the members of our management.

56



If the holders of our company’s stock options and warrants exercise their rights to purchase our common stock, the ownership of our stockholders will be diluted.
As of September 30, 2019, we have (i) warrants issued and outstanding to purchase 891,582 shares of our common stock at an exercise price of $0.07 per share, 731,908 shares of our common stock at an exercise price of $10.36 and 9,005 shares of our common stock at an exercise price of $33.31; and (ii) we have 1,802,895 options issued and outstanding to purchase our common stock at a weighted average exercise price of $14.99 per share. If the holders of our outstanding stock options and warrants exercise their rights to acquire our common stock, the percentage ownership of our stockholders existing prior to the exercise of rights will be diluted.
We do not anticipate paying any dividends in the foreseeable future.
Our current expectation is that we will retain our future earnings to fund the development and growth of our business. As a result, capital appreciation, if any, of our shares will be your sole source of gain, if any, for the foreseeable future.
If we fail to attract and retain management and other key personnel and directors, we may be unable to continue to successfully develop or commercialize our product candidates or otherwise implement our business plan.
Our ability to compete in the highly competitive pharmaceuticals industry depends on our ability to attract and retain highly qualified managerial, scientific, medical, legal, sales and marketing, other personnel, and directors for our board. We are highly dependent on our management, scientific personnel, and our directors. The loss of the services of any of these individuals could impede, delay or prevent the successful development of our product pipeline, completion of our planned clinical trials, commercialization of our product candidates or in-licensing or acquisition of new assets and could impact negatively our ability to implement successfully our business plan and in a way that complies with all applicable laws. If we lose the services of any of these individuals, we might not be able to find suitable replacements on a timely basis or at all, and our business could be harmed as a result. We might not be able to attract or retain qualified management and other key personnel or directors in the future due to the intense competition for qualified individuals among biotechnology, pharmaceutical and other businesses.
Our ability to use our net operating loss carryforwards to offset future taxable income may be subject to certain limitations.
As of December 31, 2018, we had approximately $36.5 million of federal and $30.9 million of state operating loss carryforwards available to offset future taxable income, which expire in varying amounts beginning in 2030 for federal and state purposes if unused. It is possible that we will not generate taxable income in time to use these loss carryforwards before their expiration. Our net operating loss carryforwards may also be subject to limitation as a result of prior shifts in equity ownership in connection with the Merger. In addition, we may experience ownership changes in the future as a result of offerings of our stock or subsequent shifts in our stock ownership, some of which are outside of our control. In that case, the ability to use net operating loss carryforwards to offset future taxable income will be limited following any such ownership change.
We may be affected adversely by natural disasters and other catastrophic events and by man-made problems such as war or terrorism or labor disruptions that could disrupt our business operations, and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster.
Our corporate office is located in Boulder, Colorado, near a major flood and blizzard zone. If a disaster, power outage, computer hacking, or other event occurred that prevented us from using all or a significant portion of our office, that damaged critical infrastructure (such as enterprise financial systems, IT systems, manufacturing resource planning or enterprise quality systems), or that otherwise disrupted operations, it may be difficult or, in certain cases, impossible for us to continue our business for a substantial period of time. Our contract manufacturers’ and suppliers’ facilities are located in multiple locations where other natural disasters or similar events, such as tornadoes, earthquakes, storms, fires, explosions or large-scale accidents or power outages, or IT threats, could severely disrupt our operations, could expose us to liability and could have a material adverse effect on our business, financial condition, operating results, and prospects. In addition, acts of terrorism and other geo-political unrest or labor unrest could cause disruptions in our business or the businesses of our partners, manufacturers, or the economy as a whole. All of the aforementioned risks may be further increased if we do not implement a disaster recovery plan or our partners’ or manufacturers’ disaster recovery plans prove to be inadequate. To the extent that any of the above should result in delays in the regulatory approval, manufacture, distribution, or commercialization of sofpironium bromide, this could expose us to liability, and our business, financial condition, operating results, and prospects would suffer.

57



Our business and operations would suffer in the event of system failures, cyber-attacks, or a deficiency in our cyber-security.
Despite the implementation of security measures, our internal computer systems and those of our current and future CROs and other contractors and consultants are vulnerable to damage from computer viruses, unauthorized access, computer hacking or breaches, natural disasters, terrorism, war, labor unrest, and telecommunication and electrical failures. The risk of a security breach or disruption, particularly through cyber-attacks or cyber-intrusion, including by computer hackers, foreign governments, and cyber-terrorists, has generally increased as the number, intensity and sophistication of attempted attacks and intrusions from around the world have increased. While we have not experienced any such material system failure, accident, or security breach to date, if such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our development programs and our business operations. In addition, since we sponsor clinical trials, any breach that compromises patient data and identities causing a breach of privacy could generate significant reputational damage and legal liabilities and costs to recover and repair, including affecting trust in us to recruit for future clinical trials. For example, the loss of clinical trial data from completed or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications or inappropriate disclosure of confidential or proprietary information, we could incur liability and the further development and commercialization of our products and product candidates could be delayed.
Risks Related to Our Intellectual Property
We may not be able to obtain, maintain or enforce global patent rights or other intellectual property rights that cover sofpironium bromide and related technologies that are of sufficient breadth.
Our success with respect to sofpironium bromide will depend, in part, on our ability to obtain and maintain patent and other intellectual property protections in both the United States and other countries, to preserve our trade secrets and to prevent third parties from infringing on our proprietary rights. Our ability to protect sofpironium bromide from unauthorized or infringing use by third parties depends in substantial part on our ability to obtain and maintain valid and enforceable patents and other intellectual property rights around the world.
The patent application process, also known as patent prosecution, is expensive and time-consuming, and we and our current or future licensors and licensees may not be able to prepare, file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner in all the countries that may be desirable. It is also possible that we or our current licensors and licensees, or any future licensors or licensees, will fail to identify patentable aspects of inventions made in the course of development and commercialization activities before it is too late to obtain patent protection on them. Therefore, these and any of our patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business. Moreover, our competitors independently may develop equivalent knowledge, methods and know-how or discover workarounds to our patents that would not constitute infringement. Any of these outcomes could impair our ability to enforce the exclusivity of our patents effectively, which may have an adverse impact on our business, financial condition, operating results, and prospects.
Due to constantly shifting global legal standards relating to patentability, validity, enforceability and claim scope of patents covering pharmaceutical inventions, our ability to obtain, maintain and enforce patents in any jurisdiction is uncertain and involves complex legal and factual questions especially across countries. Accordingly, rights under any existing patents or any patents we might obtain or license may not cover our product candidates or may not provide us with sufficient protection for our product candidates to afford a sustainable commercial advantage against competitive products or processes, including those from branded, generic, and over-the-counter pharmaceutical companies. In addition, we cannot guarantee that any patents or other intellectual property rights will issue from any pending or future patent or other similar applications owned by or licensed to us. Even if patents or other intellectual property rights have issued or will issue, we cannot guarantee that the claims of these patents and other rights are or will be held valid or enforceable by the courts or other legal authorities, through injunction or otherwise, or will provide us with any significant protection against competitive products or otherwise be commercially valuable to us in every country of commercial significance that we may target, or that a legislative or executive branch of government may alter the rights and enforceability thereof at any time.
Competitors in the field of dermatologic therapeutics have created a substantial amount of prior art, including scientific publications, abstracts, posters, presentations, patents and patent applications and other public disclosures including on the Internet and various social media. Our ability to obtain and maintain valid and enforceable patents and other intellectual property rights depends on whether the differences between our proprietary technology and the prior art allow our technology to be patentable over the prior art. We do not have outstanding issued patents covering all of the recent developments in our technology and are unsure of the patent protection that we will be successful in obtaining, if any. Even if the patents do issue successfully,

58



third parties may design around or challenge the validity, enforceability or scope of such issued patents or any other issued patents or intellectual property we own or license, which may result in such patents and/or other intellectual property being narrowed, invalidated, or held unenforceable. If the breadth or strength of protection provided by the patents and other intellectual property we hold or pursue with respect to our product candidates is challenged, regardless of our future success, it could dissuade companies from collaborating with us to develop, or threaten our ability to commercialize or finance, our product candidates.
The laws of some foreign jurisdictions do not provide intellectual property rights to the same extent or duration as in the United States, and many companies have encountered significant difficulties in acquiring, maintaining, protecting, defending, and especially enforcing such rights in foreign jurisdictions. If we encounter such difficulties in protecting, or are otherwise precluded from effectively protecting, our intellectual property in foreign jurisdictions, our business prospects could be substantially harmed, especially internationally.
Patents have a limited lifespan. In the United States, the natural expiration of a patent is generally 20 years after it is filed, with patent term extensions granted in certain instances to compensate for part of the period in which the drug was under development and could not be commercialized while under the patent. Without patent protection for sofpironium bromide, we may be open to competition from generic versions of sofpironium bromide. The issued U.S. patents relating to sofpironium bromide run through 2031, including expected extensions just described. We also filed jointly with Kaken a new composition of matter provisional patent application in the United States that would provide expected coverage through 2040, but only in the event of a grant of this patent.
Proprietary trade secrets and unpatented know-how are also very important to our business. Although we have taken steps to protect our trade secrets and unpatented know-how by entering into confidentiality agreements with third parties and intellectual property protection agreements with officers, directors, employees, and certain consultants and advisors, there can be no assurance that binding agreements will not be breached or enforced by courts or other legal authorities, that we would have adequate remedies for any breach, including injunctive and other equitable relief, or that our trade secrets and unpatented know-how will not otherwise become known, be inadvertently disclosed by us or our agents and representatives, or be independently discovered by our competitors. If trade secrets are independently discovered, we would not be able to prevent their use and if we and our agents or representatives inadvertently disclose trade secrets and/or unpatented know-how, we may not be allowed to retrieve the inadvertently disclosed trade secret and/or unpatented know-how and maintain the exclusivity we previously enjoyed.
We may not be able to protect our intellectual property rights throughout the world.
Filing, prosecuting, and defending patents on our product candidates does not guarantee exclusivity. The requirements for patentability differ in certain countries, particularly developing countries, and can change over time in the same country. In addition, the laws of some other countries do not protect intellectual property rights to the same extent as laws in the United States, especially when it comes to granting use and other kinds of patents and what kind of enforcement rights will be allowed, especially injunctive relief in a civil infringement proceeding. Consequently, we may not be able to prevent third parties from practicing our inventions in countries outside the United States and even in launching an identical version of our product notwithstanding us having a valid patent or other intellectual property rights in that country. Competitors may use our technologies in jurisdictions where we or our licensors have not obtained patent or other protections to develop their own products, or produce copy products, and, further, may export otherwise infringing products to territories where we have patent and other protections but enforcement against infringing activities is inadequate or where we have no patents or other intellectual property rights. These products may compete with our products, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from commercialization or other uses.
Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly in developing countries, do not favor the enforcement of patents and other intellectual property protection, particularly those relating to pharmaceuticals, and the judicial and government systems are often corrupt, apathetic or ineffective, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our intellectual property rights generally. Proceedings to enforce our intellectual property rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our global patents and other rights at risk of being invalidated or interpreted narrowly and our global patent applications at risk of not issuing, and could provoke third parties to assert claims against us. We may not prevail in any lawsuit that we initiate or infringement action brought against us, and the damages or other remedies awarded, if any, may not be commercially meaningful when we are the plaintiff. When we are the defendant, we may be required to post large bonds to stay in the market while we defend ourselves from an infringement action.

59



In addition, certain countries in Europe and certain developing countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties, especially if the patent owner does not enforce or use its patents over a protracted period of time. In some cases, the courts will force compulsory licenses on the patent holder even when finding the patentholder’s patents are valid if the court believes it is in the best interests of the country to have widespread access to an essential product covered by the patent. Further, there is no guarantee that any country will not adopt or impose compulsory licensing in the future. In these situations the royalty the court requires to be paid by the licenseholder receiving the compulsory license may not be calculated at fair market value and can be inconsequential, thereby disaffecting the patentholder’s business. In these countries, we may have limited remedies if our patents are infringed or if we are compelled to grant a license to our patents to a third party, which could also materially diminish the value of those patents. This would limit our potential revenue opportunities. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we own or license, especially in comparison to what we enjoy from enforcing our intellectual property rights in the United States. Finally, our ability to protect and enforce our intellectual property rights may be adversely affected by unforeseen changes in both U.S. and foreign intellectual property laws, or changes to the policies in various government agencies in these countries, including but not limited to the patent office issuing patents and the health agency issuing pharmaceutical product approvals. For example, in Brazil, pharmaceutical patents require prior initial approval of the Brazilian health agency (ANVISA). Finally, many countries have large backlogs in patent prosecution, and in some countries in Latin America it can take years, even decades, just to get a pharmaceutical patent application reviewed notwithstanding the merits of the application.
Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment, and other requirements imposed by governmental patent and similar agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.
Periodic maintenance and annuity fees on any issued patent are due to be paid to the USPTO and foreign patent agencies in several stages over the lifetime of a patent. The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. While an inadvertent lapse can, in many cases, be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction just for failure to know about and/or timely pay such fee. Non-compliance events that could result in abandonment or lapse of a patent or patent application include failure to respond to official actions within prescribed time limits, non-payment of fees in prescribed time periods, and failure to properly legalize and submit formal documents in the format and style the country requires. If we or our licensors fail to maintain the patents and patent applications covering our product candidates for any reason, our competitors might be able to otherwise enter the market, which would have an adverse effect on our business, financial condition, operating results, and prospects.
In addition, countries continue to increase the fees that are charged to acquire, maintain, and enforce patents and other intellectual property rights, which may become prohibitive to initiate or continue paying in certain circumstances.
If we fail to comply with our obligations under our intellectual property license agreements, we could lose license rights that are important to our business. Additionally, these agreements may be subject to disagreement over contract interpretation, which could narrow the scope of our rights to the relevant intellectual property or technology, or increase our financial or other obligations to our licensors.
We have entered into in-license arrangements with respect to certain of our product candidates. These license agreements impose various diligence, milestone, royalty, insurance, reporting and other obligations on us. If we fail to comply with these obligations, the respective licensors may have the right to terminate or modify the license, or trigger other more disadvantageous contract clauses, in which event we may not be able to finance, develop or market the affected product candidate. The loss of such rights could expose us to liability and could materially adversely affect our business, financial condition, operating results, and prospects.
Our commercial success depends on our ability to develop, manufacture, market and sell our product candidates and use our proprietary technologies without infringing the proprietary rights of third parties and do this in one or more countries. We cannot assure that marketing and selling such product candidates and using such technologies will not infringe existing or future patents. Numerous U.S.- and foreign-issued patents and pending patent applications owned by third parties exist in the fields relating to our product candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that others may assert that our product candidates, technologies, or methods of delivery or use(s) infringe their patent or other intellectual property rights. Moreover, it is not always clear to industry participants, including us, which patents and other intellectual property rights cover various drugs, biologics, drug delivery systems and formulations, manufacturing processes,

60



or their methods of use, and which of these patents may be valid and enforceable. Thus, because of the large number of patents issued and patent applications filed in our fields across many countries, there may be a risk that third parties may allege they have patent or other rights encompassing our product candidates, technologies, or methods.
In addition, there may be issued patents of third parties that are infringed or are alleged to be infringed by our product candidates or proprietary technologies notwithstanding the patents we may possess. Because some patent applications in the United States and other countries may be maintained in secrecy until the patents are issued, because patent applications in the United States and many foreign jurisdictions are typically not published until 18 months or some other time after filing, and because publications in the scientific literature or other public disclosures often lag behind actual discoveries, we cannot be certain that others have not filed patent applications for technology covered by our own and in-licensed issued patents or our pending applications. Our competitors may have filed, and may in the future file, patent applications covering our product candidates or technology similar to our technology. Any such patent application may have priority over our own and in-licensed patent applications or patents, which could further require us to obtain rights to issued patents covering such technologies, which may mean paying significant licensing fees or royalties, or the like. If another party has filed a U.S. patent application on inventions similar to those owned or in-licensed to us, we or, in the case of in-licensed technology, the licensor, may have to participate in the United States in an interference proceeding to determine priority of invention.
We may be exposed to, or threatened with, future litigation by third parties having patent or other intellectual property rights alleging that our product candidates or proprietary technologies infringe such third parties’ intellectual property rights, including litigation resulting from filing in the United States under Paragraph IV of the Hatch-Waxman Act or other countries’ laws similar to the Hatch-Waxman Act. These lawsuits could claim that there are existing patent rights for such drug, and this type of litigation can be costly and could adversely affect our operating results and divert the attention of managerial and technical personnel, even if we do not infringe such patents or the patents asserted against us are ultimately established as invalid. There is a risk that a court or other legal authority would decide that we are infringing the third party’s patents and would order us to stop the activities covered by the patents. In addition, there is a risk that a court or other legal authority will order us to pay the other party significant damages for having violated the other party’s patents or intellectual property rights.
Because we rely on certain third-party licensors and partners and will continue to do so in the future, around the world, if one of our licensors or partners is sued for infringing a third party’s intellectual property rights, this could expose us to liability and our business, financial condition, operating results, and prospects could suffer in the same manner as if we were sued directly. In addition to facing litigation risks, we have agreed to indemnify certain third-party licensors and partners against claims of infringement caused by our proprietary technologies, and we have entered or may enter into cost-sharing agreements with some of our licensors and partners that could require us to pay some of the costs of patent or other intellectual property rights litigation brought against those third parties whether or not the alleged infringement is caused by our proprietary technologies. In certain instances, these cost-sharing agreements could also require us to assume greater responsibility for infringement damages than would be assumed just on the basis of our technology.
The occurrence of any of the foregoing could expose us to liability or adversely affect our business, financial condition, operating results, and prospects at any time.
We may be subject to claims that our officers, directors, employees, consultants, or independent contractors have wrongfully used or disclosed to us alleged trade secrets or other confidential and proprietary information of their former employers or their former or current customers.
As is common in the biotechnology and pharmaceutical industries, certain of our employees were formerly employed by other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Moreover, we engage the services of consultants to assist us in the development of our products and product candidates, many of whom were previously employed at, or may have previously been or are currently providing consulting services to, other biotechnology or pharmaceutical companies, including our competitors or potential competitors. We may be subject to claims that these employees and consultants or we have inadvertently or otherwise used or disclosed trade secrets or other proprietary confidential information of their former employers or their former or current customers. Although we have no knowledge of any such claims being alleged to date, if such claims were to arise, litigation may be necessary to defend against any such claims. Even if we are successful in defending against any such claims, any litigation like this could be protracted, expensive, a distraction to our management team, not viewed favorably by investors and other third parties, and may potentially result in an unfavorable outcome.


61



ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

Not applicable.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

Not applicable.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5. OTHER INFORMATION

Not applicable.

ITEM 6. EXHIBITS
 
 
 
 
Exhibit
Number
 
Description of Exhibit
Filed Herewith
 
Restated Certificate of Incorporation, as currently in effect (incorporated by reference to Exhibit 3.2 to the Company’s Current Report on Form 8-K filed with the Commission on September 3, 2019).
 
 
Amended and Restated Bylaws (incorporated by reference to Exhibit 3.3 to the Company’s Current Report on Form 8-K filed with the Commission on September 3, 2019).
 
 
Certificate of Merger (incorporated by reference to Exhibit 3.4 to the Company’s Current Report on 8-K filed with the Commission on September 3, 2019).
 
 
Specimen Common Stock Certificate (incorporated by reference to Exhibit 4.1 to the Company’s Registration Statement on Form S-8 filed with the Commission on September 10, 2019).
 
 
Certification of Principal Executive Officer pursuant to Rule13a-14(a) and Rule 15d-14(a) of the Securities and Exchange Act, as amended.
 
Certification of Principal Financial Officer pursuant to Rule13a-14(a) and Rule 15d-14(a) of the Securities and Exchange Act, as amended.
 
Certification of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS**
 
XBRL Instance Document
101.SCH**
 
XBRL Taxonomy Extension Schema Document
101.CAL**
 
XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF**
 
XBRL Taxonomy Extension Definition Linkbase Document
101.LAB**
 
XBRL Taxonomy Extension Label Linkbase Document
101.PRE**
 
XBRL Taxonomy Extension Presentation Linkbase Document
__________________
*
This certification is being furnished pursuant to 18 U.S.C. Section 1350 and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Registrant, whether made before or after the date hereof.

**
In accordance with Rule 406T of Regulation S-T, the Interactive Data Files in Exhibit 101 are deemed not filed or part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, are deemed not filed for purposes of Section 18 of the Exchange Act of 1934, as amended, and otherwise are not subject to liability under these sections.


62



SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Quarterly Report to be signed on its behalf by the undersigned thereunto duly authorized.

 
 
Brickell Biotech, Inc.
 
 
 
 
 
Date: November 14, 2019
 
By:
 
/s/ Robert. B. Brown
 
 
 
 
Robert B. Brown
 
 
 
 
Chief Executive Officer
(Principal Executive Officer)
 
 
 
 
 
 
 
By:
 
/s/ R. Michael Carruthers
 
 
 
 
R. Michael Carruthers
 
 
 
 
Chief Financial Officer
(Principal Financial Officer; Principal Accounting Officer)



63
EX-31.1 2 ex311.htm EXHIBIT 31.1 Exhibit

Exhibit 31.1



CERTIFICATION

I, Robert. B. Brown, certify that:
1.
I have reviewed this Quarterly Report on Form 10-Q, or this report, of Brickell Biotech, Inc., a Delaware corporation;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

 
 
 
 
 
Date: November 14, 2019
 
By:
/s/ Robert. B. Brown
 
 
 
Robert. B. Brown
 
 
 
Chief Executive Officer
 
 
 
(Principal Executive Officer)
 
 



EX-31.2 3 ex312.htm EXHIBIT 31.2 Exhibit

Exhibit 31.2


CERTIFICATION

I, R. Michael Carruthers, certify that:
1.
I have reviewed this Quarterly Report on Form 10-Q, or this report, of Brickell Biotech, Inc., a Delaware corporation;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

 
 
 
 
 
Date: November 14, 2019
 
By:
/s/ R. Michael Carruthers
 
 
 
R. Michael Carruthers
 
 
 
Chief Financial Officer
 
 
 
(Principal Financial Officer)



EX-32.1 4 ex321.htm EXHIBIT 32.1 Exhibit

Exhibit 32.1


SECTION 1350 CERTIFICATION

Each of the undersigned, Robert. B. Brown Chief Executive Officer of Brickell Biotech, Inc., a Delaware corporation (the “Company”), and R. Michael Carruthers, Chief Financial Officer of the Company, do hereby certify, pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of his knowledge (1) the Quarterly Report on Form 10-Q of the Company for the quarterly period ended June 30, 2019, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and (2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
 
Brickell Biotech, Inc.
 
 
 
 
 
By:
 
/s/ Robert. B. Brown
 
 
 
Robert B. Brown
 
 
 
Chief Executive Officer
(Principal Executive Officer)
 
 
 
Date: November 14, 2019
 
 
 
 
 
By:
 
/s/ R. Michael Carruthers
 
 
 
R. Michael Carruthers
 
 
 
Chief Financial Officer
(Principal Financial Officer)
 
 
 
Date: November 14, 2019
 
 
 
 
 
This certification accompanies and is being “furnished” with this Report, shall not be deemed “filed” by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to liability under that Section and shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Report, irrespective of any general incorporation language contained in such filing. A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.



EX-101.SCH 5 bbi-20190930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 2105100 - Disclosure - ACCRUED LIABILITIES link:presentationLink link:calculationLink link:definitionLink 2405402 - Disclosure - ACCRUED LIABILITIES - Summary of Accrued Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2305301 - Disclosure - ACCRUED LIABILITIES (Tables) link:presentationLink link:calculationLink link:definitionLink 2109100 - Disclosure - CAPITAL STOCK link:presentationLink link:calculationLink link:definitionLink 2409402 - Disclosure - CAPITAL STOCK - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2409403 - Disclosure - CAPITAL STOCK - Reserved Authorized Shares of Common Stock (Details) link:presentationLink link:calculationLink link:definitionLink 2409404 - Disclosure - CAPITAL STOCK - Summary of Preferred Stock (Details) link:presentationLink link:calculationLink link:definitionLink 2309301 - Disclosure - CAPITAL STOCK (Tables) link:presentationLink link:calculationLink link:definitionLink 2108100 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 2408401 - Disclosure - COMMITMENTS AND CONTINGENCIES - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 1001000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 1001501 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (PARENTHETICAL) link:presentationLink link:calculationLink link:definitionLink 1005000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 1002000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 1004000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY (DEFICIT) link:presentationLink link:calculationLink link:definitionLink 1003000 - Statement - CONDENSED CONSOLIDATED STATMENTS OF COMPREHENSIVE LOSS link:presentationLink link:calculationLink link:definitionLink 1003001 - Statement - CONDENSED CONSOLIDATED STATMENTS OF COMPREHENSIVE LOSS (PARENTHETICAL) link:presentationLink link:calculationLink link:definitionLink 2106100 - Disclosure - CONVERTIBLE PROMISSORY NOTES link:presentationLink link:calculationLink link:definitionLink 2406401 - Disclosure - CONVERTIBLE PROMISSORY NOTES - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0001000 - Document - COVER PAGE link:presentationLink link:calculationLink link:definitionLink 2107100 - Disclosure - NOTE PAYABLE link:presentationLink link:calculationLink link:definitionLink 2407401 - Disclosure - NOTE PAYABLE - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2104100 - Disclosure - NOVAQUEST FUNDING ARRANGEMENT link:presentationLink link:calculationLink link:definitionLink 2404401 - Disclosure - NOVAQUEST FUNDING ARRANGEMENT - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2101100 - Disclosure - ORGANIZATION AND NATURE OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 2401401 - Disclosure - ORGANIZATION AND NATURE OF OPERATIONS - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2103100 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS link:presentationLink link:calculationLink link:definitionLink 2403403 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS - Effects of Topic 842 (Details) link:presentationLink link:calculationLink link:definitionLink 2403402 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2303301 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 2110100 - Disclosure - STOCK-BASED COMPENSATION link:presentationLink link:calculationLink link:definitionLink 2410402 - Disclosure - STOCK-BASED COMPENSATION - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2410404 - Disclosure - STOCK-BASED COMPENSATION - Share-based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 2310301 - Disclosure - STOCK-BASED COMPENSATION (Tables) link:presentationLink link:calculationLink link:definitionLink 2111100 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 2102100 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 2402407 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Fair Value Measurement Inputs (Details) link:presentationLink link:calculationLink link:definitionLink 2402406 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Fair Value Measurements Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2402405 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Fair Value of Assets and Liabilities Measured on a Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 2402403 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Merger Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2202201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 2402408 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Reconciliation of Level 3 Financial Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 2402409 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Redeemable Convertible Preferred Stock Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2402410 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2402411 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Summary of Common Shares Excluded from EPS Calculations (Details) link:presentationLink link:calculationLink link:definitionLink 2402404 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Summary of Net Assets Acquired (Details) link:presentationLink link:calculationLink link:definitionLink 2302302 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 6 bbi-20190930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 7 bbi-20190930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 8 bbi-20190930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Share-based Payment Arrangement [Abstract] Share-based Compensation Expense Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Statement of Cash Flows [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES: Net Cash Provided by (Used in) Operating Activities [Abstract] Net loss Net Income (Loss) Attributable to Parent Adjustments to reconcile net loss to net cash provided by (used in) operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Depreciation Depreciation Accretion of discount on marketable securities Debt Securities, Available-for-Sale, Accretion Of Discount Debt Securities, Available-for-Sale, Accretion Of Discount Non-cash interest expense Paid-in-Kind Interest Change in fair value of derivative liability Liabilities, Fair Value Adjustment Change in fair value of warrant liability Fair Value Adjustment of Warrants Gain on extinguishment Gain (Loss) on Extinguishment of Debt Amortization of operating lease right-of-use assets Operating Lease, Cost Amortization of convertible promissory notes discount Amortization Of Debt Discount Amortization Of Debt Discount Amortization of debt discounts and financing costs Amortization of Debt Issuance Costs and Discounts Stock-based compensation Share-based Payment Arrangement, Noncash Expense Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Accounts payable Increase (Decrease) in Accounts Payable Accrued liabilities Increase (Decrease) in Accrued Liabilities Lease liability Increase (Decrease) In Operating Lease Liability Increase (Decrease) In Operating Lease Liability Research and development funding liability Increase (Decrease) in Other Noncurrent Liabilities Deferred revenue Increase (Decrease) in Contract with Customer, Liability Net cash provided by (used in) operating activities Net Cash Provided by (Used in) Operating Activities CASH FLOWS FROM INVESTING ACTIVITIES: Net Cash Provided by (Used in) Investing Activities [Abstract] Cash and cash equivalents acquired in recapitalization Cash Acquired from Acquisition Maturities of marketable securities Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale Capital expenditures Payments to Acquire Productive Assets Net cash provided by (used in) investing activities Net Cash Provided by (Used in) Investing Activities CASH FLOWS FROM FINANCING ACTIVITIES: Net Cash Provided by (Used in) Financing Activities [Abstract] Payments of principal of note payable Repayments of Notes Payable Proceeds from issuance of convertible promissory notes Proceeds from Convertible Debt Proceeds from the exercise of stock options Proceeds from Stock Options Exercised Net cash provided by (used in) financing activities Net Cash Provided by (Used in) Financing Activities NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect CASH AND CASH EQUIVALENTS—BEGINNING Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents CASH AND CASH EQUIVALENTS—ENDING Supplement Disclosure of Cash Flow Information: Supplemental Cash Flow Information [Abstract] Interest paid Interest Paid, Excluding Capitalized Interest, Operating Activities Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Conversion of redeemable convertible preferred stock and preferred stock dividends to common stock Temporary Stock Issued During Period, Value, Conversion Of Convertible Securities Temporary Stock Issued During Period, Value, Conversion Of Convertible Securities Accretion (reduction) of redeemable convertible preferred stock to redemption value Temporary Equity, Accretion (Reduction) To Redemption Value Temporary Equity, Accretion (Reduction) To Redemption Value Shares issued in recapitalization Shares Issued In Recapitalization Shares Issued In Recapitalization Accretion of redeemable convertible preferred stock issuance costs Temporary Equity, Accretion Of Stock Issuance Costs Temporary Equity, Accretion Of Stock Issuance Costs Derivative liability issued with convertible promissory notes Convertible Debt, Derivative Liability Issued Convertible Debt, Derivative Liability Issued Warrants to purchase common stock issued with funding agreement Funding Commitment, Warrants Issued Funding Commitment, Warrants Issued Warrants to purchase common stock issued with convertible promissory notes Convertible Debt, Warrants Issued Convertible Debt, Warrants Issued Change in unrealized loss on available-for-sale marketable securities Change In Unrealized Gain (Loss) Available for Sale, Debt Securities Change In Unrealized Gain (Loss) Available for Sale, Debt Securities Commitments and Contingencies Disclosure [Abstract] COMMITMENTS AND CONTINGENCIES Commitments and Contingencies Disclosure [Text Block] Cover page. Document Type Document Type Document Quarterly Report Document Quarterly Report Document Period End Date Document Period End Date Document Transition Report Document Transition Report Entity File Number Entity File Number Entity Registrant Name Entity Registrant Name Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Title of 12(b) Security Title of 12(b) Security Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Interactive Data Current Entity Interactive Data Current Entity Current Reporting Status Entity Current Reporting Status Entity Filer Category Entity Filer Category Entity Small Business Entity Small Business Entity Emerging Growth Company Entity Emerging Growth Company Entity Shell Company Entity Shell Company Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Entity Central Index Key Entity Central Index Key Document Fiscal Period Focus Document Fiscal Period Focus Amendment Flag Amendment Flag Document Fiscal Year Focus Document Fiscal Year Focus Current Fiscal Year End Date Current Fiscal Year End Date Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Award Type [Axis] Award Type [Axis] Award Type [Domain] Award Type [Domain] Options Share-based Payment Arrangement, Option [Member] Plan Name [Axis] Plan Name [Axis] Plan Name [Domain] Plan Name [Domain] 2009 Plan Equity Incentive Plan 2009 [Member] Equity Incentive Plan 2009 [Member] Vical Plan Vical Stock Incentive Plan [Member] Vical Stock Incentive Plan [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Shares authorized (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Shares available for grant (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant Expiration term Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period Maximum shares permitted to be granted in a single calendar year (in shares) Share-based Compensation Arrangement By Share-based Payment Award, Number Of Shares Authorized For Grant In One Year Share-based Compensation Arrangement By Share-based Payment Award, Number Of Shares Authorized For Grant In One Year Statement of Comprehensive Income [Abstract] Unrealized loss arising during holding period, tax benefit (expense) Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, Tax Accounting Policies [Abstract] SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Significant Accounting Policies [Text Block] Research and Development [Abstract] Schedule of Research and Development Arrangement, Contract to Perform for Others [Table] Schedule of Research and Development Arrangement, Contract to Perform for Others [Table] Class of Warrant or Right [Axis] Class of Warrant or Right [Axis] Class of Warrant or Right [Domain] Class of Warrant or Right [Domain] NovaQuest Warrants NovaQuest Warrants [Member] NovaQuest Warrants [Member] Measurement Input Type [Axis] Measurement Input Type [Axis] Measurement Input Type [Domain] Measurement Input Type [Domain] Expected volatility Measurement Input, Price Volatility [Member] Risk free interest rate Measurement Input, Risk Free Interest Rate [Member] Expected term (in years) Measurement Input, Expected Term [Member] Expected dividend yield Measurement Input, Expected Dividend Rate [Member] Statistical Measurement [Axis] Statistical Measurement [Axis] Statistical Measurement [Domain] Statistical Measurement [Domain] Minimum Minimum [Member] Maximum Maximum [Member] Counterparty Name [Axis] Counterparty Name [Axis] Counterparty Name [Domain] Counterparty Name [Domain] NovaQuest NovaQuest Capital Management LLC [Member] NovaQuest Capital Management LLC [Member] Research and Development Arrangement, Contract to Perform for Others [Line Items] Research and Development Arrangement, Contract to Perform for Others [Line Items] Commitment amount Research And Development Arrangement, Contract To Perform For Others, Funding Commitment Research And Development Arrangement, Contract To Perform For Others, Funding Commitment Monthly distribution amount as percent of invoiced R&D Research and Development Arrangement, Contract To Perform For Others, Monthly Distribution, Percent Of Invoiced Research And Development Research and Development Arrangement, Contract To Perform For Others, Monthly Distribution, Percent Of Invoiced Research And Development Potential milestone payments Research and Development Arrangement, Contract To Perform For Others, Potential Milestone Payments Research and Development Arrangement, Contract To Perform For Others, Potential Milestone Payments Potential milestone payments due upon approval Research and Development Arrangement, Contract To Perform For Others, Potential Milestone Payments, Due Upon Approval Research and Development Arrangement, Contract To Perform For Others, Potential Milestone Payments, Due Upon Approval Termination amount Research and Development Arrangement, Contract To Perform For Others, Termination Amount Research and Development Arrangement, Contract To Perform For Others, Termination Amount Termination amount, interest rate Research and Development Arrangement, Contract To Perform For Others, Termination Amount, Interest Rate Research and Development Arrangement, Contract To Perform For Others, Termination Amount, Interest Rate Stock issuable upon warrants (in shares) Class of Warrant or Right, Number of Securities Called by Warrants or Rights Exercise price (in usd per share) Class of Warrant or Right, Exercise Price of Warrants or Rights Coverage percent Debt Instrument, Warrants Issuance, Coverage Percent Debt Instrument, Warrants Issuance, Coverage Percent Warrants, measurement input Warrants and Rights Outstanding, Measurement Input Commitment funding amount Proceeds From Research and Development Arrangement, Funding Agreement Proceeds From Research and Development Arrangement, Funding Agreement Fair Value Measurement Inputs and Valuation Techniques [Table] Fair Value Measurement Inputs and Valuation Techniques [Table] Individual cumulative achievement probabilities Measurement Input, Individual Cumulative Achievement Probabilities [Member] Measurement Input, Individual Cumulative Achievement Probabilities [Member] Discount rate Measurement Input, Discount Rate [Member] Fair Value Measurement Inputs and Valuation Techniques [Line Items] Fair Value Measurement Inputs and Valuation Techniques [Line Items] Marketable securities, available-for-sale, amortized cost Debt Securities, Available-for-sale, Amortized Cost U.S. treasuries Debt Securities, Available-for-sale Marketable securities, available-for-sale, accumulated unrealized gain Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax Contingent consideration, measurement input Business Combination, Contingent Consideration, Liability, Measurement Input Operating lease liability Operating Lease, Liability Income Statement [Abstract] Collaboration revenue Revenue from Contract with Customer, Excluding Assessed Tax Operating expenses: Operating Expenses [Abstract] Research and development Research and Development Expense General and administrative General and Administrative Expense Total operating expenses Operating Expenses Loss from operations Operating Income (Loss) Investment and other income, net Investment Income, Interest Gain on extinguishment Interest expense Interest Expense Change in fair value of derivative liability Change in fair value of warrant liability Net loss Reduction (accretion) of redeemable convertible preferred stock to redemption value Temporary Equity, Accretion to Redemption Value, Adjustment Net loss attributable to common stockholders Net Income (Loss) Available to Common Stockholders, Basic Net loss per share attributable to common stockholders, basic and diluted (in usd per share) Earnings Per Share, Basic and Diluted Weighted-average shares used to compute net loss per share attributable to common stockholders, basic and diluted (in shares) Weighted Average Number of Shares Outstanding, Basic and Diluted Equity [Abstract] Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] Class of Stock [Axis] Class of Stock [Axis] Class of Stock [Domain] Class of Stock [Domain] Warrants to purchase common stock Redeemable Convertible Preferred Stock [Member] Common Stock Common Stock [Member] Class of Stock [Line Items] Class of Stock [Line Items] Conversion ratio Business Combination, Stock Conversation Ratio Business Combination, Stock Conversation Ratio Organization, Consolidation and Presentation of Financial Statements [Abstract] ORGANIZATION AND NATURE OF OPERATIONS Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Other comprehensive loss: Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] Unrealized loss on available-for-sale marketable securities arising during holding period, net of tax benefit of $0 Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, after Tax Total comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Series A, B, C & C-1 Redeemable Convertible Preferred Stock Legal Entity [Axis] Legal Entity [Axis] Entity [Domain] Entity [Domain] Vical Vical [Member] Vical [Member] Ownership [Axis] Ownership [Axis] Ownership [Domain] Ownership [Domain] Brickell Former Securityholders Brickell Former Securityholders [Member] Brickell Former Securityholders [Member] Vical Former Securityholders Vical Former Securityholders [Member] Vical Former Securityholders [Member] Equity Components [Axis] Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Business Acquisition [Line Items] Business Acquisition [Line Items] Common stock, par value (in usd per share) Common Stock, Par or Stated Value Per Share Reverse stock split ratio Stockholders' Equity Note, Stock Split, Conversion Ratio Common stock, shares outstanding Common Stock, Shares, Outstanding Common stock, shares issued Common Stock, Shares, Issued Percent of shares owned Common Stock, Shares Issued And Outstanding, Percent Common Stock, Shares Issued And Outstanding, Percent Net cash used in operating activities Cash, cash equivalents and marketable securities Cash, Cash Equivalents, and Short-term Investments Accumulated deficit Retained Earnings (Accumulated Deficit) Statement of Stockholders' Equity [Abstract] Statement [Table] Statement [Table] Stock Conversion Description [Axis] Stock Conversion Description [Axis] Conversion of Stock, Name [Domain] Conversion of Stock, Name [Domain] Redeemable Convertible Preferred Stock and Preferred Stock Dividends to Common Stock Redeemable Convertible Preferred Stock And Preferred Stock Dividends To Common Stock [Member] Redeemable Convertible Preferred Stock And Preferred Stock Dividends To Common Stock [Member] Convertible Notes Payable and Accrued Interest to Common Stock Convertible Notes Payable And Accrued Interest To Common Stock [Member] Convertible Notes Payable And Accrued Interest To Common Stock [Member] Additional Paid-In Capital Additional Paid-in Capital [Member] Accumulated Other Comprehensive Loss AOCI Attributable to Parent [Member] Accumulated Deficit Retained Earnings [Member] Adjustments for New Accounting Pronouncements [Axis] Adjustments for New Accounting Pronouncements [Axis] Type of Adoption [Domain] Type of Adoption [Domain] Accounting Standards Update 2014-09 Accounting Standards Update 2014-09 [Member] Statement [Line Items] Statement [Line Items] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Beginning Balance (in shares) Beginning Balance Stockholders' Equity Attributable to Parent Effect of adoption of Topic 606 Cumulative Effect of New Accounting Principle in Period of Adoption Reduction of redeemable convertible preferred stock to redemption value Preferred Stock Redemption Discount Accretion of redeemable convertible preferred stock to redemption value Preferred Stock, Accretion of Redemption Discount Conversion of securities (in shares) Stock Issued During Period, Shares, Conversion of Convertible Securities Conversion of securities Stock Issued During Period, Value, Conversion of Convertible Securities, Net of Adjustments Common stock issued in recapitalization (in shares) Stock Issued During Period, Shares, Acquisitions Common stock issued in recapitalization Stock Issued During Period, Value, Acquisitions Stock based compensation APIC, Share-based Payment Arrangement, Increase for Cost Recognition Issuance of common stock through exercise of stock option (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Issuance of common stock through exercise of stock option Stock Issued During Period, Value, Stock Options Exercised Reclassification of warrant liability to equity Adjustments To Additional Paid In Capital, Reclassification Of Warrant And Derivative Liability Adjustments To Additional Paid In Capital, Reclassification Of Warrant And Derivative Liability Common stock warrants issued in connection with the research and development funding liability Adjustments to Additional Paid in Capital, Warrant Issued Unrealized loss on available-for-sale marketable securities Net income (loss) Ending Balance (in shares) Ending Balance Increase (Decrease) in Temporary Equity [Roll Forward] Increase (Decrease) in Temporary Equity [Roll Forward] Beginning Balance (in shares) Temporary Equity, Shares Outstanding Beginning Balance Temporary Equity, Carrying Amount, Attributable to Parent Shares converted (in shares) Temporary Stock Issued During Period, Shares, Conversion Of Convertible Securities Temporary Stock Issued During Period, Shares, Conversion Of Convertible Securities Shares converted Accretion of redeemable convertible preferred stock to redemption value Temporary Equity, Accretion to Redemption Value Reduction of redeemable convertible preferred stock to redemption value Ending Balance (in shares) Ending Balance Statement of Financial Position [Abstract] Assets Assets [Abstract] Current assets: Assets, Current [Abstract] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Marketable securities, available-for-sale Debt Securities, Available-for-sale, Current Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Total current assets Assets, Current Property and equipment, net Property, Plant and Equipment, Net Operating lease right-of-use asset Operating Lease, Right-of-Use Asset Intangible assets Intangible Assets, Net (Excluding Goodwill) Total assets Assets Liabilities, redeemable convertible preferred stock, and stockholders’ equity (deficit) Liabilities and Equity [Abstract] Current liabilities: Liabilities, Current [Abstract] Accounts payable Accounts Payable, Current Accrued liabilities Accrued Liabilities, Current Lease liability, current portion Operating Lease, Liability, Current Deferred revenue, current portion Contract with Customer, Liability, Current Note payable Notes Payable, Current Total current liabilities Liabilities, Current Contingent consideration Business Combination, Contingent Consideration, Liability, Noncurrent Lease liability, net of current portion Operating Lease, Liability, Noncurrent Warrant liability Warrant Liability Warrant Liability Deferred revenue, net of current portion Contract with Customer, Liability, Noncurrent Research and development funding liability Other Liabilities, Noncurrent Total liabilities Liabilities Redeemable convertible preferred stock (Series A, B, C and C-1), $0.01 par value, 5,000,000 and 4,182,943 shares authorized at September 30, 2019 and December 31, 2018, respectively; 0 and 1,256,466 shares issued and outstanding at September 30, 2019 and December 31, 2018, respectively; aggregate liquidation preference of $0 and $46,985 at September 30, 2019 and December 31, 2018, respectively Commitments and contingencies (Note 8) Commitments and Contingencies Stockholders’ equity (deficit): Stockholders' Equity Attributable to Parent [Abstract] Common stock, $0.01 par value, 50,000,000 and 8,000,000 shares authorized at September 30, 2019 and December 31, 2018, respectively; 7,810,680 and 589,001 issued and outstanding at September 30, 2019 and December 31, 2018, respectively Common Stock, Value, Issued Additional paid-in capital Additional Paid in Capital Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Total stockholders’ equity (deficit) Total liabilities, redeemable convertible preferred stock, and stockholders’ equity (deficit) Liabilities and Equity NOVAQUEST FUNDING ARRANGEMENT Research, Development, and Computer Software Disclosure [Text Block] Temporary Equity, by Class of Stock [Table] Temporary Equity, by Class of Stock [Table] Series A Series A Preferred Stock [Member] Series B Series B Preferred Stock [Member] Series C Series C Preferred Stock [Member] Series C-1 Series C-1 Preferred Stock [Member] Series C-1 Preferred Stock [Member] Temporary Equity [Line Items] Temporary Equity [Line Items] Preferred Shares Authorized (in shares) Temporary Equity, Shares Authorized Preferred Shares Issued (in shares) Temporary Equity, Shares Issued Preferred Shares Outstanding (in shares) Par Value Temporary Equity, Par Value Carrying Value Common Stock Issued Upon Conversion (in shares) Debt Disclosure [Abstract] CONVERTIBLE PROMISSORY NOTES Debt Disclosure [Text Block] Lease term Lessee, Operating Lease, Term of Contract Renewal term Lessee, Operating Lease, Renewal Term Number of additional terms Lessee, Operating Lease, Number Of Renewal Terms Lessee, Operating Lease, Number Of Renewal Terms Area of leased property Lessee, Operating Lease, Area Leased Lessee, Operating Lease, Area Leased Monthly payment, initial year Lessee, Operating Lease, Monthly Payment, Initial Year Lessee, Operating Lease, Monthly Payment, Initial Year Annual payment percentage increase Lessee, Operating Lease, Annual Increase Lessee, Operating Lease, Annual Increase Monthly fees Lessee, Operating Lease, Monthly Expenses Lessee, Operating Lease, Monthly Expenses Discount rate Lessee, Operating Lease, Discount Rate Expected remaining term Operating Lease, Weighted Average Remaining Lease Term Amortization of operating lease right-of-use asset Remaining lease term Operating Lease, Remaining Lease Term Operating Lease, Remaining Lease Term Lease expense Lease, Cost Payables and Accruals [Abstract] Accrued contracted research and development services Accrued Research And Development Fees, Current Accrued Research And Development Fees, Current Accrued professional fees Accrued Professional Fees, Current Accrued compensation Employee-related Liabilities, Current Accrued note issuance costs Accrued Debt Issuance Costs, Current Accrued Debt Issuance Costs, Current Accrued liabilities NOTE PAYABLE New Accounting Pronouncements or Change in Accounting Principle [Table] New Accounting Pronouncements or Change in Accounting Principle [Table] Topic 842 Accounting Standards Update 2016-02 [Member] Impact of Adoption Adjustments for New Accounting Pronouncement [Member] New Accounting Pronouncements or Change in Accounting Principle [Line Items] New Accounting Pronouncements or Change in Accounting Principle [Line Items] Lease liability, current portion Lease liability, net of current portion Schedule of New Accounting Pronouncements and Changes in Accounting Principles Schedule of New Accounting Pronouncements and Changes in Accounting Principles [Table Text Block] Reserved Authorized Shares of Common Stock Schedule of Stock by Class [Table Text Block] Summary of Preferred Stock Temporary Equity [Table Text Block] Fair value measurement input Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Warrants to purchase common stock Warrant [Member] Options to purchase common stock Redeemable convertible preferred stock (as converted into common stock) Warrants to purchase redeemable convertible preferred stock (as converted into common stock) Convertible Debt Securities [Member] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Shares excluded from the calculation of EPS (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Summary of Net Assets Acquired Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] Fair Value Measurements, Recurring and Nonrecurring Fair Value Measurements, Recurring and Nonrecurring [Table Text Block] Fair Value Measurement Inputs and Valuation Techniques Fair Value Measurement Inputs and Valuation Techniques [Table Text Block] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Business Acquisition [Axis] Business Acquisition [Axis] Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Vical Warrants [Member] Vical Warrants [Member] Vical Warrants [Member] Net acquired tangible assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net Warrants converted (in shares) Conversion of Stock, Shares Converted Exercise price (in usd per share) Debt Instrument, Convertible, Conversion Price CAPITAL STOCK Stockholders' Equity Note Disclosure [Text Block] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Income Statement Location [Axis] Income Statement Location [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Research and development Research and Development Expense [Member] General and administrative General and Administrative Expense [Member] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Share-based compensation expense Share-based Payment Arrangement, Expense Schedule of Short-term Debt [Table] Schedule of Short-term Debt [Table] Short-term Debt, Type [Axis] Short-term Debt, Type [Axis] Short-term Debt, Type [Domain] Short-term Debt, Type [Domain] Convertible Promissory Notes Convertible Notes Payable [Member] Short-term Debt [Line Items] Short-term Debt [Line Items] Stated rate Debt Instrument, Interest Rate, Stated Percentage Debt term Debt Instrument, Term Conversion price (in usd per share) Qualified financing threshold Debt Instrument, Convertible, Conversion Trigger Threshold, Amount Debt Instrument, Convertible, Conversion Trigger Threshold, Amount Conversion price as percent of price paid per share Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger Share price threshold (in usd per share) Debt Instrument, Convertible, Stock Price Trigger Shares issued in conversion (in shares) Debt Conversion, Converted Instrument, Shares Issued Term of warrants Class Of Warrant Or Right, Term Class Of Warrant Or Right, Term Premium percentage on effective price Class Of Warrant Or Right, Exercise Price, Percentage Of Effective Price Paid On Share Basis Class Of Warrant Or Right, Exercise Price, Percentage Of Effective Price Paid On Share Basis Derivative liability, fair value Derivative Liability Effective rate Debt Instrument, Interest Rate, Effective Percentage Interest expense Interest Expense, Debt Accretion of discounts Amortization of Debt Discount (Premium) Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Use of Estimates Use of Estimates, Policy [Policy Text Block] Fair Value Measurements Fair Value Measurement, Policy [Policy Text Block] Leases Lessee, Leases [Policy Text Block] Redeemable Convertible Preferred Stock and Warrants Temporary Equity, Policy [Policy Text Block] Temporary Equity, Policy [Policy Text Block] Revenue Recognition Revenue from Contract with Customer [Policy Text Block] Net Income (Loss) per Common Share Earnings Per Share, Policy [Policy Text Block] New Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] STOCK-BASED COMPENSATION Share-based Payment Arrangement [Text Block] Redeemable convertible preferred stock, par value (in usd per share) Temporary Equity, Par or Stated Value Per Share Redeemable convertible preferred stock, shares authorized Redeemable convertible preferred stock, shares issued Redeemable convertible preferred stock, shares outstanding Redeemable convertible preferred stock, liquidation preference (in usd) Temporary Equity, Liquidation Preference Common stock, shares authorized Common Stock, Shares Authorized RECENT ACCOUNTING PRONOUNCEMENTS Accounting Changes [Text Block] Subsequent Events [Abstract] SUBSEQUENT EVENTS Subsequent Events [Text Block] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Product and Service [Axis] Product and Service [Axis] Product and Service [Domain] Product and Service [Domain] Sublicensing Costs Sublicensing Costs [Member] Sublicensing Costs [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement Collaborative Arrangement [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Non-refundable upfront fees Collaborative Arrangement, Non-refundable Upfront Fees Collaborative Arrangement, Non-refundable Upfront Fees Development milestone payments Collaborative Arrangement, Development Milestone Payments Collaborative Arrangement, Development Milestone Payments Commercialization milestone payments Collaborative Arrangement, Commercialization Milestone Payments Collaborative Arrangement, Commercialization Milestone Payments Expected performance period Revenue From Contract With Customer, Term Revenue From Contract With Customer, Term Basis point reduction Revenue From Contract With Customer, Contract Modification, Basis Point Reduction Revenue From Contract With Customer, Contract Modification, Basis Point Reduction Revenue recognized Prepayment option percent Collaboration Arrangement, Prepayment Option, Percentage Of Milestone Payment Collaboration Arrangement, Prepayment Option, Percentage Of Milestone Payment Prepayment amount Collaboration Arrangement, Prepayment Option, Amount Collaboration Arrangement, Prepayment Option, Amount Milestone payment received Collaborative Arrangement, Receipt Of Development Milestone Payments Collaborative Arrangement, Receipt Of Development Milestone Payments Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Liability Class [Axis] Liability Class [Axis] Fair Value by Liability Class [Domain] Fair Value by Liability Class [Domain] Derivative Liability Derivative Financial Instruments, Liabilities [Member] Common Stock Warrant Liability Common Stock Warrant Liability [Member] Common Stock Warrant Liability [Member] Redeemable Convertible Preferred Stock Warrant Liability Redeemable Convertible Preferred Stock Warrant Liability [Member] Redeemable Convertible Preferred Stock Warrant Liability [Member] Contingent Consideration Liabilities Contingent Consideration Liability [Member] Contingent Consideration Liability [Member] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Beginning Balance Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Fair value of financial instruments issued Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances Change in fair value Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Increase (Decrease) In Fair Value Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Increase (Decrease) In Fair Value Reclassification to equity Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers out of Level 3 Ending Balance Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Measurement Frequency [Axis] Measurement Frequency [Axis] Measurement Frequency [Domain] Measurement Frequency [Domain] Fair Value, Recurring Fair Value, Recurring [Member] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Level 1 Fair Value, Inputs, Level 1 [Member] Level 2 Fair Value, Inputs, Level 2 [Member] Level 3 Fair Value, Inputs, Level 3 [Member] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Assets: Assets, Fair Value Disclosure [Abstract] Money market funds Cash and Cash Equivalents, Fair Value Disclosure Total Assets, Fair Value Disclosure Liabilities: Liabilities, Fair Value Disclosure [Abstract] Contingent consideration Business Combination, Contingent Consideration, Liability Total Financial and Nonfinancial Liabilities, Fair Value Disclosure Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Hercules Capital Warrants Hercules Capital Warrants [Member] Hercules Capital Warrants [Member] Applicable Interest Rate [Axis] Applicable Interest Rate [Axis] Applicable Interest Rate [Axis] Applicable Interest Rate [Domain] Applicable Interest Rate [Domain] [Domain] for Applicable Interest Rate [Axis] Interest Rate Option 1 Interest Rate Option One [Member] Interest Rate Option One [Member] Interest Rate Option 2 Interest Rate Option Two [Member] Interest Rate Option Two [Member] Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Note Payable Notes Payable, Other Payables [Member] Variable Rate [Axis] Variable Rate [Axis] Variable Rate [Domain] Variable Rate [Domain] Prime Rate Prime Rate [Member] Debt Instrument [Line Items] Debt Instrument [Line Items] Face amount Debt Instrument, Face Amount Basis spread on variable rate Debt Instrument, Basis Spread on Variable Rate End of term payment rate Debt Instrument, Termination Payment, Rate Debt Instrument, Termination Payment, Rate Applicable percent of aggregate unfunded term loan commitments Debt Instrument, Termination Payment, Percentage Of Applicable Outstanding Commitments Debt Instrument, Termination Payment, Percentage Of Applicable Outstanding Commitments Increase in termination payment Debt Instrument, Termination Payment, Increase (Decrease) Debt Instrument, Termination Payment, Increase (Decrease) Facility fees Payments of Debt Issuance Costs Warrant liability Warrants and Rights Outstanding Payment of associated accrued interest and aggregate end-of-term payment Payments Of Debt Exit Costs Payments Of Debt Exit Costs ACCRUED LIABILITIES Accounts Payable and Accrued Liabilities Disclosure [Text Block] Cash and cash equivalents Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents Marketable securities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Marketable Securities Prepaid expenses and other current assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets Accrued liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities Net acquired tangible assets Schedule of Accrued Liabilities Schedule of Accrued Liabilities [Table Text Block] Common stock options outstanding Share-based Payment Arrangement, Option - Outstanding [Member] Share-based Payment Arrangement, Option - Outstanding [Member] Options available for grant under the 2009 Plan Share-based Payment Arrangement, Option - Available For Grant [Member] Share-based Payment Arrangement, Option - Available For Grant [Member] Common stock warrants Common Stock Warrants [Member] Common Stock Warrants [Member] Shares of common stock reserved for future issuance Common Stock, Capital Shares Reserved for Future Issuance EX-101.PRE 9 bbi-20190930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 10 a20190930-10q_htm.xml IDEA: XBRL DOCUMENT 0000819050 2019-01-01 2019-09-30 0000819050 2019-11-07 0000819050 2018-12-31 0000819050 2019-09-30 0000819050 2018-01-01 2018-09-30 0000819050 2018-07-01 2018-09-30 0000819050 2019-07-01 2019-09-30 0000819050 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0000819050 us-gaap:CommonStockMember 2018-07-01 2018-09-30 0000819050 us-gaap:RedeemableConvertiblePreferredStockMember 2018-03-31 0000819050 us-gaap:RedeemableConvertiblePreferredStockMember 2018-07-01 2018-09-30 0000819050 us-gaap:CommonStockMember 2018-01-01 2018-03-31 0000819050 us-gaap:CommonStockMember 2018-09-30 0000819050 us-gaap:AdditionalPaidInCapitalMember 2018-04-01 2018-06-30 0000819050 2018-01-01 2018-03-31 0000819050 us-gaap:AdditionalPaidInCapitalMember 2018-06-30 0000819050 us-gaap:AdditionalPaidInCapitalMember 2018-03-31 0000819050 us-gaap:AccountingStandardsUpdate201409Member 2018-01-01 0000819050 us-gaap:RetainedEarningsMember 2018-03-31 0000819050 us-gaap:RedeemableConvertiblePreferredStockMember 2017-12-31 0000819050 us-gaap:RetainedEarningsMember 2018-06-30 0000819050 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-09-30 0000819050 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-06-30 0000819050 2018-04-01 2018-06-30 0000819050 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-03-31 0000819050 us-gaap:CommonStockMember 2018-03-31 0000819050 us-gaap:CommonStockMember 2017-12-31 0000819050 us-gaap:AdditionalPaidInCapitalMember 2018-09-30 0000819050 us-gaap:RetainedEarningsMember 2018-04-01 2018-06-30 0000819050 us-gaap:CommonStockMember 2018-06-30 0000819050 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0000819050 us-gaap:AccountingStandardsUpdate201409Member us-gaap:RetainedEarningsMember 2018-01-01 0000819050 us-gaap:RetainedEarningsMember 2018-01-01 2018-03-31 0000819050 us-gaap:RetainedEarningsMember 2018-07-01 2018-09-30 0000819050 us-gaap:AdditionalPaidInCapitalMember 2018-07-01 2018-09-30 0000819050 us-gaap:RedeemableConvertiblePreferredStockMember 2018-09-30 0000819050 2018-06-30 0000819050 us-gaap:RedeemableConvertiblePreferredStockMember 2018-04-01 2018-06-30 0000819050 us-gaap:RetainedEarningsMember 2018-09-30 0000819050 us-gaap:RedeemableConvertiblePreferredStockMember 2018-06-30 0000819050 2018-03-31 0000819050 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-03-31 0000819050 2017-12-31 0000819050 2018-09-30 0000819050 us-gaap:RetainedEarningsMember 2017-12-31 0000819050 us-gaap:RedeemableConvertiblePreferredStockMember 2018-01-01 2018-03-31 0000819050 2019-01-01 2019-03-31 0000819050 2019-03-31 0000819050 us-gaap:RetainedEarningsMember 2019-03-31 0000819050 us-gaap:AdditionalPaidInCapitalMember 2019-09-30 0000819050 us-gaap:RedeemableConvertiblePreferredStockMember 2019-01-01 2019-03-31 0000819050 us-gaap:RetainedEarningsMember 2018-12-31 0000819050 2019-04-01 2019-06-30 0000819050 bbi:RedeemableConvertiblePreferredStockAndPreferredStockDividendsToCommonStockMember us-gaap:CommonStockMember 2019-07-01 2019-09-30 0000819050 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0000819050 us-gaap:CommonStockMember 2019-07-01 2019-09-30 0000819050 us-gaap:CommonStockMember 2019-09-30 0000819050 us-gaap:AdditionalPaidInCapitalMember 2019-07-01 2019-09-30 0000819050 us-gaap:RedeemableConvertiblePreferredStockMember 2018-12-31 0000819050 us-gaap:CommonStockMember 2019-03-31 0000819050 us-gaap:CommonStockMember 2019-06-30 0000819050 us-gaap:RedeemableConvertiblePreferredStockMember 2019-04-01 2019-06-30 0000819050 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-06-30 0000819050 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0000819050 us-gaap:RetainedEarningsMember 2019-06-30 0000819050 bbi:ConvertibleNotesPayableAndAccruedInterestToCommonStockMember us-gaap:AdditionalPaidInCapitalMember 2019-07-01 2019-09-30 0000819050 us-gaap:RedeemableConvertiblePreferredStockMember 2019-03-31 0000819050 us-gaap:CommonStockMember 2018-12-31 0000819050 bbi:RedeemableConvertiblePreferredStockAndPreferredStockDividendsToCommonStockMember us-gaap:RedeemableConvertiblePreferredStockMember 2019-07-01 2019-09-30 0000819050 us-gaap:RedeemableConvertiblePreferredStockMember 2019-06-30 0000819050 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0000819050 us-gaap:RedeemableConvertiblePreferredStockMember 2019-09-30 0000819050 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-03-31 0000819050 us-gaap:RetainedEarningsMember 2019-04-01 2019-06-30 0000819050 us-gaap:RetainedEarningsMember 2019-09-30 0000819050 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-07-01 2019-09-30 0000819050 us-gaap:RetainedEarningsMember 2019-07-01 2019-09-30 0000819050 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0000819050 us-gaap:RedeemableConvertiblePreferredStockMember 2019-07-01 2019-09-30 0000819050 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-09-30 0000819050 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0000819050 2019-06-30 0000819050 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0000819050 us-gaap:AdditionalPaidInCapitalMember 2019-04-01 2019-06-30 0000819050 bbi:ConvertibleNotesPayableAndAccruedInterestToCommonStockMember 2019-07-01 2019-09-30 0000819050 bbi:RedeemableConvertiblePreferredStockAndPreferredStockDividendsToCommonStockMember 2019-07-01 2019-09-30 0000819050 bbi:ConvertibleNotesPayableAndAccruedInterestToCommonStockMember us-gaap:CommonStockMember 2019-07-01 2019-09-30 0000819050 bbi:RedeemableConvertiblePreferredStockAndPreferredStockDividendsToCommonStockMember us-gaap:AdditionalPaidInCapitalMember 2019-07-01 2019-09-30 0000819050 bbi:VicalFormerSecurityholdersMember 2019-08-31 0000819050 bbi:BrickellFormerSecurityholdersMember 2019-08-31 0000819050 bbi:VicalMember 2019-08-31 0000819050 bbi:NovaQuestCapitalManagementLLCMember 2018-09-30 0000819050 2019-08-31 0000819050 us-gaap:CommonStockMember 2019-09-30 0000819050 us-gaap:RedeemableConvertiblePreferredStockMember 2019-08-31 0000819050 bbi:NovaQuestCapitalManagementLLCMember 2019-09-30 0000819050 bbi:VicalMember 2019-08-31 2019-08-31 0000819050 us-gaap:WarrantMember 2018-01-01 2018-09-30 0000819050 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-09-30 0000819050 us-gaap:ConvertibleDebtSecuritiesMember 2019-01-01 2019-09-30 0000819050 us-gaap:RedeemableConvertiblePreferredStockMember 2019-01-01 2019-09-30 0000819050 us-gaap:ConvertibleDebtSecuritiesMember 2018-01-01 2018-09-30 0000819050 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-09-30 0000819050 us-gaap:WarrantMember 2019-01-01 2019-09-30 0000819050 us-gaap:RedeemableConvertiblePreferredStockMember 2018-01-01 2018-09-30 0000819050 bbi:VicalMember 2019-08-31 2019-08-31 0000819050 us-gaap:CollaborativeArrangementMember 2018-05-01 2018-05-31 0000819050 us-gaap:CollaborativeArrangementMember 2015-03-01 2015-03-31 0000819050 us-gaap:CollaborativeArrangementMember 2015-03-31 0000819050 us-gaap:CollaborativeArrangementMember 2018-01-01 2018-03-31 0000819050 srt:MinimumMember us-gaap:MeasurementInputDiscountRateMember 2019-09-30 0000819050 bbi:SublicensingCostsMember us-gaap:CollaborativeArrangementMember 2017-10-01 2017-10-31 0000819050 bbi:VicalMember 2019-08-31 0000819050 bbi:VicalWarrantsMember 2018-06-02 0000819050 us-gaap:CollaborativeArrangementMember 2017-12-01 2017-12-31 0000819050 us-gaap:RedeemableConvertiblePreferredStockMember 2019-01-01 2019-09-30 0000819050 us-gaap:CollaborativeArrangementMember 2019-01-01 2019-09-30 0000819050 us-gaap:CollaborativeArrangementMember 2019-07-01 2019-09-30 0000819050 bbi:SublicensingCostsMember us-gaap:CollaborativeArrangementMember 2018-01-01 2018-03-31 0000819050 bbi:VicalWarrantsMember 2018-06-02 2018-06-02 0000819050 us-gaap:CollaborativeArrangementMember 2017-10-01 2017-10-31 0000819050 us-gaap:RedeemableConvertiblePreferredStockMember 2018-01-01 2018-09-30 0000819050 srt:MaximumMember bbi:MeasurementInputIndividualCumulativeAchievementProbabilitiesMember 2019-09-30 0000819050 srt:MaximumMember us-gaap:MeasurementInputDiscountRateMember 2019-09-30 0000819050 srt:MinimumMember bbi:MeasurementInputIndividualCumulativeAchievementProbabilitiesMember 2019-09-30 0000819050 us-gaap:CollaborativeArrangementMember 2019-09-30 0000819050 us-gaap:CollaborativeArrangementMember 2018-03-01 2018-03-31 0000819050 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-09-30 0000819050 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-09-30 0000819050 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-09-30 0000819050 us-gaap:MeasurementInputExpectedDividendRateMember 2018-12-31 0000819050 us-gaap:MeasurementInputPriceVolatilityMember 2018-12-31 0000819050 us-gaap:MeasurementInputRiskFreeInterestRateMember 2018-12-31 0000819050 us-gaap:MeasurementInputExpectedTermMember 2018-12-31 0000819050 bbi:RedeemableConvertiblePreferredStockWarrantLiabilityMember 2018-12-31 0000819050 bbi:CommonStockWarrantLiabilityMember 2018-12-31 0000819050 us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember 2019-01-01 2019-09-30 0000819050 bbi:RedeemableConvertiblePreferredStockWarrantLiabilityMember 2019-09-30 0000819050 us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember 2019-09-30 0000819050 bbi:ContingentConsiderationLiabilityMember 2019-01-01 2019-09-30 0000819050 bbi:RedeemableConvertiblePreferredStockWarrantLiabilityMember 2019-01-01 2019-09-30 0000819050 bbi:CommonStockWarrantLiabilityMember 2019-01-01 2019-09-30 0000819050 bbi:CommonStockWarrantLiabilityMember 2019-09-30 0000819050 us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember 2018-12-31 0000819050 bbi:ContingentConsiderationLiabilityMember 2018-12-31 0000819050 bbi:ContingentConsiderationLiabilityMember 2019-09-30 0000819050 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000819050 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000819050 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000819050 us-gaap:AccountingStandardsUpdate201602Member 2019-01-01 0000819050 us-gaap:NewAccountingPronouncementMember 2019-01-01 0000819050 2019-01-01 0000819050 us-gaap:MeasurementInputRiskFreeInterestRateMember 2019-09-30 0000819050 us-gaap:MeasurementInputPriceVolatilityMember 2019-09-30 0000819050 us-gaap:MeasurementInputExpectedTermMember 2019-09-30 0000819050 srt:MaximumMember 2019-01-01 2019-09-30 0000819050 2019-09-03 2019-09-03 0000819050 bbi:NovaQuestWarrantsMember 2019-09-03 2019-09-03 0000819050 srt:MinimumMember 2019-01-01 2019-09-30 0000819050 us-gaap:MeasurementInputExpectedDividendRateMember 2019-09-30 0000819050 us-gaap:ConvertibleNotesPayableMember 2019-07-01 2019-09-30 0000819050 us-gaap:ConvertibleNotesPayableMember 2019-03-31 0000819050 us-gaap:ConvertibleNotesPayableMember 2019-09-30 0000819050 us-gaap:ConvertibleNotesPayableMember 2019-03-01 2019-03-31 0000819050 us-gaap:ConvertibleNotesPayableMember 2019-03-01 2019-08-31 0000819050 us-gaap:ConvertibleNotesPayableMember us-gaap:CommonStockMember 2019-08-31 2019-08-31 0000819050 us-gaap:ConvertibleNotesPayableMember 2019-08-31 2019-08-31 0000819050 us-gaap:ConvertibleNotesPayableMember 2019-08-31 0000819050 us-gaap:ConvertibleNotesPayableMember 2019-01-01 2019-09-30 0000819050 bbi:InterestRateOptionTwoMember us-gaap:NotesPayableOtherPayablesMember us-gaap:PrimeRateMember 2016-02-18 2016-02-18 0000819050 us-gaap:NotesPayableOtherPayablesMember 2016-02-18 0000819050 us-gaap:NotesPayableOtherPayablesMember 2016-02-18 2018-07-31 0000819050 us-gaap:NotesPayableOtherPayablesMember 2017-12-01 2018-07-31 0000819050 bbi:InterestRateOptionOneMember us-gaap:NotesPayableOtherPayablesMember 2016-02-18 0000819050 bbi:InterestRateOptionTwoMember us-gaap:NotesPayableOtherPayablesMember 2016-02-18 0000819050 bbi:HerculesCapitalWarrantsMember 2018-06-02 0000819050 bbi:HerculesCapitalWarrantsMember 2018-06-02 2018-06-02 0000819050 bbi:SharebasedPaymentArrangementOptionOutstandingMember 2019-09-30 0000819050 bbi:SharebasedPaymentArrangementOptionAvailableForGrantMember bbi:EquityIncentivePlan2009Member 2019-09-30 0000819050 bbi:SharebasedPaymentArrangementOptionAvailableForGrantMember bbi:VicalStockIncentivePlanMember 2019-09-30 0000819050 bbi:CommonStockWarrantsMember 2019-09-30 0000819050 bbi:SeriesC1PreferredStockMember 2018-12-31 0000819050 us-gaap:SeriesCPreferredStockMember 2018-12-31 0000819050 us-gaap:SeriesAPreferredStockMember 2018-12-31 0000819050 bbi:SeriesC1PreferredStockMember 2018-12-31 2018-12-31 0000819050 us-gaap:SeriesBPreferredStockMember 2018-12-31 0000819050 us-gaap:SeriesCPreferredStockMember 2018-12-31 2018-12-31 0000819050 2018-12-31 2018-12-31 0000819050 us-gaap:SeriesAPreferredStockMember 2018-12-31 2018-12-31 0000819050 us-gaap:SeriesBPreferredStockMember 2018-12-31 2018-12-31 0000819050 us-gaap:SeriesCPreferredStockMember 2019-08-31 0000819050 bbi:SeriesC1PreferredStockMember 2019-08-31 0000819050 us-gaap:SeriesAPreferredStockMember 2019-08-31 2019-08-31 0000819050 us-gaap:SeriesAPreferredStockMember 2019-08-31 0000819050 us-gaap:SeriesBPreferredStockMember 2019-08-31 0000819050 2019-08-31 2019-08-31 0000819050 us-gaap:SeriesBPreferredStockMember 2019-08-31 2019-08-31 0000819050 bbi:SeriesC1PreferredStockMember 2019-08-31 2019-08-31 0000819050 us-gaap:SeriesCPreferredStockMember 2019-08-31 2019-08-31 0000819050 us-gaap:EmployeeStockOptionMember bbi:EquityIncentivePlan2009Member 2019-09-30 0000819050 us-gaap:EmployeeStockOptionMember bbi:VicalStockIncentivePlanMember 2019-09-30 0000819050 bbi:VicalStockIncentivePlanMember 2019-01-01 2019-09-30 0000819050 bbi:VicalStockIncentivePlanMember 2019-09-30 0000819050 us-gaap:GeneralAndAdministrativeExpenseMember 2019-01-01 2019-09-30 0000819050 us-gaap:ResearchAndDevelopmentExpenseMember 2018-07-01 2018-09-30 0000819050 us-gaap:GeneralAndAdministrativeExpenseMember 2018-07-01 2018-09-30 0000819050 us-gaap:GeneralAndAdministrativeExpenseMember 2019-07-01 2019-09-30 0000819050 us-gaap:ResearchAndDevelopmentExpenseMember 2018-01-01 2018-09-30 0000819050 us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-09-30 0000819050 us-gaap:GeneralAndAdministrativeExpenseMember 2018-01-01 2018-09-30 0000819050 us-gaap:ResearchAndDevelopmentExpenseMember 2019-07-01 2019-09-30 pure shares iso4217:USD shares iso4217:USD utreg:sqft bbi:renewal_term 0.015 false --12-31 Q3 2019 0000819050 0 0 0.01 0.01 8000000 50000000 589001 7810680 7810680 589001 7810680 7810680 1100000 22000 100000 P5Y 0 0 0 0 18225000 -11000 92276000 78000 -74118000 0.1429 0 46985000 0 0.01 0.01 5000000 0 1256466 312423 401309 286151 256583 0 0 1256466 312423 401309 286151 256583 10-Q true 2019-09-30 false 000-21088 BRICKELL BIOTECH, INC. DE 93-0948554 5777 Central Avenue,  Boulder, CO 80301 720 505-4755 Common stock, $0.01 par value per share BBI NASDAQ Yes Yes Non-accelerated Filer true false false 7810680 7225000 8067000 18473000 0 5034000 204000 30732000 8271000 20000 37000 176000 441000 441000 31369000 8749000 1291000 4067000 3475000 3272000 75000 2464000 8117000 0 4639000 7305000 20095000 145000 145000 94000 0 242000 0 1595000 5600000 0 13144000 22077000 0 58290000 78000 6000 92276000 0 -11000 0 -74118000 -71624000 18225000 -71618000 31369000 8749000 1183000 3042000 7248000 8415000 3337000 4135000 13585000 8571000 3901000 1206000 7290000 4694000 7238000 5341000 20875000 13265000 -6055000 -2299000 -13627000 -4850000 54000 23000 64000 45000 2318000 0 2318000 0 1098000 267000 1982000 769000 0 0 -11000 0 0 -2000 -223000 -8000 -4781000 -2541000 -13015000 -5566000 82000 966000 -10274000 5071000 -4863000 -3507000 -2741000 -10637000 -1.65 -5.98 -1.98 -18.13 2943896 586738 1382592 586701 -4781000 -2541000 -13015000 -5566000 -11000 0 -11000 0 -4792000 -2541000 -13026000 -5566000 1256466 58290000 589001 6000 0 0 -71624000 -71618000 384000 384000 -10521000 10521000 10521000 -4580000 -4580000 1256466 47769000 589001 6000 384000 0 -65683000 -65293000 299000 299000 165000 165000 165000 -3654000 -3654000 1256466 47934000 589001 6000 518000 0 -69337000 -68813000 82000 82000 82000 1256466 48016000 2783951 28000 47988000 48016000 3367988 34000 36059000 36093000 1069740 10000 5082000 5092000 1511000 1511000 876000 876000 324000 324000 -11000 -11000 -4781000 -4781000 1256466 52354000 585262 6000 0 0 -59942000 -59936000 2734000 2734000 190000 190000 1438 17000 17000 3240000 207000 3033000 3240000 527000 527000 1256466 55594000 586700 6000 0 0 -59714000 -59708000 175000 175000 865000 175000 690000 865000 -3552000 -3552000 1256466 56459000 586700 6000 0 0 -63956000 -63950000 151000 151000 863 10000 10000 966000 161000 805000 966000 -2541000 -2541000 1256466 57425000 587563 6000 0 0 -67302000 -67296000 -13015000 -5566000 25000 37000 25000 0 666000 0 -11000 0 -223000 -8000 2318000 0 50000 828000 0 215000 310000 1007000 516000 2480000 -14000 -2776000 473000 -2207000 -343000 -50000 5600000 0 -7248000 12188000 -21940000 7621000 13017000 0 5500000 0 8000 8000 18509000 -8000 4808000 509000 7397000 0 0 27000 2589000 -482000 -842000 7131000 8067000 5399000 7225000 12530000 319000 310000 48016000 0 -10377000 5041000 23076000 0 103000 30000 1442000 0 876000 0 1492000 0 -11000 0 <span style="font-family:inherit;font-size:10pt;font-weight:bold;">ORGANIZATION AND NATURE OF OPERATIONS</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Brickell Biotech, Inc. (the “Company” or “Brickell”) is a clinical-stage pharmaceutical company focused on the development of innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases. The Company’s pipeline consists of potential novel therapeutics for hyperhidrosis, cutaneous T-cell lymphoma, psoriasis, and other prevalent dermatological conditions. Its pivotal Phase 3-ready clinical-stage product candidate, sofpironium bromide, is a proprietary new molecular entity that belongs to a class of medications called anticholinergics. The Company is developing sofpironium bromide as a potential best-in-class, self-administered, once daily, topical therapy for the treatment of primary axillary hyperhidrosis. The Company’s operations to date have been limited to business planning, raising capital, developing its pipeline assets (in particular sofpironium bromide), identifying product candidates, and other research and development.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On August 31, 2019, the Company, then known as Vical Incorporated (“Vical”), and Brickell Biotech, Inc., a then privately-held Delaware corporation that began activities in September 2009 (“Private Brickell”), completed a recapitalization in accordance with the terms of the Agreement and Plan of Merger and Reorganization, dated June 2, 2019, as further amended on August 20, 2019 and on August 30, 2019 (the “Merger Agreement”), by and among Vical, Vical Subsidiary, Inc., a wholly owned subsidiary of Vical (“Merger Sub”), and Private Brickell. Pursuant to the Merger Agreement, Merger Sub merged with and into Private Brickell, with Private Brickell surviving as a wholly-owned subsidiary of Vical (the “Merger”). Additionally, on August 31, 2019, immediately after the completion of the Merger, the Company changed its name from “Vical Incorporated” to “Brickell Biotech, Inc.” and Private Brickell changed its name from "Brickell Biotech, Inc." to "Brickell Subsidiary, Inc."</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The accompanying condensed consolidated financial statements and related notes reflect the historical results of Private Brickell prior to the Merger and of the combined company following the Merger, and do not include the historical results of Vical prior to the completion of the Merger. These financial statements and related notes should be read in conjunction with the audited financial statements of Private Brickell for the year ended December 31, 2018, included in the Company’s Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on September 3, 2019.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On August 31, 2019, in connection with, and prior to the consummation of the Merger, Vical effected a reverse stock split of its common stock, par value </span><span style="font-family:inherit;font-size:10pt;"><span>$0.01</span></span><span style="font-family:inherit;font-size:10pt;"> per share, at a ratio of 1-for-7 (the “Reverse Stock Split”). Unless otherwise noted herein, references to share and per-share amounts give retroactive effect to the Reverse Stock Split. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On August 31, 2019, all shares of preferred stock of Private Brickell converted into shares of common stock of Private Brickell on a </span><span style="font-family:inherit;font-size:10pt;"><span>one</span></span><span style="font-family:inherit;font-size:10pt;">-for-one basis. </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">At the effective date of the Merger, the Company issued shares of its common stock to Private Brickell stockholders, at an exchange rate of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>2.4165</span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock in exchange for each share of Private Brickell common stock outstanding immediately prior to the Merger (the “Exchange Ratio”). The exchange rate was calculated by a formula that was determined through arms-length negotiations between the Vical and Private Brickell. Unless otherwise noted herein, references to share and per-share amounts give retroactive effect to the Reverse Stock Split and the Exchange Ratio, which was effected upon the Merger.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Immediately following the consummation of the Merger, there were </span><span style="font-family:inherit;font-size:10pt;"><span>7,810,680</span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock issued and outstanding, with Private Brickell’s former securityholders beneficially owning approximately </span><span style="font-family:inherit;font-size:10pt;"><span>57%</span></span><span style="font-family:inherit;font-size:10pt;"> of the outstanding shares of common stock and Vical’s former securityholders beneficially owning approximately </span><span style="font-family:inherit;font-size:10pt;"><span>43%</span></span><span style="font-family:inherit;font-size:10pt;"> of the outstanding shares of common stock.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Funding Agreement with NovaQuest</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On August 31, 2019, concurrent with the Merger Agreement, the Company entered into a research and development arrangement with NovaQuest Capital Management, LLC (“NovaQuest”) pursuant to which NovaQuest committed up to </span><span style="font-family:inherit;font-size:10pt;"><span>$25.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> in research and development funding to the Company following the closing of the Merger (the “Funding Agreement”). These proceeds will partially fund the Company's Phase 3 clinical trials in the United States for sofpironium bromide. The Company issued a warrant to NovaQuest to purchase </span><span style="font-family:inherit;font-size:10pt;"><span>241,225</span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock. Additional details of this agreement are described in </span><span style="font-family:inherit;font-size:10pt;">Note 4</span><span style="font-family:inherit;font-size:10pt;">. In October 2019, additional funding was temporarily suspended. Refer to Note 11 for additional details.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Liquidity and Capital Resources </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The accompanying condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. The condensed consolidated financial statements do not reflect any adjustments relating to the recoverability and reclassification of assets and liabilities that might be necessary if the Company is unable to continue as a going concern. The Company has incurred significant operating losses and has an accumulated deficit as a result of ongoing efforts to develop product candidates, including conducting preclinical and clinical trials and providing general and administrative support for these operations. For the </span><span style="font-family:inherit;font-size:10pt;">nine months ended</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company had a net loss of </span><span style="font-family:inherit;font-size:10pt;"><span>$13.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> and net cash used in operating activities of </span><span style="font-family:inherit;font-size:10pt;"><span>$21.9 million</span></span><span style="font-family:inherit;font-size:10pt;">. As of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company had cash, cash equivalents, and marketable securities of </span><span style="font-family:inherit;font-size:10pt;"><span>$25.7 million</span></span><span style="font-family:inherit;font-size:10pt;">, and an accumulated deficit of </span><span style="font-family:inherit;font-size:10pt;"><span>$74.1 million</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pending resolution of the contentious matter discussed further in Note 11 and NovaQuest resuming additional funding, the Company intends to conserve its resources. The advancement of the Phase 3 clinical trials for sofpironium bromide may be negatively impacted by these developments. The Company may take actions to reduce its cash spend, including delaying the start of the clinical trials or staff reductions. Taking these measures into account, the Company believes that its cash, cash equivalents, and marketable securities as of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> would be sufficient to fund its operations for at least the next 12 months from the issuance of these condensed consolidated financial statements.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div>The Company expects to continue to incur additional substantial losses in the foreseeable future as a result of the Company’s research and development activities. Additional funding will be required in the future to maintain the Company’s current and proposed research activities. There can be no assurance that additional equity or debt financing will be available on acceptable terms, if at all. If the Company is unable to raise additional funding to meet its working capital needs in the future, it will be forced to delay or reduce the scope of its research programs and/or limit or cease its operations. 0.01 1 2.4165 7810680 0.57 0.43 25000000.0 241225 -13000000.0 -21900000 25700000 -74100000 <span style="font-family:inherit;font-size:10pt;font-weight:bold;">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Basis of Presentation </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The accompanying condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, Brickell Subsidiary, Inc., are presented in U.S. dollars and have been prepared in accordance with accounting principles generally accepted in the United States of America (“</span><span style="font-family:inherit;font-size:10pt;">US GAAP</span><span style="font-family:inherit;font-size:10pt;">”) and applicable rules and regulations of the SEC for interim reporting. As permitted under those rules and regulations, certain footnotes or other financial information normally included in financial statements prepared in accordance with </span><span style="font-family:inherit;font-size:10pt;">US GAAP</span><span style="font-family:inherit;font-size:10pt;"> have been condensed or omitted. These condensed consolidated financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments, consisting only of normal recurring adjustments, which are necessary for a fair presentation of the Company’s financial information. The results of operations for the </span><span style="font-family:inherit;font-size:10pt;">three and nine months ended</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> are not necessarily indicative of the results to be expected for the full year ending </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, for any other interim period, or for any other future period. The condensed consolidated balance sheet as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;"> has been derived from audited financial statements at that date but does not include all of the information required by </span><span style="font-family:inherit;font-size:10pt;">US GAAP</span><span style="font-family:inherit;font-size:10pt;"> for complete financial statements. All intercompany balances and transactions have been eliminated in consolidation.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Merger has been accounted for as a recapitalization. Prior to the Merger, Vical wound down its pre-merger business assets and liabilities. The owners and management of Private Brickell have actual and effective voting and operating control of the combined company. In the Merger transaction, Vical is the accounting acquiree and Private Brickell is the accounting acquirer. A recapitalization is equivalent to the issuance of stock by the private operating company for the net monetary assets of the accounting acquiree accompanied by a recapitalization with accounting similar to that resulting from a reverse acquisition, except that no goodwill or intangible assets are recorded. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In connection with the Merger, </span><span style="font-family:inherit;font-size:10pt;"><span>3,367,988</span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock were transferred to the existing Vical stockholders and the Company assumed approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$36.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> in net tangible assets from Vical, which were recorded as charges against additional paid-in capital. The following table summarizes the net assets acquired based on their estimated fair values immediately prior to the Merger (in thousands):</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:87%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,017</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;">Marketable securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23,959</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;">Prepaid expenses and other current assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,474</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;">Accrued liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,357</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;">Net acquired tangible assets</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>36,093</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In connection with the Merger, the Company assumed warrants previously held by Vical, which provide the warrantholder the right to purchase </span><span style="font-family:inherit;font-size:10pt;"><span>891,582</span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock at an exercise price of </span><span style="font-family:inherit;font-size:10pt;"><span>$0.07</span></span><span style="font-family:inherit;font-size:10pt;"> (the “Vical Warrants”). The Vical Warrants were classified as equity.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The combined company assumed all the outstanding options, under Vical’s equity incentive plan (the "Vical Plan") with such options representing the right to purchase a number of shares of Brickell common stock previously represented by such options, as adjusted for the recapitalization. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company’s condensed consolidated financial statements are prepared in accordance with </span><span style="font-family:inherit;font-size:10pt;">US GAAP</span><span style="font-family:inherit;font-size:10pt;">, which requires it to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Although these estimates are based on the Company’s knowledge of current events and actions it may take in the future, actual results may ultimately differ from these estimates and assumptions.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Risks and Uncertainties </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company’s business is subject to significant risks common to early-stage companies in the pharmaceutical industry including, but not limited to, the ability to develop appropriate formulations, scale up and production of the compounds, dependence on collaborative parties, uncertainties associated with obtaining and enforcing patents and other intellectual property rights, clinical implementation and success, the lengthy and expensive regulatory approval process, compliance with regulatory and other legal requirements, competition from other products; uncertainty of broad adoption of its approved products, if any, by physicians and patients; significant competition; ability to manage third-party manufacturers, suppliers, contract research organizations, business partners and other alliance management, and obtaining additional financing to fund the Company’s efforts. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The product candidates developed by the Company require approvals from the U.S. Food and Drug Administration (“FDA”) and foreign regulatory agencies prior to commercial sales in the United States or foreign jurisdictions, respectively. There can be no assurance that the Company’s current and future product candidates will receive the necessary approvals. If the Company is denied approval or approval is delayed, it may have a material adverse impact on the Company’s business and its financial condition.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company expects to incur substantial operating losses for the next several years and will need to obtain additional financing in order to complete clinical studies and launch and commercialize any product candidates for which it receives regulatory approval. There can be no assurance that such financing will be available or will be at terms acceptable by the Company. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Fair Value Measurements </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair value is the price that the Company would receive to sell an asset or pay to transfer a liability in a timely transaction with an independent counterparty in the principal market or in the absence of a principal market, the most advantageous market for the asset or liability. A three-tier hierarchy is established to distinguish between (1) inputs that reflect the assumptions market participants would use in pricing an asset or liability developed based on market data obtained from sources independent of the reporting entity (observable inputs) and (2) inputs that reflect the reporting entity’s own assumptions about the assumptions market participants would use in pricing an asset or liability developed based on the best information available in the circumstances (unobservable inputs), and establishes a classification of fair value measurements for disclosure purposes. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The hierarchy is summarized in the three broad levels listed below:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;padding-left:24px;text-indent:-24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 1</span><span style="font-family:inherit;font-size:10pt;">—quoted prices in active markets for identical assets and liabilities </span></div><div style="line-height:120%;text-align:justify;padding-left:24px;text-indent:-24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 2</span><span style="font-family:inherit;font-size:10pt;">—other significant observable inputs (including quoted prices for similar assets and liabilities, interest rates, credit risk, etc.) </span></div><div style="line-height:120%;text-align:justify;padding-left:24px;text-indent:-24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 3</span><span style="font-family:inherit;font-size:10pt;">—significant unobservable inputs (including the Company’s own assumptions in determining the fair value of assets and liabilities) </span></div><div style="line-height:120%;text-align:justify;padding-left:24px;text-indent:-24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following tables set forth the fair value of the Company’s financial assets and liabilities measured at fair value on a recurring basis based on the three-tier fair value hierarchy as of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;"> (in thousands): </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 1</span><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 2</span><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 3</span><span style="font-family:inherit;font-size:8pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Money market funds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,225</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. treasuries</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18,473</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25,698</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contingent consideration</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>145</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 3</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Money market funds</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,067</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Redeemable convertible preferred stock warrant liability</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>242</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contingent consideration</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>145</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>387</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Fair Value of Financial Instruments </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following methods and assumptions were used by the Company in estimating the fair values of each class of financial instrument disclosed herein: </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Money Market Funds—</span><span style="font-family:inherit;font-size:10pt;">The carrying amounts reported as cash and cash equivalents in the condensed consolidated balance sheets approximate their fair values due to their short-term nature and/or market rates of interest (Level 1 of the fair value hierarchy). </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">U.S. Treasuries—</span><span style="font-family:inherit;font-size:10pt;">The Company has designated its investments in U.S. treasury securities as available-for-sale securities and accounts for them at their respective fair values. The securities are classified as short-term or long-term based on the nature of the securities and their availability to meet current operating requirements. Securities that are readily available for use in current operations are classified as short-term available-for-sale marketable securities and are reported as a component of current assets in the condensed consolidated balance sheets (Level 1 of the fair value hierarchy).</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Securities that are classified as available-for-sale are measured at fair value, including accrued interest, with temporary unrealized gains and losses reported as a component of stockholders’ equity until their disposition. The Company reviews available-for-sale securities at the end of each period to determine whether they remain available-for-sale based on its then current intent. The cost of securities sold is based on the specific identification method. The securities are subject to a periodic impairment review. An impairment charge would occur when a decline in the fair value of the investments below the cost basis is judged to be other-than-temporary.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company’s available-for-sale securities had an amortized cost of </span><span style="font-family:inherit;font-size:10pt;"><span>$18.5 million</span></span><span style="font-family:inherit;font-size:10pt;">, fair value of </span><span style="font-family:inherit;font-size:10pt;"><span>$18.5 million</span></span><span style="font-family:inherit;font-size:10pt;">, and an unrealized gain of </span><span style="font-family:inherit;font-size:10pt;"><span>$20 thousand</span></span><span style="font-family:inherit;font-size:10pt;">. Because the securities were acquired in August 2019 in connection to the Merger, there were </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;"> related balances as of December 31, 2018.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Contingent Consideration—</span><span style="font-family:inherit;font-size:10pt;">These amounts represent future payments in conjunction with various business combinations related to the acquisition of certain early-stage pipeline assets. The ultimate amount of future payments is based on specified future criteria, such as the achievement of certain future development and regulatory milestones. The Company evaluates its estimates of the fair value of contingent consideration on a quarterly basis. The fair value of the contingent consideration was determined with the assistance of a third-party valuation firm applying the income approach. This approach estimates the fair value of the contingent consideration related to the achievement of future development and regulatory milestones by assigning an achievement probability and date of expected completion to each potential milestone and discounting the associated cash payment to its present value using a risk-adjusted rate of return. The probability of success of each milestone assumes that the prerequisite developmental milestones are successfully completed and is based on the asset’s current stage of development and anticipated regulatory requirements. The probability of success for each milestone is determined by multiplying the preceding probabilities of success. The unobservable inputs (Level 3 of the fair value hierarchy) to the valuation models that have the most significant effect on the fair value of the Company’s contingent consideration are the probabilities that certain in-process development projects will meet specified development milestones, including ultimate approval by the FDA, with individual cumulative probabilities ranging from </span><span style="font-family:inherit;font-size:10pt;"><span>2.1%</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>20.9%</span></span><span style="font-family:inherit;font-size:10pt;">. Other unobservable inputs used in this approach include risk-adjusted discount rates ranging from </span><span style="font-family:inherit;font-size:10pt;"><span>15.5%</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>27.1%</span></span><span style="font-family:inherit;font-size:10pt;"> and estimates of the timing of the achievement of the various product development, regulatory approval, and sales milestones. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Redeemable Convertible Preferred Stock Warrant Liability</span><span style="font-family:inherit;font-size:10pt;">—These amounts represented potential future obligations to transfer assets to the holders at a future date. The Company remeasured these warrants to current fair value at each balance sheet date, and any change in fair value was recognized as a change in fair value of warrant liability in the condensed consolidated statements of operations. The Company estimated the fair value of these warrants at December 31, 2018 using the Black-Scholes option-pricing model (Level 3 of the fair value hierarchy table). These warrants converted from warrants exercisable for redeemable convertible preferred stock to common stock in August 2019 in connection to the Merger (see further discussion in </span><span style="font-family:inherit;font-size:10pt;">Note 7</span><span style="font-family:inherit;font-size:10pt;">). </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inputs used to determine estimated fair value of the warrant liabilities included the estimated fair value of the underlying stock at the valuation date, the estimated term of the warrants, risk-free interest rates, expected dividends, and the expected volatility of the underlying stock. The most significant unobservable inputs used in the fair value measurement of the convertible preferred stock warrant liability were the fair value of the underlying stock at the valuation date and the estimated term of the warrants. Generally, increases (decreases) in the fair value of the underlying stock and estimated term resulted in a directionally similar impact to the fair value measurement. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The fair value of the outstanding warrants was remeasured as of each period end using the Black-Scholes option-pricing model with the following assumptions: </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"/></tr><tr><td style="width:87%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected term (in years)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected volatility</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30.00</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Risk free interest rate</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.59</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected dividend yield</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The fair value of the shares of the convertible preferred stock underlying the preferred stock warrants was historically determined with the assistance of a third-party valuation firm. Because there had been no public market for the Company’s convertible preferred stock, the third-party valuation firm determined fair value of the convertible preferred stock at each balance sheet date by considering a number of objective and subjective factors, including valuation of comparable companies, sales of convertible preferred stock to unrelated third parties, operating and financial performance, the lack of liquidity of capital stock, and general and industry specific economic outlook, among other factors. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Remaining Term.</span><span style="font-family:inherit;font-size:10pt;"> The Company derived the expected term based on the time from the balance sheet date until the preferred stock warrant’s expiration date. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Expected Volatility.</span><span style="font-family:inherit;font-size:10pt;"> Since the Company was a private entity with no historical data regarding the volatility of its preferred stock, the expected volatility used was based on volatility of a group of similar entities. In evaluating similarity, the Company considered factors such as industry, stage of life cycle, and size. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Risk-free Interest Rate</span><span style="font-family:inherit;font-size:10pt;">. The risk-free interest rate was based on U.S. Treasury zero-coupon issues with remaining terms similar to the expected term of the warrants. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Expected Dividend Rate</span><span style="font-family:inherit;font-size:10pt;">. The Company has never paid any dividends and does not plan to pay dividends in the foreseeable future and, therefore, used an expected dividend rate of </span><span style="font-family:inherit;font-size:10pt;">zero</span><span style="font-family:inherit;font-size:10pt;"> in the valuation model. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Derivative Liability—</span><span style="font-family:inherit;font-size:10pt;">These amounts represented potential future obligations to transfer assets to the holders at a future date. The fair value of the derivative liability has historically been determined with the assistance of a third-party valuation firm (Level 3 of the fair value hierarchy table) (see further discussion in </span><span style="font-family:inherit;font-size:10pt;">Note 6</span><span style="font-family:inherit;font-size:10pt;">). At the inception of the liability, there was no public market for the Company’s common stock, and a third-party valuation firm determined fair value of the stock by considering a number of objective and subjective factors, including valuation of comparable companies, sales of common stock to unrelated third parties, operating and financial performance, the lack of liquidity of capital stock, and general and industry specific economic outlook, among other factors. The derivative liability was marked-to-market each measurement period and any change in fair value was recorded in the condensed consolidated statements of operations. In August 2019, in connection to the Merger, the derivative liability was reclassified to equity in the condensed consolidated balance sheet (see further discussion in </span><span style="font-family:inherit;font-size:10pt;">Note 6</span><span style="font-family:inherit;font-size:10pt;">). </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Common Stock Warrant Liability</span><span style="font-family:inherit;font-size:10pt;">—These amounts represented potential future obligations to transfer assets to the holders at a future date. The fair value of the warrants was historically determined with the assistance of a third-party valuation firm (Level 3 of the fair value hierarchy table) (see further discussion in </span><span style="font-family:inherit;font-size:10pt;">Note 6</span><span style="font-family:inherit;font-size:10pt;">). At the inception of the liability, there was no public market for the Company’s common stock, and a third-party valuation firm determined fair value of the stock by considering a number of objective and subjective factors, including valuation of comparable companies, sales of common stock to unrelated third parties, operating and financial performance, the lack of liquidity of capital stock, and general and industry specific economic outlook, among other factors. The warrant liability was remeasured to fair value at each balance sheet date, and any change in fair value was recognized as a change in fair value of warrant liability in the condensed consolidated statements of operations. The Company estimated the fair value of these warrants using the Black-Scholes option-pricing model. In August 2019, in connection to the Merger, the warrant liability was reclassified to equity in the condensed consolidated balance sheet (see further discussion in </span><span style="font-family:inherit;font-size:10pt;">Note 6</span><span style="font-family:inherit;font-size:10pt;">).</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inputs used to determine estimated fair value of the warrant liabilities included the estimated fair value of the underlying stock at the valuation date, the estimated term of the warrants, risk-free interest rates, expected dividends, and the expected volatility of the underlying stock. The most significant unobservable inputs used in the fair value measurement of the warrant liability were the fair value of the underlying stock at the valuation date and the estimated term of the warrants. Generally, increases (decreases) in the fair value of the underlying stock and estimated term resulted in a directionally similar impact to the fair value measurement. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table sets forth a summary of the changes in the fair value of the Company’s Level 3 financial instruments as follows (in thousands): </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Derivative <br/>Liability</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Common <br/>Stock <br/>Warrant <br/>Liability</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Redeemable <br/>Convertible <br/>Preferred <br/>Stock Warrant <br/>Liability</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Contingent <br/>Consideration <br/>Liabilities</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair value as of December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>242</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>145</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair value of financial instruments issued</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,442</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,492</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Change in fair value</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(240</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Reclassification to equity</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,453</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,509</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair value as of September 30, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>145</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Leases </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On January 1, 2019, the Company adopted Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 842, Leases (“ASC 842”), using the modified retrospective method for all lease arrangements at the beginning of the </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">period of adoption. Results for reporting periods beginning January 1, 2019 are presented under ASC 842, while prior period amounts were not adjusted and continue to be presented in accordance with the Company’s historical accounting under ASC Topic 840, Leases. ASC 842 had an impact on the Company’s condensed consolidated balance sheets but did not have a significant impact on the Company’s net loss.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Under ASC 842, the Company determines if an arrangement is a lease at inception. Leases with a term greater than </span><span style="font-family:inherit;font-size:10pt;">one year</span><span style="font-family:inherit;font-size:10pt;"> are recognized on the balance sheet as right-of-use assets, lease liabilities and, if applicable, long-term lease liabilities. The Company has elected the practical expedient not to recognize on the balance sheet leases with terms of </span><span style="font-family:inherit;font-size:10pt;">one</span><span style="font-family:inherit;font-size:10pt;">-year or less and not to separate lease components and non-lease components for long-term real-estate leases. Lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company estimates the incremental borrowing rate based on industry peers in determining the present value of lease payments. The Company’s facility operating lease has </span><span style="font-family:inherit;font-size:10pt;">one</span><span style="font-family:inherit;font-size:10pt;"> single component. The lease component results in a right-of-use asset being recorded on the balance sheet, which is amortized as lease expense on a straight-line basis in the Company’s condensed consolidated statements of operations. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Redeemable Convertible Preferred Stock </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Redeemable convertible preferred stock was classified as a mezzanine instrument outside of the Company’s capital accounts. Accretion of redeemable convertible preferred stock included the greater of an adjustment to fair market value or the accrual of dividends on and accretion of issuance costs of the Company’s redeemable convertible preferred stock. The carrying values of the redeemable convertible preferred stock were increased or reduced by periodic accretion or reduction to their respective redemption values from the date of issuance to August 31, 2019, the date that all outstanding shares of redeemable convertible preferred stock converted into shares of common stock. The carrying value adjustments were recorded as charges against additional paid-in capital balance. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Preferred stock issuance costs represent costs related to the Company’s issuance of redeemable convertible preferred stock. These amounts were included as a reduction of redeemable convertible preferred stock and were amortized over the estimated redemption period until its conversion to common stock in August 2019. For the </span><span style="font-family:inherit;font-size:10pt;">nine months ended</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, amortization of preferred stock issuance costs amounted to approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$0.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$30 thousand</span></span><span style="font-family:inherit;font-size:10pt;">, respectively. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Redeemable Convertible Preferred Stock Warrants </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company accounted for warrants to purchase shares of its redeemable convertible preferred stock as liabilities at their estimated fair value because the underlying shares were redeemable, which obligated the Company to transfer assets to the holders at a future date. The warrants were subject to remeasurement to fair value at each balance sheet date, and any fair value adjustments were recognized as change in fair value of redeemable convertible preferred stock warrant liability in the condensed consolidated statements of operations. The Company continued to adjust the liability for changes in fair value until the conversion of the redeemable convertible preferred stock into common stock in August 2019. At that time, the redeemable convertible preferred stock warrant liability was adjusted to fair value in the condensed consolidated statements of operations with the final fair value reclassified to equity. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue Recognition </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company recognizes revenue upon the transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies the performance obligations. At contract inception, the Company assesses the goods or services promised within each contract and assesses whether each promised good or service is distinct and determines those that are performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">To date, the Company’s drug candidates have not been approved for sale by the FDA or any other country’s regulatory authority, and the Company has not generated or recognized any revenue from the sale of products. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In March 2015, the Company entered into a license and collaboration agreement with Kaken Pharmaceutical, Co., Ltd. (“Kaken”), which is referred to as the “Collaboration Agreement.” Under the Collaboration Agreement, the Company granted to Kaken an exclusive right to develop, manufacture, and commercialize the Company’s sofpironium bromide compound (formerly BBI-4000), a topical anticholinergic, in Japan and certain other Asian countries (the “Territory”). In exchange, Kaken paid the Company an upfront, non-refundable payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$11.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> (the “upfront fee”). In addition, the Company is entitled to receive aggregate payments of up to </span><span style="font-family:inherit;font-size:10pt;"><span>$10.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> upon the achievement of specified development milestones, and </span><span style="font-family:inherit;font-size:10pt;"><span>$30.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> upon the achievement of commercial milestones, as well as tiered royalties based on a percentage of net sales of licensed products in the Territory. The Collaboration Agreement further provides that Kaken will be responsible for funding all development and commercial costs for the program in the Territory and, until such time, if any, as Kaken elects to establish its own source of supply of drug product, Kaken can purchase product supply from the Company to perform all non-clinical studies, and Phase 1 and Phase 2 clinical trials in Japan at cost. Kaken is also required to enter into negotiations with the Company, to supply the Company, at cost, with clinical supplies to perform Phase 3 clinical trials in the United States.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Collaboration Arrangement Subsequent to Adoption of Topic 606 </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company evaluates collaboration arrangements to determine whether units of account within the collaboration arrangement exhibit the characteristics of a vendor and customer relationship. The Company determined that the licenses transferred to Kaken in exchange for the upfront fees were representative of this type of a relationship. If a license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from non-refundable, upfront fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other performance obligations, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition on a prospective basis. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Under Topic 606, the Company evaluated the terms of the Collaboration Agreement and the transfer of intellectual property and manufacturing rights (the “license”) was identified as the only performance obligation as of the inception of the agreement. The Company concluded that the license for the intellectual property was distinct from its ongoing supply obligations. The Company further determined that the transaction price under the arrangement was comprised of the </span><span style="font-family:inherit;font-size:10pt;"><span>$11.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> upfront payment. The future potential milestone amounts were not included in the transaction price, as they were all determined to be fully constrained. As part of its evaluation of the development and regulatory milestones constraint, the Company determined that the achievement of such milestones is contingent upon success in future clinical trials and regulatory approvals, each of which is uncertain at this time. The Company will re-evaluate the transaction price each quarter and as uncertain events are resolved or other changes in circumstances occur. Future potential milestone amounts would be recognized as revenue from collaboration arrangements, if unconstrained. The remainder of the arrangement, which largely consisted of both parties incurring costs in their respective territories, provides for the reimbursement of the ongoing supply costs. These costs were representative of a collaboration arrangement outside of the scope of Topic 606 as it does not have the characteristics of a vendor and customer relationship. Reimbursable program costs are recognized proportionately with the delivery of drug substance and are accounted for as reductions to research and development expense and are excluded from the transaction price. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Under Topic 606, the entire transaction price of </span><span style="font-family:inherit;font-size:10pt;"><span>$11.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> was allocated to the license performance obligation. The license was deemed to be delivered in </span><span style="font-family:inherit;font-size:10pt;">2015</span><span style="font-family:inherit;font-size:10pt;"> in connection with the execution of the Collaboration Agreement and upon transfer of the underlying intellectual property the performance obligation was fully satisfied. As a result, a cumulative adjustment to reduce deferred revenue and the corresponding sublicensing costs of </span><span style="font-family:inherit;font-size:10pt;"><span>$2.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> was recorded upon the adoption of Topic 606 on January 1, 2018. As of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company does not have a deferred revenue or deferred sublicensing costs balance related to the upfront fee on the condensed consolidated balance sheet. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In May 2018, the Company entered into an amendment to the Collaboration Agreement (as further amended, “Collaboration Agreement”), pursuant to which, the Company received an upfront non-refundable fee of </span><span style="font-family:inherit;font-size:10pt;"><span>$15.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> (the “Collaboration R&amp;D Payment”), which was initially recorded as deferred revenue, to provide the Company with research and development funds for the sole purpose of conducting certain clinical trials and other such research and development activities required to support the submission of a NDA for sofpironium bromide. These clinical trials have a benefit to Kaken and have the characteristics of a vendor and customer relationship. The Company has accounted for these under the provisions of Topic 606. This Collaboration R&amp;D Payment will be initially recognized using an input method over the average estimated performance period of </span><span style="font-family:inherit;font-size:10pt;"><span>1.45 years</span></span><span style="font-family:inherit;font-size:10pt;"> in proportion to the cost incurred. Upon receipt of the Collaboration R&amp;D Payment, on May 31, 2018, a milestone payment </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">originally due upon the first commercial sale in Japan was removed from the Collaboration Agreement and all future royalties to the Company under the Collaboration Agreement were reduced </span><span style="font-family:inherit;font-size:10pt;">150</span><span style="font-family:inherit;font-size:10pt;"> basis points. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Consequently, during the </span><span style="font-family:inherit;font-size:10pt;">three and nine months ended</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company recognized revenue of </span><span style="font-family:inherit;font-size:10pt;"><span>$1.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$7.2 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively related to the Collaboration R&amp;D Payment. As of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company has a deferred revenue balance related to the Collaboration R&amp;D Payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$2.5 million</span></span><span style="font-family:inherit;font-size:10pt;">, which is recorded in deferred revenue, current portion on the accompanying condensed consolidated balance sheets. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Milestones </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">At the inception of each arrangement that includes milestone payments (variable consideration), the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company or the Company’s collaboration partner’s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such milestones and any related constraint, and if necessary, adjust the Company’s estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration or other revenues and earnings in the period of adjustment. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In October 2017, the Company entered into an amendment to the Collaboration Agreement, pursuant to which, the Company granted Kaken a prepayment option (the “Kaken Option”) on </span><span style="font-family:inherit;font-size:10pt;"><span>50%</span></span><span style="font-family:inherit;font-size:10pt;"> of the Initiation of Phase 3 milestone (the “Phase 3 Milestone”). The Kaken Option was exercisable by Kaken within </span><span style="font-family:inherit;font-size:10pt;">25</span><span style="font-family:inherit;font-size:10pt;"> business days of receipt of the BBI-4000-CL-203 study topline results. In December 2017, Kaken exercised the Kaken Option and paid the Company </span><span style="font-family:inherit;font-size:10pt;"><span>$5.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> (the “Kaken Option Payment”). Upon receipt of the non-refundable Kaken Option Payment, the Company provided Kaken the right to negotiate an exclusive license to develop, manufacture and commercialize each of the Company’s other product candidates in Japan (“ROFN Agreement”). Under the ROFN Agreement, following the completion of any Initial Proof of Concept Clinical Trial (“Initial POC”) for the Company’s other product candidates, the Company must provide Kaken with certain information relating to the results of the clinical trial (“Initial POC Package”). The ROFN Agreement is exercisable by Kaken within </span><span style="font-family:inherit;font-size:10pt;">30</span><span style="font-family:inherit;font-size:10pt;"> days of receipt of the Initial POC Package. In December 2017, the Company recognized collaboration revenue related to the Collaboration Agreement of </span><span style="font-family:inherit;font-size:10pt;"><span>$5.0 million</span></span><span style="font-family:inherit;font-size:10pt;">, in connection with the Kaken Option. Additionally, the Company recognized sublicensing costs of </span><span style="font-family:inherit;font-size:10pt;"><span>$1.0 million</span></span><span style="font-family:inherit;font-size:10pt;">, which are included in general and administrative expenses. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Collaboration Agreement was further amended in March 2018 to accelerate payment of the Phase 3 Milestone. The Phase 3 Milestone was modified to be due upon the successful completion of the End of Phase 2 Meeting with the PMDA by Kaken on March 8, 2018, as determined by Kaken in its reasonable discretion (the “Third Milestone”). In March 2018, Kaken triggered the Third Milestone and paid the Company </span><span style="font-family:inherit;font-size:10pt;"><span>$5.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> (the “Third Milestone Payment”). Upon receipt of the non-refundable Third Milestone Payment, the ROFN Agreement was amended (the “Amended ROFN Agreement”) to grant an additional option to exercise upon completion of a Subsequent Clinical Trial (first clinical trial after the Initial POC) for the Company’s other product candidates. The Company has determined that the ROFN Agreement is not a material right and has not allocated transaction price to this provision. As of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, Kaken has not exercised the Amended ROFN Agreement. In March 2018, the Company recognized collaboration revenue related to the Collaboration Agreement of </span><span style="font-family:inherit;font-size:10pt;"><span>$5.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> in connection with the Third Milestone. Additionally, the Company recognized sublicensing costs of </span><span style="font-family:inherit;font-size:10pt;"><span>$1.0 million</span></span><span style="font-family:inherit;font-size:10pt;">, which are included in general and administrative expenses. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Royalties </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognized revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue from any collaborative arrangement. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Under collaborative arrangements, the Company has been reimbursed for a portion of the Company’s research and development expenses, including costs of drug supplies. When the research and development services are performed under a reimbursement </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">or cost sharing model with a collaboration partner, the Company records these reimbursements as a reduction of research and development expense in the Company’s condensed consolidated statements of operations. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Net Loss per Common Share </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic and diluted net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares outstanding. When the effects are not anti-dilutive, diluted earnings per share is computed by dividing the Company’s net earnings by the weighted average number of common shares outstanding and the impact of all dilutive potential common shares. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Diluted earnings per share gives effect to all dilutive potential common shares outstanding during the period, including stock options and warrants, using the treasury stock method, and redeemable convertible preferred stock, using the if-converted method. In computing diluted earnings per share, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants. Potentially dilutive common share equivalents are excluded from the diluted earnings per share computation in net loss periods because their effect would be anti-dilutive. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table sets forth the potential common shares excluded from the calculation of net loss per common share, because their inclusion would be anti-dilutive: </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:73%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three and Nine Months Ended<br/>September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Warrants to purchase common stock</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,632,495</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>55,360</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Options to purchase common stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,802,895</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,347,500</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Redeemable convertible preferred stock (as converted into common stock)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,256,466</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Warrants to purchase redeemable convertible preferred stock (as converted into common stock)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,005</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,435,390</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,668,331</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Basis of Presentation </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The accompanying condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, Brickell Subsidiary, Inc., are presented in U.S. dollars and have been prepared in accordance with accounting principles generally accepted in the United States of America (“</span><span style="font-family:inherit;font-size:10pt;">US GAAP</span><span style="font-family:inherit;font-size:10pt;">”) and applicable rules and regulations of the SEC for interim reporting. As permitted under those rules and regulations, certain footnotes or other financial information normally included in financial statements prepared in accordance with </span><span style="font-family:inherit;font-size:10pt;">US GAAP</span><span style="font-family:inherit;font-size:10pt;"> have been condensed or omitted. These condensed consolidated financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments, consisting only of normal recurring adjustments, which are necessary for a fair presentation of the Company’s financial information. The results of operations for the </span><span style="font-family:inherit;font-size:10pt;">three and nine months ended</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> are not necessarily indicative of the results to be expected for the full year ending </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, for any other interim period, or for any other future period. The condensed consolidated balance sheet as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;"> has been derived from audited financial statements at that date but does not include all of the information required by </span><span style="font-family:inherit;font-size:10pt;">US GAAP</span><span style="font-family:inherit;font-size:10pt;"> for complete financial statements. All intercompany balances and transactions have been eliminated in consolidation.</span></div> 3367988 36100000 The following table summarizes the net assets acquired based on their estimated fair values immediately prior to the Merger (in thousands):<div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:87%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,017</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;">Marketable securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23,959</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;">Prepaid expenses and other current assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,474</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;">Accrued liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,357</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;">Net acquired tangible assets</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>36,093</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 13017000 23959000 1474000 2357000 36093000 891582 0.07 <div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company’s condensed consolidated financial statements are prepared in accordance with </span><span style="font-family:inherit;font-size:10pt;">US GAAP</span><span style="font-family:inherit;font-size:10pt;">, which requires it to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Although these estimates are based on the Company’s knowledge of current events and actions it may take in the future, actual results may ultimately differ from these estimates and assumptions.</span></div> <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Fair Value Measurements </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair value is the price that the Company would receive to sell an asset or pay to transfer a liability in a timely transaction with an independent counterparty in the principal market or in the absence of a principal market, the most advantageous market for the asset or liability. A three-tier hierarchy is established to distinguish between (1) inputs that reflect the assumptions market participants would use in pricing an asset or liability developed based on market data obtained from sources independent of the reporting entity (observable inputs) and (2) inputs that reflect the reporting entity’s own assumptions about the assumptions market participants would use in pricing an asset or liability developed based on the best information available in the circumstances (unobservable inputs), and establishes a classification of fair value measurements for disclosure purposes. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The hierarchy is summarized in the three broad levels listed below:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;padding-left:24px;text-indent:-24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 1</span><span style="font-family:inherit;font-size:10pt;">—quoted prices in active markets for identical assets and liabilities </span></div><div style="line-height:120%;text-align:justify;padding-left:24px;text-indent:-24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 2</span><span style="font-family:inherit;font-size:10pt;">—other significant observable inputs (including quoted prices for similar assets and liabilities, interest rates, credit risk, etc.) </span></div><div style="line-height:120%;text-align:justify;padding-left:24px;text-indent:-24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 3</span><span style="font-family:inherit;font-size:10pt;">—significant unobservable inputs (including the Company’s own assumptions in determining the fair value of assets and liabilities) </span></div><div style="line-height:120%;text-align:justify;padding-left:24px;text-indent:-24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following tables set forth the fair value of the Company’s financial assets and liabilities measured at fair value on a recurring basis based on the three-tier fair value hierarchy as of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;"> (in thousands): </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 1</span><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 2</span><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 3</span><span style="font-family:inherit;font-size:8pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Money market funds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,225</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. treasuries</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18,473</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25,698</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contingent consideration</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>145</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 3</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Money market funds</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,067</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Redeemable convertible preferred stock warrant liability</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>242</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contingent consideration</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>145</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>387</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Fair Value of Financial Instruments </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following methods and assumptions were used by the Company in estimating the fair values of each class of financial instrument disclosed herein: </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Money Market Funds—</span><span style="font-family:inherit;font-size:10pt;">The carrying amounts reported as cash and cash equivalents in the condensed consolidated balance sheets approximate their fair values due to their short-term nature and/or market rates of interest (Level 1 of the fair value hierarchy). </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">U.S. Treasuries—</span><span style="font-family:inherit;font-size:10pt;">The Company has designated its investments in U.S. treasury securities as available-for-sale securities and accounts for them at their respective fair values. The securities are classified as short-term or long-term based on the nature of the securities and their availability to meet current operating requirements. Securities that are readily available for use in current operations are classified as short-term available-for-sale marketable securities and are reported as a component of current assets in the condensed consolidated balance sheets (Level 1 of the fair value hierarchy).</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Securities that are classified as available-for-sale are measured at fair value, including accrued interest, with temporary unrealized gains and losses reported as a component of stockholders’ equity until their disposition. The Company reviews available-for-sale securities at the end of each period to determine whether they remain available-for-sale based on its then current intent. The cost of securities sold is based on the specific identification method. The securities are subject to a periodic impairment review. An impairment charge would occur when a decline in the fair value of the investments below the cost basis is judged to be other-than-temporary.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company’s available-for-sale securities had an amortized cost of </span><span style="font-family:inherit;font-size:10pt;"><span>$18.5 million</span></span><span style="font-family:inherit;font-size:10pt;">, fair value of </span><span style="font-family:inherit;font-size:10pt;"><span>$18.5 million</span></span><span style="font-family:inherit;font-size:10pt;">, and an unrealized gain of </span><span style="font-family:inherit;font-size:10pt;"><span>$20 thousand</span></span><span style="font-family:inherit;font-size:10pt;">. Because the securities were acquired in August 2019 in connection to the Merger, there were </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;"> related balances as of December 31, 2018.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Contingent Consideration—</span><span style="font-family:inherit;font-size:10pt;">These amounts represent future payments in conjunction with various business combinations related to the acquisition of certain early-stage pipeline assets. The ultimate amount of future payments is based on specified future criteria, such as the achievement of certain future development and regulatory milestones. The Company evaluates its estimates of the fair value of contingent consideration on a quarterly basis. The fair value of the contingent consideration was determined with the assistance of a third-party valuation firm applying the income approach. This approach estimates the fair value of the contingent consideration related to the achievement of future development and regulatory milestones by assigning an achievement probability and date of expected completion to each potential milestone and discounting the associated cash payment to its present value using a risk-adjusted rate of return. The probability of success of each milestone assumes that the prerequisite developmental milestones are successfully completed and is based on the asset’s current stage of development and anticipated regulatory requirements. The probability of success for each milestone is determined by multiplying the preceding probabilities of success. The unobservable inputs (Level 3 of the fair value hierarchy) to the valuation models that have the most significant effect on the fair value of the Company’s contingent consideration are the probabilities that certain in-process development projects will meet specified development milestones, including ultimate approval by the FDA, with individual cumulative probabilities ranging from </span><span style="font-family:inherit;font-size:10pt;"><span>2.1%</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>20.9%</span></span><span style="font-family:inherit;font-size:10pt;">. Other unobservable inputs used in this approach include risk-adjusted discount rates ranging from </span><span style="font-family:inherit;font-size:10pt;"><span>15.5%</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>27.1%</span></span><span style="font-family:inherit;font-size:10pt;"> and estimates of the timing of the achievement of the various product development, regulatory approval, and sales milestones. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Redeemable Convertible Preferred Stock Warrant Liability</span><span style="font-family:inherit;font-size:10pt;">—These amounts represented potential future obligations to transfer assets to the holders at a future date. The Company remeasured these warrants to current fair value at each balance sheet date, and any change in fair value was recognized as a change in fair value of warrant liability in the condensed consolidated statements of operations. The Company estimated the fair value of these warrants at December 31, 2018 using the Black-Scholes option-pricing model (Level 3 of the fair value hierarchy table). These warrants converted from warrants exercisable for redeemable convertible preferred stock to common stock in August 2019 in connection to the Merger (see further discussion in </span><span style="font-family:inherit;font-size:10pt;">Note 7</span><span style="font-family:inherit;font-size:10pt;">). </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inputs used to determine estimated fair value of the warrant liabilities included the estimated fair value of the underlying stock at the valuation date, the estimated term of the warrants, risk-free interest rates, expected dividends, and the expected volatility of the underlying stock. The most significant unobservable inputs used in the fair value measurement of the convertible preferred stock warrant liability were the fair value of the underlying stock at the valuation date and the estimated term of the warrants. Generally, increases (decreases) in the fair value of the underlying stock and estimated term resulted in a directionally similar impact to the fair value measurement. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The fair value of the outstanding warrants was remeasured as of each period end using the Black-Scholes option-pricing model with the following assumptions: </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"/></tr><tr><td style="width:87%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected term (in years)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected volatility</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30.00</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Risk free interest rate</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.59</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected dividend yield</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The fair value of the shares of the convertible preferred stock underlying the preferred stock warrants was historically determined with the assistance of a third-party valuation firm. Because there had been no public market for the Company’s convertible preferred stock, the third-party valuation firm determined fair value of the convertible preferred stock at each balance sheet date by considering a number of objective and subjective factors, including valuation of comparable companies, sales of convertible preferred stock to unrelated third parties, operating and financial performance, the lack of liquidity of capital stock, and general and industry specific economic outlook, among other factors. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Remaining Term.</span><span style="font-family:inherit;font-size:10pt;"> The Company derived the expected term based on the time from the balance sheet date until the preferred stock warrant’s expiration date. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Expected Volatility.</span><span style="font-family:inherit;font-size:10pt;"> Since the Company was a private entity with no historical data regarding the volatility of its preferred stock, the expected volatility used was based on volatility of a group of similar entities. In evaluating similarity, the Company considered factors such as industry, stage of life cycle, and size. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Risk-free Interest Rate</span><span style="font-family:inherit;font-size:10pt;">. The risk-free interest rate was based on U.S. Treasury zero-coupon issues with remaining terms similar to the expected term of the warrants. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Expected Dividend Rate</span><span style="font-family:inherit;font-size:10pt;">. The Company has never paid any dividends and does not plan to pay dividends in the foreseeable future and, therefore, used an expected dividend rate of </span><span style="font-family:inherit;font-size:10pt;">zero</span><span style="font-family:inherit;font-size:10pt;"> in the valuation model. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Derivative Liability—</span><span style="font-family:inherit;font-size:10pt;">These amounts represented potential future obligations to transfer assets to the holders at a future date. The fair value of the derivative liability has historically been determined with the assistance of a third-party valuation firm (Level 3 of the fair value hierarchy table) (see further discussion in </span><span style="font-family:inherit;font-size:10pt;">Note 6</span><span style="font-family:inherit;font-size:10pt;">). At the inception of the liability, there was no public market for the Company’s common stock, and a third-party valuation firm determined fair value of the stock by considering a number of objective and subjective factors, including valuation of comparable companies, sales of common stock to unrelated third parties, operating and financial performance, the lack of liquidity of capital stock, and general and industry specific economic outlook, among other factors. The derivative liability was marked-to-market each measurement period and any change in fair value was recorded in the condensed consolidated statements of operations. In August 2019, in connection to the Merger, the derivative liability was reclassified to equity in the condensed consolidated balance sheet (see further discussion in </span><span style="font-family:inherit;font-size:10pt;">Note 6</span><span style="font-family:inherit;font-size:10pt;">). </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Common Stock Warrant Liability</span><span style="font-family:inherit;font-size:10pt;">—These amounts represented potential future obligations to transfer assets to the holders at a future date. The fair value of the warrants was historically determined with the assistance of a third-party valuation firm (Level 3 of the fair value hierarchy table) (see further discussion in </span><span style="font-family:inherit;font-size:10pt;">Note 6</span><span style="font-family:inherit;font-size:10pt;">). At the inception of the liability, there was no public market for the Company’s common stock, and a third-party valuation firm determined fair value of the stock by considering a number of objective and subjective factors, including valuation of comparable companies, sales of common stock to unrelated third parties, operating and financial performance, the lack of liquidity of capital stock, and general and industry specific economic outlook, among other factors. The warrant liability was remeasured to fair value at each balance sheet date, and any change in fair value was recognized as a change in fair value of warrant liability in the condensed consolidated statements of operations. The Company estimated the fair value of these warrants using the Black-Scholes option-pricing model. In August 2019, in connection to the Merger, the warrant liability was reclassified to equity in the condensed consolidated balance sheet (see further discussion in </span><span style="font-family:inherit;font-size:10pt;">Note 6</span><span style="font-family:inherit;font-size:10pt;">).</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inputs used to determine estimated fair value of the warrant liabilities included the estimated fair value of the underlying stock at the valuation date, the estimated term of the warrants, risk-free interest rates, expected dividends, and the expected volatility of the underlying stock. The most significant unobservable inputs used in the fair value measurement of the warrant liability were the fair value of the underlying stock at the valuation date and the estimated term of the warrants. Generally, increases (decreases) in the fair value of the underlying stock and estimated term resulted in a directionally similar impact to the fair value measurement. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div> <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following tables set forth the fair value of the Company’s financial assets and liabilities measured at fair value on a recurring basis based on the three-tier fair value hierarchy as of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;"> (in thousands): </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 1</span><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 2</span><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 3</span><span style="font-family:inherit;font-size:8pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Money market funds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,225</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. treasuries</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18,473</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25,698</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contingent consideration</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>145</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 3</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Money market funds</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,067</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Redeemable convertible preferred stock warrant liability</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>242</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contingent consideration</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>145</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>387</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 7225000 0 0 18473000 0 0 25698000 0 0 0 0 145000 8067000 0 0 0 0 242000 0 0 145000 0 0 387000 18500000 18500000 20000 0 0.021 0.209 0.155 0.271 <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The fair value of the outstanding warrants was remeasured as of each period end using the Black-Scholes option-pricing model with the following assumptions: </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"/></tr><tr><td style="width:87%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected term (in years)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected volatility</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30.00</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Risk free interest rate</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.59</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected dividend yield</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 7.1 0.3000 0.0259 0 <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table sets forth a summary of the changes in the fair value of the Company’s Level 3 financial instruments as follows (in thousands): </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Derivative <br/>Liability</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Common <br/>Stock <br/>Warrant <br/>Liability</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Redeemable <br/>Convertible <br/>Preferred <br/>Stock Warrant <br/>Liability</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Contingent <br/>Consideration <br/>Liabilities</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair value as of December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>242</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>145</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair value of financial instruments issued</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,442</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,492</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Change in fair value</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(240</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Reclassification to equity</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,453</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,509</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair value as of September 30, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>145</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 0 0 242000 145000 1442000 1492000 0 0 11000 17000 -240000 0 1453000 1509000 2000 0 0 0 0 145000 <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Leases </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On January 1, 2019, the Company adopted Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 842, Leases (“ASC 842”), using the modified retrospective method for all lease arrangements at the beginning of the </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">period of adoption. Results for reporting periods beginning January 1, 2019 are presented under ASC 842, while prior period amounts were not adjusted and continue to be presented in accordance with the Company’s historical accounting under ASC Topic 840, Leases. ASC 842 had an impact on the Company’s condensed consolidated balance sheets but did not have a significant impact on the Company’s net loss.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Under ASC 842, the Company determines if an arrangement is a lease at inception. Leases with a term greater than </span><span style="font-family:inherit;font-size:10pt;">one year</span><span style="font-family:inherit;font-size:10pt;"> are recognized on the balance sheet as right-of-use assets, lease liabilities and, if applicable, long-term lease liabilities. The Company has elected the practical expedient not to recognize on the balance sheet leases with terms of </span><span style="font-family:inherit;font-size:10pt;">one</span><span style="font-family:inherit;font-size:10pt;">-year or less and not to separate lease components and non-lease components for long-term real-estate leases. Lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company estimates the incremental borrowing rate based on industry peers in determining the present value of lease payments. The Company’s facility operating lease has </span><span style="font-family:inherit;font-size:10pt;">one</span><span style="font-family:inherit;font-size:10pt;"> single component. The lease component results in a right-of-use asset being recorded on the balance sheet, which is amortized as lease expense on a straight-line basis in the Company’s condensed consolidated statements of operations. </span></div> <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Redeemable Convertible Preferred Stock </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Redeemable convertible preferred stock was classified as a mezzanine instrument outside of the Company’s capital accounts. Accretion of redeemable convertible preferred stock included the greater of an adjustment to fair market value or the accrual of dividends on and accretion of issuance costs of the Company’s redeemable convertible preferred stock. The carrying values of the redeemable convertible preferred stock were increased or reduced by periodic accretion or reduction to their respective redemption values from the date of issuance to August 31, 2019, the date that all outstanding shares of redeemable convertible preferred stock converted into shares of common stock. The carrying value adjustments were recorded as charges against additional paid-in capital balance. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Preferred stock issuance costs represent costs related to the Company’s issuance of redeemable convertible preferred stock. These amounts were included as a reduction of redeemable convertible preferred stock and were amortized over the estimated redemption period until its conversion to common stock in August 2019. For the </span><span style="font-family:inherit;font-size:10pt;">nine months ended</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, amortization of preferred stock issuance costs amounted to approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$0.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$30 thousand</span></span><span style="font-family:inherit;font-size:10pt;">, respectively. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Redeemable Convertible Preferred Stock Warrants </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company accounted for warrants to purchase shares of its redeemable convertible preferred stock as liabilities at their estimated fair value because the underlying shares were redeemable, which obligated the Company to transfer assets to the holders at a future date. The warrants were subject to remeasurement to fair value at each balance sheet date, and any fair value adjustments were recognized as change in fair value of redeemable convertible preferred stock warrant liability in the condensed consolidated statements of operations. The Company continued to adjust the liability for changes in fair value until the conversion of the redeemable convertible preferred stock into common stock in August 2019. At that time, the redeemable convertible preferred stock warrant liability was adjusted to fair value in the condensed consolidated statements of operations with the final fair value reclassified to equity. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 100000 30000 <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue Recognition </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company recognizes revenue upon the transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies the performance obligations. At contract inception, the Company assesses the goods or services promised within each contract and assesses whether each promised good or service is distinct and determines those that are performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">To date, the Company’s drug candidates have not been approved for sale by the FDA or any other country’s regulatory authority, and the Company has not generated or recognized any revenue from the sale of products. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In March 2015, the Company entered into a license and collaboration agreement with Kaken Pharmaceutical, Co., Ltd. (“Kaken”), which is referred to as the “Collaboration Agreement.” Under the Collaboration Agreement, the Company granted to Kaken an exclusive right to develop, manufacture, and commercialize the Company’s sofpironium bromide compound (formerly BBI-4000), a topical anticholinergic, in Japan and certain other Asian countries (the “Territory”). In exchange, Kaken paid the Company an upfront, non-refundable payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$11.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> (the “upfront fee”). In addition, the Company is entitled to receive aggregate payments of up to </span><span style="font-family:inherit;font-size:10pt;"><span>$10.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> upon the achievement of specified development milestones, and </span><span style="font-family:inherit;font-size:10pt;"><span>$30.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> upon the achievement of commercial milestones, as well as tiered royalties based on a percentage of net sales of licensed products in the Territory. The Collaboration Agreement further provides that Kaken will be responsible for funding all development and commercial costs for the program in the Territory and, until such time, if any, as Kaken elects to establish its own source of supply of drug product, Kaken can purchase product supply from the Company to perform all non-clinical studies, and Phase 1 and Phase 2 clinical trials in Japan at cost. Kaken is also required to enter into negotiations with the Company, to supply the Company, at cost, with clinical supplies to perform Phase 3 clinical trials in the United States.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Collaboration Arrangement Subsequent to Adoption of Topic 606 </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company evaluates collaboration arrangements to determine whether units of account within the collaboration arrangement exhibit the characteristics of a vendor and customer relationship. The Company determined that the licenses transferred to Kaken in exchange for the upfront fees were representative of this type of a relationship. If a license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from non-refundable, upfront fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other performance obligations, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition on a prospective basis. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Under Topic 606, the Company evaluated the terms of the Collaboration Agreement and the transfer of intellectual property and manufacturing rights (the “license”) was identified as the only performance obligation as of the inception of the agreement. The Company concluded that the license for the intellectual property was distinct from its ongoing supply obligations. The Company further determined that the transaction price under the arrangement was comprised of the </span><span style="font-family:inherit;font-size:10pt;"><span>$11.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> upfront payment. The future potential milestone amounts were not included in the transaction price, as they were all determined to be fully constrained. As part of its evaluation of the development and regulatory milestones constraint, the Company determined that the achievement of such milestones is contingent upon success in future clinical trials and regulatory approvals, each of which is uncertain at this time. The Company will re-evaluate the transaction price each quarter and as uncertain events are resolved or other changes in circumstances occur. Future potential milestone amounts would be recognized as revenue from collaboration arrangements, if unconstrained. The remainder of the arrangement, which largely consisted of both parties incurring costs in their respective territories, provides for the reimbursement of the ongoing supply costs. These costs were representative of a collaboration arrangement outside of the scope of Topic 606 as it does not have the characteristics of a vendor and customer relationship. Reimbursable program costs are recognized proportionately with the delivery of drug substance and are accounted for as reductions to research and development expense and are excluded from the transaction price. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Under Topic 606, the entire transaction price of </span><span style="font-family:inherit;font-size:10pt;"><span>$11.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> was allocated to the license performance obligation. The license was deemed to be delivered in </span><span style="font-family:inherit;font-size:10pt;">2015</span><span style="font-family:inherit;font-size:10pt;"> in connection with the execution of the Collaboration Agreement and upon transfer of the underlying intellectual property the performance obligation was fully satisfied. As a result, a cumulative adjustment to reduce deferred revenue and the corresponding sublicensing costs of </span><span style="font-family:inherit;font-size:10pt;"><span>$2.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> was recorded upon the adoption of Topic 606 on January 1, 2018. As of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company does not have a deferred revenue or deferred sublicensing costs balance related to the upfront fee on the condensed consolidated balance sheet. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In May 2018, the Company entered into an amendment to the Collaboration Agreement (as further amended, “Collaboration Agreement”), pursuant to which, the Company received an upfront non-refundable fee of </span><span style="font-family:inherit;font-size:10pt;"><span>$15.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> (the “Collaboration R&amp;D Payment”), which was initially recorded as deferred revenue, to provide the Company with research and development funds for the sole purpose of conducting certain clinical trials and other such research and development activities required to support the submission of a NDA for sofpironium bromide. These clinical trials have a benefit to Kaken and have the characteristics of a vendor and customer relationship. The Company has accounted for these under the provisions of Topic 606. This Collaboration R&amp;D Payment will be initially recognized using an input method over the average estimated performance period of </span><span style="font-family:inherit;font-size:10pt;"><span>1.45 years</span></span><span style="font-family:inherit;font-size:10pt;"> in proportion to the cost incurred. Upon receipt of the Collaboration R&amp;D Payment, on May 31, 2018, a milestone payment </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">originally due upon the first commercial sale in Japan was removed from the Collaboration Agreement and all future royalties to the Company under the Collaboration Agreement were reduced </span><span style="font-family:inherit;font-size:10pt;">150</span><span style="font-family:inherit;font-size:10pt;"> basis points. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Consequently, during the </span><span style="font-family:inherit;font-size:10pt;">three and nine months ended</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company recognized revenue of </span><span style="font-family:inherit;font-size:10pt;"><span>$1.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$7.2 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively related to the Collaboration R&amp;D Payment. As of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company has a deferred revenue balance related to the Collaboration R&amp;D Payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$2.5 million</span></span><span style="font-family:inherit;font-size:10pt;">, which is recorded in deferred revenue, current portion on the accompanying condensed consolidated balance sheets. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Milestones </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">At the inception of each arrangement that includes milestone payments (variable consideration), the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company or the Company’s collaboration partner’s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such milestones and any related constraint, and if necessary, adjust the Company’s estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration or other revenues and earnings in the period of adjustment. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In October 2017, the Company entered into an amendment to the Collaboration Agreement, pursuant to which, the Company granted Kaken a prepayment option (the “Kaken Option”) on </span><span style="font-family:inherit;font-size:10pt;"><span>50%</span></span><span style="font-family:inherit;font-size:10pt;"> of the Initiation of Phase 3 milestone (the “Phase 3 Milestone”). The Kaken Option was exercisable by Kaken within </span><span style="font-family:inherit;font-size:10pt;">25</span><span style="font-family:inherit;font-size:10pt;"> business days of receipt of the BBI-4000-CL-203 study topline results. In December 2017, Kaken exercised the Kaken Option and paid the Company </span><span style="font-family:inherit;font-size:10pt;"><span>$5.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> (the “Kaken Option Payment”). Upon receipt of the non-refundable Kaken Option Payment, the Company provided Kaken the right to negotiate an exclusive license to develop, manufacture and commercialize each of the Company’s other product candidates in Japan (“ROFN Agreement”). Under the ROFN Agreement, following the completion of any Initial Proof of Concept Clinical Trial (“Initial POC”) for the Company’s other product candidates, the Company must provide Kaken with certain information relating to the results of the clinical trial (“Initial POC Package”). The ROFN Agreement is exercisable by Kaken within </span><span style="font-family:inherit;font-size:10pt;">30</span><span style="font-family:inherit;font-size:10pt;"> days of receipt of the Initial POC Package. In December 2017, the Company recognized collaboration revenue related to the Collaboration Agreement of </span><span style="font-family:inherit;font-size:10pt;"><span>$5.0 million</span></span><span style="font-family:inherit;font-size:10pt;">, in connection with the Kaken Option. Additionally, the Company recognized sublicensing costs of </span><span style="font-family:inherit;font-size:10pt;"><span>$1.0 million</span></span><span style="font-family:inherit;font-size:10pt;">, which are included in general and administrative expenses. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Collaboration Agreement was further amended in March 2018 to accelerate payment of the Phase 3 Milestone. The Phase 3 Milestone was modified to be due upon the successful completion of the End of Phase 2 Meeting with the PMDA by Kaken on March 8, 2018, as determined by Kaken in its reasonable discretion (the “Third Milestone”). In March 2018, Kaken triggered the Third Milestone and paid the Company </span><span style="font-family:inherit;font-size:10pt;"><span>$5.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> (the “Third Milestone Payment”). Upon receipt of the non-refundable Third Milestone Payment, the ROFN Agreement was amended (the “Amended ROFN Agreement”) to grant an additional option to exercise upon completion of a Subsequent Clinical Trial (first clinical trial after the Initial POC) for the Company’s other product candidates. The Company has determined that the ROFN Agreement is not a material right and has not allocated transaction price to this provision. As of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, Kaken has not exercised the Amended ROFN Agreement. In March 2018, the Company recognized collaboration revenue related to the Collaboration Agreement of </span><span style="font-family:inherit;font-size:10pt;"><span>$5.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> in connection with the Third Milestone. Additionally, the Company recognized sublicensing costs of </span><span style="font-family:inherit;font-size:10pt;"><span>$1.0 million</span></span><span style="font-family:inherit;font-size:10pt;">, which are included in general and administrative expenses. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Royalties </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognized revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue from any collaborative arrangement. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Under collaborative arrangements, the Company has been reimbursed for a portion of the Company’s research and development expenses, including costs of drug supplies. When the research and development services are performed under a reimbursement </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">or cost sharing model with a collaboration partner, the Company records these reimbursements as a reduction of research and development expense in the Company’s condensed consolidated statements of operations. </span></div> 11000000.0 10000000.0 30000000.0 11000000.0 11000000.0 2700000 15600000 P1Y5M12D 1200000 7200000 2500000 0.50 5000000.0 5000000.0 1000000.0 5000000.0 5000000.0 1000000.0 <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Net Loss per Common Share </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic and diluted net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares outstanding. When the effects are not anti-dilutive, diluted earnings per share is computed by dividing the Company’s net earnings by the weighted average number of common shares outstanding and the impact of all dilutive potential common shares. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Diluted earnings per share gives effect to all dilutive potential common shares outstanding during the period, including stock options and warrants, using the treasury stock method, and redeemable convertible preferred stock, using the if-converted method. In computing diluted earnings per share, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants. Potentially dilutive common share equivalents are excluded from the diluted earnings per share computation in net loss periods because their effect would be anti-dilutive. </span></div> <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table sets forth the potential common shares excluded from the calculation of net loss per common share, because their inclusion would be anti-dilutive: </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:73%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three and Nine Months Ended<br/>September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Warrants to purchase common stock</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,632,495</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>55,360</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Options to purchase common stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,802,895</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,347,500</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Redeemable convertible preferred stock (as converted into common stock)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,256,466</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Warrants to purchase redeemable convertible preferred stock (as converted into common stock)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,005</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,435,390</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,668,331</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 1632495 55360 1802895 1347500 0 1256466 0 9005 3435390 2668331 <span style="font-family:inherit;font-size:10pt;font-weight:bold;">RECENT ACCOUNTING PRONOUNCEMENTS</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement (“ASU 2018-13”), which amends certain disclosure requirements over Level 1, Level 2, and Level 3 fair value measurements. ASU 2018-13 is effective for fiscal years beginning after December 15, 2019 and interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the impact of adopting ASU 2018-13, but does not anticipate it will have a material impact on its disclosures. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU No. 2016-02, “Leases (Topic 842)” (“ASU 2016-02”). ASU 2016-02 is aimed at making leasing activities more transparent and comparable and requires substantially all leases be recognized by lessees on their balance sheets as a right-of-use asset and corresponding lease liability, including leases currently accounted for as operating leases. The Company adopted ASU 2016-02 on January 1, 2019 using the modified retrospective approach. The adoption did not have a material impact on the Company’s condensed consolidated statements of operations. The new standard has required the Company to establish liabilities and corresponding right-of-use assets on its condensed balance sheet for operating leases of </span><span style="font-family:inherit;font-size:10pt;"><span>$0.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> that existed as of the January 1, 2019 adoption date. The impact on the condensed consolidated balance sheets as of January 1, 2019 was as follows (in thousands): </span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:34%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:19%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:19%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:19%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance Sheet</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">Topic 840 <br/></span><span style="font-family:inherit;font-size:8pt;font-weight:bold;">January 1, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">Topic 842 <br/></span><span style="font-family:inherit;font-size:8pt;font-weight:bold;">January 1, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Impact of <br/>Adoption</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease right-of-use asset</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>219</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>219</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Lease liability, current portion</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(68</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(68</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Lease liability, net of current portion</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(151</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(151</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement (“ASU 2018-13”), which amends certain disclosure requirements over Level 1, Level 2, and Level 3 fair value measurements. ASU 2018-13 is effective for fiscal years beginning after December 15, 2019 and interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the impact of adopting ASU 2018-13, but does not anticipate it will have a material impact on its disclosures. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU No. 2016-02, “Leases (Topic 842)” (“ASU 2016-02”). ASU 2016-02 is aimed at making leasing activities more transparent and comparable and requires substantially all leases be recognized by lessees on their balance sheets as a right-of-use asset and corresponding lease liability, including leases currently accounted for as operating leases. The Company adopted ASU 2016-02 on January 1, 2019 using the modified retrospective approach. The adoption did not have a material impact on the Company’s condensed consolidated statements of operations. The new standard has required the Company to establish liabilities and corresponding right-of-use assets on its condensed balance sheet for operating leases of </span><span style="font-family:inherit;font-size:10pt;"><span>$0.2 million</span></span> that existed as of the January 1, 2019 adoption date. 200000 The impact on the condensed consolidated balance sheets as of January 1, 2019 was as follows (in thousands): <div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:34%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:19%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:19%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:19%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance Sheet</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">Topic 840 <br/></span><span style="font-family:inherit;font-size:8pt;font-weight:bold;">January 1, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">Topic 842 <br/></span><span style="font-family:inherit;font-size:8pt;font-weight:bold;">January 1, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Impact of <br/>Adoption</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease right-of-use asset</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>219</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>219</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Lease liability, current portion</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(68</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(68</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Lease liability, net of current portion</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(151</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(151</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 219000 219000 68000 68000 151000 151000 <span style="font-family:inherit;font-size:10pt;font-weight:bold;">NOVAQUEST FUNDING ARRANGEMENT</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On August 31, 2019, concurrent with the Merger Agreement, the Company entered into a research and development arrangement with NovaQuest pursuant to which NovaQuest committed up to </span><span style="font-family:inherit;font-size:10pt;"><span>$25.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> in research and development funding to the </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Company following the closing of the Merger. These proceeds will partially fund the Company’s Phase 3 clinical trials in the United States for its product candidate that contains sofpironium bromide, which treats hyperhidrosis of the skin. The Company is obligated to use commercially reasonable efforts to complete the clinical trials and file to obtain regulatory approval. The funding was projected to cover </span><span style="font-family:inherit;font-size:10pt;"><span>67%</span></span><span style="font-family:inherit;font-size:10pt;"> of the product development costs up to </span><span style="font-family:inherit;font-size:10pt;"><span>$25.0 million</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As there is a substantive and genuine transfer of risk, the development funding is accounted for as an obligation to perform contractual services. However, given the potential obligation to repay the amounts received, the Company defer any funding received as a liability unless and until it becomes probable that the Company will not have to make a repayment of the received funding to NovaQuest. If the research and development is successful and the product candidate is ultimately approved by the FDA, NovaQuest will be entitled to a payment in the amount of </span><span style="font-family:inherit;font-size:10pt;"><span>$37.5 million</span></span><span style="font-family:inherit;font-size:10pt;">, with </span><span style="font-family:inherit;font-size:10pt;"><span>$20.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> due upon approval and the remainder due within two years of approval. Additionally, NovaQuest will be entitled to royalty payments based on annual net sales (except for Japan and certain other Asian countries) of the product candidate based on a sliding scale starting from the date that is two years after the first commercial sale. The portion of the approval payment, should it occur, that exceeds any liabilities recorded on the balance sheet, will be expensed immediately as interest expense. The royalties will be expensed as incurred and will also be included in cost of sales. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If the funding arrangement is terminated in certain circumstances, the Company will be required to pay NovaQuest </span><span style="font-family:inherit;font-size:10pt;"><span>$25.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> plus interest, ranging from </span><span style="font-family:inherit;font-size:10pt;"><span>8%</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>12%</span></span><span style="font-family:inherit;font-size:10pt;">. However, in the event that the Company terminates its development program for sofpironium bromide for other specified reasons, including serious safety issues, a failure of the product’s Phase 3 studies, or the FDA’s unwillingness to approve the product, the Company will not be obligated to make any payments to NovaQuest.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In conjunction with the transaction, the Company issued a fully vested warrant to NovaQuest providing it with the right to purchase </span><span style="font-family:inherit;font-size:10pt;"><span>241,225</span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock at an exercise price of </span><span style="font-family:inherit;font-size:10pt;"><span>$10.36</span></span><span style="font-family:inherit;font-size:10pt;"> that is exercisable any time within ten years of the execution of the research and development arrangement (the “NovaQuest Warrant”). At issuance, the NovaQuest Warrant was classified as equity and recorded at fair value with no subsequent remeasurement. The fair value of the outstanding warrants was derived from the Black-Scholes option-pricing model using the following assumptions: </span><span style="font-family:inherit;font-size:10pt;">expected volatility</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;"><span>85.56%</span></span><span style="font-family:inherit;font-size:10pt;">; </span><span style="font-family:inherit;font-size:10pt;">risk free interest rate</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;"><span>1.50%</span></span><span style="font-family:inherit;font-size:10pt;">; </span><span style="font-family:inherit;font-size:10pt;">expected term</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;"><span>10</span></span><span style="font-family:inherit;font-size:10pt;"> years; and </span><span style="font-family:inherit;font-size:10pt;">expected dividend yield</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;"><span>0.00%</span></span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of September 30, 2019, </span><span style="font-family:inherit;font-size:10pt;"><span>$5.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> of funding had been received from NovaQuest, of which </span><span style="font-family:inherit;font-size:10pt;"><span>$0.9 million</span></span><span style="font-family:inherit;font-size:10pt;"> was allocated to the NovaQuest Warrant and deferred on the balance sheet within other current assets and will be recorded as interest expense over the term of the NovaQuest Warrant. In October 2019, NovaQuest notified the Company that additional funding was suspended temporarily based on a material adverse event. Refer to </span><span style="font-family:inherit;font-size:10pt;">Note 11</span><span style="font-family:inherit;font-size:10pt;"> for additional details.</span></div> 25000000.0 0.67 25000000.0 37500000 20000000.0 25000000.0 0.08 0.12 241225 10.36 0.8556 0.0150 10 0.0000 5600000 900000 <span style="font-family:inherit;font-size:10pt;font-weight:bold;">ACCRUED LIABILITIES</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued liabilities consisted of the following (in thousands): </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, <br/>2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued contracted research and development services</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,715</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>847</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued professional fees</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>992</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,269</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued compensation</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>768</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>569</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued note issuance costs</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>587</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,475</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,272</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> <div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued liabilities consisted of the following (in thousands): </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, <br/>2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued contracted research and development services</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,715</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>847</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued professional fees</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>992</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,269</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued compensation</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>768</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>569</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued note issuance costs</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>587</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,475</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,272</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 1715000 847000 992000 1269000 768000 569000 0 587000 3475000 3272000 <span style="font-family:inherit;font-size:10pt;font-weight:bold;">CONVERTIBLE PROMISSORY NOTES</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In March 2019, the Company initiated a convertible promissory notes offering pursuant to which the Company issued unsecured convertible promissory notes (the “Prom Notes”), bearing interest at </span><span style="font-family:inherit;font-size:10pt;"><span>12.00%</span></span><span style="font-family:inherit;font-size:10pt;"> with a maturity of </span><span style="font-family:inherit;font-size:10pt;"><span>one year</span></span><span style="font-family:inherit;font-size:10pt;"> and convertible into shares of Series C-1 redeemable convertible preferred stock or the most senior preferred equity outstanding at the time of conversion at the option of the holder at a conversion price of </span><span style="font-family:inherit;font-size:10pt;"><span>$31.05</span></span><span style="font-family:inherit;font-size:10pt;"> per share. In addition, the Prom Notes were automatically convertible upon closing of a qualified financing of at least </span><span style="font-family:inherit;font-size:10pt;"><span>$15.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> before maturity at a conversion price equal to </span><span style="font-family:inherit;font-size:10pt;"><span>80%</span></span><span style="font-family:inherit;font-size:10pt;"> of the effective price per share paid in the qualified financing, but not to exceed </span><span style="font-family:inherit;font-size:10pt;"><span>$38.82</span></span><span style="font-family:inherit;font-size:10pt;"> per share. Through </span><span style="font-family:inherit;font-size:10pt;">August 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company had raised an aggregate principal amount of </span><span style="font-family:inherit;font-size:10pt;"><span>$7.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> in Prom Notes. On </span><span style="font-family:inherit;font-size:10pt;">August 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, prior to the Merger, the Prom Notes and related accrued interest converted into </span><span style="font-family:inherit;font-size:10pt;"><span>1,069,740</span></span><span style="font-family:inherit;font-size:10pt;"> shares of Private Brickell common stock at a conversion price of </span><span style="font-family:inherit;font-size:10pt;"><span>$7.54</span></span><span style="font-family:inherit;font-size:10pt;"> per share (the “Conversion”).</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Prom Notes also provided for the issuance of warrants at </span><span style="font-family:inherit;font-size:10pt;"><span>50%</span></span><span style="font-family:inherit;font-size:10pt;"> coverage, to acquire </span><span style="font-family:inherit;font-size:10pt;"><span>490,683</span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock. The warrants are exercisable for a term of </span><span style="font-family:inherit;font-size:10pt;"><span>five years</span></span><span style="font-family:inherit;font-size:10pt;"> at an exercise price of </span><span style="font-family:inherit;font-size:10pt;"><span>$10.36</span></span><span style="font-family:inherit;font-size:10pt;">. Prior to the Merger, the warrants were exercisable at an exercise price of </span><span style="font-family:inherit;font-size:10pt;"><span>$42.70</span></span><span style="font-family:inherit;font-size:10pt;"> or </span><span style="font-family:inherit;font-size:10pt;"><span>10%</span></span><span style="font-family:inherit;font-size:10pt;"> premium to the effective price per share paid in a qualified financing. The Company evaluated the various financial instruments under ASC 480 and ASC 815 and determined the warrants required fair value accounting. The fair value of the warrants was recorded as a warrant liability upon issuance. The fair value of the warrants on the dates of issuance of </span><span style="font-family:inherit;font-size:10pt;"><span>$1.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> was determined with the assistance of a third-party valuation firm. The fair value of the warrants was recorded as a debt discount upon issuance and was amortized to interest expense over the term of the Prom Notes based on the effective interest method. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">At inception of the Prom Notes offering, the Company analyzed the conversion feature of the agreement for derivative accounting consideration under ASC 815 and determined that the embedded conversion features should be classified as a derivative because the exercise price of the Prom Notes are subject to a variable conversion rate. The Company determined that the variable conversion feature was a redemption feature that was not clearly and closely related to the Prom Notes and was therefore required to be bifurcated. In accordance with AC 815, the Company bifurcated the conversion feature of the Prom Notes and recorded a derivative liability. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The embedded derivative for the Prom Notes was carried on the Company’s condensed consolidated balance sheet at fair value. The derivative liability was marked-to-market each measurement period and any change in fair value was recorded as a component of the statements of operations. The fair value of the derivative liabilities on the date of issuance of </span><span style="font-family:inherit;font-size:10pt;"><span>$1.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> was determined with the assistance of a third-party valuation firm. The fair value of the conversion feature was recorded as a debt discount upon issuance and was amortized to interest expense over the term of the Prom Notes based on the effective interest method. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company evaluated the conversion option to discern whether a beneficial conversion feature existed based upon comparing the effective exercise price of the convertible notes to the fair value of the shares they were convertible into. The Company concluded no beneficial conversion feature existed. During the </span><span style="font-family:inherit;font-size:10pt;">three months ended</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company recognized </span><span style="font-family:inherit;font-size:10pt;">$1.1 million</span><span style="font-family:inherit;font-size:10pt;"> of interest expense, including </span><span style="font-family:inherit;font-size:10pt;"><span>$0.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> of accretion of discounts using an effective interest rate of </span><span style="font-family:inherit;font-size:10pt;"><span>12.00%</span></span><span style="font-family:inherit;font-size:10pt;">. During the </span><span style="font-family:inherit;font-size:10pt;">nine months ended</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company recognized </span><span style="font-family:inherit;font-size:10pt;"><span>$2.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> of interest expense, including </span><span style="font-family:inherit;font-size:10pt;"><span>$0.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> of accretion of discounts using an effective interest rate of </span><span style="font-family:inherit;font-size:10pt;"><span>12.00%</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As a result of the Conversion on </span><span style="font-family:inherit;font-size:10pt;">August 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Prom Notes payable, warrant liability, and derivative liability balances were reclassified to equity in the condensed consolidated balance sheets. A gain of </span><span style="font-family:inherit;font-size:10pt;"><span>$2.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> resulted from the Conversion of the Prom Notes, which is included in the gain on extinguishment line in the condensed consolidated statements of operations.</span></div><span style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTE PAYABLE</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On February 18, 2016, the Company entered into a loan and security agreement (the “Loan Agreement”) with Hercules Capital, Inc. (the “Lender”) under which the Company borrowed </span><span style="font-family:inherit;font-size:10pt;"><span>$7.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> upon the execution of the Loan Agreement on February 18, 2016. The interest rate applicable to each tranche was variable based upon the greater of either (i) </span><span style="font-family:inherit;font-size:10pt;"><span>9.2%</span></span><span style="font-family:inherit;font-size:10pt;"> and (ii) the sum of (a) the Prime Rate as reported in The Wall Street Journal minus </span><span style="font-family:inherit;font-size:10pt;"><span>3.5%</span></span><span style="font-family:inherit;font-size:10pt;">, plus (b) </span><span style="font-family:inherit;font-size:10pt;"><span>9.2%</span></span><span style="font-family:inherit;font-size:10pt;">; notwithstanding the above, such rate could not exceed the permissible rates of interest on commercial loans under the laws of the State of California. Payments under the Loan Agreement were interest only until June 1, 2017, followed by equal monthly payments of principal and interest through the maturity date of September 1, 2019. The Company was required to make an end of term payment of </span><span style="font-family:inherit;font-size:10pt;"><span>4.5%</span></span><span style="font-family:inherit;font-size:10pt;"> of the sum of (i) term loan advances, plus (ii) </span><span style="font-family:inherit;font-size:10pt;"><span>50%</span></span><span style="font-family:inherit;font-size:10pt;"> of the aggregate unfunded term loan commitments. The Loan Agreement was further amended in December 2017, March 2018, and July 2018 (as further amended, “Loan Agreement”) to provide for an additional combined interest-only period of eight months, and the outstanding loan balance continued to be paid in equal monthly installments of principal and interest. As a result of the amendments, the Company was required to increase the end-of-term payment by </span><span style="font-family:inherit;font-size:10pt;"><span>$0.1 million</span></span><span style="font-family:inherit;font-size:10pt;">. At the inception of the loan and the following amendment dates, the Company paid the Lender aggregate facility fees of </span><span style="font-family:inherit;font-size:10pt;"><span>$0.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> in connection with the Loan Agreement.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In connection with the Loan Agreement, the Company issued warrants to the Lender, which are exercisable for </span><span style="font-family:inherit;font-size:10pt;"><span>9,005</span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock at a per share exercise price of </span><span style="font-family:inherit;font-size:10pt;"><span>$33.31</span></span><span style="font-family:inherit;font-size:10pt;"> (the “Hercules Capital Warrants”). The Hercules Capital Warrants will terminate, if not earlier exercised, on February 18, 2026. The fair value of the Hercules Capital Warrants was recorded at inception as a redeemable convertible preferred stock warrant liability upon issuance. The fair value of the Hercules Capital Warrants on the date of issuance of </span><span style="font-family:inherit;font-size:10pt;"><span>$0.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> was determined using the Black-Scholes option-pricing model and was recorded as a debt discount upon issuance and was amortized to interest expense over the term of the loan based on the effective interest method. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span style="font-family:inherit;font-size:10pt;">On September 3, 2019, the Company repaid the remaining outstanding loan balance of </span><span style="font-family:inherit;font-size:10pt;"><span>$2.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> and an associated accrued interest and aggregate end-of-term payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$0.6 million</span></span><span style="font-family:inherit;font-size:10pt;">, and the Loan Agreement was terminated. At the effective time of the Merger, the warrant liability was reclassified to equity in the condensed consolidated balance sheet. As of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span>, there were no remaining unaccreted debt discounts and issuance costs. 0.1200 P1Y 31.05 15000000.0 0.80 38.82 7400000 1069740 7.54 0.50 490683 P5Y 10.36 42.70 0.10 1500000 1400000 400000 0.1200 2000000.0 800000 0.1200 2300000 7500000 0.092 0.035 0.092 0.045 0.50 100000 200000 9005 33.31 300000 2600000 600000 <span style="font-family:inherit;font-size:10pt;font-weight:bold;">COMMITMENTS AND CONTINGENCIES</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Operating Leases </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In August 2016, the Company entered into a </span><span style="font-family:inherit;font-size:10pt;">five</span><span style="font-family:inherit;font-size:10pt;">-year lease for office space in Boulder, Colorado that expires on October 31, 2021 (the “Boulder Lease”) subject to the Company’s option to renew the Boulder Lease for </span><span style="font-family:inherit;font-size:10pt;"><span>two</span></span><span style="font-family:inherit;font-size:10pt;"> additional terms of </span><span style="font-family:inherit;font-size:10pt;"><span>three years</span></span><span style="font-family:inherit;font-size:10pt;"> each. Pursuant to the Boulder Lease, the Company leased </span><span style="font-family:inherit;font-size:10pt;"><span>3,038</span></span><span style="font-family:inherit;font-size:10pt;"> square feet of space in a multi-suite building. Rent payments under the Boulder Lease included base rent of </span><span style="font-family:inherit;font-size:10pt;"><span>$4,430</span></span><span style="font-family:inherit;font-size:10pt;"> per month during the first year of the Boulder Lease with an annual increase of </span><span style="font-family:inherit;font-size:10pt;"><span>3.5%</span></span><span style="font-family:inherit;font-size:10pt;">, and additional monthly fees to cover the Company’s share of certain facility expenses, including utilities, property taxes, insurance, and maintenance, which were </span><span style="font-family:inherit;font-size:10pt;"><span>$2,160</span></span><span style="font-family:inherit;font-size:10pt;"> per month during the first year of the Boulder Lease. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company recognized a right-of-use asset and corresponding lease liability on January 1, 2019, by calculating the present value of lease payments, discounted at </span><span style="font-family:inherit;font-size:10pt;"><span>12.0%</span></span><span style="font-family:inherit;font-size:10pt;">, the Company’s estimated incremental borrowing rate, over the </span><span style="font-family:inherit;font-size:10pt;"><span>2.8 years</span></span><span style="font-family:inherit;font-size:10pt;"> expected remaining term. As the Company’s lease does not provide an implicit rate, the Company estimated the incremental borrowing rate based on industry peers. Industry peers consist of several public companies in the biotechnology industry with comparable characteristics, including clinical trials progress and therapeutic indications. Amortization of the operating lease right-of-use asset for the Boulder Lease amounted to </span><span style="font-family:inherit;font-size:10pt;"><span>$17 thousand</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$50 thousand</span></span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">three and nine months ended</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, respectively, and was included in operating expense. As of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, the remaining lease term was </span><span style="font-family:inherit;font-size:10pt;"><span>2.1 years</span></span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The terms of the Boulder Lease provide for rental payments on a monthly basis on a graduated scale. The Company recognizes rent expense on a straight-line basis over the lease period. Lease expense for the </span><span style="font-family:inherit;font-size:10pt;">three and nine months ended</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> was </span><span style="font-family:inherit;font-size:10pt;"><span>$22 thousand</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$0.1 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div> 2 P3Y 3038 4430 0.035 2160 0.120 P2Y9M18D 17000 50000 P2Y1M6D 22000 100000 <span style="font-family:inherit;font-size:10pt;font-weight:bold;">CAPITAL STOCK</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Common Stock</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Each share of common stock is entitled to one vote, and the holders of common stock are entitled to receive dividends when and as declared or paid by its board of directors. At the effective date of the Merger, each outstanding share of the Company’s common stock was converted into the right to receive approximately </span><span style="font-family:inherit;font-size:10pt;"><span>2.4165</span></span><span style="font-family:inherit;font-size:10pt;"> shares of the Private Brickell’s common stock.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has reserved authorized shares of common stock, on an as-converted basis, for future issuance at </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> as follows: </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"/></tr><tr><td style="width:86%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:9px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30, 2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Common stock options outstanding</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,802,895</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Common stock warrants</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,632,495</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Options available for grant under the Vical Plan</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>119,070</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Options available for grant under the 2009 Plan</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17,232</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,571,692</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Preferred Stock</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In August 2019, in conjunction with the Merger, all outstanding shares of redeemable convertible preferred stock converted into shares of common stock at a ratio of </span><span style="font-family:inherit;font-size:10pt;"><span>1</span></span><span style="font-family:inherit;font-size:10pt;">:1 and were immediately exchanged for common stock at an Exchange Ratio of </span><span style="font-family:inherit;font-size:10pt;"><span>2.4165</span></span><span style="font-family:inherit;font-size:10pt;"> as a result of the Merger.  </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Redeemable convertible preferred stock consisted of the following prior to the conversion on August 31, 2019 (in thousands, except share data):</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:31%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Preferred <br/>Shares <br/>Authorized</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Preferred <br/>Shares <br/>Issued and <br/>Outstanding</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Par <br/>Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Carrying <br/>Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Common <br/>Stock Issued<br/>Upon <br/>Conversion</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Series A</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,162,505</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>401,309</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,164</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>401,309</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Series B</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>882,216</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>286,151</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,084</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>286,151</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Series C</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>869,565</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>256,583</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,630</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>256,583</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Series C-1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,531,942</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>312,423</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14,138</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>312,423</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,446,228</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,256,466</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>48,016</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,256,466</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Redeemable convertible preferred stock consisted of the following as of December 31, 2018 (in thousands, except share data): </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:31%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Preferred <br/>Shares <br/>Authorized</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Preferred <br/>Shares <br/>Issued and <br/>Outstanding</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Par <br/>Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Carrying <br/>Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Common <br/>Stock Issuable <br/>Upon <br/>Conversion</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Series A</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,162,505</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>401,309</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,098</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>401,309</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Series B</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>882,216</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>286,151</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,011</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>286,151</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Series C</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>869,565</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>256,583</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,018</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>256,583</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Series C-1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,268,657</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>312,423</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,163</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>312,423</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,182,943</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,256,466</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>58,290</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,256,466</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company had no outstanding shares of redeemable convertible preferred stock and had not designated the rights, preferences, or privileges of any class or series of preferred stock. Although, the Company’s board of directors has the authority, at its discretion, to issue preferred stock in one or more classes or series and to fix the designations, powers, preferences and rights, and the qualifications, limitations, or restrictions thereof, including dividend rights, conversion right, voting rights, terms of redemption, liquidation preferences, and the number of shares constituting any class or series of preferred stock, without further vote or action by the stockholders.</span></div> 2.4165 <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has reserved authorized shares of common stock, on an as-converted basis, for future issuance at </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> as follows: </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"/></tr><tr><td style="width:86%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:9px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30, 2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Common stock options outstanding</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,802,895</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Common stock warrants</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,632,495</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Options available for grant under the Vical Plan</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>119,070</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Options available for grant under the 2009 Plan</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17,232</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,571,692</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 1802895 1632495 119070 17232 3571692 1 2.4165 <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Redeemable convertible preferred stock consisted of the following prior to the conversion on August 31, 2019 (in thousands, except share data):</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:31%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Preferred <br/>Shares <br/>Authorized</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Preferred <br/>Shares <br/>Issued and <br/>Outstanding</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Par <br/>Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Carrying <br/>Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Common <br/>Stock Issued<br/>Upon <br/>Conversion</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Series A</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,162,505</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>401,309</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,164</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>401,309</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Series B</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>882,216</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>286,151</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,084</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>286,151</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Series C</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>869,565</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>256,583</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,630</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>256,583</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Series C-1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,531,942</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>312,423</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14,138</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>312,423</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,446,228</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,256,466</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>48,016</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,256,466</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Redeemable convertible preferred stock consisted of the following as of December 31, 2018 (in thousands, except share data): </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:31%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Preferred <br/>Shares <br/>Authorized</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Preferred <br/>Shares <br/>Issued and <br/>Outstanding</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Par <br/>Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Carrying <br/>Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Common <br/>Stock Issuable <br/>Upon <br/>Conversion</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Series A</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,162,505</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>401,309</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,098</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>401,309</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Series B</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>882,216</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>286,151</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,011</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>286,151</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Series C</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>869,565</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>256,583</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,018</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>256,583</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Series C-1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,268,657</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>312,423</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,163</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>312,423</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,182,943</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,256,466</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:left;padding-left:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>58,290</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:right;padding-left:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,256,466</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 1162505 401309 4000 12164000 401309 882216 286151 3000 10084000 286151 869565 256583 3000 11630000 256583 1531942 312423 3000 14138000 312423 4446228 1256466 13000 48016000 1256466 1162505 401309 4000 16098000 401309 882216 286151 3000 13011000 286151 869565 256583 3000 13018000 256583 1268657 312423 3000 16163000 312423 4182943 1256466 13000 58290000 1256466 <span style="font-family:inherit;font-size:10pt;font-weight:bold;">STOCK-BASED COMPENSATION</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Equity Incentive Plans</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company’s 2009 Equity Incentive Plan, as amended and restated (the “2009 Plan”), provides for the Company to sell or issue common stock or restricted common stock, or to grant incentive stock options or nonqualified stock options for the purchase of common stock, to employees, members of the Board of Directors, and consultants of the Company. At </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, the total shares authorized under the 2009 Plan were </span><span style="font-family:inherit;font-size:10pt;"><span>1,634,655</span></span><span style="font-family:inherit;font-size:10pt;"> shares. The Board of Directors or a designated Committee of the Board is responsible for the administration of the 2009 Plan and determines the term, exercise price, and vesting terms of each option. Options granted under the 2009 Plan have an exercise price equal to the market value of the common stock at the date of grant and expire ten years from the date of grant. At </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, a total of </span><span style="font-family:inherit;font-size:10pt;"><span>17,232</span></span><span style="font-family:inherit;font-size:10pt;"> shares were available for grant under the 2009 Plan. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In connection with the Merger, the Company adopted Vical’s Equity Incentive Plan (the “Vical Plan”). At </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, the total shares authorized under the Vical Plan were </span><span style="font-family:inherit;font-size:10pt;"><span>413,710</span></span><span style="font-family:inherit;font-size:10pt;"> shares The Vical Plan, as amended, provides for the Company to sell or issue common stock or restricted common stock, or to grant incentive stock options or nonqualified stock options for the purchase of common stock, to employees, members of the Board of Directors, and consultants of the Company. The plan provides for the grant of incentive and nonstatutory stock options and the direct award or sale of shares, including restricted stock. The exercise price of stock options must equal at least the fair market value of the underlying common stock on the date of grant. The maximum term of options granted under the plan is </span><span style="font-family:inherit;font-size:10pt;"><span>ten years</span></span><span style="font-family:inherit;font-size:10pt;">. The Vical Plan also limits the number of options that may be granted to any plan participant in a single calendar year to </span><span style="font-family:inherit;font-size:10pt;"><span>1,300,000</span></span><span style="font-family:inherit;font-size:10pt;"> shares. At </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, a total of </span><span style="font-family:inherit;font-size:10pt;"><span>119,070</span></span><span style="font-family:inherit;font-size:10pt;"> shares were available for grant under the Vical Plan.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Share-based Compensation Expense</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total stock-based compensation expense related to stock options granted under the 2009 Plan was allocated as follows (in thousands): </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended<br/>September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended<br/>September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>81</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>76</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>237</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>263</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">General and administrative</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>243</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>75</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>770</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>253</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total stock-based compensation expense</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>324</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>151</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,007</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>516</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 1634655 17232 413710 P10Y 1300000 119070 <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Share-based Compensation Expense</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total stock-based compensation expense related to stock options granted under the 2009 Plan was allocated as follows (in thousands): </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended<br/>September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended<br/>September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:9px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>81</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>76</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>237</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>263</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">General and administrative</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>243</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>75</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>770</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>253</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total stock-based compensation expense</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>324</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>151</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,007</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>516</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 81000 76000 237000 263000 243000 75000 770000 253000 324000 151000 1007000 516000 <span style="font-family:inherit;font-size:10pt;font-weight:bold;">SUBSEQUENT EVENTS</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On October 23, 2019, Bodor Laboratories, Inc. (“Bodor”) notified the Company of its termination of the license agreement entered into between Bodor and the Company, dated December 15, 2012, as amended by Amendment No. 1 to License Agreement, effective as of October 21, 2013, and Amendment No. 2 to License Agreement, effective as of March 31, 2015 (the “License Agreement”). Bodor alleges that the Company materially breached the License Agreement resulting in its termination.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On October 23, 2019, Bodor and Nicholas S. Bodor (the “Plaintiffs”), filed a complaint (the “Bodor Complaint”) against the Company in the United States District Court for the Southern District of Florida. The complaint alleges damages incurred by the Plaintiffs in connection with the Company’s alleged breach of the License Agreement. The complaint seeks: (i) a declaratory judgment that the termination of the License Agreement by the Plaintiffs was valid and enforceable; (ii) an injunction requiring the Company to cease and desist use of the Plaintiffs’ intellectual property; and (iii) damages for breach of contract and breach of the covenant of good faith and fair dealing. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On October 25, 2019, NovaQuest provided written notice to the Company of its determination that a “Material Adverse Event” (as defined in Section 1.1 of the Funding Agreement) occurred as a result of the matters described above. As a result, NovaQuest exercised its right under Section 3.3(e) of the Funding Agreement to suspend further Development Payments (as defined in Section 3.1(a) of the Funding Agreement). Pursuant to the Funding Agreement, NovaQuest is obligated to resume Development Payments if the Material Adverse Event is resolved or cured by the Company to NovaQuest’s reasonable satisfaction by October 25, 2020. If the Material Adverse Event is not resolved or cured to NovaQuest’s reasonable satisfaction by such date, then NovaQuest may, in its sole discretion, terminate any future payment obligation under the Funding Agreement and Brickell may be obligated to make certain payments to NovaQuest.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On October 30, 2019, the Company initiated an arbitration proceeding pursuant to Article 9 of the License Agreement with the American Arbitration Association (“AAA”) in Florida against Bodor and Nicholas S. Bodor. This arbitration seeks a declaratory judgment that the purported termination of the License Agreement by Bodor and Nicholas S. Bodor was invalid and unenforceable and asserts (i) a claim for breach of the License Agreement against Bodor and Nicholas S. Bodor, in his individual capacity, and (ii) a claim against Bodor and Nicholas S. Bodor, in his individual capacity, for tortious interference with the Company’s business relations. The Company requested expedited treatment of the arbitration proceeding and concurrent mandatory mediation under the AAA rules. On October 30, 2019, the Company concurrently filed with the United States District Court for the Southern District of Florida a motion to dismiss the complaint brought against the Company by Bodor and Nicholas S. Bodor described above.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As a result of the matters described above, the timeline for the Company’s Phase 3 clinical trials in patients with primary axillary hyperhidrosis in the United States may be negatively impacted. Any potential impact to the financial statements with respect to loss contingencies for asserted legal and other claims is not estimable by the Company at this time.</span></div> ZIP 11 0000819050-19-000030-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000819050-19-000030-xbrl.zip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

C8>'N$'[GE'X%I* MIC'E@KG4.! 0M-',7JBW03MQA%LCL]=8:U*AU;3T3+1^D!UFCK# D@= M!U':?$U10X_OSD0-<3>$QVZYW:<^SY> M[+*I]SP=C./1Z&/$,2J82IW ?=R=+<&>>6=,EAZYX'!XO_ 0"113A/O MO9.42*>0QA92AP6),JEW=M@NQ4]G/1VE:GH/$?B?RIO%[Q'#Q]4\./F=03-. MC/- 0N*%0R0B4T0^$66=95%-H2VEXBR0GD$ $ M"8B[-H(,(>0DY)1;7J\#=CL4?QK>%J.'27%ULX.$1RE%;VA)S>?RNIC=E+,[ M7\Z6>:SS0T49FOM(8%AS0;70 ED!)+,>L#4G!7+0_E1JI3:LRI[(H[.(7J.E M(*+)YJ!C4G*'XS^@)DQ5- JK+JQ^R#G 4;N"Q'&B."O"<.^HE @FG.CO(=!EQ[L6 U)XIQ8.[A?[1X4"//<>^00EI1S G% M%=NDL7GME/N'MWQAUT#/29P]%WZ6QV-_*R=1>)/QXL?!VSZUQ@?LHTA1>6MM\!V!KC];D0Y[[?%\/5P>'=T4A[/3CN#@QZS01E M+BXY*03$IJ(::)!SZZB'V?H=("R;Q^=&EAU_&X^*Z>@D7;;[)0%20:/;;+F6 M%A&#B-LP6'L >ICKWR'2LGE](N+FL\43M,5_>XFT^*OP,3DY.SS&9W\? MI$8(2,MMW.\5=P#$/;^:,^$\QSWLH28ZHWN8P_;6H;)3X[QX(J2:[A!9ZA@G MQ"+!@2*;><>=^S+L\!-E]5+2)_&L35G_93P=WSWLMF!>/1,40@A#BZ*)IC"! MU/E-K$TS+B^D3M3)$BN;X5NK,A]\/RSSI\\$Y02W7A+C.3:&$()P%6@W(#+C M,MR?1F2>P;JB=<'# 'FGKC4IPH++8WR ME40L)3)G[^SA1?<>G+>>06HGJL>,F:X391^O\N_0HTU^(A"!--4.1]=%"*P! M<]Q53!& 95W=Z1^4N\51V0N990)Y1[3 $]TPAY3W#0%GBH:_" XI=F%5 MV]XBP'-EU@,@/\T*ZP#43S\7F#. 8\6E,I2FG'_#JFW0:T%S\DI[6#+N(@"> M(;^S7@+[\) BJU/OIE8_\W!& 241')9 M9TTXB1BOTBV]$?5ZN[^=>G9GP?MY1'56:+OOT;,>SXME4OGF+S>D["V:=\K[ M H#,<$J($#!N==IYO$G)\1AG7?WN82&]_L&X80&=:(0\K[!33>*QS.2W8C;X M6JRC/CLLBZ/>$71<>A Z%?<6[8 T@C"\V6XPS8F(]["XWMG,A3:%TI6BW%?V M[65.\1[]>,QK@A5**(FC#62@1T(0 =;!?P:L5MU6ZHM"^E)>(D([$,V)"O%Z M5@Z+8C3WD5$'3>ZJ]DZ58;!#06:],Q!@C<8* .(LQ!1+S*I#78>YR^IG_>\S MQ/-(:=!!A:BKV=?!=/ROEW=3H<#R;+=C7+H&.-\E&-O#]*U!/"J.,VNL?26Z8]9,YB;ADG MS->ZPMA#_AU7L:[I3P4MK, .(LJ@(Q;#J,%5XFIA])2R$E&22J&)N(M%/],1;"3G1"%!4*UF#>WP[S%-3C_,XT8_ MGZOA/Q_&\_%2S/K'DW^K7T"OWJL",T@XIZR6,*Z^Z \Q)-=<83(O5G*Q2JLV MDG96TVM%.'V^,Z(N3-D.-XW56T=;.'KX\KEOV!#I3,VSDFX$B;8TQ8SB&*BP_B MU,&QHI&HR\KN;7TO:YKA'9]U+J=9MX3KDX<#9,(8EE0WI=!+R$BT)-=4,6-S MLJ=ZI)8:E.[VH\?36=K=O;11U,6#39NH9<>HZTH^R_D?K.E3^QW!2R 83-TZ M+6.$1@W/*\W.'<479FGG@.#53;%V6%P/9O,*9_-B^,>OY;??1L5X!;'XPTMD MQ5^%]\77P<1-%^/%CQT[V9:G0IREULQ2+Q34*%4D,FH]]:BT=4['RAYFY;>^ M=^6SN"5TK.:SY\G].2)@!05A'OIK;620.#AQKH7AEU*4?C3)5$VP;8V@R=7OT\C MVV[']WOB;,^>"5[%R<8-"1*H-: $0UK-W6I.+NRR22G:CB]?H0T)>SNV*V3@'^<5M. M1NF^ZC[57V-D4.DJ'V >82J Q1JJ5+MC28+SF%V(6Y EO+)-CN;L^\]G1Q-US\2-T R^GR)+-F MZ'/;N""!0Q1Y8*QA6#HEL*VV4L<%R4DC[>&MO^[#GPTPO2N O9CJP2CHUN># M2[UTF.&"(>J)%0+):D5&0M6%=6]H2,YE\YSM+'!>WMV5TWIQSU?/!@^1=)!Q M*'U<98IBR>F:)@^YNS"T9,KU9<@\DYM=(62+JGU?HT+;OF$A[O50J_@_901V MS#,(JI-);Q#,B7SV\"YO9]M6@SP_@_ZY'LRN9DN-//K;8/*0+@U]NHT,KJ>1 M=HT.VAGBH,= >$I$)-5Q4-&MM,C!6@]U5#,0V*VJ&F)S=U9WG//:/5BI[P_E MHEC^]M/]9+Q8G2[-(Y<^)N'NN_YZ[*L"5@82XQ2TR@+'@!,2;=2YL3EA_!ZY M=:T"KV6>GQH<6I,:E\67=;V#Y936LUG^8CF?72&BNN.#9=&']8XX SFP2 !- MUHM* T103B?1'IX0-@JA-AE]ALUQJ62?7ENLMRN^&A:(LY(+33#R!$1B,6:5 MD4D5MCDF>P_/)MK>#G/Y>S8DI1O:Q>@8$*U&!&]T*O*+L *<2@\X]+JR32W/ M2N#L8<2I&_R1I=6N&0PMQ7FA7H MK*.N'KIZC6]A+?+Z1 "]M=+8-+*6"R,\MY@PB0Q$K&**DS GM;.'=90:!^ 9 M9=%Q\G /:X IB*))RCPU4&$LD&%TPR]$88ZQUL/B2>ULMIV*H"O(?B@6[Z;# M\JYX7\[W ?#9JK^+#'\ MQMG<1;V7CT5RJ.-4TXW=Y&'/RFG\<5@\TV"=%W=Y,J%R$EE7U*G8LGM00$XI M31&4BB!L%(8:Z>?P&[FYMB&)V\F\_E_7@H"#IWU::F%[9# MQCB@HS85@F#*-*'824.C."Q$KE:&>5O.R>^[I'(U6P'KW?3I$^/I<'P_*0X5 M6\IZ;\!6:2PX4LI'R)JX%3%=\4LA\)6@$M;62UY<@1*8@GIN)%-(HN+*>R(]R\W,I:E$A7Z/P3=;8\'SVBD"&L?V6APM.DQWJQV#T%.]90>8JTEJ9>-,[HS!;>A M_U,Z21S,1O._WH^B9Q:?9P =Q%2M\<%RC)47'$/(@:/66^$KVB7,:C[80Y#E MB7^GR=T<@[N+0N]:7P=Q=6AHB"R+^IUZYXQ5RCK.)*HH)A3D[)$]#,LT"JF& M>7M^-.VW$S;QJQ9S-$<_[8C OEJ?.5S=_G1=J/B_V%F+>-RY$W<"<]PXYI)4E!EEB-^J!H MS M:#O$QLO:YPU*X3R(>S\>?!E/TL6VA]EL>TY6O8$A1?V(I$ ! +E62DBXL4,, M8:@3+2A7F)L67],)P^>?!GJ9TC@S]CZ4T^&I\'L<&ZSSA@H#(Y6 <$H M1S%=718]FTIY[))U=?-T0A^+92*5*>>+^?)^T)O!C[KMG/)>'+AA(DK) M64PQQW%K<1@SYU)+8:%IO=C^F3FFGQ)61Q=EOCEP(2._A"008L4YMS0:W)%G M!DFAG;FP\Y"N %:>4TCGTTB]<5CZJJ$ ]S+N9P( AJ7$4L&XI1@M,&"*LGHE M%-HVGAZ!^)3 )W?LYOK'*["JWP>S4?T6=)G?",9Y[2C6T%E*&//QO[SB(V+F MPIRKKD"WTZSJ5ER=)1PL)Q@_>2ACZNESP1&-O%)& <\LAU'M8X"-U50:R&76 M+<@>0N\,&'B9=9#!_[JJEZ6W\XQP6"!J ,P MM]!)@A.-&BHB<%:SF5Y>@#@O4%Y6A&U(+%U!KR+[P#;]]+&@'"',:6(19Y$B M2G4J?+3:;1B4.85>>I@#<_Y=.H/Y7S:-PRTQ=HT)&&&*)304088D MPXCA#2,DSPJ0]G G:0 %3;*S-P[O^J8?%;3D;_VMOT<[&OQ5T%)JRSE$2E1'5 M4I/4AF_)4P,1S,EL[^&.W"4(F\)_0Z)[:\OAVV \20K'E[,_IXIM':R*EY\, MEC(D8)2QCMNK(%82;BH.>\\N[!K2!2R.3 EVND:^'";WRTMRW??[\6SY\'4Q M&Y<'MXHFOA$$E]@!B"TD5ELF);35CF^L-3FE5?IH*9UY%9Q!9". M5JW:=].K:?&?Q6"7=]G^AX.1"! >I4@!B5ZU5MI6GK61YN(Z_':/^5[*\7QI M/MLE$-=U_/'?J3\[LC"(@X@CJRR&G$*AF&9B>?D$F!1:K>7"MYWZLSD9*F;? MQL-BQTJ;+"<7?[JZ^5@,RZ_3A.:5+E\RH7X:4(/?"Y(2 HF1VFMC#([;"+(5 M?[E3%Q:M[0J,.U."SB>ZKNS>567E35/.]VM*#IQ"[AD5#,#6.Y*J&5B'/?'Q M_VLZF='RPDZ2SHR5LBVYG!E_!X\O]XX+6'/*N+$><.8]C!K N36M' -[81AL M1.KUD'02?[LK3;RM;\;:8CN8QU-C=%#24LZA!S159;;$ J(JNHD2%W:)J2$, MO"I.W#2?N\+7GXMI,1M,XL35Z&X\'27(-H0SOD"B&6ZOB'PXP:N/;\K+98=]I^H?>APMJ@;#M4>*+X.M%R M#U_FQ3\?DK/VK3AG2Y:7$ZFALW8-285\!7$ \4]4A!19J"%A)KH:7 ESUGH MY<64:VF376."!!ASYP1)[A1FUF#Z_]J[LN4V;FW[?K\&\_!RJS#FN,J.7+:3 M\XBBQ9;-&XFM.2LD\L(A4NE*K*41? S_2L.Y4@WZ^Q#-DD64C)]WLWOUZMEWVX,3<\%VD/! MN2,*.N6D9$*FK'DI]R73\<^5TN&V(^E.!T66XI2GJ\SU%]]_JY?I53174QK/ M5'QT/OT]GR_*7Z,E.5NF]IN=97;]?3Z+R]%)+X0V'QNH!40[#!GB%#D#A/"B M1!N;T073-T"[?+#:Z>H$;W\*JI"9Y%"3@(1'U#H'L9 J:I1#K$H)F=6U2H4. MCW_#($O>BF[Z9-])5X/#C8)',!H90HN4BH!:Z036I92&HY&=L=17=@7V7(1L M7_Q)1]+7FXSC=R>O?T\W#I89+)#2P@AN!(E[4^-V4F-0)YW_&^'3N>H_P:C: M&/?%K(_1W,_^S&^C&E,^Z+/)]6K[X!Q"DCFJB%>0($L8MJ7L'NI*Q8??S@UM M!_QJ N:^*/9IMOS++[+LW3RJ(ENN/DU6IWU8JG<25$1!2" ]M )#PX25.XPY M4W5"]088I-0!V1K#NN_ETLY^S*;9?'H1XPYW$@3FQ$GF$=:0 ,>9M3L[A,A: MC!M@B%"'RV=MK+MB7$N;I/<5O*G:?G0 'IFH1<:\9 !2+C67.RM;XY$Y!@YR MNSLP'76&$0X$91RC?Y[B"3VL@> M8S3'>$G"O<.80&\M$1Q0!A#5)=J6H)&5GFB"=EU>DIRGG0O7V^5B]60,Q-_V M^1__%#ZE"/L#-R'//@\6*4,UI-A% )5&6L<]W_:=L: C"VX;AOKS^HIHG3P' M=])[WPAQ=V8MM<@RJ U@F/,X-#?OK308BR_8A;K:U_1%F+6IZP^S^>QN??BZ MX<5W0K2]D)$$(<&@$])ISV3Y[E#RD=R37JRQO!G<6M7YY)_3.G_ZG4 HQHA M#2W36NJ4WQB6[T[Y6/*D-:+S&KB]1:\)$1'B5$2Y(+12 YXJ?948&3ZR.Z!! MF0\-Z^:M>DT0ZKT !""CE>2,I%C;K90:\6I>>L-?CYI3=G6OB?.0O3#)W/[S MW\VGZ7I@/;DUZ[OU;7%FHB(HV8_B.Q\7^=X-@(QR M+W2Y &@#VE49# MM"#PR.JP-,BZUC#^==]8_\I "QI-&\]2ODAB+1 :@BWB1O):B4@&Z+\Q2$-Q M8#KN+,W#DZ31GR>WF"[0&0P^U$5((2=:&>R0 M9G="FD L2,Y\GESS&U(7P.9>Z^O-UN!;/K;(E\N_XB(3F[32/PMVG\Z MN\D7V9?)/Y=/R-7Z#U0!!1"6Z51.:6@8PJ6A:3&JE63TY[%-6I^E6U%F5P-! MKY<1G^72Y'=?9_,".I,75]M18_&GY2S29>N1LE'&PQF^4 WT'H"T4$&I/+'1 MFG2.6TI*W)P7=>YU!NCN.MA!T+TJ!^@Y=75342V%'L;F4L4MT$!Q*JVE1GI M@=ZJCV,N6:627<,]H.C"?VJ;_9 P:!#6Q&FK#><4^1V.2+.1;;Z:(%0+!P:7 MJ*+S\S;]= [UBR(WS_7#B3O1"JT#5G$;Z:&' @LFN<*886R,Q(022.S(_/5Z MX,LAQC:FD\ZY^-I[G[P?K= Z<&E%ROW&A?+ 1#/$5I(!O%PIB.:Y3 MQVVDQY2-+;#-J:77V>^E&!>MM@?["18P9RS1FJD(,:/$4%MB@>.,,-+YL"&" M5)D2&X*^R%+.;7R8S7MFN7 (:;5 MQKM/7J&+>+5M%2@"1AN!M=&,6Z&T=]M#3!['KZLS=0UY=>V<5Y?AW2>O\$6\ MPJ6<5 DGG4!$2 >.4TH]U*6EC,5CHPL$=& =AP]:*\S-XE"M)VDC^4GJEPDG6H;/ 7: M9O0[1J+7OA8T\%@!@%)E,X \-P2A=&OM&2$,(3VN":TE=C2 [# 6RHL7R. 5 M\U);2*RPRA!CJ?);R+B.1!V7X=7R+-,HUL-Q*_^0+;YEB]%FX$Q:(=8AK8DG M GH* 0!109QI1XCNLV3AKIYMN7ZIZ[_7L^4L*7JI'Y[\=LHK_-RN@D224H1E M7/PP8LX8PVB)"K2RDA/]VS$_FJ#'P6+$K2#>M2'\Y'5/>)X=:!%2 C"C%&71 MBK** X;<#DC$S,BRP;2G_@.F;3VX^Z13^G&1G4YB=;)M0 @Y+YFG5","*: M%(+*W9)N:Z6\&^#FN;.5J"G >R75R57H2*M4T!X9Z2T1" ))#3<:EW)*YNIX MTP]P,FI WU48=!&V==:>LLK&Z37H^3<#Z. M+L6\*W9]7N77?[U;+M?9U*[3?=S';#'+IY^_1V2?P73LN*=J'\$B[.-L[72Z M%R84& QV(Y6CL5TS-4.'_9.>EL#N\:[S4W:=?YNGY$#OIA'6V@6A4-X;JQYE MQF)D:WIC!*O<1X#0&V6T MA1AZPK1ET*$=!J36?#? '&.M$*TML(=S75O^.YH+6L8%DH :H5 <\YY)R,1& M$=8I72W^HB7+*7G*7=WLO?O#YO]?(N0Z/O>O8P91I0Z"AY9)X57<.1,9J4@( ME"4"R,.1A< W085]*Z<-G+M:8_Y8QGVR6ZYF=Y/541_^YU\,DL6]!H(0,F % M% 3$;7,I#5=\9"6J6V!-+3S[3,IQ[C14N8]HWFO"H-#:6ZA290F-;(F!M+S. M#>L 3=T6.-46U)TY(D:#+,O>QY??6AJ5"':D5:#*[N\T6T3%/PW.JAZNQ3M6F EE--32HG" WE/B7B+(70 M'-29=.BH&=(2PEW--9^R']E\G?D(4?+63Q#\>[;Z;M;+57Z7+:I//^=U%(S2 MQAOC#!$:<*"@UZY$(R[]=;;#;G&NSG M=A6$IXP:K"4!7"NCT^8%V%14EQJ(:V5=$3\%Y5I&?#C'A^GV9WX]NYT5#[BZ MV21"\K/Y)/YUDLGJNT,KE QIZ5+">8X.18P RCN.,#)'>HFJ3E^I/ M,6;B854]T_+)=4 Q(Y;G#6'%'H384H5)6+:J- MZ;?#OOZHF9/ 7H!,-*4>R*\+KS(?8F' M4;6*J@V9M?WSZX771)MZN_#8V>1W=_F\\!;:S^)PU'7_9+O@$16><<:-YRK* M@3PL87+3G8-0X2OTL=3@^>2[N+\@$+62 M&ZB71:K-(X':"Q./ TA)Q'E!2( MUE,IB$&FSN'U *]KATG#5E3U!O=9[\_)7M[@XX(T'B(EA".(<2Y5',\[9*E3 M8RV;-)ACA?YT^09'B9G<7J?"WRFT([^]]?GB/Y/%M)LA\_JS@\8 "Z4-$M@X M2:'SC):8RS@W_=K7-4?;]L90(\KMTT\R.26\D''O!FSY:2\OZG:-+?HZTZ>R M]O,"<\P*1#0E#$/@D8,&;+'UR7^BRX%SOPES7$T6J[ M_3\U7GU^O4BNNS;;_/MNOGO @8UZ=R\0N+586RVQ8='80!AY1TI I15C+=8T MF.$R:'4/?>79B?QE,9DO(].65^M5Z=#4PLIS]'E!>@#:%A;'RT4EHP33@BW'&"O4'E0 MZN//==:BLZ- -EL?-Y_^&CV]:7A(+K,G;X5&FST=<&TQ<,@PY)3RSCK!G#04 M0F(4195N)=N1="_P23]L$]85^CCE!GNZ<7#>6$&CP,P3K72Z8]E)3J+A-*XS MS"8HD+>,<7<9VJ+U5*0/>?+")]Q4#[8)3EN"+79>8JXMF8@[CC_;/&:5=/./OER 5$28$4.2,<\S&P5>..U$KO\, B=. M=E_/-GLYI-W%P9ZT+TYZ7E;N(\0=#-9QM^^QP@Q$FS#5.-UB@&"U>BAOAU9U M2/ BZK4=B+NBV=[47,6YXE"3((13""L-I-, .RR=0*6$T208F8-$BXM:0PAW MQ2%UET?>_W<;.[AU%IY_,_FRJ$.9JF$E,_)H)>**781H*G-^5GKP]\7)RS1AG3Z5'U*F=-/2QX M[JR-\[74E'!K+(W_E<@B+$:6'[L)BAVL@]:33BY<^I:+U1.6Q]_V&1[_%#XN M\NGZ>G6U^)PM?LRNLP.' (>^&D'%5E&&D0$V BJ1M7 KB8]S[_7X06@!)!=?4D>1?KC!0I4Q5*UL.GUWU5?J2&[7!O-"W MY//Z:YQVL_FR-,2.1FP<^'8@0EN/(#<(>!JG:5-X]G9 M5FOZ?^OEJI@U?;XXDI_FQ,GT6?T$@16A@$"+I27:>$0EWPTJ*496I&3?/[!,C),\O7OAX8DL0K["263,3__-J,I].%M/E'_?3R2J+WR= GN14I?;!"2\\PTQ;#9%W'&$- M2]D)V\G@+PB DKXA"6$1:L'*!ZAX=S=2RX MXO.' \.C,235#O>,!@O+;,*"@4LM\4.V,MJ'+_W.1C @<,48:\H)Q0HY#&@)1(6ES7.\9)N H(*0T<-T@Y)@1G1HERW MH/-\9(6@^N%%WIE^&B:?33$H^7VQ-LQNL^4JGV2\YW@&!>1TW MJ0$6Y!HZ-]O16G?!-$>%<_]YCK)$ ?8+FP01"T!;W4W]8GS>WD_;C([C>;N*O" MZHU6\'52\+?LZF9_FW=Z@W]QUX'$94018 TBEL2AR:&G)0A:DSKWZ_(7.8]M M];O263HIM.@A,"*L)3'E9M#+.,^O*@#7/OZI 1@E]LO)B-%ZFG MJR7\MVR>+2:W$3,UO9O-9RG$ICAW^.<^FR^/13B=:!F,@Y!(F1R>/5(86X]+ MORJ<4FS7H>.O&Z+75^YF==+P6?RG[#J;W:^N;AJ\':K49Y#"P6@O:\H5I49 M0J$HQ2:45XI)/$3%7_=$U8_DV]#6<()\=]_:U@M*Y:"7F]U<-DV[/7>_?)+\ M;'1%:X753$)MJ=3<"*HE=ML%C@#,98]%:Q\=3%1\]>GL=IV(^3DE@"LRV3U5 M4E3>_7JU#47?K^Y=/>JWB0=%4Y5;A[30!$9@M:+15MTARO!(HJ>:I-;!B-\> M]-&9_VX]T?3#ZQVH6I1I92C*G%3EJ =C@K.S+OS;Y(NN]0/!B% M]CMP?I_<92=SH)UJ&KC$0BOCA >NJ6OCJP39!Z0@_E(XYJ!BUS')/2AF-\B.K0M(:<9H">)QY'"'6QBF'#!=* M(V2@LF7"'J!\+9)5]XC<%1QHMT14:Q1K"^X.+XO+M[;9U]4C-A5BO8ZV#$IQ M:X@TG,7_C-# [1)L)(CK),8:H(-B:P1K%N8WLOM]7R&TJZE'A.2\08PBCF%- M(25("58B*(RM4VMR@(OM./:UEVKOC?#_X 5TH_T'S2B31!&&*;+ MLEHW,,-C?O>4:Y;S%REM@!KY$2W6JKKO]>SR(^Q7;D8D1RSF;,<.2T@ M(\YOL^QP#2VHY/+1]I6+7B\CGY<;'2R+Y+=+_?#DM^J7*M6Z"@BF^':C)2*( M:8NI+NU?K@TE=5P&ASC9-$"/@]U=+XRLN?N-0XT")PJ 'T*LVY*48L M[JG*0#%NXAPYLB1,[:D_;P/N/NFT65=.WQ><;!NT@8Y!CKCVA! D.+8[F15F M(YNT:FN^ I/JX'NAZ].?T2*Y/9HH]]*B[QR"))Y3;(DUOH3)T3KT$?)'2_'EV* M>=?LBONYK[-YH\,;LYL$A5:_UP$F(E4I%_*+U6IJNUOM:#'\;<^,%Q#O YD%HZ$V. MATVHT^:;'R:+O[)5:OEXH-+5\#CU'B&E,Z6 :TV(8U)+SE$YX5F"6277R[>S M'@Q_M#2LL#<_>(J0F-ET&X80OW^U^IXM-I_U,8B.O4^P'',AHS&*.2804F.5 M*W7#E*@3N#+ _#UO:S UJ+@W/*B>?-#MZ'GR00 ,(R(0,P10YX U1B-L4KR& M89::.F=BU6_==TX=WR:K;/KEUVBIK:BW."Q^SX[=GS3\I("=E,YQ8 AE)KFF M*@9*-0MEZQA;YZ3VY^;\>>K9#@WE<5QQ7BN([F@-JK!()MH(#AG&%I@ M$4.,6YJ^SKR)<\BKTZSK-#4EZ@;'5_PKTJWE8T\*1CBO9+ 4 24EDBJ ME%9[@RDGR/P\,6"5R77P,K,/A72UG/K);/'GY'9=SIC/!/F039;K*-Y5FF6C M@9"2"Q6AP(ORUR)I5F6.-_^P8*16#D'FH$?&LFC .U^BBJ@'XSK!:('FO>OD M+3$]M2]H\B6[_CZ?_;W.NB7_R><'QCTS6G$B%+.:D*@!5V+O&1I9Y9Z!CH>F MU=3Y$#DNFDPI'"]H/TOZ^39?:___/_4$L#!!0 ( !"-;4]5 M(_&1)@@ *@Q ) 97@S,3$N:'1M[5MK;]LX%OW<_@J.![.; +9E)TX[ M==P ;9+!!IAM.T$6Q7ZD1"KB1A(U(F7'\^OW7%)VY$?:.'6F29&B34SQDO=U M[H.4._KIY./QQ7\_G;+$9BG[])_WOY\=LU8G"#[O'P?!R<4)^]?%OW]G@VZO MSRY*GAMEEG5XG*E1V%/@AF 4UMU&HQ909.TWEVU:L M<]N)>:;2Z?!"9=*P#W+"SG7&\T,W9]1?15P.WKQY_>O!Z]ZKZ"#LR0/.17C0.AH%'/_=4Y;*32%)CV-_K M_7)HY;7M\%1=YD.GG'^@<@&;#/<&Q?6J0"-ZLDX5E2>R5';-BK"$0/2X(=?W M%,D-)YYGJ%.!+6K7L?U^M_\-LO[MUGH0A@WPN+E-[!#!3;)\$!\=GYY?G/UV M=OSNXNSCAWLY:5O";>JE@@N!O-()M;4Z&_X*$#>D2F6\%>2Y&T68:SB*;,)M\-%B2T/4PF"-*WE>]OJM=S8%#R:C6L)UJCPI3S&5O6Q ML)@5L_TF2M@$UL$^E+*LH,GZ0^!(%\C'I$;$T]ID5A>MC0)C)C[9>MCS3#ZMME//R*D T0_*\RY*>MX( E?"Q9*<=*3E#3;*(,^Z/B);"?3MFY M+'1IF<[9;[K,6+_7^:/-=.G)2C>)<0P J>@*8&#OE;8R2MKL+(^Z;<;9B4SY MA)? CBY!SJD>'ZXQC?-CX&"V47P,%N-CBZ;90UQP YM ^VS*KG(]2:6XE.VF M]DQH8#G7Z JPGJN<\7S*JMR6E00W] FN98").,LP*A5/6 +,=R2")DR2:)BA)F M*OIQLWXBX1:_"2F0*9.B Z&>9J)L @5-(2,G(.U;0#0MH":@"Z.$TZ89#N^= MWQ[.?_M?\)]DL M"AB-_$TX0#3,'5K;TBRQ!F:$ZU#;1%&E(( 7-4SMV!DG3\1-PN)43\S,Q:6\ M5,:BO;6,TT,O-Z1L-SQE9L*L2/L8G37HLHL%S?YI:D?418E@J>-88;AC=IW" M9XSR"ID6IE)4GV ")@TE$6426D%D&:*2(I/&0IDHU:9R^0A!JE-OXZ+4D11X M;-@.3"HD?.3M=GH=)3R_E.P=0N&\2D'1W^>=_L&.]%+T#X0?^:&BKB'WOJ7] M&<5+P^7>!23+G1G%"XQB,(I="EX$ B@HE0^W[=R%:KC?VTZ;O\-W41D,^$!Y MEY>^[AE7>")>F;LOH=P52EBYYN2SH:Y*;( H&2OC8@]4,G?[4.=S$[7-R"]1 MQYS;ZG1X8_IVG15H4B&"(8O1J1+NC&BJT"BA>*E( >63MLM%.>U4&4JD#NC& M95T7J3B)0B <#-VB@E.K4*6<$@S48? M!A;A,BSN'$XKZ+A[(-X9) #66 GR/3QY:@ZOSH7.11MD#:*-4NL5W7"A45.BD#=%.5B=!7"2> *]J7,D?Q2($4 MS,B"($@D:$@\&@!552"W/!$\1+OL=,S3RL42&4O&,>JH&D--LZ8>HFK<(2OX MX?KBZ!R/A8AHXTMPJ"M[.^^[Y"T^IY;47\1?[Z=8..M<'):EMP&USK3YT_"= M0"Q[XZP:F9KDNMRYF24?;A"[E+!U%%4E&;&1'1?VR[2Q>$)'>NQB<.YB?_HS M#MM9(8Z! $32$ETM)IHQZ;IY:O3S:B[+KI/B@&'6*D<,G):5\GCBEZ M=IR7ZM9^B;[]#09Y$'QL 0T']^KOW-E4S$#4OHD*"M*F4V\"A)RS0=%8J>:0 MBZ.66UV:>89V#[!9AO.:E7)MV@DULC_-" 69W/(=.!U1;BB+X#?U$C-TRC\K M!9$='JL\O6V77>0DTDOZ)TZ:N52YBN MSKKC[^R(;O&)5#;AK&DBS*8VYWQ:[^T?;I2^5BG8TDY*^>7 M]55%60>FS(I43R5F)XGVH<@7O XO?6/Z[C["3'7O-Q"W7,TV5J]<+#9?5]"X MN7U.0$OG>EM=T);N,G*CR]@-WB#5]ZP]Z!4B+&39B72:\L+(X>S#BL(WE[4@ M ?O\;6O0NOUNUK/8>_-+XR9WZ9KW]>US![=/#1I;-ODVI+KE[M4C:C$:Z:JY M:?GFN$9@\Y%[H3.L[Z<;#B?"G^ M RK]K.NSKD]=U^\:N ]33T_0<@S9!U@T"V7I->\/VNZK$8_4VS\:FA_@_?'[ MZ? >RM5=12UZO[AF[J:4_=QS?YX0J@,3K+Q ?VSQ_*/#^EF_IZW? Z2EYY!\ MANRS?H\J)(\3)6-V>BVCBMZ=L(_^DO];ONT;FSB?_.IBGJ^&Y^[6O MZ"U]^_<;+DBWXI='+L)#W4LO?>GZ>WW_^\4HH/^TU:;6_;MA;^W/X* MSL-V$\"V[-C95L<-T+P4"["U79"AN!\ID8IX(XDJ2=GQ?OU]#B4[_#_XX.62M3A!\'!P&P='9 M$?O][,\_V+#;Z[,SPW.KG-(Y3X/@^%V+M1+GBE$03*?3[G30U>8\.#L-:*IA MD&IM95OU7[*,V%VK"YQ).N53N'U\F*E1N'%276"RH5QN' M6LR8=;-4OF[%.G>=F&R>G[%1G/-_SSZSZ1X[ZO<+MD>)"3?;' MG.4\PUC;WXUW!\/!D+]Z)8?1[H"'O^T,PE\DCWD4]7N\M3\..'[]J/F?^N-7UQW1GG>8J3Z11ZT:$!NO3[88:WU # M?SFME@AU*C!%'1@VZ'=W;J_:@_BB$1C_;!,'14"J- _BH';\Y. MWK^[4_3N2[E- 51P(9"SG5 [I[/1;\5E4ZM4QO<"ZI,V.^VR/U64<)FR0VY, MZ2!JVRR2QJEXQES"W6A9;X@0GZ&'](?"B2^(3,B/B:>TWIXO61MDQ5Y\OW.G^UF3:5F/$/<1VS Z.B"P"&'2CM M9)2TV4D>==N,LR.9\BDWP)II*<2[;3>N9T,![KE&:,9ZKG/%\QLKG/U?BI1%BJ2 M JII 3,!;S@EG#7=L'=G(GRX^ T^$S_)8I7#0^3L*X\ KSG$B3$;SU4> _L> MN/@D/+=B-2=J[,BK:/,5C#+CM;LNP_ MM@Y$7;@(ECJ.%2ZW[+8W^(01KY!KX2I%-0PN8-(2B2B;T @2RY"5E)ET+92- M4FU+ST=(4IU6/BZ,CJ3 ;7J*7YN61OD JG90J)_H!W^KM; MLM*BORNJJ^I247N15[&E^1GE2R/D50A(EULO%"\M%&.AV%/P,A @050^NN_@ M+I6N06]>[[\NW%M\&Y7!8AT8[WGIRY'QA2?BI;W]$.*N4,++]4H5&^K28 )D MR419GWN0DKF?A[JCJZQM9KY!'?-AJ^GPRO7MFA7HH4(&0Q>K4R7\1LV6H55" M<:/( %61MN>BG&8J+1&I![KUK.LS%=M!*(3=F1]4<&HGRI03P< LK\05(6-$ M1>_-JH1/H21!< #&2W'O.?\PL BOP^+6Z;2"CMLGXJU! F!-E*#8V"YK@XH2G90% MNJG*1.BKA%? %^USF:-XI$ *GLB"($@B:$@J- "JJ@"W/!$\1-OL>,+3TN<2 M.4O&,>JHFL!,NZ8>HFK<@A6JR_7%T0<> Y'1MBK!H2[=S6O?AK?X0EI2?Q%_ MN9]BX;QS\5B6E0^H=:;)GT;L!'*YZ;%>: M)-PNR@?EH$>,%)ZG'4-73"TOX'),NS7G)1K:2?48']Z(A1T M\L.W$'1DN246P7_J)>;HE)]*!94]'LL\\LW^]M-IW=Y@;T/54B%>U'Q2&QLI M">_6[+IHH::27Q!=5M7*$Z:OLW[[.]_G;!2SNMNI6O\UZ<0%!EJYR*8U\:WK M,H01*I3/=L76%E1MRRQ#L_:/]&;4;+5V+_B$F!A=U1L0;FP Y#;\)WWB(0)^ MVU^'JETQF,HG.IU(HK&G%Z;.59D5J9Y)/)TFNLI.O@0$!.XK&;W[)%QZ MYR\/;CCH;8Q>.:%L'O31=7/ZG-"8+FQTNJ I_5'@1J>Z&WS74Q_8]F!7B-R1 MIA/I-.6%E:/YAQ6#KTY](8+E\]>M8>OF0]YJB9U7/S6.A*^=%_]Z\[/=FQ\- M&U,VUVUH=<,A;H6Q93#1F6O3\\WK&I/-6_Y[H]'JV2]E AWOC!(E$.2].K0[ M]P35GW_L_]*[\<3ULZ?KWZ'1S[8^V_K4;?U7$_=AM@=':$)&[!T\FH725);W MAVW_$L,CC?;WAN8'^#;Z8#:Z@W%U5U&KWB\NF3].93_V_,\30G5@@_5?QS^V MI/[>L?ULW].V[P&XZ3DO'T%5V?"SYGY M;-]W9]\WR,S[*I=;'ZJOCI&1*[FY_:77^:Z]4OQMWV1>?8?YWWJ=^L4XH/?K M]U^._8O_^_\'4$L#!!0 ( !"-;4_" Y*;P 8 /@[ ) 97@S,C$N M:'1M[5MM;]NV%O[<_HHS%QT2P+8LVTU3QPW0.BEN+K:V2ST4^TB)1Q97F=1( M*H[OK[^'E.0XL3,T15Z\046:A.0ASWG."R4S?,8_G7R:3/_X? JIG6?P^??W MOYQ-H-4)@J^#21"<3$_@/]-??X%AMQ?"5#-IA!5*LBP(3C^VH)5:FX^"8+%8 M=!>#KM*S8'H>N*6&0::4P2ZWO'7\?.RZCI\_&Z?(./U\-OZITX$3%1=SE!9B MCR]>A,.$L3^\#6/H@.,AHR%P]>'!X/XX*!U/ X8 M_?>SZF^UYDQ([*3H8(S"X?#ED<5+VV&9F,F1![>I?^QZMEDN9(I:;)L1:=+O MNM?,>$0+?'-1JHA4QFF)*C PZ'?#[S.MWWOY,+Y8"XP?NXN#8LI4U _BH2^G MD^G9IX\0#E[U8')Z/CW[<#9YY[J^WU\/8.E=LNF&"7\6QHID>1\VG+(X!96 M31$*R5$;4H"\334;H;9=>$]?6BTD3%*!"9Q>8EQ8<8'P*4E$C-I-?J]%_ VS M#-X+93%.VW FXVX;&)Q@QA9,(\1*YTHSM[W!GE/V\XO#?K]W-%'SG,FE;X5' M^S1'L6N!6KI=K %= $C)9 H\Y1 M;<@+;0I&OK$*PD/XO?NE.^G"%XR]03XSF '&5>YVRG7I6N9-[Z!6](7IB$DT MG4^7&2[A76S=2+_7Z[=IG-FVF^<$(S1^*!4&ODFUR)#/$/;"?3_Z6\$T95*V MA',DWY"DA ]*SR'L=7Z[ 0H2I7W[K]6DG *J." %C<-_"XDPZ+7]#MYV6!)! MVF A;%K:3&&C!!"T(SL/GUZ2>^7,KS\7QCB$].4D.3TLO/_(@O5(E49>!2HI M,K(B)OLRM^I*D\:_"J'1/7J,0W'EY#VV#P0C?+7']U>^O+)K95/ET/#-8.BA MT-/!@2QS8Z]?>D](D<_9$6& MR;;M:6UVSCBGMX>.DQSU\LMRMJ"PR+*]OKQT@D95%&FP'M M%=7HVU:OY=LF9W'=OOO+Q$)PF]*OA"M2FK:Q3JRRC.4&1_4O&X"=.;0!6T[A M=NKEV];0O6)8[K[IU6AE3:GBU>'+HUKHYMCP]J'P]J'!ZZNQ+6HOW!86LZRR M/%+6JOG1M7CTR;?KSEYOE_+7NOR[B.^Y'F-%JI),+4:IX!37A\K)V@DKIP]: MCX_U84IP^W-P"_R=BG-5M7U7H@\<\P9K@_4?C76G"O??%M0'VI27HQW!MTOQ MJ]Z2*NO#_!*,R@2'%SW_[Q\4W\ $&Q]6F\IM\#7X_@Y?5?_^L]E&\3]&V98E MVU1LD]$-OIUYEMYRQGOKH=(]J-S[K(6,1'6DP>U.=QJ#K=^\'!KVVV(IGP;? V^ MW3[A:NJVR>L&WRX^5F^Y2?A(YUP;>IMSK@9?@^_)=X7FG&LWH]U@;;#>^SE7 MX*\B;U!7:@U_QU6YY;KTO1CXV/?&RZ83'PE+:\>TQM3Q%4KJ!"5">0T^COT] M]YH_0 (14FQKMT@L,?HA#0:LI]$%L(@V"*Z$]:SM$U,L$BD0F[+%DPGL>Q MTN40;S.?YD6.B5"36ZB+K->8H$89NQ&2\"!H:7+6#4Y'K>D:A"O+!QN6WQGM M(D4'%N:,.S8*^1+=.BRQE6)/]O!FK45*Z(H7X?X42X/.UAE*U/3&>@76.28C M]06;X74&ABGBM(+\%]=X-U=1 M UZ3&IG[."VMST\Y(]1Q3;#QS6MA]K0>YW^'V%G#;$&.\"%F>8Y,&T\<6>:D MVK%*?/965!+,R!"MI(CAPK&C'%'F[@!2Y@J&9'.M+@0O(AD_%>7PV#AP)]OCYV+-SC_\/4$L! A0#% @ $(UM3YV_BYVF-P( MA?H6 !$ ( ! &$R,#$Y,#DS,"TQ,'$N:'1M4$L! A0# M% @ $(UM3X:%6>Q#$0 JJ\ ! ( !U3<" &)B:2TR M,#$Y,#DS,"YX!=9% ">8@, % @ &U80( 8F)I+3(P,3DP.3,P M7V1E9BYX;6Q02P$"% ,4 " 0C6U/CB*.X4FL !!0D % M @ &]IP( 8F)I+3(P,3DP.3,P7VQA8BYX;6Q02P$"% ,4 " 0C6U/ M#=]$Y>YM "[7@4 % @ $X5 , 8F)I+3(P,3DP.3,P7W!R M92YX;6Q02P$"% ,4 " 0C6U/52/QD28( "H,0 "0 M@ %8P@, 97@S,3$N:'1M4$L! A0#% @ $(UM3S[P''PJ" 4S D M ( !I#,R,2YH=&U02P4& D ,"0 J @ W=D# end XML 12 R12.htm IDEA: XBRL DOCUMENT v3.19.3
NOVAQUEST FUNDING ARRANGEMENT
9 Months Ended
Sep. 30, 2019
Research and Development [Abstract]  
NOVAQUEST FUNDING ARRANGEMENT NOVAQUEST FUNDING ARRANGEMENT

On August 31, 2019, concurrent with the Merger Agreement, the Company entered into a research and development arrangement with NovaQuest pursuant to which NovaQuest committed up to $25.0 million in research and development funding to the
Company following the closing of the Merger. These proceeds will partially fund the Company’s Phase 3 clinical trials in the United States for its product candidate that contains sofpironium bromide, which treats hyperhidrosis of the skin. The Company is obligated to use commercially reasonable efforts to complete the clinical trials and file to obtain regulatory approval. The funding was projected to cover 67% of the product development costs up to $25.0 million.

As there is a substantive and genuine transfer of risk, the development funding is accounted for as an obligation to perform contractual services. However, given the potential obligation to repay the amounts received, the Company defer any funding received as a liability unless and until it becomes probable that the Company will not have to make a repayment of the received funding to NovaQuest. If the research and development is successful and the product candidate is ultimately approved by the FDA, NovaQuest will be entitled to a payment in the amount of $37.5 million, with $20.0 million due upon approval and the remainder due within two years of approval. Additionally, NovaQuest will be entitled to royalty payments based on annual net sales (except for Japan and certain other Asian countries) of the product candidate based on a sliding scale starting from the date that is two years after the first commercial sale. The portion of the approval payment, should it occur, that exceeds any liabilities recorded on the balance sheet, will be expensed immediately as interest expense. The royalties will be expensed as incurred and will also be included in cost of sales.

If the funding arrangement is terminated in certain circumstances, the Company will be required to pay NovaQuest $25.0 million plus interest, ranging from 8% to 12%. However, in the event that the Company terminates its development program for sofpironium bromide for other specified reasons, including serious safety issues, a failure of the product’s Phase 3 studies, or the FDA’s unwillingness to approve the product, the Company will not be obligated to make any payments to NovaQuest.

In conjunction with the transaction, the Company issued a fully vested warrant to NovaQuest providing it with the right to purchase 241,225 shares of common stock at an exercise price of $10.36 that is exercisable any time within ten years of the execution of the research and development arrangement (the “NovaQuest Warrant”). At issuance, the NovaQuest Warrant was classified as equity and recorded at fair value with no subsequent remeasurement. The fair value of the outstanding warrants was derived from the Black-Scholes option-pricing model using the following assumptions: expected volatility of 85.56%; risk free interest rate of 1.50%; expected term of 10 years; and expected dividend yield of 0.00%.

As of September 30, 2019, $5.6 million of funding had been received from NovaQuest, of which $0.9 million was allocated to the NovaQuest Warrant and deferred on the balance sheet within other current assets and will be recorded as interest expense over the term of the NovaQuest Warrant. In October 2019, NovaQuest notified the Company that additional funding was suspended temporarily based on a material adverse event. Refer to Note 11 for additional details.

XML 13 R16.htm IDEA: XBRL DOCUMENT v3.19.3
COMMITMENTS AND CONTINGENCIES
9 Months Ended
Sep. 30, 2019
Commitments and Contingencies Disclosure [Abstract]  
COMMITMENTS AND CONTINGENCIES COMMITMENTS AND CONTINGENCIES

Operating Leases

In August 2016, the Company entered into a five-year lease for office space in Boulder, Colorado that expires on October 31, 2021 (the “Boulder Lease”) subject to the Company’s option to renew the Boulder Lease for two additional terms of three years each. Pursuant to the Boulder Lease, the Company leased 3,038 square feet of space in a multi-suite building. Rent payments under the Boulder Lease included base rent of $4,430 per month during the first year of the Boulder Lease with an annual increase of 3.5%, and additional monthly fees to cover the Company’s share of certain facility expenses, including utilities, property taxes, insurance, and maintenance, which were $2,160 per month during the first year of the Boulder Lease.

The Company recognized a right-of-use asset and corresponding lease liability on January 1, 2019, by calculating the present value of lease payments, discounted at 12.0%, the Company’s estimated incremental borrowing rate, over the 2.8 years expected remaining term. As the Company’s lease does not provide an implicit rate, the Company estimated the incremental borrowing rate based on industry peers. Industry peers consist of several public companies in the biotechnology industry with comparable characteristics, including clinical trials progress and therapeutic indications. Amortization of the operating lease right-of-use asset for the Boulder Lease amounted to $17 thousand and $50 thousand for the three and nine months ended September 30, 2019, respectively, and was included in operating expense. As of September 30, 2019, the remaining lease term was 2.1 years.

The terms of the Boulder Lease provide for rental payments on a monthly basis on a graduated scale. The Company recognizes rent expense on a straight-line basis over the lease period. Lease expense for the three and nine months ended September 30, 2019 and 2018 was $22 thousand and $0.1 million, respectively.
XML 14 R35.htm IDEA: XBRL DOCUMENT v3.19.3
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Summary of Common Shares Excluded from EPS Calculations (Details) - shares
9 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Shares excluded from the calculation of EPS (in shares) 3,435,390 2,668,331
Warrants to purchase common stock    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Shares excluded from the calculation of EPS (in shares) 1,632,495 55,360
Options to purchase common stock    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Shares excluded from the calculation of EPS (in shares) 1,802,895 1,347,500
Redeemable convertible preferred stock (as converted into common stock)    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Shares excluded from the calculation of EPS (in shares) 0 1,256,466
Warrants to purchase redeemable convertible preferred stock (as converted into common stock)    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Shares excluded from the calculation of EPS (in shares) 0 9,005
XML 16 R31.htm IDEA: XBRL DOCUMENT v3.19.3
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Fair Value Measurement Inputs (Details)
Sep. 30, 2019
Dec. 31, 2018
Expected term (in years)    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Fair value measurement input 10 7.1
Expected volatility    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Fair value measurement input 0.8556 0.3000
Risk free interest rate    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Fair value measurement input 0.0150 0.0259
Expected dividend yield    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Fair value measurement input 0.0000 0
XML 17 R39.htm IDEA: XBRL DOCUMENT v3.19.3
ACCRUED LIABILITIES - Summary of Accrued Liabilities (Details) - USD ($)
$ in Thousands
Sep. 30, 2019
Dec. 31, 2018
Payables and Accruals [Abstract]    
Accrued contracted research and development services $ 1,715 $ 847
Accrued professional fees 992 1,269
Accrued compensation 768 569
Accrued note issuance costs 0 587
Accrued liabilities $ 3,475 $ 3,272
XML 19 R3.htm IDEA: XBRL DOCUMENT v3.19.3
CONDENSED CONSOLIDATED BALANCE SHEETS (PARENTHETICAL) - USD ($)
$ in Thousands
Sep. 30, 2019
Dec. 31, 2018
Statement of Financial Position [Abstract]    
Redeemable convertible preferred stock, par value (in usd per share) $ 0.01 $ 0.01
Redeemable convertible preferred stock, shares authorized 5,000,000 4,182,943
Redeemable convertible preferred stock, shares issued 0 1,256,466
Redeemable convertible preferred stock, shares outstanding 0 1,256,466
Redeemable convertible preferred stock, liquidation preference (in usd) $ 0 $ 46,985
Common stock, par value (in usd per share) $ 0.01 $ 0.01
Common stock, shares authorized 50,000,000 8,000,000
Common stock, shares issued 7,810,680 589,001
Common stock, shares outstanding 7,810,680 589,001
XML 20 R7.htm IDEA: XBRL DOCUMENT v3.19.3
CONDENSED CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY (DEFICIT) - USD ($)
Total
Series A, B, C & C-1 Redeemable Convertible Preferred Stock
Common Stock
Additional Paid-In Capital
Accumulated Other Comprehensive Loss
Accumulated Deficit
Redeemable Convertible Preferred Stock and Preferred Stock Dividends to Common Stock
Redeemable Convertible Preferred Stock and Preferred Stock Dividends to Common Stock
Series A, B, C & C-1 Redeemable Convertible Preferred Stock
Redeemable Convertible Preferred Stock and Preferred Stock Dividends to Common Stock
Common Stock
Redeemable Convertible Preferred Stock and Preferred Stock Dividends to Common Stock
Additional Paid-In Capital
Convertible Notes Payable and Accrued Interest to Common Stock
Convertible Notes Payable and Accrued Interest to Common Stock
Common Stock
Convertible Notes Payable and Accrued Interest to Common Stock
Additional Paid-In Capital
Beginning Balance (in shares) at Dec. 31, 2017     585,262                    
Beginning Balance at Dec. 31, 2017 $ (59,936,000)   $ 6,000 $ 0 $ 0 $ (59,942,000)              
Increase (Decrease) in Stockholders' Equity [Roll Forward]                          
Accretion of redeemable convertible preferred stock to redemption value (3,240,000)     (207,000)   (3,033,000)              
Stock based compensation 190,000     190,000                  
Issuance of common stock through exercise of stock option (in shares)     1,438                    
Issuance of common stock through exercise of stock option 17,000     17,000                  
Net income (loss) 527,000         527,000              
Ending Balance (in shares) at Mar. 31, 2018     586,700                    
Ending Balance at Mar. 31, 2018 (59,708,000)   $ 6,000 0 0 (59,714,000)              
Beginning Balance (in shares) at Dec. 31, 2017   1,256,466                      
Beginning Balance at Dec. 31, 2017   $ 52,354,000                      
Increase (Decrease) in Temporary Equity [Roll Forward]                          
Accretion of redeemable convertible preferred stock to redemption value   $ 3,240,000                      
Ending Balance (in shares) at Mar. 31, 2018   1,256,466                      
Ending Balance at Mar. 31, 2018   $ 55,594,000                      
Beginning Balance (in shares) at Dec. 31, 2017     585,262                    
Beginning Balance at Dec. 31, 2017 (59,936,000)   $ 6,000 0 0 (59,942,000)              
Increase (Decrease) in Stockholders' Equity [Roll Forward]                          
Unrealized loss on available-for-sale marketable securities 0                        
Net income (loss) (5,566,000)                        
Ending Balance (in shares) at Sep. 30, 2018     587,563                    
Ending Balance at Sep. 30, 2018 (67,296,000)   $ 6,000 0 0 (67,302,000)              
Beginning Balance (in shares) at Dec. 31, 2017   1,256,466                      
Beginning Balance at Dec. 31, 2017   $ 52,354,000                      
Increase (Decrease) in Temporary Equity [Roll Forward]                          
Shares converted 0                        
Reduction of redeemable convertible preferred stock to redemption value 5,041,000                        
Ending Balance (in shares) at Sep. 30, 2018   1,256,466                      
Ending Balance at Sep. 30, 2018   $ 57,425,000                      
Beginning Balance (in shares) at Mar. 31, 2018     586,700                    
Beginning Balance at Mar. 31, 2018 (59,708,000)   $ 6,000 0 0 (59,714,000)              
Increase (Decrease) in Stockholders' Equity [Roll Forward]                          
Accretion of redeemable convertible preferred stock to redemption value (865,000)     (175,000)   (690,000)              
Stock based compensation 175,000     175,000                  
Net income (loss) (3,552,000)         (3,552,000)              
Ending Balance (in shares) at Jun. 30, 2018     586,700                    
Ending Balance at Jun. 30, 2018 (63,950,000)   $ 6,000 0 0 (63,956,000)              
Beginning Balance (in shares) at Mar. 31, 2018   1,256,466                      
Beginning Balance at Mar. 31, 2018   $ 55,594,000                      
Increase (Decrease) in Temporary Equity [Roll Forward]                          
Accretion of redeemable convertible preferred stock to redemption value   $ 865,000                      
Ending Balance (in shares) at Jun. 30, 2018   1,256,466                      
Ending Balance at Jun. 30, 2018   $ 56,459,000                      
Increase (Decrease) in Stockholders' Equity [Roll Forward]                          
Accretion of redeemable convertible preferred stock to redemption value (966,000)     (161,000)   (805,000)              
Stock based compensation 151,000     151,000                  
Issuance of common stock through exercise of stock option (in shares)     863                    
Issuance of common stock through exercise of stock option 10,000     10,000                  
Unrealized loss on available-for-sale marketable securities 0                        
Net income (loss) (2,541,000)         (2,541,000)              
Ending Balance (in shares) at Sep. 30, 2018     587,563                    
Ending Balance at Sep. 30, 2018 $ (67,296,000)   $ 6,000 0 0 (67,302,000)              
Increase (Decrease) in Temporary Equity [Roll Forward]                          
Accretion of redeemable convertible preferred stock to redemption value   $ 966,000                      
Ending Balance (in shares) at Sep. 30, 2018   1,256,466                      
Ending Balance at Sep. 30, 2018   $ 57,425,000                      
Beginning Balance (in shares) at Dec. 31, 2018 589,001   589,001                    
Beginning Balance at Dec. 31, 2018 $ (71,618,000)   $ 6,000 0 0 (71,624,000)              
Increase (Decrease) in Stockholders' Equity [Roll Forward]                          
Reduction of redeemable convertible preferred stock to redemption value 10,521,000         10,521,000              
Stock based compensation 384,000     384,000                  
Net income (loss) (4,580,000)         (4,580,000)              
Ending Balance (in shares) at Mar. 31, 2019     589,001                    
Ending Balance at Mar. 31, 2019 $ (65,293,000)   $ 6,000 384,000 0 (65,683,000)              
Beginning Balance (in shares) at Dec. 31, 2018 1,256,466 1,256,466                      
Beginning Balance at Dec. 31, 2018 $ 58,290,000 $ 58,290,000                      
Increase (Decrease) in Temporary Equity [Roll Forward]                          
Reduction of redeemable convertible preferred stock to redemption value   $ (10,521,000)                      
Ending Balance (in shares) at Mar. 31, 2019   1,256,466                      
Ending Balance at Mar. 31, 2019   $ 47,769,000                      
Beginning Balance (in shares) at Dec. 31, 2018 589,001   589,001                    
Beginning Balance at Dec. 31, 2018 $ (71,618,000)   $ 6,000 0 0 (71,624,000)              
Increase (Decrease) in Stockholders' Equity [Roll Forward]                          
Unrealized loss on available-for-sale marketable securities (11,000)                        
Net income (loss) $ (13,015,000)                        
Ending Balance (in shares) at Sep. 30, 2019 7,810,680   7,810,680                    
Ending Balance at Sep. 30, 2019 $ 18,225,000   $ 78,000 92,276,000 (11,000) (74,118,000)              
Beginning Balance (in shares) at Dec. 31, 2018 1,256,466 1,256,466                      
Beginning Balance at Dec. 31, 2018 $ 58,290,000 $ 58,290,000                      
Increase (Decrease) in Temporary Equity [Roll Forward]                          
Shares converted (48,016,000)                        
Reduction of redeemable convertible preferred stock to redemption value $ (10,377,000)                        
Ending Balance (in shares) at Sep. 30, 2019 0 0                      
Ending Balance at Sep. 30, 2019 $ 0 $ 0                      
Beginning Balance (in shares) at Mar. 31, 2019     589,001                    
Beginning Balance at Mar. 31, 2019 (65,293,000)   $ 6,000 384,000 0 (65,683,000)              
Increase (Decrease) in Stockholders' Equity [Roll Forward]                          
Accretion of redeemable convertible preferred stock to redemption value (165,000)     (165,000)                  
Stock based compensation 299,000     299,000                  
Net income (loss) (3,654,000)         (3,654,000)              
Ending Balance (in shares) at Jun. 30, 2019     589,001                    
Ending Balance at Jun. 30, 2019 (68,813,000)   $ 6,000 518,000 0 (69,337,000)              
Beginning Balance (in shares) at Mar. 31, 2019   1,256,466                      
Beginning Balance at Mar. 31, 2019   $ 47,769,000                      
Increase (Decrease) in Temporary Equity [Roll Forward]                          
Accretion of redeemable convertible preferred stock to redemption value   $ 165,000                      
Ending Balance (in shares) at Jun. 30, 2019   1,256,466                      
Ending Balance at Jun. 30, 2019   $ 47,934,000                      
Increase (Decrease) in Stockholders' Equity [Roll Forward]                          
Accretion of redeemable convertible preferred stock to redemption value (82,000)     (82,000)                  
Conversion of securities (in shares)                 2,783,951     1,069,740  
Conversion of securities             $ 48,016,000   $ 28,000 $ 47,988,000 $ 5,092,000 $ 10,000 $ 5,082,000
Common stock issued in recapitalization (in shares)     3,367,988                    
Common stock issued in recapitalization 36,093,000   $ 34,000 36,059,000                  
Stock based compensation 324,000     324,000                  
Reclassification of warrant liability to equity 1,511,000     1,511,000                  
Common stock warrants issued in connection with the research and development funding liability 876,000     876,000                  
Unrealized loss on available-for-sale marketable securities (11,000)       (11,000)                
Net income (loss) $ (4,781,000)         (4,781,000)              
Ending Balance (in shares) at Sep. 30, 2019 7,810,680   7,810,680                    
Ending Balance at Sep. 30, 2019 $ 18,225,000   $ 78,000 $ 92,276,000 $ (11,000) $ (74,118,000)              
Increase (Decrease) in Temporary Equity [Roll Forward]                          
Shares converted (in shares)               (1,256,466)          
Shares converted               $ (48,016,000)          
Accretion of redeemable convertible preferred stock to redemption value   $ 82,000                      
Ending Balance (in shares) at Sep. 30, 2019 0 0                      
Ending Balance at Sep. 30, 2019 $ 0 $ 0                      
XML 21 R28.htm IDEA: XBRL DOCUMENT v3.19.3
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Summary of Net Assets Acquired (Details) - Vical
$ in Thousands
Aug. 31, 2019
USD ($)
Business Acquisition [Line Items]  
Cash and cash equivalents $ 13,017
Marketable securities 23,959
Prepaid expenses and other current assets 1,474
Accrued liabilities (2,357)
Net acquired tangible assets $ 36,093
XML 22 R20.htm IDEA: XBRL DOCUMENT v3.19.3
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
9 Months Ended
Sep. 30, 2019
Accounting Policies [Abstract]  
Basis of Presentation

Basis of Presentation

The accompanying condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, Brickell Subsidiary, Inc., are presented in U.S. dollars and have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”) and applicable rules and regulations of the SEC for interim reporting. As permitted under those rules and regulations, certain footnotes or other financial information normally included in financial statements prepared in accordance with US GAAP have been condensed or omitted. These condensed consolidated financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments, consisting only of normal recurring adjustments, which are necessary for a fair presentation of the Company’s financial information. The results of operations for the three and nine months ended September 30, 2019 are not necessarily indicative of the results to be expected for the full year ending December 31, 2019, for any other interim period, or for any other future period. The condensed consolidated balance sheet as of December 31, 2018 has been derived from audited financial statements at that date but does not include all of the information required by US GAAP for complete financial statements. All intercompany balances and transactions have been eliminated in consolidation.
Use of Estimates
Use of Estimates

The Company’s condensed consolidated financial statements are prepared in accordance with US GAAP, which requires it to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Although these estimates are based on the Company’s knowledge of current events and actions it may take in the future, actual results may ultimately differ from these estimates and assumptions.
Fair Value Measurements
Fair Value Measurements

Fair value is the price that the Company would receive to sell an asset or pay to transfer a liability in a timely transaction with an independent counterparty in the principal market or in the absence of a principal market, the most advantageous market for the asset or liability. A three-tier hierarchy is established to distinguish between (1) inputs that reflect the assumptions market participants would use in pricing an asset or liability developed based on market data obtained from sources independent of the reporting entity (observable inputs) and (2) inputs that reflect the reporting entity’s own assumptions about the assumptions market participants would use in pricing an asset or liability developed based on the best information available in the circumstances (unobservable inputs), and establishes a classification of fair value measurements for disclosure purposes.

The hierarchy is summarized in the three broad levels listed below:
 
Level 1—quoted prices in active markets for identical assets and liabilities
Level 2—other significant observable inputs (including quoted prices for similar assets and liabilities, interest rates, credit risk, etc.)
Level 3—significant unobservable inputs (including the Company’s own assumptions in determining the fair value of assets and liabilities)

The following tables set forth the fair value of the Company’s financial assets and liabilities measured at fair value on a recurring basis based on the three-tier fair value hierarchy as of September 30, 2019 and December 31, 2018 (in thousands):
 
September 30, 2019
 
Level 1 
 
Level 2 
 
Level 3 
Assets:
 
 
 
 
 
Money market funds
$
7,225

 
$

 
$

U.S. treasuries
18,473

 

 

Total
$
25,698

 
$

 
$

Liabilities:
 
 
 
 
 
Contingent consideration
$

 
$

 
$
145

 
December 31, 2018
 
Level 1
 
Level 2
 
Level 3
Assets:
 
 
 
 
 
Money market funds
$
8,067

 
$

 
$

Liabilities:
 
 
 
 
 
Redeemable convertible preferred stock warrant liability
$

 
$

 
$
242

Contingent consideration

 

 
145

Total
$

 
$

 
$
387



Fair Value of Financial Instruments

The following methods and assumptions were used by the Company in estimating the fair values of each class of financial instrument disclosed herein:

Money Market Funds—The carrying amounts reported as cash and cash equivalents in the condensed consolidated balance sheets approximate their fair values due to their short-term nature and/or market rates of interest (Level 1 of the fair value hierarchy).

U.S. Treasuries—The Company has designated its investments in U.S. treasury securities as available-for-sale securities and accounts for them at their respective fair values. The securities are classified as short-term or long-term based on the nature of the securities and their availability to meet current operating requirements. Securities that are readily available for use in current operations are classified as short-term available-for-sale marketable securities and are reported as a component of current assets in the condensed consolidated balance sheets (Level 1 of the fair value hierarchy).

Securities that are classified as available-for-sale are measured at fair value, including accrued interest, with temporary unrealized gains and losses reported as a component of stockholders’ equity until their disposition. The Company reviews available-for-sale securities at the end of each period to determine whether they remain available-for-sale based on its then current intent. The cost of securities sold is based on the specific identification method. The securities are subject to a periodic impairment review. An impairment charge would occur when a decline in the fair value of the investments below the cost basis is judged to be other-than-temporary.

As of September 30, 2019, the Company’s available-for-sale securities had an amortized cost of $18.5 million, fair value of $18.5 million, and an unrealized gain of $20 thousand. Because the securities were acquired in August 2019 in connection to the Merger, there were no related balances as of December 31, 2018.

Contingent Consideration—These amounts represent future payments in conjunction with various business combinations related to the acquisition of certain early-stage pipeline assets. The ultimate amount of future payments is based on specified future criteria, such as the achievement of certain future development and regulatory milestones. The Company evaluates its estimates of the fair value of contingent consideration on a quarterly basis. The fair value of the contingent consideration was determined with the assistance of a third-party valuation firm applying the income approach. This approach estimates the fair value of the contingent consideration related to the achievement of future development and regulatory milestones by assigning an achievement probability and date of expected completion to each potential milestone and discounting the associated cash payment to its present value using a risk-adjusted rate of return. The probability of success of each milestone assumes that the prerequisite developmental milestones are successfully completed and is based on the asset’s current stage of development and anticipated regulatory requirements. The probability of success for each milestone is determined by multiplying the preceding probabilities of success. The unobservable inputs (Level 3 of the fair value hierarchy) to the valuation models that have the most significant effect on the fair value of the Company’s contingent consideration are the probabilities that certain in-process development projects will meet specified development milestones, including ultimate approval by the FDA, with individual cumulative probabilities ranging from 2.1% to 20.9%. Other unobservable inputs used in this approach include risk-adjusted discount rates ranging from 15.5% to 27.1% and estimates of the timing of the achievement of the various product development, regulatory approval, and sales milestones.

Redeemable Convertible Preferred Stock Warrant Liability—These amounts represented potential future obligations to transfer assets to the holders at a future date. The Company remeasured these warrants to current fair value at each balance sheet date, and any change in fair value was recognized as a change in fair value of warrant liability in the condensed consolidated statements of operations. The Company estimated the fair value of these warrants at December 31, 2018 using the Black-Scholes option-pricing model (Level 3 of the fair value hierarchy table). These warrants converted from warrants exercisable for redeemable convertible preferred stock to common stock in August 2019 in connection to the Merger (see further discussion in Note 7).

Inputs used to determine estimated fair value of the warrant liabilities included the estimated fair value of the underlying stock at the valuation date, the estimated term of the warrants, risk-free interest rates, expected dividends, and the expected volatility of the underlying stock. The most significant unobservable inputs used in the fair value measurement of the convertible preferred stock warrant liability were the fair value of the underlying stock at the valuation date and the estimated term of the warrants. Generally, increases (decreases) in the fair value of the underlying stock and estimated term resulted in a directionally similar impact to the fair value measurement.

The fair value of the outstanding warrants was remeasured as of each period end using the Black-Scholes option-pricing model with the following assumptions:
 
2018
Expected term (in years)
7.1

Expected volatility
30.00
%
Risk free interest rate
2.59
%
Expected dividend yield
%


The fair value of the shares of the convertible preferred stock underlying the preferred stock warrants was historically determined with the assistance of a third-party valuation firm. Because there had been no public market for the Company’s convertible preferred stock, the third-party valuation firm determined fair value of the convertible preferred stock at each balance sheet date by considering a number of objective and subjective factors, including valuation of comparable companies, sales of convertible preferred stock to unrelated third parties, operating and financial performance, the lack of liquidity of capital stock, and general and industry specific economic outlook, among other factors.

Remaining Term. The Company derived the expected term based on the time from the balance sheet date until the preferred stock warrant’s expiration date.

Expected Volatility. Since the Company was a private entity with no historical data regarding the volatility of its preferred stock, the expected volatility used was based on volatility of a group of similar entities. In evaluating similarity, the Company considered factors such as industry, stage of life cycle, and size.

Risk-free Interest Rate. The risk-free interest rate was based on U.S. Treasury zero-coupon issues with remaining terms similar to the expected term of the warrants.

Expected Dividend Rate. The Company has never paid any dividends and does not plan to pay dividends in the foreseeable future and, therefore, used an expected dividend rate of zero in the valuation model.

Derivative Liability—These amounts represented potential future obligations to transfer assets to the holders at a future date. The fair value of the derivative liability has historically been determined with the assistance of a third-party valuation firm (Level 3 of the fair value hierarchy table) (see further discussion in Note 6). At the inception of the liability, there was no public market for the Company’s common stock, and a third-party valuation firm determined fair value of the stock by considering a number of objective and subjective factors, including valuation of comparable companies, sales of common stock to unrelated third parties, operating and financial performance, the lack of liquidity of capital stock, and general and industry specific economic outlook, among other factors. The derivative liability was marked-to-market each measurement period and any change in fair value was recorded in the condensed consolidated statements of operations. In August 2019, in connection to the Merger, the derivative liability was reclassified to equity in the condensed consolidated balance sheet (see further discussion in Note 6).

Common Stock Warrant Liability—These amounts represented potential future obligations to transfer assets to the holders at a future date. The fair value of the warrants was historically determined with the assistance of a third-party valuation firm (Level 3 of the fair value hierarchy table) (see further discussion in Note 6). At the inception of the liability, there was no public market for the Company’s common stock, and a third-party valuation firm determined fair value of the stock by considering a number of objective and subjective factors, including valuation of comparable companies, sales of common stock to unrelated third parties, operating and financial performance, the lack of liquidity of capital stock, and general and industry specific economic outlook, among other factors. The warrant liability was remeasured to fair value at each balance sheet date, and any change in fair value was recognized as a change in fair value of warrant liability in the condensed consolidated statements of operations. The Company estimated the fair value of these warrants using the Black-Scholes option-pricing model. In August 2019, in connection to the Merger, the warrant liability was reclassified to equity in the condensed consolidated balance sheet (see further discussion in Note 6).

Inputs used to determine estimated fair value of the warrant liabilities included the estimated fair value of the underlying stock at the valuation date, the estimated term of the warrants, risk-free interest rates, expected dividends, and the expected volatility of the underlying stock. The most significant unobservable inputs used in the fair value measurement of the warrant liability were the fair value of the underlying stock at the valuation date and the estimated term of the warrants. Generally, increases (decreases) in the fair value of the underlying stock and estimated term resulted in a directionally similar impact to the fair value measurement.

Leases
Leases

On January 1, 2019, the Company adopted Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 842, Leases (“ASC 842”), using the modified retrospective method for all lease arrangements at the beginning of the
period of adoption. Results for reporting periods beginning January 1, 2019 are presented under ASC 842, while prior period amounts were not adjusted and continue to be presented in accordance with the Company’s historical accounting under ASC Topic 840, Leases. ASC 842 had an impact on the Company’s condensed consolidated balance sheets but did not have a significant impact on the Company’s net loss.

Under ASC 842, the Company determines if an arrangement is a lease at inception. Leases with a term greater than one year are recognized on the balance sheet as right-of-use assets, lease liabilities and, if applicable, long-term lease liabilities. The Company has elected the practical expedient not to recognize on the balance sheet leases with terms of one-year or less and not to separate lease components and non-lease components for long-term real-estate leases. Lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company estimates the incremental borrowing rate based on industry peers in determining the present value of lease payments. The Company’s facility operating lease has one single component. The lease component results in a right-of-use asset being recorded on the balance sheet, which is amortized as lease expense on a straight-line basis in the Company’s condensed consolidated statements of operations.
Redeemable Convertible Preferred Stock and Warrants
Redeemable Convertible Preferred Stock

Redeemable convertible preferred stock was classified as a mezzanine instrument outside of the Company’s capital accounts. Accretion of redeemable convertible preferred stock included the greater of an adjustment to fair market value or the accrual of dividends on and accretion of issuance costs of the Company’s redeemable convertible preferred stock. The carrying values of the redeemable convertible preferred stock were increased or reduced by periodic accretion or reduction to their respective redemption values from the date of issuance to August 31, 2019, the date that all outstanding shares of redeemable convertible preferred stock converted into shares of common stock. The carrying value adjustments were recorded as charges against additional paid-in capital balance.

Preferred stock issuance costs represent costs related to the Company’s issuance of redeemable convertible preferred stock. These amounts were included as a reduction of redeemable convertible preferred stock and were amortized over the estimated redemption period until its conversion to common stock in August 2019. For the nine months ended September 30, 2019 and 2018, amortization of preferred stock issuance costs amounted to approximately $0.1 million and $30 thousand, respectively.
 
Redeemable Convertible Preferred Stock Warrants

The Company accounted for warrants to purchase shares of its redeemable convertible preferred stock as liabilities at their estimated fair value because the underlying shares were redeemable, which obligated the Company to transfer assets to the holders at a future date. The warrants were subject to remeasurement to fair value at each balance sheet date, and any fair value adjustments were recognized as change in fair value of redeemable convertible preferred stock warrant liability in the condensed consolidated statements of operations. The Company continued to adjust the liability for changes in fair value until the conversion of the redeemable convertible preferred stock into common stock in August 2019. At that time, the redeemable convertible preferred stock warrant liability was adjusted to fair value in the condensed consolidated statements of operations with the final fair value reclassified to equity.

Revenue Recognition
Revenue Recognition

The Company recognizes revenue upon the transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies the performance obligations. At contract inception, the Company assesses the goods or services promised within each contract and assesses whether each promised good or service is distinct and determines those that are performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.

To date, the Company’s drug candidates have not been approved for sale by the FDA or any other country’s regulatory authority, and the Company has not generated or recognized any revenue from the sale of products.

In March 2015, the Company entered into a license and collaboration agreement with Kaken Pharmaceutical, Co., Ltd. (“Kaken”), which is referred to as the “Collaboration Agreement.” Under the Collaboration Agreement, the Company granted to Kaken an exclusive right to develop, manufacture, and commercialize the Company’s sofpironium bromide compound (formerly BBI-4000), a topical anticholinergic, in Japan and certain other Asian countries (the “Territory”). In exchange, Kaken paid the Company an upfront, non-refundable payment of $11.0 million (the “upfront fee”). In addition, the Company is entitled to receive aggregate payments of up to $10.0 million upon the achievement of specified development milestones, and $30.0 million upon the achievement of commercial milestones, as well as tiered royalties based on a percentage of net sales of licensed products in the Territory. The Collaboration Agreement further provides that Kaken will be responsible for funding all development and commercial costs for the program in the Territory and, until such time, if any, as Kaken elects to establish its own source of supply of drug product, Kaken can purchase product supply from the Company to perform all non-clinical studies, and Phase 1 and Phase 2 clinical trials in Japan at cost. Kaken is also required to enter into negotiations with the Company, to supply the Company, at cost, with clinical supplies to perform Phase 3 clinical trials in the United States.

Collaboration Arrangement Subsequent to Adoption of Topic 606

The Company evaluates collaboration arrangements to determine whether units of account within the collaboration arrangement exhibit the characteristics of a vendor and customer relationship. The Company determined that the licenses transferred to Kaken in exchange for the upfront fees were representative of this type of a relationship. If a license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from non-refundable, upfront fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other performance obligations, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition on a prospective basis.

Under Topic 606, the Company evaluated the terms of the Collaboration Agreement and the transfer of intellectual property and manufacturing rights (the “license”) was identified as the only performance obligation as of the inception of the agreement. The Company concluded that the license for the intellectual property was distinct from its ongoing supply obligations. The Company further determined that the transaction price under the arrangement was comprised of the $11.0 million upfront payment. The future potential milestone amounts were not included in the transaction price, as they were all determined to be fully constrained. As part of its evaluation of the development and regulatory milestones constraint, the Company determined that the achievement of such milestones is contingent upon success in future clinical trials and regulatory approvals, each of which is uncertain at this time. The Company will re-evaluate the transaction price each quarter and as uncertain events are resolved or other changes in circumstances occur. Future potential milestone amounts would be recognized as revenue from collaboration arrangements, if unconstrained. The remainder of the arrangement, which largely consisted of both parties incurring costs in their respective territories, provides for the reimbursement of the ongoing supply costs. These costs were representative of a collaboration arrangement outside of the scope of Topic 606 as it does not have the characteristics of a vendor and customer relationship. Reimbursable program costs are recognized proportionately with the delivery of drug substance and are accounted for as reductions to research and development expense and are excluded from the transaction price.

Under Topic 606, the entire transaction price of $11.0 million was allocated to the license performance obligation. The license was deemed to be delivered in 2015 in connection with the execution of the Collaboration Agreement and upon transfer of the underlying intellectual property the performance obligation was fully satisfied. As a result, a cumulative adjustment to reduce deferred revenue and the corresponding sublicensing costs of $2.7 million was recorded upon the adoption of Topic 606 on January 1, 2018. As of September 30, 2019, the Company does not have a deferred revenue or deferred sublicensing costs balance related to the upfront fee on the condensed consolidated balance sheet.

In May 2018, the Company entered into an amendment to the Collaboration Agreement (as further amended, “Collaboration Agreement”), pursuant to which, the Company received an upfront non-refundable fee of $15.6 million (the “Collaboration R&D Payment”), which was initially recorded as deferred revenue, to provide the Company with research and development funds for the sole purpose of conducting certain clinical trials and other such research and development activities required to support the submission of a NDA for sofpironium bromide. These clinical trials have a benefit to Kaken and have the characteristics of a vendor and customer relationship. The Company has accounted for these under the provisions of Topic 606. This Collaboration R&D Payment will be initially recognized using an input method over the average estimated performance period of 1.45 years in proportion to the cost incurred. Upon receipt of the Collaboration R&D Payment, on May 31, 2018, a milestone payment
originally due upon the first commercial sale in Japan was removed from the Collaboration Agreement and all future royalties to the Company under the Collaboration Agreement were reduced 150 basis points.

Consequently, during the three and nine months ended September 30, 2019, the Company recognized revenue of $1.2 million and $7.2 million, respectively related to the Collaboration R&D Payment. As of September 30, 2019, the Company has a deferred revenue balance related to the Collaboration R&D Payment of $2.5 million, which is recorded in deferred revenue, current portion on the accompanying condensed consolidated balance sheets.

Milestones

At the inception of each arrangement that includes milestone payments (variable consideration), the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company or the Company’s collaboration partner’s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such milestones and any related constraint, and if necessary, adjust the Company’s estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration or other revenues and earnings in the period of adjustment.

In October 2017, the Company entered into an amendment to the Collaboration Agreement, pursuant to which, the Company granted Kaken a prepayment option (the “Kaken Option”) on 50% of the Initiation of Phase 3 milestone (the “Phase 3 Milestone”). The Kaken Option was exercisable by Kaken within 25 business days of receipt of the BBI-4000-CL-203 study topline results. In December 2017, Kaken exercised the Kaken Option and paid the Company $5.0 million (the “Kaken Option Payment”). Upon receipt of the non-refundable Kaken Option Payment, the Company provided Kaken the right to negotiate an exclusive license to develop, manufacture and commercialize each of the Company’s other product candidates in Japan (“ROFN Agreement”). Under the ROFN Agreement, following the completion of any Initial Proof of Concept Clinical Trial (“Initial POC”) for the Company’s other product candidates, the Company must provide Kaken with certain information relating to the results of the clinical trial (“Initial POC Package”). The ROFN Agreement is exercisable by Kaken within 30 days of receipt of the Initial POC Package. In December 2017, the Company recognized collaboration revenue related to the Collaboration Agreement of $5.0 million, in connection with the Kaken Option. Additionally, the Company recognized sublicensing costs of $1.0 million, which are included in general and administrative expenses.

The Collaboration Agreement was further amended in March 2018 to accelerate payment of the Phase 3 Milestone. The Phase 3 Milestone was modified to be due upon the successful completion of the End of Phase 2 Meeting with the PMDA by Kaken on March 8, 2018, as determined by Kaken in its reasonable discretion (the “Third Milestone”). In March 2018, Kaken triggered the Third Milestone and paid the Company $5.0 million (the “Third Milestone Payment”). Upon receipt of the non-refundable Third Milestone Payment, the ROFN Agreement was amended (the “Amended ROFN Agreement”) to grant an additional option to exercise upon completion of a Subsequent Clinical Trial (first clinical trial after the Initial POC) for the Company’s other product candidates. The Company has determined that the ROFN Agreement is not a material right and has not allocated transaction price to this provision. As of September 30, 2019, Kaken has not exercised the Amended ROFN Agreement. In March 2018, the Company recognized collaboration revenue related to the Collaboration Agreement of $5.0 million in connection with the Third Milestone. Additionally, the Company recognized sublicensing costs of $1.0 million, which are included in general and administrative expenses.

Royalties

For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognized revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue from any collaborative arrangement.

Under collaborative arrangements, the Company has been reimbursed for a portion of the Company’s research and development expenses, including costs of drug supplies. When the research and development services are performed under a reimbursement
or cost sharing model with a collaboration partner, the Company records these reimbursements as a reduction of research and development expense in the Company’s condensed consolidated statements of operations.
Net Income (Loss) per Common Share
Net Loss per Common Share

Basic and diluted net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares outstanding. When the effects are not anti-dilutive, diluted earnings per share is computed by dividing the Company’s net earnings by the weighted average number of common shares outstanding and the impact of all dilutive potential common shares.

Diluted earnings per share gives effect to all dilutive potential common shares outstanding during the period, including stock options and warrants, using the treasury stock method, and redeemable convertible preferred stock, using the if-converted method. In computing diluted earnings per share, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants. Potentially dilutive common share equivalents are excluded from the diluted earnings per share computation in net loss periods because their effect would be anti-dilutive.
New Accounting Pronouncements

In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement (“ASU 2018-13”), which amends certain disclosure requirements over Level 1, Level 2, and Level 3 fair value measurements. ASU 2018-13 is effective for fiscal years beginning after December 15, 2019 and interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the impact of adopting ASU 2018-13, but does not anticipate it will have a material impact on its disclosures.

In February 2016, the FASB issued ASU No. 2016-02, “Leases (Topic 842)” (“ASU 2016-02”). ASU 2016-02 is aimed at making leasing activities more transparent and comparable and requires substantially all leases be recognized by lessees on their balance sheets as a right-of-use asset and corresponding lease liability, including leases currently accounted for as operating leases. The Company adopted ASU 2016-02 on January 1, 2019 using the modified retrospective approach. The adoption did not have a material impact on the Company’s condensed consolidated statements of operations. The new standard has required the Company to establish liabilities and corresponding right-of-use assets on its condensed balance sheet for operating leases of $0.2 million that existed as of the January 1, 2019 adoption date.
XML 23 R24.htm IDEA: XBRL DOCUMENT v3.19.3
CAPITAL STOCK (Tables)
9 Months Ended
Sep. 30, 2019
Equity [Abstract]  
Reserved Authorized Shares of Common Stock
The Company has reserved authorized shares of common stock, on an as-converted basis, for future issuance at September 30, 2019 as follows:
 
September 30, 2019
Common stock options outstanding
1,802,895

Common stock warrants
1,632,495

Options available for grant under the Vical Plan
119,070

Options available for grant under the 2009 Plan
17,232

Total
3,571,692


Summary of Preferred Stock
Redeemable convertible preferred stock consisted of the following prior to the conversion on August 31, 2019 (in thousands, except share data):
 
Preferred
Shares
Authorized
 
Preferred
Shares
Issued and
Outstanding
 
Par
Value
 
Carrying
Value
 
Common
Stock Issued
Upon
Conversion
Series A
1,162,505

 
401,309

 
$
4

 
$
12,164

 
401,309

Series B
882,216

 
286,151

 
3

 
10,084

 
286,151

Series C
869,565

 
256,583

 
3

 
11,630

 
256,583

Series C-1
1,531,942

 
312,423

 
3

 
14,138

 
312,423

 
4,446,228

 
1,256,466

 
$
13

 
$
48,016

 
1,256,466


Redeemable convertible preferred stock consisted of the following as of December 31, 2018 (in thousands, except share data):
 
Preferred
Shares
Authorized
 
Preferred
Shares
Issued and
Outstanding
 
Par
Value
 
Carrying
Value
 
Common
Stock Issuable
Upon
Conversion
Series A
1,162,505

 
401,309

 
$
4

 
$
16,098

 
401,309

Series B
882,216

 
286,151

 
3

 
13,011

 
286,151

Series C
869,565

 
256,583

 
3

 
13,018

 
256,583

Series C-1
1,268,657

 
312,423

 
3

 
16,163

 
312,423

 
4,182,943

 
1,256,466

 
$
13

 
$
58,290

 
1,256,466


XML 24 R45.htm IDEA: XBRL DOCUMENT v3.19.3
CAPITAL STOCK - Summary of Preferred Stock (Details) - USD ($)
$ in Thousands
Aug. 31, 2019
Dec. 31, 2018
Sep. 30, 2019
Temporary Equity [Line Items]      
Preferred Shares Authorized (in shares) 4,446,228 4,182,943 5,000,000
Preferred Shares Issued (in shares) 1,256,466 1,256,466 0
Preferred Shares Outstanding (in shares) 1,256,466 1,256,466 0
Par Value $ 13 $ 13  
Carrying Value $ 48,016 $ 58,290 $ 0
Common Stock Issued Upon Conversion (in shares) 1,256,466 1,256,466  
Series A      
Temporary Equity [Line Items]      
Preferred Shares Authorized (in shares) 1,162,505 1,162,505  
Preferred Shares Issued (in shares) 401,309 401,309  
Preferred Shares Outstanding (in shares) 401,309 401,309  
Par Value $ 4 $ 4  
Carrying Value $ 12,164 $ 16,098  
Common Stock Issued Upon Conversion (in shares) 401,309 401,309  
Series B      
Temporary Equity [Line Items]      
Preferred Shares Authorized (in shares) 882,216 882,216  
Preferred Shares Issued (in shares) 286,151 286,151  
Preferred Shares Outstanding (in shares) 286,151 286,151  
Par Value $ 3 $ 3  
Carrying Value $ 10,084 $ 13,011  
Common Stock Issued Upon Conversion (in shares) 286,151 286,151  
Series C      
Temporary Equity [Line Items]      
Preferred Shares Authorized (in shares) 869,565 869,565  
Preferred Shares Issued (in shares) 256,583 256,583  
Preferred Shares Outstanding (in shares) 256,583 256,583  
Par Value $ 3 $ 3  
Carrying Value $ 11,630 $ 13,018  
Common Stock Issued Upon Conversion (in shares) 256,583 256,583  
Series C-1      
Temporary Equity [Line Items]      
Preferred Shares Authorized (in shares) 1,531,942 1,268,657  
Preferred Shares Issued (in shares) 312,423 312,423  
Preferred Shares Outstanding (in shares) 312,423 312,423  
Par Value $ 3 $ 3  
Carrying Value $ 14,138 $ 16,163  
Common Stock Issued Upon Conversion (in shares) 312,423 312,423  
XML 25 R41.htm IDEA: XBRL DOCUMENT v3.19.3
NOTE PAYABLE - Narrative (Details) - USD ($)
8 Months Ended 9 Months Ended 29 Months Ended
Sep. 03, 2019
Jun. 02, 2018
Feb. 18, 2016
Jul. 31, 2018
Sep. 30, 2019
Sep. 30, 2018
Jul. 31, 2018
Debt Instrument [Line Items]              
Payments of principal of note payable $ (2,600,000)       $ (4,808,000) $ (509,000)  
Payment of associated accrued interest and aggregate end-of-term payment $ 600,000            
Note Payable              
Debt Instrument [Line Items]              
Face amount     $ 7,500,000        
End of term payment rate     4.50%        
Applicable percent of aggregate unfunded term loan commitments     50.00%        
Increase in termination payment       $ 100,000      
Facility fees             $ 200,000
Interest Rate Option 1 | Note Payable              
Debt Instrument [Line Items]              
Stated rate     9.20%        
Interest Rate Option 2 | Note Payable              
Debt Instrument [Line Items]              
Stated rate     9.20%        
Interest Rate Option 2 | Note Payable | Prime Rate              
Debt Instrument [Line Items]              
Basis spread on variable rate     3.50%        
Hercules Capital Warrants              
Debt Instrument [Line Items]              
Warrants converted (in shares)   9,005          
Exercise price (in usd per share)   $ 33.31          
Warrant liability   $ 300,000          
XML 26 R2.htm IDEA: XBRL DOCUMENT v3.19.3
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
Sep. 30, 2019
Dec. 31, 2018
Current assets:    
Cash and cash equivalents $ 7,225,000 $ 8,067,000
Marketable securities, available-for-sale 18,473,000 0
Prepaid expenses and other current assets 5,034,000 204,000
Total current assets 30,732,000 8,271,000
Property and equipment, net 20,000 37,000
Operating lease right-of-use asset 176,000  
Intangible assets 441,000 441,000
Total assets 31,369,000 8,749,000
Current liabilities:    
Accounts payable 1,291,000 4,067,000
Accrued liabilities 3,475,000 3,272,000
Lease liability, current portion 75,000  
Deferred revenue, current portion 2,464,000 8,117,000
Note payable 0 4,639,000
Total current liabilities 7,305,000 20,095,000
Contingent consideration 145,000 145,000
Lease liability, net of current portion 94,000  
Warrant liability 0 242,000
Deferred revenue, net of current portion 0 1,595,000
Research and development funding liability 5,600,000 0
Total liabilities 13,144,000 22,077,000
Redeemable convertible preferred stock (Series A, B, C and C-1), $0.01 par value, 5,000,000 and 4,182,943 shares authorized at September 30, 2019 and December 31, 2018, respectively; 0 and 1,256,466 shares issued and outstanding at September 30, 2019 and December 31, 2018, respectively; aggregate liquidation preference of $0 and $46,985 at September 30, 2019 and December 31, 2018, respectively 0 58,290,000
Commitments and contingencies (Note 8)
Stockholders’ equity (deficit):    
Common stock, $0.01 par value, 50,000,000 and 8,000,000 shares authorized at September 30, 2019 and December 31, 2018, respectively; 7,810,680 and 589,001 issued and outstanding at September 30, 2019 and December 31, 2018, respectively 78,000 6,000
Additional paid-in capital 92,276,000 0
Accumulated other comprehensive loss (11,000) 0
Accumulated deficit (74,118,000) (71,624,000)
Total stockholders’ equity (deficit) 18,225,000 (71,618,000)
Total liabilities, redeemable convertible preferred stock, and stockholders’ equity (deficit) $ 31,369,000 $ 8,749,000
XML 27 R6.htm IDEA: XBRL DOCUMENT v3.19.3
CONDENSED CONSOLIDATED STATMENTS OF COMPREHENSIVE LOSS (PARENTHETICAL) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2019
Sep. 30, 2018
Statement of Comprehensive Income [Abstract]        
Unrealized loss arising during holding period, tax benefit (expense) $ 0 $ 0 $ 0 $ 0
XML 28 R21.htm IDEA: XBRL DOCUMENT v3.19.3
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
9 Months Ended
Sep. 30, 2019
Accounting Policies [Abstract]  
Summary of Net Assets Acquired The following table summarizes the net assets acquired based on their estimated fair values immediately prior to the Merger (in thousands):
Cash and cash equivalents
$
13,017

Marketable securities
23,959

Prepaid expenses and other current assets
1,474

Accrued liabilities
(2,357
)
Net acquired tangible assets
$
36,093


Fair Value Measurements, Recurring and Nonrecurring
The following tables set forth the fair value of the Company’s financial assets and liabilities measured at fair value on a recurring basis based on the three-tier fair value hierarchy as of September 30, 2019 and December 31, 2018 (in thousands):
 
September 30, 2019
 
Level 1 
 
Level 2 
 
Level 3 
Assets:
 
 
 
 
 
Money market funds
$
7,225

 
$

 
$

U.S. treasuries
18,473

 

 

Total
$
25,698

 
$

 
$

Liabilities:
 
 
 
 
 
Contingent consideration
$

 
$

 
$
145

 
December 31, 2018
 
Level 1
 
Level 2
 
Level 3
Assets:
 
 
 
 
 
Money market funds
$
8,067

 
$

 
$

Liabilities:
 
 
 
 
 
Redeemable convertible preferred stock warrant liability
$

 
$

 
$
242

Contingent consideration

 

 
145

Total
$

 
$

 
$
387


Fair Value Measurement Inputs and Valuation Techniques
The fair value of the outstanding warrants was remeasured as of each period end using the Black-Scholes option-pricing model with the following assumptions:
 
2018
Expected term (in years)
7.1

Expected volatility
30.00
%
Risk free interest rate
2.59
%
Expected dividend yield
%

Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation
The following table sets forth a summary of the changes in the fair value of the Company’s Level 3 financial instruments as follows (in thousands):
 
Derivative
Liability
 
Common
Stock
Warrant
Liability
 
Redeemable
Convertible
Preferred
Stock Warrant
Liability
 
Contingent
Consideration
Liabilities
Fair value as of December 31, 2018
$

 
$

 
$
242

 
$
145

Fair value of financial instruments issued
1,442

 
1,492

 

 

Change in fair value
11

 
17

 
(240
)
 

Reclassification to equity
(1,453
)
 
(1,509
)
 
(2
)
 

Fair value as of September 30, 2019
$

 
$

 
$

 
$
145


Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share
The following table sets forth the potential common shares excluded from the calculation of net loss per common share, because their inclusion would be anti-dilutive:
 
Three and Nine Months Ended
September 30,
 
2019
 
2018
Warrants to purchase common stock
1,632,495

 
55,360

Options to purchase common stock
1,802,895

 
1,347,500

Redeemable convertible preferred stock (as converted into common stock)

 
1,256,466

Warrants to purchase redeemable convertible preferred stock (as converted into common stock)

 
9,005

Total
3,435,390

 
2,668,331


XML 29 R25.htm IDEA: XBRL DOCUMENT v3.19.3
STOCK-BASED COMPENSATION (Tables)
9 Months Ended
Sep. 30, 2019
Share-based Payment Arrangement [Abstract]  
Share-based Compensation Expense
Share-based Compensation Expense

Total stock-based compensation expense related to stock options granted under the 2009 Plan was allocated as follows (in thousands):
 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
 
2019
 
2018
 
2019
 
2018
Research and development
$
81

 
$
76

 
$
237

 
$
263

General and administrative
243

 
75

 
770

 
253

Total stock-based compensation expense
$
324

 
$
151

 
$
1,007

 
$
516



XML 30 R29.htm IDEA: XBRL DOCUMENT v3.19.3
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Fair Value of Assets and Liabilities Measured on a Recurring Basis (Details) - USD ($)
Sep. 30, 2019
Mar. 31, 2019
Dec. 31, 2018
Assets:      
U.S. treasuries $ 18,500,000   $ 0
Liabilities:      
Warrant liability 0 $ 1,500,000 242,000
Fair Value, Recurring | Level 1      
Assets:      
Money market funds 7,225,000   8,067,000
U.S. treasuries 18,473,000    
Total 25,698,000    
Liabilities:      
Contingent consideration 0   0
Warrant liability     0
Total     0
Fair Value, Recurring | Level 2      
Assets:      
Money market funds 0   0
U.S. treasuries 0    
Total 0    
Liabilities:      
Contingent consideration 0   0
Warrant liability     0
Total     0
Fair Value, Recurring | Level 3      
Assets:      
Money market funds 0   0
U.S. treasuries 0    
Total 0    
Liabilities:      
Contingent consideration $ 145,000   145,000
Warrant liability     242,000
Total     $ 387,000
XML 31 R44.htm IDEA: XBRL DOCUMENT v3.19.3
CAPITAL STOCK - Reserved Authorized Shares of Common Stock (Details)
Sep. 30, 2019
shares
Class of Stock [Line Items]  
Shares of common stock reserved for future issuance 3,571,692
Common stock options outstanding  
Class of Stock [Line Items]  
Shares of common stock reserved for future issuance 1,802,895
Common stock warrants  
Class of Stock [Line Items]  
Shares of common stock reserved for future issuance 1,632,495
Vical Plan | Options available for grant under the 2009 Plan  
Class of Stock [Line Items]  
Shares of common stock reserved for future issuance 119,070
2009 Plan | Options available for grant under the 2009 Plan  
Class of Stock [Line Items]  
Shares of common stock reserved for future issuance 17,232
XML 32 R40.htm IDEA: XBRL DOCUMENT v3.19.3
CONVERTIBLE PROMISSORY NOTES - Narrative (Details) - USD ($)
1 Months Ended 3 Months Ended 6 Months Ended 9 Months Ended
Aug. 31, 2019
Mar. 31, 2019
Sep. 30, 2019
Sep. 30, 2018
Aug. 31, 2019
Sep. 30, 2019
Sep. 30, 2018
Dec. 31, 2018
Short-term Debt [Line Items]                
Proceeds from issuance of convertible promissory notes           $ 7,397,000 $ 0  
Warrant liability   $ 1,500,000 $ 0     0   $ 242,000
Derivative liability, fair value   $ 1,400,000            
Gain on extinguishment     $ 2,318,000 $ 0   $ 2,318,000 $ 0  
Convertible Promissory Notes                
Short-term Debt [Line Items]                
Stated rate   12.00%            
Debt term   1 year            
Conversion price (in usd per share) $ 7.54 $ 31.05     $ 7.54      
Qualified financing threshold   $ 15,000,000.0            
Conversion price as percent of price paid per share   80.00%            
Share price threshold (in usd per share)   $ 38.82            
Proceeds from issuance of convertible promissory notes         $ 7,400,000      
Coverage percent   50.00%            
Stock issuable upon warrants (in shares)   490,683            
Term of warrants   5 years            
Exercise price (in usd per share) $ 42.70 $ 10.36     $ 42.70      
Premium percentage on effective price 10.00%              
Effective rate     12.00%     12.00%    
Interest expense     $ 1,100,000     $ 2,000,000.0    
Accretion of discounts     $ 400,000     $ 800,000    
Gain on extinguishment $ 2,300,000              
Convertible Promissory Notes | Common Stock                
Short-term Debt [Line Items]                
Shares issued in conversion (in shares) 1,069,740              
JSON 33 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "a20190930-10q.htm": { "axisCustom": 1, "axisStandard": 23, "contextCount": 211, "dts": { "calculationLink": { "local": [ "bbi-20190930_cal.xml" ] }, "definitionLink": { "local": [ "bbi-20190930_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml", "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml" ] }, "inline": { "local": [ "a20190930-10q.htm" ] }, "labelLink": { "local": [ "bbi-20190930_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "bbi-20190930_pre.xml" ] }, "referenceLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-ref-2019-01-31.xml", "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "bbi-20190930.xsd" ], "remote": [ "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd", "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd", "http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd", "http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-parts-codification-2019-01-31.xsd" ] } }, "elementCount": 411, "entityCount": 1, "hidden": { "http://brickellbio.com/20190930": 1, "http://fasb.org/us-gaap/2019-01-31": 45, "http://xbrl.sec.gov/dei/2019-01-31": 5, "total": 51 }, "keyCustom": 50, "keyStandard": 263, "memberCustom": 22, "memberStandard": 32, "nsprefix": "bbi", "nsuri": "http://brickellbio.com/20190930", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "a20190930-10q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001000 - Document - COVER PAGE", "role": "http://brickellbio.com/role/CoverPage", "shortName": "COVER PAGE", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "a20190930-10q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "a20190930-10q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2102100 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "role": "http://brickellbio.com/role/SummaryOfSignificantAccountingPolicies", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "a20190930-10q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "a20190930-10q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountingChangesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2103100 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS", "role": "http://brickellbio.com/role/RecentAccountingPronouncements", "shortName": "RECENT ACCOUNTING PRONOUNCEMENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "a20190930-10q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountingChangesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "a20190930-10q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2104100 - Disclosure - NOVAQUEST FUNDING ARRANGEMENT", "role": "http://brickellbio.com/role/NovaquestFundingArrangement", "shortName": "NOVAQUEST FUNDING ARRANGEMENT", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "a20190930-10q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "a20190930-10q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2105100 - Disclosure - ACCRUED LIABILITIES", "role": "http://brickellbio.com/role/AccruedLiabilities", "shortName": "ACCRUED LIABILITIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "a20190930-10q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "a20190930-10q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2106100 - Disclosure - CONVERTIBLE PROMISSORY NOTES", "role": "http://brickellbio.com/role/ConvertiblePromissoryNotes", "shortName": "CONVERTIBLE PROMISSORY NOTES", "subGroupType": "", "uniqueAnchor": null }, "R15": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "a20190930-10q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2107100 - Disclosure - NOTE PAYABLE", "role": "http://brickellbio.com/role/NotePayable", "shortName": "NOTE PAYABLE", "subGroupType": "", "uniqueAnchor": null }, "R16": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "a20190930-10q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2108100 - Disclosure - COMMITMENTS AND CONTINGENCIES", "role": "http://brickellbio.com/role/CommitmentsAndContingencies", "shortName": "COMMITMENTS AND CONTINGENCIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "a20190930-10q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "a20190930-10q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2109100 - Disclosure - CAPITAL STOCK", "role": "http://brickellbio.com/role/CapitalStock", "shortName": "CAPITAL STOCK", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "a20190930-10q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "a20190930-10q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2110100 - Disclosure - STOCK-BASED COMPENSATION", "role": "http://brickellbio.com/role/StockBasedCompensation", "shortName": "STOCK-BASED COMPENSATION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "a20190930-10q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "a20190930-10q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2111100 - Disclosure - SUBSEQUENT EVENTS", "role": "http://brickellbio.com/role/SubsequentEvents", "shortName": "SUBSEQUENT EVENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "a20190930-10q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "a20190930-10q.htm", "contextRef": "FI2019Q3", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS", "role": "http://brickellbio.com/role/CondensedConsolidatedBalanceSheets", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "a20190930-10q.htm", "contextRef": "FI2019Q3", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "a20190930-10q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2202201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "role": "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesPolicies", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "a20190930-10q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "a20190930-10q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2302302 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "role": "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesTables", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "a20190930-10q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "a20190930-10q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2303301 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS (Tables)", "role": "http://brickellbio.com/role/RecentAccountingPronouncementsTables", "shortName": "RECENT ACCOUNTING PRONOUNCEMENTS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "a20190930-10q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "a20190930-10q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2305301 - Disclosure - ACCRUED LIABILITIES (Tables)", "role": "http://brickellbio.com/role/AccruedLiabilitiesTables", "shortName": "ACCRUED LIABILITIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "a20190930-10q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "a20190930-10q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockByClassTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2309301 - Disclosure - CAPITAL STOCK (Tables)", "role": "http://brickellbio.com/role/CapitalStockTables", "shortName": "CAPITAL STOCK (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "a20190930-10q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockByClassTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "a20190930-10q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2310301 - Disclosure - STOCK-BASED COMPENSATION (Tables)", "role": "http://brickellbio.com/role/StockBasedCompensationTables", "shortName": "STOCK-BASED COMPENSATION (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "a20190930-10q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "a20190930-10q.htm", "contextRef": "I2019Q3Aug31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2401401 - Disclosure - ORGANIZATION AND NATURE OF OPERATIONS - Narrative (Details)", "role": "http://brickellbio.com/role/OrganizationAndNatureOfOperationsNarrativeDetails", "shortName": "ORGANIZATION AND NATURE OF OPERATIONS - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "a20190930-10q.htm", "contextRef": "I2019Q3Aug31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "a20190930-10q.htm", "contextRef": "D2018Q2Jun2_us-gaap_ClassOfWarrantOrRightAxis_bbi_VicalWarrantsMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ConversionOfStockSharesConverted1", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402403 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Merger Narrative (Details)", "role": "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesMergerNarrativeDetails", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Merger Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "a20190930-10q.htm", "contextRef": "D2018Q2Jun2_us-gaap_ClassOfWarrantOrRightAxis_bbi_VicalWarrantsMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ConversionOfStockSharesConverted1", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "a20190930-10q.htm", "contextRef": "I2019Q3Aug31_us-gaap_BusinessAcquisitionAxis_bbi_VicalMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402404 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Summary of Net Assets Acquired (Details)", "role": "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfNetAssetsAcquiredDetails", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Summary of Net Assets Acquired (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "a20190930-10q.htm", "contextRef": "I2019Q3Aug31_us-gaap_BusinessAcquisitionAxis_bbi_VicalMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "a20190930-10q.htm", "contextRef": "FI2019Q3", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402405 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Fair Value of Assets and Liabilities Measured on a Recurring Basis (Details)", "role": "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesFairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Fair Value of Assets and Liabilities Measured on a Recurring Basis (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "a20190930-10q.htm", "contextRef": "FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember", "decimals": "-3", "lang": null, "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:TemporaryEquityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "a20190930-10q.htm", "contextRef": "FI2018Q4", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:TemporaryEquitySharesAuthorized", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001501 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (PARENTHETICAL)", "role": "http://brickellbio.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (PARENTHETICAL)", "subGroupType": "", "uniqueAnchor": null }, "R30": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "a20190930-10q.htm", "contextRef": "FI2019Q3", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402406 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Fair Value Measurements Narrative (Details)", "role": "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesFairValueMeasurementsNarrativeDetails", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Fair Value Measurements Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "a20190930-10q.htm", "contextRef": "FI2019Q3", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "a20190930-10q.htm", "contextRef": "FI2019Q3_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput", "reportCount": 1, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402407 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Fair Value Measurement Inputs (Details)", "role": "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesFairValueMeasurementInputsDetails", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Fair Value Measurement Inputs (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R32": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "a20190930-10q.htm", "contextRef": "FI2018Q4_us-gaap_FairValueByLiabilityClassAxis_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402408 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Reconciliation of Level 3 Financial Instruments (Details)", "role": "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesReconciliationOfLevel3FinancialInstrumentsDetails", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Reconciliation of Level 3 Financial Instruments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "a20190930-10q.htm", "contextRef": "FI2018Q4_us-gaap_FairValueByLiabilityClassAxis_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "a20190930-10q.htm", "contextRef": "FD2019Q3YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AmortizationOfFinancingCostsAndDiscounts", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402409 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Redeemable Convertible Preferred Stock Narrative (Details)", "role": "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesRedeemableConvertiblePreferredStockNarrativeDetails", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Redeemable Convertible Preferred Stock Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "bbi:TemporaryEquityPolicyPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "a20190930-10q.htm", "contextRef": "FD2019Q3YTD_us-gaap_StatementClassOfStockAxis_us-gaap_RedeemableConvertiblePreferredStockMember", "decimals": "-5", "lang": null, "name": "us-gaap:AmortizationOfFinancingCostsAndDiscounts", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "a20190930-10q.htm", "contextRef": "FD2019Q3QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402410 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition Narrative (Details)", "role": "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionNarrativeDetails", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "a20190930-10q.htm", "contextRef": "D2018Q2May_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember", "decimals": "-5", "lang": null, "name": "bbi:CollaborativeArrangementNonrefundableUpfrontFees", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "body", "html" ], "baseRef": "a20190930-10q.htm", "contextRef": "FD2019Q3YTD", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402411 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Summary of Common Shares Excluded from EPS Calculations (Details)", "role": "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfCommonSharesExcludedFromEpsCalculationsDetails", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Summary of Common Shares Excluded from EPS Calculations (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "body", "html" ], "baseRef": "a20190930-10q.htm", "contextRef": "FD2019Q3YTD", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "span", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "a20190930-10q.htm", "contextRef": "I2019Q1Jan1", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseLiability", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403402 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS - Narrative (Details)", "role": "http://brickellbio.com/role/RecentAccountingPronouncementsNarrativeDetails", "shortName": "RECENT ACCOUNTING PRONOUNCEMENTS - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "a20190930-10q.htm", "contextRef": "I2019Q1Jan1", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseLiability", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "a20190930-10q.htm", "contextRef": "FI2019Q3", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403403 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS - Effects of Topic 842 (Details)", "role": "http://brickellbio.com/role/RecentAccountingPronouncementsEffectsOfTopic842Details", "shortName": "RECENT ACCOUNTING PRONOUNCEMENTS - Effects of Topic 842 (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "a20190930-10q.htm", "contextRef": "I2019Q1Jan1_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member", "decimals": "-3", "lang": null, "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "a20190930-10q.htm", "contextRef": "FD2019Q3YTD", "decimals": "INF", "first": true, "lang": null, "name": "bbi:ResearchandDevelopmentArrangementContractToPerformForOthersMonthlyDistributionPercentOfInvoicedResearchAndDevelopment", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2404401 - Disclosure - NOVAQUEST FUNDING ARRANGEMENT - Narrative (Details)", "role": "http://brickellbio.com/role/NovaquestFundingArrangementNarrativeDetails", "shortName": "NOVAQUEST FUNDING ARRANGEMENT - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "a20190930-10q.htm", "contextRef": "FD2019Q3YTD", "decimals": "INF", "first": true, "lang": null, "name": "bbi:ResearchandDevelopmentArrangementContractToPerformForOthersMonthlyDistributionPercentOfInvoicedResearchAndDevelopment", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "body", "html" ], "baseRef": "a20190930-10q.htm", "contextRef": "FI2019Q3", "decimals": "-3", "first": true, "lang": null, "name": "bbi:AccruedResearchAndDevelopmentFeesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2405402 - Disclosure - ACCRUED LIABILITIES - Summary of Accrued Liabilities (Details)", "role": "http://brickellbio.com/role/AccruedLiabilitiesSummaryOfAccruedLiabilitiesDetails", "shortName": "ACCRUED LIABILITIES - Summary of Accrued Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "body", "html" ], "baseRef": "a20190930-10q.htm", "contextRef": "FI2019Q3", "decimals": "-3", "first": true, "lang": null, "name": "bbi:AccruedResearchAndDevelopmentFeesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "a20190930-10q.htm", "contextRef": "FD2019Q3QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS", "role": "http://brickellbio.com/role/CondensedConsolidatedStatementsOfOperations", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "a20190930-10q.htm", "contextRef": "FD2019Q3QTD", "decimals": "-3", "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "a20190930-10q.htm", "contextRef": "FD2019Q3YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProceedsFromConvertibleDebt", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406401 - Disclosure - CONVERTIBLE PROMISSORY NOTES - Narrative (Details)", "role": "http://brickellbio.com/role/ConvertiblePromissoryNotesNarrativeDetails", "shortName": "CONVERTIBLE PROMISSORY NOTES - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "a20190930-10q.htm", "contextRef": "FI2019Q1", "decimals": "-5", "lang": null, "name": "us-gaap:DerivativeLiabilities", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "span", "ix:continuation", "div", "body", "html" ], "baseRef": "a20190930-10q.htm", "contextRef": "D2019Q3Sep3", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:RepaymentsOfNotesPayable", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407401 - Disclosure - NOTE PAYABLE - Narrative (Details)", "role": "http://brickellbio.com/role/NotePayableNarrativeDetails", "shortName": "NOTE PAYABLE - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "ix:continuation", "div", "body", "html" ], "baseRef": "a20190930-10q.htm", "contextRef": "D2019Q3Sep3", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:RepaymentsOfNotesPayable", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "a20190930-10q.htm", "contextRef": "FI2019Q3", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseRenewalTerm", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408401 - Disclosure - COMMITMENTS AND CONTINGENCIES - Narrative (Details)", "role": "http://brickellbio.com/role/CommitmentsAndContingenciesNarrativeDetails", "shortName": "COMMITMENTS AND CONTINGENCIES - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "a20190930-10q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "lang": "en-US", "name": "bbi:OperatingLeaseRemainingLeaseTerm", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "a20190930-10q.htm", "contextRef": "FI2019Q3_us-gaap_StatementClassOfStockAxis_us-gaap_RedeemableConvertiblePreferredStockMember", "decimals": "INF", "first": true, "lang": null, "name": "bbi:BusinessCombinationStockConversationRatio", "reportCount": 1, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409402 - Disclosure - CAPITAL STOCK - Narrative (Details)", "role": "http://brickellbio.com/role/CapitalStockNarrativeDetails", "shortName": "CAPITAL STOCK - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "a20190930-10q.htm", "contextRef": "FI2019Q3_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember", "decimals": "INF", "lang": null, "name": "bbi:BusinessCombinationStockConversationRatio", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfStockByClassTextBlock", "ix:continuation", "body", "html" ], "baseRef": "a20190930-10q.htm", "contextRef": "FI2019Q3", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409403 - Disclosure - CAPITAL STOCK - Reserved Authorized Shares of Common Stock (Details)", "role": "http://brickellbio.com/role/CapitalStockReservedAuthorizedSharesOfCommonStockDetails", "shortName": "CAPITAL STOCK - Reserved Authorized Shares of Common Stock (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfStockByClassTextBlock", "ix:continuation", "body", "html" ], "baseRef": "a20190930-10q.htm", "contextRef": "FI2019Q3", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:TemporaryEquityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "a20190930-10q.htm", "contextRef": "I2019Q3Aug31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:TemporaryEquitySharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409404 - Disclosure - CAPITAL STOCK - Summary of Preferred Stock (Details)", "role": "http://brickellbio.com/role/CapitalStockSummaryOfPreferredStockDetails", "shortName": "CAPITAL STOCK - Summary of Preferred Stock (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:TemporaryEquityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "a20190930-10q.htm", "contextRef": "I2019Q3Aug31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:TemporaryEquitySharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "a20190930-10q.htm", "contextRef": "FD2019Q3YTD_us-gaap_PlanNameAxis_bbi_VicalStockIncentivePlanMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410402 - Disclosure - STOCK-BASED COMPENSATION - Narrative (Details)", "role": "http://brickellbio.com/role/StockBasedCompensationNarrativeDetails", "shortName": "STOCK-BASED COMPENSATION - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "a20190930-10q.htm", "contextRef": "FD2019Q3YTD_us-gaap_PlanNameAxis_bbi_VicalStockIncentivePlanMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "body", "html" ], "baseRef": "a20190930-10q.htm", "contextRef": "FD2019Q3QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410404 - Disclosure - STOCK-BASED COMPENSATION - Share-based Compensation Expense (Details)", "role": "http://brickellbio.com/role/StockBasedCompensationShareBasedCompensationExpenseDetails", "shortName": "STOCK-BASED COMPENSATION - Share-based Compensation Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "body", "html" ], "baseRef": "a20190930-10q.htm", "contextRef": "FD2019Q3QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "a20190930-10q.htm", "contextRef": "FD2019Q3QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003000 - Statement - CONDENSED CONSOLIDATED STATMENTS OF COMPREHENSIVE LOSS", "role": "http://brickellbio.com/role/CondensedConsolidatedStatmentsOfComprehensiveLoss", "shortName": "CONDENSED CONSOLIDATED STATMENTS OF COMPREHENSIVE LOSS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "a20190930-10q.htm", "contextRef": "FD2019Q3QTD", "decimals": "-3", "lang": null, "name": "us-gaap:ComprehensiveIncomeNetOfTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": null, "groupType": "statement", "isDefault": "false", "longName": "1003001 - Statement - CONDENSED CONSOLIDATED STATMENTS OF COMPREHENSIVE LOSS (PARENTHETICAL)", "role": "http://brickellbio.com/role/CondensedConsolidatedStatmentsOfComprehensiveLossParenthetical", "shortName": "CONDENSED CONSOLIDATED STATMENTS OF COMPREHENSIVE LOSS (PARENTHETICAL)", "subGroupType": "", "uniqueAnchor": null }, "R7": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "a20190930-10q.htm", "contextRef": "FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesOutstanding", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS\u2019 EQUITY (DEFICIT)", "role": "http://brickellbio.com/role/CondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS\u2019 EQUITY (DEFICIT)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "a20190930-10q.htm", "contextRef": "FD2018Q1QTD", "decimals": "-3", "lang": null, "name": "us-gaap:PreferredStockAccretionOfRedemptionDiscount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "a20190930-10q.htm", "contextRef": "FD2019Q3YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "role": "http://brickellbio.com/role/CondensedConsolidatedStatementsOfCashFlows", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "a20190930-10q.htm", "contextRef": "FD2019Q3YTD", "decimals": "-3", "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "a20190930-10q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101100 - Disclosure - ORGANIZATION AND NATURE OF OPERATIONS", "role": "http://brickellbio.com/role/OrganizationAndNatureOfOperations", "shortName": "ORGANIZATION AND NATURE OF OPERATIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "a20190930-10q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9999": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "a20190930-10q.htm", "contextRef": "I2018Q1Jan1_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "", "isDefault": "false", "longName": "Uncategorized Items - a20190930-10q.htm", "role": "http://xbrl.sec.gov/role/uncategorizedFacts", "shortName": "Uncategorized Items - a20190930-10q.htm", "subGroupType": "", "uniqueAnchor": null } }, "segmentCount": 58, "tag": { "bbi_AccruedDebtIssuanceCostsCurrent": { "auth_ref": [], "calculation": { "http://brickellbio.com/role/AccruedLiabilitiesSummaryOfAccruedLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accrued Debt Issuance Costs, Current", "label": "Accrued Debt Issuance Costs, Current", "verboseLabel": "Accrued note issuance costs" } } }, "localname": "AccruedDebtIssuanceCostsCurrent", "nsuri": "http://brickellbio.com/20190930", "presentation": [ "http://brickellbio.com/role/AccruedLiabilitiesSummaryOfAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "bbi_AccruedResearchAndDevelopmentFeesCurrent": { "auth_ref": [], "calculation": { "http://brickellbio.com/role/AccruedLiabilitiesSummaryOfAccruedLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accrued Research And Development Fees, Current", "label": "Accrued Research And Development Fees, Current", "terseLabel": "Accrued contracted research and development services" } } }, "localname": "AccruedResearchAndDevelopmentFeesCurrent", "nsuri": "http://brickellbio.com/20190930", "presentation": [ "http://brickellbio.com/role/AccruedLiabilitiesSummaryOfAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "bbi_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantAndDerivativeLiability": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Adjustments To Additional Paid In Capital, Reclassification Of Warrant And Derivative Liability", "label": "Adjustments To Additional Paid In Capital, Reclassification Of Warrant And Derivative Liability", "terseLabel": "Reclassification of warrant liability to equity" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantAndDerivativeLiability", "nsuri": "http://brickellbio.com/20190930", "presentation": [ "http://brickellbio.com/role/CondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "bbi_AmortizationOfDebtDiscount": { "auth_ref": [], "calculation": { "http://brickellbio.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amortization Of Debt Discount", "label": "Amortization Of Debt Discount", "terseLabel": "Amortization of convertible promissory notes discount" } } }, "localname": "AmortizationOfDebtDiscount", "nsuri": "http://brickellbio.com/20190930", "presentation": [ "http://brickellbio.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "bbi_ApplicableInterestRateAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Applicable Interest Rate [Axis]", "label": "Applicable Interest Rate [Axis]", "terseLabel": "Applicable Interest Rate [Axis]" } } }, "localname": "ApplicableInterestRateAxis", "nsuri": "http://brickellbio.com/20190930", "presentation": [ "http://brickellbio.com/role/NotePayableNarrativeDetails" ], "xbrltype": "stringItemType" }, "bbi_ApplicableInterestRateDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "[Domain] for Applicable Interest Rate [Axis]", "label": "Applicable Interest Rate [Domain]", "terseLabel": "Applicable Interest Rate [Domain]" } } }, "localname": "ApplicableInterestRateDomain", "nsuri": "http://brickellbio.com/20190930", "presentation": [ "http://brickellbio.com/role/NotePayableNarrativeDetails" ], "xbrltype": "domainItemType" }, "bbi_BrickellFormerSecurityholdersMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Brickell Former Securityholders [Member]", "label": "Brickell Former Securityholders [Member]", "terseLabel": "Brickell Former Securityholders" } } }, "localname": "BrickellFormerSecurityholdersMember", "nsuri": "http://brickellbio.com/20190930", "presentation": [ "http://brickellbio.com/role/OrganizationAndNatureOfOperationsNarrativeDetails" ], "xbrltype": "domainItemType" }, "bbi_BusinessCombinationStockConversationRatio": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Business Combination, Stock Conversation Ratio", "label": "Business Combination, Stock Conversation Ratio", "terseLabel": "Conversion ratio" } } }, "localname": "BusinessCombinationStockConversationRatio", "nsuri": "http://brickellbio.com/20190930", "presentation": [ "http://brickellbio.com/role/CapitalStockNarrativeDetails", "http://brickellbio.com/role/OrganizationAndNatureOfOperationsNarrativeDetails" ], "xbrltype": "pureItemType" }, "bbi_ChangeInUnrealizedGainLossAvailableforSaleDebtSecurities": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Change In Unrealized Gain (Loss) Available for Sale, Debt Securities", "label": "Change In Unrealized Gain (Loss) Available for Sale, Debt Securities", "terseLabel": "Change in unrealized loss on available-for-sale marketable securities" } } }, "localname": "ChangeInUnrealizedGainLossAvailableforSaleDebtSecurities", "nsuri": "http://brickellbio.com/20190930", "presentation": [ "http://brickellbio.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "bbi_ClassOfWarrantOrRightExercisePricePercentageOfEffectivePricePaidOnShareBasis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Class Of Warrant Or Right, Exercise Price, Percentage Of Effective Price Paid On Share Basis", "label": "Class Of Warrant Or Right, Exercise Price, Percentage Of Effective Price Paid On Share Basis", "terseLabel": "Premium percentage on effective price" } } }, "localname": "ClassOfWarrantOrRightExercisePricePercentageOfEffectivePricePaidOnShareBasis", "nsuri": "http://brickellbio.com/20190930", "presentation": [ "http://brickellbio.com/role/ConvertiblePromissoryNotesNarrativeDetails" ], "xbrltype": "percentItemType" }, "bbi_ClassOfWarrantOrRightTerm": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Class Of Warrant Or Right, Term", "label": "Class Of Warrant Or Right, Term", "terseLabel": "Term of warrants" } } }, "localname": "ClassOfWarrantOrRightTerm", "nsuri": "http://brickellbio.com/20190930", "presentation": [ "http://brickellbio.com/role/ConvertiblePromissoryNotesNarrativeDetails" ], "xbrltype": "durationItemType" }, "bbi_CollaborationArrangementPrepaymentOptionAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Collaboration Arrangement, Prepayment Option, Amount", "label": "Collaboration Arrangement, Prepayment Option, Amount", "terseLabel": "Prepayment amount" } } }, "localname": "CollaborationArrangementPrepaymentOptionAmount", "nsuri": "http://brickellbio.com/20190930", "presentation": [ "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "bbi_CollaborationArrangementPrepaymentOptionPercentageOfMilestonePayment": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Collaboration Arrangement, Prepayment Option, Percentage Of Milestone Payment", "label": "Collaboration Arrangement, Prepayment Option, Percentage Of Milestone Payment", "terseLabel": "Prepayment option percent" } } }, "localname": "CollaborationArrangementPrepaymentOptionPercentageOfMilestonePayment", "nsuri": "http://brickellbio.com/20190930", "presentation": [ "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionNarrativeDetails" ], "xbrltype": "percentItemType" }, "bbi_CollaborativeArrangementCommercializationMilestonePayments": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Collaborative Arrangement, Commercialization Milestone Payments", "label": "Collaborative Arrangement, Commercialization Milestone Payments", "terseLabel": "Commercialization milestone payments" } } }, "localname": "CollaborativeArrangementCommercializationMilestonePayments", "nsuri": "http://brickellbio.com/20190930", "presentation": [ "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "bbi_CollaborativeArrangementDevelopmentMilestonePayments": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Collaborative Arrangement, Development Milestone Payments", "label": "Collaborative Arrangement, Development Milestone Payments", "terseLabel": "Development milestone payments" } } }, "localname": "CollaborativeArrangementDevelopmentMilestonePayments", "nsuri": "http://brickellbio.com/20190930", "presentation": [ "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "bbi_CollaborativeArrangementNonrefundableUpfrontFees": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Collaborative Arrangement, Non-refundable Upfront Fees", "label": "Collaborative Arrangement, Non-refundable Upfront Fees", "terseLabel": "Non-refundable upfront fees" } } }, "localname": "CollaborativeArrangementNonrefundableUpfrontFees", "nsuri": "http://brickellbio.com/20190930", "presentation": [ "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "bbi_CollaborativeArrangementReceiptOfDevelopmentMilestonePayments": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Collaborative Arrangement, Receipt Of Development Milestone Payments", "label": "Collaborative Arrangement, Receipt Of Development Milestone Payments", "terseLabel": "Milestone payment received" } } }, "localname": "CollaborativeArrangementReceiptOfDevelopmentMilestonePayments", "nsuri": "http://brickellbio.com/20190930", "presentation": [ "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "bbi_CommonStockSharesIssuedAndOutstandingPercent": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Common Stock, Shares Issued And Outstanding, Percent", "label": "Common Stock, Shares Issued And Outstanding, Percent", "terseLabel": "Percent of shares owned" } } }, "localname": "CommonStockSharesIssuedAndOutstandingPercent", "nsuri": "http://brickellbio.com/20190930", "presentation": [ "http://brickellbio.com/role/OrganizationAndNatureOfOperationsNarrativeDetails" ], "xbrltype": "percentItemType" }, "bbi_CommonStockWarrantLiabilityMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Common Stock Warrant Liability [Member]", "label": "Common Stock Warrant Liability [Member]", "terseLabel": "Common Stock Warrant Liability" } } }, "localname": "CommonStockWarrantLiabilityMember", "nsuri": "http://brickellbio.com/20190930", "presentation": [ "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesReconciliationOfLevel3FinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "bbi_CommonStockWarrantsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Common Stock Warrants [Member]", "label": "Common Stock Warrants [Member]", "terseLabel": "Common stock warrants" } } }, "localname": "CommonStockWarrantsMember", "nsuri": "http://brickellbio.com/20190930", "presentation": [ "http://brickellbio.com/role/CapitalStockReservedAuthorizedSharesOfCommonStockDetails" ], "xbrltype": "domainItemType" }, "bbi_ContingentConsiderationLiabilityMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Contingent Consideration Liability [Member]", "label": "Contingent Consideration Liability [Member]", "terseLabel": "Contingent Consideration Liabilities" } } }, "localname": "ContingentConsiderationLiabilityMember", "nsuri": "http://brickellbio.com/20190930", "presentation": [ "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesReconciliationOfLevel3FinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "bbi_ConvertibleDebtDerivativeLiabilityIssued": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Convertible Debt, Derivative Liability Issued", "label": "Convertible Debt, Derivative Liability Issued", "terseLabel": "Derivative liability issued with convertible promissory notes" } } }, "localname": "ConvertibleDebtDerivativeLiabilityIssued", "nsuri": "http://brickellbio.com/20190930", "presentation": [ "http://brickellbio.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "bbi_ConvertibleDebtWarrantsIssued": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Convertible Debt, Warrants Issued", "label": "Convertible Debt, Warrants Issued", "terseLabel": "Warrants to purchase common stock issued with convertible promissory notes" } } }, "localname": "ConvertibleDebtWarrantsIssued", "nsuri": "http://brickellbio.com/20190930", "presentation": [ "http://brickellbio.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "bbi_ConvertibleNotesPayableAndAccruedInterestToCommonStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Convertible Notes Payable And Accrued Interest To Common Stock [Member]", "label": "Convertible Notes Payable And Accrued Interest To Common Stock [Member]", "terseLabel": "Convertible Notes Payable and Accrued Interest to Common Stock" } } }, "localname": "ConvertibleNotesPayableAndAccruedInterestToCommonStockMember", "nsuri": "http://brickellbio.com/20190930", "presentation": [ "http://brickellbio.com/role/CondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "bbi_DebtInstrumentConvertibleConversionTriggerThresholdAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Debt Instrument, Convertible, Conversion Trigger Threshold, Amount", "label": "Debt Instrument, Convertible, Conversion Trigger Threshold, Amount", "terseLabel": "Qualified financing threshold" } } }, "localname": "DebtInstrumentConvertibleConversionTriggerThresholdAmount", "nsuri": "http://brickellbio.com/20190930", "presentation": [ "http://brickellbio.com/role/ConvertiblePromissoryNotesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "bbi_DebtInstrumentTerminationPaymentIncreaseDecrease": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Debt Instrument, Termination Payment, Increase (Decrease)", "label": "Debt Instrument, Termination Payment, Increase (Decrease)", "terseLabel": "Increase in termination payment" } } }, "localname": "DebtInstrumentTerminationPaymentIncreaseDecrease", "nsuri": "http://brickellbio.com/20190930", "presentation": [ "http://brickellbio.com/role/NotePayableNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "bbi_DebtInstrumentTerminationPaymentPercentageOfApplicableOutstandingCommitments": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt Instrument, Termination Payment, Percentage Of Applicable Outstanding Commitments", "label": "Debt Instrument, Termination Payment, Percentage Of Applicable Outstanding Commitments", "terseLabel": "Applicable percent of aggregate unfunded term loan commitments" } } }, "localname": "DebtInstrumentTerminationPaymentPercentageOfApplicableOutstandingCommitments", "nsuri": "http://brickellbio.com/20190930", "presentation": [ "http://brickellbio.com/role/NotePayableNarrativeDetails" ], "xbrltype": "percentItemType" }, "bbi_DebtInstrumentTerminationPaymentRate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt Instrument, Termination Payment, Rate", "label": "Debt Instrument, Termination Payment, Rate", "terseLabel": "End of term payment rate" } } }, "localname": "DebtInstrumentTerminationPaymentRate", "nsuri": "http://brickellbio.com/20190930", "presentation": [ "http://brickellbio.com/role/NotePayableNarrativeDetails" ], "xbrltype": "percentItemType" }, "bbi_DebtInstrumentWarrantsIssuanceCoveragePercent": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt Instrument, Warrants Issuance, Coverage Percent", "label": "Debt Instrument, Warrants Issuance, Coverage Percent", "terseLabel": "Coverage percent" } } }, "localname": "DebtInstrumentWarrantsIssuanceCoveragePercent", "nsuri": "http://brickellbio.com/20190930", "presentation": [ "http://brickellbio.com/role/ConvertiblePromissoryNotesNarrativeDetails", "http://brickellbio.com/role/NovaquestFundingArrangementNarrativeDetails" ], "xbrltype": "percentItemType" }, "bbi_DebtSecuritiesAvailableforSaleAccretionOfDiscount": { "auth_ref": [], "calculation": { "http://brickellbio.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Debt Securities, Available-for-Sale, Accretion Of Discount", "label": "Debt Securities, Available-for-Sale, Accretion Of Discount", "negatedTerseLabel": "Accretion of discount on marketable securities" } } }, "localname": "DebtSecuritiesAvailableforSaleAccretionOfDiscount", "nsuri": "http://brickellbio.com/20190930", "presentation": [ "http://brickellbio.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "bbi_EquityIncentivePlan2009Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Equity Incentive Plan 2009 [Member]", "label": "Equity Incentive Plan 2009 [Member]", "terseLabel": "2009 Plan" } } }, "localname": "EquityIncentivePlan2009Member", "nsuri": "http://brickellbio.com/20190930", "presentation": [ "http://brickellbio.com/role/CapitalStockReservedAuthorizedSharesOfCommonStockDetails", "http://brickellbio.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "bbi_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityIncreaseDecreaseInFairValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Increase (Decrease) In Fair Value", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Increase (Decrease) In Fair Value", "terseLabel": "Change in fair value" } } }, "localname": "FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityIncreaseDecreaseInFairValue", "nsuri": "http://brickellbio.com/20190930", "presentation": [ "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesReconciliationOfLevel3FinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "bbi_FundingCommitmentWarrantsIssued": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Funding Commitment, Warrants Issued", "label": "Funding Commitment, Warrants Issued", "terseLabel": "Warrants to purchase common stock issued with funding agreement" } } }, "localname": "FundingCommitmentWarrantsIssued", "nsuri": "http://brickellbio.com/20190930", "presentation": [ "http://brickellbio.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "bbi_HerculesCapitalWarrantsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Hercules Capital Warrants [Member]", "label": "Hercules Capital Warrants [Member]", "terseLabel": "Hercules Capital Warrants" } } }, "localname": "HerculesCapitalWarrantsMember", "nsuri": "http://brickellbio.com/20190930", "presentation": [ "http://brickellbio.com/role/NotePayableNarrativeDetails" ], "xbrltype": "domainItemType" }, "bbi_IncreaseDecreaseInOperatingLeaseLiability": { "auth_ref": [], "calculation": { "http://brickellbio.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Increase (Decrease) In Operating Lease Liability", "label": "Increase (Decrease) In Operating Lease Liability", "terseLabel": "Lease liability" } } }, "localname": "IncreaseDecreaseInOperatingLeaseLiability", "nsuri": "http://brickellbio.com/20190930", "presentation": [ "http://brickellbio.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "bbi_InterestRateOptionOneMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Interest Rate Option One [Member]", "label": "Interest Rate Option One [Member]", "terseLabel": "Interest Rate Option 1" } } }, "localname": "InterestRateOptionOneMember", "nsuri": "http://brickellbio.com/20190930", "presentation": [ "http://brickellbio.com/role/NotePayableNarrativeDetails" ], "xbrltype": "domainItemType" }, "bbi_InterestRateOptionTwoMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Interest Rate Option Two [Member]", "label": "Interest Rate Option Two [Member]", "terseLabel": "Interest Rate Option 2" } } }, "localname": "InterestRateOptionTwoMember", "nsuri": "http://brickellbio.com/20190930", "presentation": [ "http://brickellbio.com/role/NotePayableNarrativeDetails" ], "xbrltype": "domainItemType" }, "bbi_LesseeOperatingLeaseAnnualIncrease": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Lessee, Operating Lease, Annual Increase", "label": "Lessee, Operating Lease, Annual Increase", "terseLabel": "Annual payment percentage increase" } } }, "localname": "LesseeOperatingLeaseAnnualIncrease", "nsuri": "http://brickellbio.com/20190930", "presentation": [ "http://brickellbio.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "percentItemType" }, "bbi_LesseeOperatingLeaseAreaLeased": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Lessee, Operating Lease, Area Leased", "label": "Lessee, Operating Lease, Area Leased", "terseLabel": "Area of leased property" } } }, "localname": "LesseeOperatingLeaseAreaLeased", "nsuri": "http://brickellbio.com/20190930", "presentation": [ "http://brickellbio.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "areaItemType" }, "bbi_LesseeOperatingLeaseMonthlyExpenses": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Lessee, Operating Lease, Monthly Expenses", "label": "Lessee, Operating Lease, Monthly Expenses", "terseLabel": "Monthly fees" } } }, "localname": "LesseeOperatingLeaseMonthlyExpenses", "nsuri": "http://brickellbio.com/20190930", "presentation": [ "http://brickellbio.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "bbi_LesseeOperatingLeaseMonthlyPaymentInitialYear": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Lessee, Operating Lease, Monthly Payment, Initial Year", "label": "Lessee, Operating Lease, Monthly Payment, Initial Year", "terseLabel": "Monthly payment, initial year" } } }, "localname": "LesseeOperatingLeaseMonthlyPaymentInitialYear", "nsuri": "http://brickellbio.com/20190930", "presentation": [ "http://brickellbio.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "bbi_LesseeOperatingLeaseNumberOfRenewalTerms": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Lessee, Operating Lease, Number Of Renewal Terms", "label": "Lessee, Operating Lease, Number Of Renewal Terms", "terseLabel": "Number of additional terms" } } }, "localname": "LesseeOperatingLeaseNumberOfRenewalTerms", "nsuri": "http://brickellbio.com/20190930", "presentation": [ "http://brickellbio.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "integerItemType" }, "bbi_MeasurementInputIndividualCumulativeAchievementProbabilitiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Measurement Input, Individual Cumulative Achievement Probabilities [Member]", "label": "Measurement Input, Individual Cumulative Achievement Probabilities [Member]", "terseLabel": "Individual cumulative achievement probabilities" } } }, "localname": "MeasurementInputIndividualCumulativeAchievementProbabilitiesMember", "nsuri": "http://brickellbio.com/20190930", "presentation": [ "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesFairValueMeasurementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "bbi_NovaQuestCapitalManagementLLCMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "NovaQuest Capital Management LLC [Member]", "label": "NovaQuest Capital Management LLC [Member]", "terseLabel": "NovaQuest" } } }, "localname": "NovaQuestCapitalManagementLLCMember", "nsuri": "http://brickellbio.com/20190930", "presentation": [ "http://brickellbio.com/role/NovaquestFundingArrangementNarrativeDetails", "http://brickellbio.com/role/OrganizationAndNatureOfOperationsNarrativeDetails" ], "xbrltype": "domainItemType" }, "bbi_NovaQuestWarrantsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "NovaQuest Warrants [Member]", "label": "NovaQuest Warrants [Member]", "terseLabel": "NovaQuest Warrants" } } }, "localname": "NovaQuestWarrantsMember", "nsuri": "http://brickellbio.com/20190930", "presentation": [ "http://brickellbio.com/role/NovaquestFundingArrangementNarrativeDetails" ], "xbrltype": "domainItemType" }, "bbi_OperatingLeaseRemainingLeaseTerm": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Operating Lease, Remaining Lease Term", "label": "Operating Lease, Remaining Lease Term", "terseLabel": "Remaining lease term" } } }, "localname": "OperatingLeaseRemainingLeaseTerm", "nsuri": "http://brickellbio.com/20190930", "presentation": [ "http://brickellbio.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "durationItemType" }, "bbi_PaymentsOfDebtExitCosts": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Payments Of Debt Exit Costs", "label": "Payments Of Debt Exit Costs", "terseLabel": "Payment of associated accrued interest and aggregate end-of-term payment" } } }, "localname": "PaymentsOfDebtExitCosts", "nsuri": "http://brickellbio.com/20190930", "presentation": [ "http://brickellbio.com/role/NotePayableNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "bbi_ProceedsFromResearchandDevelopmentArrangementFundingAgreement": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Proceeds From Research and Development Arrangement, Funding Agreement", "label": "Proceeds From Research and Development Arrangement, Funding Agreement", "terseLabel": "Commitment funding amount" } } }, "localname": "ProceedsFromResearchandDevelopmentArrangementFundingAgreement", "nsuri": "http://brickellbio.com/20190930", "presentation": [ "http://brickellbio.com/role/NovaquestFundingArrangementNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "bbi_RedeemableConvertiblePreferredStockAndPreferredStockDividendsToCommonStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Redeemable Convertible Preferred Stock And Preferred Stock Dividends To Common Stock [Member]", "label": "Redeemable Convertible Preferred Stock And Preferred Stock Dividends To Common Stock [Member]", "terseLabel": "Redeemable Convertible Preferred Stock and Preferred Stock Dividends to Common Stock" } } }, "localname": "RedeemableConvertiblePreferredStockAndPreferredStockDividendsToCommonStockMember", "nsuri": "http://brickellbio.com/20190930", "presentation": [ "http://brickellbio.com/role/CondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "bbi_RedeemableConvertiblePreferredStockWarrantLiabilityMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Redeemable Convertible Preferred Stock Warrant Liability [Member]", "label": "Redeemable Convertible Preferred Stock Warrant Liability [Member]", "terseLabel": "Redeemable Convertible Preferred Stock Warrant Liability" } } }, "localname": "RedeemableConvertiblePreferredStockWarrantLiabilityMember", "nsuri": "http://brickellbio.com/20190930", "presentation": [ "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesReconciliationOfLevel3FinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "bbi_ResearchAndDevelopmentArrangementContractToPerformForOthersFundingCommitment": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Research And Development Arrangement, Contract To Perform For Others, Funding Commitment", "label": "Research And Development Arrangement, Contract To Perform For Others, Funding Commitment", "terseLabel": "Commitment amount" } } }, "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersFundingCommitment", "nsuri": "http://brickellbio.com/20190930", "presentation": [ "http://brickellbio.com/role/NovaquestFundingArrangementNarrativeDetails", "http://brickellbio.com/role/OrganizationAndNatureOfOperationsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "bbi_ResearchandDevelopmentArrangementContractToPerformForOthersMonthlyDistributionPercentOfInvoicedResearchAndDevelopment": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Research and Development Arrangement, Contract To Perform For Others, Monthly Distribution, Percent Of Invoiced Research And Development", "label": "Research and Development Arrangement, Contract To Perform For Others, Monthly Distribution, Percent Of Invoiced Research And Development", "terseLabel": "Monthly distribution amount as percent of invoiced R&D" } } }, "localname": "ResearchandDevelopmentArrangementContractToPerformForOthersMonthlyDistributionPercentOfInvoicedResearchAndDevelopment", "nsuri": "http://brickellbio.com/20190930", "presentation": [ "http://brickellbio.com/role/NovaquestFundingArrangementNarrativeDetails" ], "xbrltype": "percentItemType" }, "bbi_ResearchandDevelopmentArrangementContractToPerformForOthersPotentialMilestonePayments": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Research and Development Arrangement, Contract To Perform For Others, Potential Milestone Payments", "label": "Research and Development Arrangement, Contract To Perform For Others, Potential Milestone Payments", "terseLabel": "Potential milestone payments" } } }, "localname": "ResearchandDevelopmentArrangementContractToPerformForOthersPotentialMilestonePayments", "nsuri": "http://brickellbio.com/20190930", "presentation": [ "http://brickellbio.com/role/NovaquestFundingArrangementNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "bbi_ResearchandDevelopmentArrangementContractToPerformForOthersPotentialMilestonePaymentsDueUponApproval": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Research and Development Arrangement, Contract To Perform For Others, Potential Milestone Payments, Due Upon Approval", "label": "Research and Development Arrangement, Contract To Perform For Others, Potential Milestone Payments, Due Upon Approval", "terseLabel": "Potential milestone payments due upon approval" } } }, "localname": "ResearchandDevelopmentArrangementContractToPerformForOthersPotentialMilestonePaymentsDueUponApproval", "nsuri": "http://brickellbio.com/20190930", "presentation": [ "http://brickellbio.com/role/NovaquestFundingArrangementNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "bbi_ResearchandDevelopmentArrangementContractToPerformForOthersTerminationAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Research and Development Arrangement, Contract To Perform For Others, Termination Amount", "label": "Research and Development Arrangement, Contract To Perform For Others, Termination Amount", "terseLabel": "Termination amount" } } }, "localname": "ResearchandDevelopmentArrangementContractToPerformForOthersTerminationAmount", "nsuri": "http://brickellbio.com/20190930", "presentation": [ "http://brickellbio.com/role/NovaquestFundingArrangementNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "bbi_ResearchandDevelopmentArrangementContractToPerformForOthersTerminationAmountInterestRate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Research and Development Arrangement, Contract To Perform For Others, Termination Amount, Interest Rate", "label": "Research and Development Arrangement, Contract To Perform For Others, Termination Amount, Interest Rate", "terseLabel": "Termination amount, interest rate" } } }, "localname": "ResearchandDevelopmentArrangementContractToPerformForOthersTerminationAmountInterestRate", "nsuri": "http://brickellbio.com/20190930", "presentation": [ "http://brickellbio.com/role/NovaquestFundingArrangementNarrativeDetails" ], "xbrltype": "percentItemType" }, "bbi_RevenueFromContractWithCustomerContractModificationBasisPointReduction": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Revenue From Contract With Customer, Contract Modification, Basis Point Reduction", "label": "Revenue From Contract With Customer, Contract Modification, Basis Point Reduction", "terseLabel": "Basis point reduction" } } }, "localname": "RevenueFromContractWithCustomerContractModificationBasisPointReduction", "nsuri": "http://brickellbio.com/20190930", "presentation": [ "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionNarrativeDetails" ], "xbrltype": "percentItemType" }, "bbi_RevenueFromContractWithCustomerTerm": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Revenue From Contract With Customer, Term", "label": "Revenue From Contract With Customer, Term", "terseLabel": "Expected performance period" } } }, "localname": "RevenueFromContractWithCustomerTerm", "nsuri": "http://brickellbio.com/20190930", "presentation": [ "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionNarrativeDetails" ], "xbrltype": "durationItemType" }, "bbi_SeriesC1PreferredStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Series C-1 Preferred Stock [Member]", "label": "Series C-1 Preferred Stock [Member]", "terseLabel": "Series C-1" } } }, "localname": "SeriesC1PreferredStockMember", "nsuri": "http://brickellbio.com/20190930", "presentation": [ "http://brickellbio.com/role/CapitalStockSummaryOfPreferredStockDetails" ], "xbrltype": "domainItemType" }, "bbi_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesAuthorizedForGrantInOneYear": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-based Compensation Arrangement By Share-based Payment Award, Number Of Shares Authorized For Grant In One Year", "label": "Share-based Compensation Arrangement By Share-based Payment Award, Number Of Shares Authorized For Grant In One Year", "terseLabel": "Maximum shares permitted to be granted in a single calendar year (in shares)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesAuthorizedForGrantInOneYear", "nsuri": "http://brickellbio.com/20190930", "presentation": [ "http://brickellbio.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "bbi_SharebasedPaymentArrangementOptionAvailableForGrantMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-based Payment Arrangement, Option - Available For Grant [Member]", "label": "Share-based Payment Arrangement, Option - Available For Grant [Member]", "terseLabel": "Options available for grant under the 2009 Plan" } } }, "localname": "SharebasedPaymentArrangementOptionAvailableForGrantMember", "nsuri": "http://brickellbio.com/20190930", "presentation": [ "http://brickellbio.com/role/CapitalStockReservedAuthorizedSharesOfCommonStockDetails" ], "xbrltype": "domainItemType" }, "bbi_SharebasedPaymentArrangementOptionOutstandingMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-based Payment Arrangement, Option - Outstanding [Member]", "label": "Share-based Payment Arrangement, Option - Outstanding [Member]", "terseLabel": "Common stock options outstanding" } } }, "localname": "SharebasedPaymentArrangementOptionOutstandingMember", "nsuri": "http://brickellbio.com/20190930", "presentation": [ "http://brickellbio.com/role/CapitalStockReservedAuthorizedSharesOfCommonStockDetails" ], "xbrltype": "domainItemType" }, "bbi_SharesIssuedInRecapitalization": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Shares Issued In Recapitalization", "label": "Shares Issued In Recapitalization", "terseLabel": "Shares issued in recapitalization" } } }, "localname": "SharesIssuedInRecapitalization", "nsuri": "http://brickellbio.com/20190930", "presentation": [ "http://brickellbio.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "bbi_SublicensingCostsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Sublicensing Costs [Member]", "label": "Sublicensing Costs [Member]", "terseLabel": "Sublicensing Costs" } } }, "localname": "SublicensingCostsMember", "nsuri": "http://brickellbio.com/20190930", "presentation": [ "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionNarrativeDetails" ], "xbrltype": "domainItemType" }, "bbi_TemporaryEquityAccretionOfStockIssuanceCosts": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Temporary Equity, Accretion Of Stock Issuance Costs", "label": "Temporary Equity, Accretion Of Stock Issuance Costs", "terseLabel": "Accretion of redeemable convertible preferred stock issuance costs" } } }, "localname": "TemporaryEquityAccretionOfStockIssuanceCosts", "nsuri": "http://brickellbio.com/20190930", "presentation": [ "http://brickellbio.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "bbi_TemporaryEquityAccretionReductionToRedemptionValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Temporary Equity, Accretion (Reduction) To Redemption Value", "label": "Temporary Equity, Accretion (Reduction) To Redemption Value", "terseLabel": "Reduction of redeemable convertible preferred stock to redemption value", "verboseLabel": "Accretion (reduction) of redeemable convertible preferred stock to redemption value" } } }, "localname": "TemporaryEquityAccretionReductionToRedemptionValue", "nsuri": "http://brickellbio.com/20190930", "presentation": [ "http://brickellbio.com/role/CondensedConsolidatedStatementsOfCashFlows", "http://brickellbio.com/role/CondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "bbi_TemporaryEquityPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Temporary Equity, Policy [Policy Text Block]", "label": "Temporary Equity, Policy [Policy Text Block]", "terseLabel": "Redeemable Convertible Preferred Stock and Warrants" } } }, "localname": "TemporaryEquityPolicyPolicyTextBlock", "nsuri": "http://brickellbio.com/20190930", "presentation": [ "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "bbi_TemporaryStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Temporary Stock Issued During Period, Shares, Conversion Of Convertible Securities", "label": "Temporary Stock Issued During Period, Shares, Conversion Of Convertible Securities", "negatedTerseLabel": "Shares converted (in shares)", "terseLabel": "Common Stock Issued Upon Conversion (in shares)" } } }, "localname": "TemporaryStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "nsuri": "http://brickellbio.com/20190930", "presentation": [ "http://brickellbio.com/role/CapitalStockSummaryOfPreferredStockDetails", "http://brickellbio.com/role/CondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "bbi_TemporaryStockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Temporary Stock Issued During Period, Value, Conversion Of Convertible Securities", "label": "Temporary Stock Issued During Period, Value, Conversion Of Convertible Securities", "negatedTerseLabel": "Shares converted", "terseLabel": "Conversion of redeemable convertible preferred stock and preferred stock dividends to common stock" } } }, "localname": "TemporaryStockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "nsuri": "http://brickellbio.com/20190930", "presentation": [ "http://brickellbio.com/role/CondensedConsolidatedStatementsOfCashFlows", "http://brickellbio.com/role/CondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "bbi_VicalFormerSecurityholdersMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Vical Former Securityholders [Member]", "label": "Vical Former Securityholders [Member]", "terseLabel": "Vical Former Securityholders" } } }, "localname": "VicalFormerSecurityholdersMember", "nsuri": "http://brickellbio.com/20190930", "presentation": [ "http://brickellbio.com/role/OrganizationAndNatureOfOperationsNarrativeDetails" ], "xbrltype": "domainItemType" }, "bbi_VicalMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Vical [Member]", "label": "Vical [Member]", "terseLabel": "Vical" } } }, "localname": "VicalMember", "nsuri": "http://brickellbio.com/20190930", "presentation": [ "http://brickellbio.com/role/OrganizationAndNatureOfOperationsNarrativeDetails", "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesMergerNarrativeDetails", "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfNetAssetsAcquiredDetails" ], "xbrltype": "domainItemType" }, "bbi_VicalStockIncentivePlanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Vical Stock Incentive Plan [Member]", "label": "Vical Stock Incentive Plan [Member]", "terseLabel": "Vical Plan" } } }, "localname": "VicalStockIncentivePlanMember", "nsuri": "http://brickellbio.com/20190930", "presentation": [ "http://brickellbio.com/role/CapitalStockReservedAuthorizedSharesOfCommonStockDetails", "http://brickellbio.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "bbi_VicalWarrantsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Vical Warrants [Member]", "label": "Vical Warrants [Member]", "terseLabel": "Vical Warrants [Member]" } } }, "localname": "VicalWarrantsMember", "nsuri": "http://brickellbio.com/20190930", "presentation": [ "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesMergerNarrativeDetails" ], "xbrltype": "domainItemType" }, "bbi_WarrantLiability": { "auth_ref": [], "calculation": { "http://brickellbio.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesFairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Warrant Liability", "label": "Warrant Liability", "terseLabel": "Warrant liability" } } }, "localname": "WarrantLiability", "nsuri": "http://brickellbio.com/20190930", "presentation": [ "http://brickellbio.com/role/CondensedConsolidatedBalanceSheets", "http://brickellbio.com/role/ConvertiblePromissoryNotesNarrativeDetails", "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesFairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://brickellbio.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://brickellbio.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://brickellbio.com/role/CoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://brickellbio.com/role/CoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://brickellbio.com/role/CoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://brickellbio.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r256" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://brickellbio.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r257" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://brickellbio.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://brickellbio.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://brickellbio.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://brickellbio.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://brickellbio.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://brickellbio.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r258" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://brickellbio.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://brickellbio.com/role/CoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://brickellbio.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]", "terseLabel": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://brickellbio.com/role/OrganizationAndNatureOfOperationsNarrativeDetails" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r258" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://brickellbio.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://brickellbio.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r258" ], "lang": { "en-US": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://brickellbio.com/role/CoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://brickellbio.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r259" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://brickellbio.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r258" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://brickellbio.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r258" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://brickellbio.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r258" ], "lang": { "en-US": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://brickellbio.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r258" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://brickellbio.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]", "terseLabel": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://brickellbio.com/role/OrganizationAndNatureOfOperationsNarrativeDetails" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://brickellbio.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r254" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://brickellbio.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r255" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://brickellbio.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://brickellbio.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r41", "r86" ], "lang": { "en-US": { "role": { "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://brickellbio.com/role/NovaquestFundingArrangementNarrativeDetails", "http://brickellbio.com/role/OrganizationAndNatureOfOperationsNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://brickellbio.com/role/NovaquestFundingArrangementNarrativeDetails", "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesFairValueMeasurementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://brickellbio.com/role/NovaquestFundingArrangementNarrativeDetails", "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesFairValueMeasurementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_OwnershipAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Ownership [Axis]", "terseLabel": "Ownership [Axis]" } } }, "localname": "OwnershipAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://brickellbio.com/role/OrganizationAndNatureOfOperationsNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_OwnershipDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Ownership [Domain]", "terseLabel": "Ownership [Domain]" } } }, "localname": "OwnershipDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://brickellbio.com/role/OrganizationAndNatureOfOperationsNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r116", "r160", "r162", "r249", "r250" ], "lang": { "en-US": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://brickellbio.com/role/NovaquestFundingArrangementNarrativeDetails", "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesFairValueMeasurementsNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://brickellbio.com/role/NovaquestFundingArrangementNarrativeDetails", "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesFairValueMeasurementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Counterparty Name [Domain]", "terseLabel": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://brickellbio.com/role/NovaquestFundingArrangementNarrativeDetails", "http://brickellbio.com/role/OrganizationAndNatureOfOperationsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingChangesTextBlock": { "auth_ref": [ "r96" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for reporting accounting changes, excludes error corrections information.", "label": "Accounting Changes [Text Block]", "verboseLabel": "RECENT ACCOUNTING PRONOUNCEMENTS" } } }, "localname": "AccountingChangesTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/RecentAccountingPronouncements" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountingStandardsUpdate201409Member": { "auth_ref": [ "r163" ], "lang": { "en-US": { "role": { "documentation": "Accounting Standards Update 2014-09 Revenue from Contracts with Customers (Topic 606).", "label": "Accounting Standards Update 2014-09 [Member]", "terseLabel": "Accounting Standards Update 2014-09" } } }, "localname": "AccountingStandardsUpdate201409Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit", "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingStandardsUpdate201602Member": { "auth_ref": [ "r220" ], "lang": { "en-US": { "role": { "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).", "label": "Accounting Standards Update 2016-02 [Member]", "terseLabel": "Topic 842" } } }, "localname": "AccountingStandardsUpdate201602Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/RecentAccountingPronouncementsEffectsOfTopic842Details" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "auth_ref": [ "r23" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.", "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]", "terseLabel": "ACCRUED LIABILITIES" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/AccruedLiabilities" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r22" ], "calculation": { "http://brickellbio.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r27" ], "calculation": { "http://brickellbio.com/role/AccruedLiabilitiesSummaryOfAccruedLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://brickellbio.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "terseLabel": "Accrued liabilities", "totalLabel": "Accrued liabilities" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/AccruedLiabilitiesSummaryOfAccruedLiabilitiesDetails", "http://brickellbio.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedProfessionalFeesCurrent": { "auth_ref": [ "r4", "r5", "r27" ], "calculation": { "http://brickellbio.com/role/AccruedLiabilitiesSummaryOfAccruedLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Professional Fees, Current", "terseLabel": "Accrued professional fees" } } }, "localname": "AccruedProfessionalFeesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/AccruedLiabilitiesSummaryOfAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r45", "r47", "r48" ], "calculation": { "http://brickellbio.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r44", "r48", "r49", "r198" ], "lang": { "en-US": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r14" ], "calculation": { "http://brickellbio.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-In Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "auth_ref": [ "r93" ], "lang": { "en-US": { "role": { "documentation": "Information by new accounting pronouncement.", "label": "Adjustments for New Accounting Pronouncements [Axis]", "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]" } } }, "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit", "http://brickellbio.com/role/RecentAccountingPronouncementsEffectsOfTopic842Details", "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r168", "r170", "r182", "r183" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Stock based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": { "auth_ref": [ "r134", "r146", "r153" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.", "label": "Adjustments to Additional Paid in Capital, Warrant Issued", "terseLabel": "Common stock warrants issued in connection with the research and development funding liability" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash provided by (used in) operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r170", "r178", "r181" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-based Payment Arrangement, Expense", "terseLabel": "Share-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/StockBasedCompensationShareBasedCompensationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfDebtDiscountPremium": { "auth_ref": [ "r60", "r74", "r216" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.", "label": "Amortization of Debt Discount (Premium)", "verboseLabel": "Accretion of discounts" } } }, "localname": "AmortizationOfDebtDiscountPremium", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/ConvertiblePromissoryNotesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCostsAndDiscounts": { "auth_ref": [ "r74", "r218" ], "calculation": { "http://brickellbio.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.", "label": "Amortization of Debt Issuance Costs and Discounts", "terseLabel": "Amortization of debt discounts and financing costs" } } }, "localname": "AmortizationOfFinancingCostsAndDiscounts", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CondensedConsolidatedStatementsOfCashFlows", "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesRedeemableConvertiblePreferredStockNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r99" ], "lang": { "en-US": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Shares excluded from the calculation of EPS (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfCommonSharesExcludedFromEpsCalculationsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r99" ], "lang": { "en-US": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfCommonSharesExcludedFromEpsCalculationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfCommonSharesExcludedFromEpsCalculationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r99" ], "lang": { "en-US": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]", "terseLabel": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfCommonSharesExcludedFromEpsCalculationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]" } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r115", "r235", "r243" ], "calculation": { "http://brickellbio.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r2", "r3", "r38" ], "calculation": { "http://brickellbio.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r200" ], "calculation": { "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesFairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "totalLabel": "Total" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesFairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets, Fair Value Disclosure [Abstract]", "terseLabel": "Assets:" } } }, "localname": "AssetsFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesFairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [ "r123" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax", "terseLabel": "Marketable securities, available-for-sale, accumulated unrealized gain" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesFairValueMeasurementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "auth_ref": [ "r121", "r124" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Amortized Cost", "terseLabel": "Marketable securities, available-for-sale, amortized cost" } } }, "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesFairValueMeasurementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r118", "r122", "r124" ], "calculation": { "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesFairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails": { "order": 2.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale", "terseLabel": "U.S. treasuries" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesFairValueMeasurementsNarrativeDetails", "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesFairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": { "auth_ref": [ "r120", "r124" ], "calculation": { "http://brickellbio.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.", "label": "Debt Securities, Available-for-sale, Current", "terseLabel": "Marketable securities, available-for-sale" } } }, "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r171", "r179" ], "lang": { "en-US": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CapitalStockReservedAuthorizedSharesOfCommonStockDetails", "http://brickellbio.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesMergerNarrativeDetails", "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfNetAssetsAcquiredDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r188", "r189" ], "lang": { "en-US": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesMergerNarrativeDetails", "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfNetAssetsAcquiredDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition [Line Items]", "terseLabel": "Business Acquisition [Line Items]" } } }, "localname": "BusinessAcquisitionLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/OrganizationAndNatureOfOperationsNarrativeDetails", "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesMergerNarrativeDetails", "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfNetAssetsAcquiredDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "auth_ref": [ "r193", "r194", "r196" ], "calculation": { "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesFairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.", "label": "Business Combination, Contingent Consideration, Liability", "terseLabel": "Contingent consideration" } } }, "localname": "BusinessCombinationContingentConsiderationLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesFairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput": { "auth_ref": [ "r205" ], "lang": { "en-US": { "role": { "documentation": "Value of input used to measure contingent consideration liability from business combination.", "label": "Business Combination, Contingent Consideration, Liability, Measurement Input", "terseLabel": "Contingent consideration, measurement input" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInput", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesFairValueMeasurementsNarrativeDetails" ], "xbrltype": "decimalItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": { "auth_ref": [ "r193", "r195" ], "calculation": { "http://brickellbio.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.", "label": "Business Combination, Contingent Consideration, Liability, Noncurrent", "terseLabel": "Contingent consideration" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": { "auth_ref": [ "r191" ], "calculation": { "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfNetAssetsAcquiredDetails": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents", "terseLabel": "Cash and cash equivalents" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfNetAssetsAcquiredDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities": { "auth_ref": [ "r191" ], "calculation": { "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfNetAssetsAcquiredDetails": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investments in debt and equity securities, including, but not limited to, held-to-maturity, trading and available-for-sale expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Marketable Securities", "terseLabel": "Marketable securities" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfNetAssetsAcquiredDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": { "auth_ref": [ "r191" ], "calculation": { "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfNetAssetsAcquiredDetails": { "order": 3.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfNetAssetsAcquiredDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities": { "auth_ref": [ "r191" ], "calculation": { "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfNetAssetsAcquiredDetails": { "order": 4.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities", "negatedTerseLabel": "Accrued liabilities" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfNetAssetsAcquiredDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": { "auth_ref": [ "r190", "r191" ], "calculation": { "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfNetAssetsAcquiredDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net", "terseLabel": "Net acquired tangible assets", "totalLabel": "Net acquired tangible assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesMergerNarrativeDetails", "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfNetAssetsAcquiredDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAcquiredFromAcquisition": { "auth_ref": [ "r63" ], "calculation": { "http://brickellbio.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).", "label": "Cash Acquired from Acquisition", "terseLabel": "Cash and cash equivalents acquired in recapitalization" } } }, "localname": "CashAcquiredFromAcquisition", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r1", "r21", "r76" ], "calculation": { "http://brickellbio.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "calculation": { "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesFairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails": { "order": 1.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "terseLabel": "Money market funds" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesFairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsAndShortTermInvestments": { "auth_ref": [ "r21" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.", "label": "Cash, Cash Equivalents, and Short-term Investments", "terseLabel": "Cash, cash equivalents and marketable securities" } } }, "localname": "CashCashEquivalentsAndShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/OrganizationAndNatureOfOperationsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r70", "r76", "r81" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "CASH AND CASH EQUIVALENTS\u2014ENDING", "periodStartLabel": "CASH AND CASH EQUIVALENTS\u2014BEGINNING" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r70", "r214" ], "calculation": { "http://brickellbio.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]", "terseLabel": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]" } } }, "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CapitalStockNarrativeDetails", "http://brickellbio.com/role/CapitalStockSummaryOfPreferredStockDetails", "http://brickellbio.com/role/CondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit", "http://brickellbio.com/role/ConvertiblePromissoryNotesNarrativeDetails", "http://brickellbio.com/role/OrganizationAndNatureOfOperationsNarrativeDetails", "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesRedeemableConvertiblePreferredStockNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]", "terseLabel": "Class of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CapitalStockNarrativeDetails", "http://brickellbio.com/role/CapitalStockReservedAuthorizedSharesOfCommonStockDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightAxis": { "auth_ref": [ "r91", "r155", "r169" ], "lang": { "en-US": { "role": { "documentation": "Information by type of warrant or right issued.", "label": "Class of Warrant or Right [Axis]", "terseLabel": "Class of Warrant or Right [Axis]" } } }, "localname": "ClassOfWarrantOrRightAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/NotePayableNarrativeDetails", "http://brickellbio.com/role/NovaquestFundingArrangementNarrativeDetails", "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesMergerNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightDomain": { "auth_ref": [ "r85" ], "lang": { "en-US": { "role": { "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.", "label": "Class of Warrant or Right [Domain]", "terseLabel": "Class of Warrant or Right [Domain]" } } }, "localname": "ClassOfWarrantOrRightDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/NotePayableNarrativeDetails", "http://brickellbio.com/role/NovaquestFundingArrangementNarrativeDetails", "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesMergerNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r90" ], "lang": { "en-US": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "terseLabel": "Exercise price (in usd per share)" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/ConvertiblePromissoryNotesNarrativeDetails", "http://brickellbio.com/role/NovaquestFundingArrangementNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "auth_ref": [ "r89" ], "lang": { "en-US": { "role": { "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.", "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "terseLabel": "Stock issuable upon warrants (in shares)" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/ConvertiblePromissoryNotesNarrativeDetails", "http://brickellbio.com/role/NovaquestFundingArrangementNarrativeDetails", "http://brickellbio.com/role/OrganizationAndNatureOfOperationsNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CollaborativeArrangementMember": { "auth_ref": [ "r197" ], "lang": { "en-US": { "role": { "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.", "label": "Collaborative Arrangement [Member]", "terseLabel": "Collaborative Arrangement" } } }, "localname": "CollaborativeArrangementMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]" } } }, "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r32", "r131", "r238", "r247" ], "calculation": { "http://brickellbio.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies (Note 8)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r130", "r132" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "COMMITMENTS AND CONTINGENCIES" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r35" ], "lang": { "en-US": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "terseLabel": "Shares of common stock reserved for future issuance" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CapitalStockReservedAuthorizedSharesOfCommonStockDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CapitalStockNarrativeDetails", "http://brickellbio.com/role/CondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit", "http://brickellbio.com/role/ConvertiblePromissoryNotesNarrativeDetails", "http://brickellbio.com/role/OrganizationAndNatureOfOperationsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r13" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in usd per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://brickellbio.com/role/OrganizationAndNatureOfOperationsNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r13" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r13" ], "lang": { "en-US": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://brickellbio.com/role/OrganizationAndNatureOfOperationsNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r13", "r146" ], "lang": { "en-US": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "periodEndLabel": "Ending Balance (in shares)", "periodStartLabel": "Beginning Balance (in shares)", "terseLabel": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://brickellbio.com/role/CondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit", "http://brickellbio.com/role/OrganizationAndNatureOfOperationsNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r13" ], "calculation": { "http://brickellbio.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock, $0.01 par value, 50,000,000 and 8,000,000 shares authorized at September 30, 2019 and December 31, 2018, respectively; 7,810,680 and 589,001 issued and outstanding at September 30, 2019 and December 31, 2018, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r51", "r53", "r54" ], "calculation": { "http://brickellbio.com/role/CondensedConsolidatedStatmentsOfComprehensiveLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Total comprehensive loss" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CondensedConsolidatedStatmentsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "auth_ref": [ "r157", "r158", "r161" ], "calculation": { "http://brickellbio.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.", "label": "Contract with Customer, Liability, Current", "terseLabel": "Deferred revenue, current portion" } } }, "localname": "ContractWithCustomerLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CondensedConsolidatedBalanceSheets", "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityNoncurrent": { "auth_ref": [ "r157", "r158", "r161" ], "calculation": { "http://brickellbio.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.", "label": "Contract with Customer, Liability, Noncurrent", "terseLabel": "Deferred revenue, net of current portion" } } }, "localname": "ContractWithCustomerLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConversionOfStockByUniqueDescriptionAxis": { "auth_ref": [ "r78", "r79", "r80" ], "lang": { "en-US": { "role": { "documentation": "Information by description of stock conversions.", "label": "Stock Conversion Description [Axis]", "terseLabel": "Stock Conversion Description [Axis]" } } }, "localname": "ConversionOfStockByUniqueDescriptionAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_ConversionOfStockNameDomain": { "auth_ref": [ "r78", "r79", "r80" ], "lang": { "en-US": { "role": { "documentation": "The unique name of a noncash or part noncash stock conversion.", "label": "Conversion of Stock, Name [Domain]", "terseLabel": "Conversion of Stock, Name [Domain]" } } }, "localname": "ConversionOfStockNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_ConversionOfStockSharesConverted1": { "auth_ref": [ "r78", "r79", "r80" ], "lang": { "en-US": { "role": { "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Conversion of Stock, Shares Converted", "terseLabel": "Warrants converted (in shares)" } } }, "localname": "ConversionOfStockSharesConverted1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/NotePayableNarrativeDetails", "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesMergerNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ConvertibleDebtSecuritiesMember": { "auth_ref": [ "r165" ], "lang": { "en-US": { "role": { "documentation": "Debt securities that can be exchanged for equity of the debt issuer at the option of the issuer or the holder.", "label": "Convertible Debt Securities [Member]", "terseLabel": "Warrants to purchase redeemable convertible preferred stock (as converted into common stock)" } } }, "localname": "ConvertibleDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfCommonSharesExcludedFromEpsCalculationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConvertibleNotesPayableMember": { "auth_ref": [ "r9", "r236", "r242", "r251" ], "lang": { "en-US": { "role": { "documentation": "Written promise to pay a note which can be exchanged for a specified quantity of securities (typically common stock), at the option of the issuer or the holder.", "label": "Convertible Notes Payable [Member]", "terseLabel": "Convertible Promissory Notes" } } }, "localname": "ConvertibleNotesPayableMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/ConvertiblePromissoryNotesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) to equity or (increase) decrease to net assets, resulting from the cumulative effect adjustment of a new accounting principle applied in the period of adoption.", "label": "Cumulative Effect of New Accounting Principle in Period of Adoption", "terseLabel": "Effect of adoption of Topic 606" } } }, "localname": "CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit", "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": { "auth_ref": [ "r78", "r80" ], "lang": { "en-US": { "role": { "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period.", "label": "Debt Conversion, Converted Instrument, Shares Issued", "terseLabel": "Shares issued in conversion (in shares)" } } }, "localname": "DebtConversionConvertedInstrumentSharesIssued1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/ConvertiblePromissoryNotesNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r140" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "CONVERTIBLE PROMISSORY NOTES", "verboseLabel": "NOTE PAYABLE" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/ConvertiblePromissoryNotes", "http://brickellbio.com/role/NotePayable" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.", "label": "Debt Instrument, Basis Spread on Variable Rate", "terseLabel": "Basis spread on variable rate" } } }, "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/NotePayableNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentConvertibleConversionPrice1": { "auth_ref": [ "r135" ], "lang": { "en-US": { "role": { "documentation": "The price per share of the conversion feature embedded in the debt instrument.", "label": "Debt Instrument, Convertible, Conversion Price", "terseLabel": "Exercise price (in usd per share)", "verboseLabel": "Conversion price (in usd per share)" } } }, "localname": "DebtInstrumentConvertibleConversionPrice1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/ConvertiblePromissoryNotesNarrativeDetails", "http://brickellbio.com/role/NotePayableNarrativeDetails", "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesMergerNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_DebtInstrumentConvertibleStockPriceTrigger": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Price of the entity's common stock which would be required to be attained for the conversion feature embedded in the debt instrument to become effective.", "label": "Debt Instrument, Convertible, Stock Price Trigger", "terseLabel": "Share price threshold (in usd per share)" } } }, "localname": "DebtInstrumentConvertibleStockPriceTrigger", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/ConvertiblePromissoryNotesNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.", "label": "Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger", "terseLabel": "Conversion price as percent of price paid per share" } } }, "localname": "DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/ConvertiblePromissoryNotesNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r217", "r219" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "terseLabel": "Face amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/NotePayableNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "auth_ref": [ "r29", "r136", "r217" ], "lang": { "en-US": { "role": { "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.", "label": "Debt Instrument, Interest Rate, Effective Percentage", "terseLabel": "Effective rate" } } }, "localname": "DebtInstrumentInterestRateEffectivePercentage", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/ConvertiblePromissoryNotesNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r29" ], "lang": { "en-US": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Stated rate" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/ConvertiblePromissoryNotesNarrativeDetails", "http://brickellbio.com/role/NotePayableNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/NotePayableNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r30", "r88", "r147", "r150", "r151", "r152", "r216", "r217", "r219", "r241" ], "lang": { "en-US": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/NotePayableNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentTerm": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Debt Instrument, Term", "terseLabel": "Debt term" } } }, "localname": "DebtInstrumentTerm", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/ConvertiblePromissoryNotesNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r74", "r127" ], "calculation": { "http://brickellbio.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This item represents derivative instrument obligations meeting the definition of a liability which are reported as of the balance sheet date. Derivative instrument obligations are generally measured at fair value, and adjustments to the carrying amount of hedged items reflect changes in their fair value (that is, losses) that are attributable to the risk being hedged and that arise while the hedge is in effect.", "label": "Derivative Financial Instruments, Liabilities [Member]", "terseLabel": "Derivative Liability" } } }, "localname": "DerivativeFinancialInstrumentsLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesReconciliationOfLevel3FinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeLiabilities": { "auth_ref": [ "r39", "r40", "r213" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Liability", "verboseLabel": "Derivative liability, fair value" } } }, "localname": "DerivativeLiabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/ConvertiblePromissoryNotesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r184" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-based Payment Arrangement [Text Block]", "terseLabel": "STOCK-BASED COMPENSATION" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/StockBasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasicAndDiluted": { "auth_ref": [ "r98" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Basic and Diluted", "terseLabel": "Net loss per share attributable to common stockholders, basic and diluted (in usd per share)" } } }, "localname": "EarningsPerShareBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r82", "r99", "r100", "r101" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Net Income (Loss) per Common Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r27" ], "calculation": { "http://brickellbio.com/role/AccruedLiabilitiesSummaryOfAccruedLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Accrued compensation" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/AccruedLiabilitiesSummaryOfAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/StockBasedCompensationShareBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r176" ], "lang": { "en-US": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-based Payment Arrangement, Option [Member]", "terseLabel": "Options to purchase common stock", "verboseLabel": "Options" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/StockBasedCompensationNarrativeDetails", "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfCommonSharesExcludedFromEpsCalculationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r146" ], "lang": { "en-US": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit", "http://brickellbio.com/role/OrganizationAndNatureOfOperationsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAdjustmentOfWarrants": { "auth_ref": [ "r74", "r141" ], "calculation": { "http://brickellbio.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://brickellbio.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 5.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.", "label": "Fair Value Adjustment of Warrants", "negatedTerseLabel": "Change in fair value of warrant liability", "terseLabel": "Change in fair value of warrant liability" } } }, "localname": "FairValueAdjustmentOfWarrants", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CondensedConsolidatedStatementsOfCashFlows", "http://brickellbio.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesFairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r200", "r201", "r202", "r211" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesFairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": { "auth_ref": [ "r200", "r201", "r202", "r210", "r211" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.", "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]", "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]", "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesFairValueMeasurementInputsDetails", "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesFairValueMeasurementsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": { "auth_ref": [ "r203" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]", "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesFairValueMeasurementInputsDetails", "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesFairValueMeasurementsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": { "auth_ref": [ "r203" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]", "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r165", "r166", "r167", "r201", "r231" ], "lang": { "en-US": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesFairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByLiabilityClassAxis": { "auth_ref": [ "r209", "r211" ], "lang": { "en-US": { "role": { "documentation": "Information by class of liability.", "label": "Liability Class [Axis]", "terseLabel": "Liability Class [Axis]" } } }, "localname": "FairValueByLiabilityClassAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesReconciliationOfLevel3FinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r200", "r201", "r204", "r205", "r212" ], "lang": { "en-US": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesFairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r165", "r166", "r167", "r201", "r232" ], "lang": { "en-US": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level 1" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesFairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r165", "r166", "r167", "r201", "r233" ], "lang": { "en-US": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level 2" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesFairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r165", "r166", "r167", "r201", "r234" ], "lang": { "en-US": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level 3" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesFairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": { "auth_ref": [ "r206" ], "lang": { "en-US": { "role": { "documentation": "Represents classes of liabilities measured and disclosed at fair value.", "label": "Fair Value by Liability Class [Domain]", "terseLabel": "Fair Value by Liability Class [Domain]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesReconciliationOfLevel3FinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesReconciliationOfLevel3FinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]", "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesReconciliationOfLevel3FinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "auth_ref": [ "r206", "r211" ], "lang": { "en-US": { "role": { "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]", "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesReconciliationOfLevel3FinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "auth_ref": [ "r206", "r211" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesFairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.", "label": "Fair Value Measurement, Policy [Policy Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueMeasurementPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3": { "auth_ref": [ "r208" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of transfers of financial instrument classified as a liability out of level 3 of the fair value hierarchy.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers out of Level 3", "negatedTerseLabel": "Reclassification to equity" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesReconciliationOfLevel3FinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues": { "auth_ref": [ "r207" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances", "terseLabel": "Fair value of financial instruments issued" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesReconciliationOfLevel3FinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "auth_ref": [ "r206" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value", "periodEndLabel": "Ending Balance", "periodStartLabel": "Beginning Balance" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesReconciliationOfLevel3FinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesFairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r209", "r212" ], "lang": { "en-US": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]", "terseLabel": "Fair Value, Recurring" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesFairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "auth_ref": [ "r74", "r138", "r139" ], "calculation": { "http://brickellbio.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://brickellbio.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 6.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.", "label": "Gain (Loss) on Extinguishment of Debt", "negatedTerseLabel": "Gain on extinguishment", "terseLabel": "Gain on extinguishment" } } }, "localname": "GainsLossesOnExtinguishmentOfDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CondensedConsolidatedStatementsOfCashFlows", "http://brickellbio.com/role/CondensedConsolidatedStatementsOfOperations", "http://brickellbio.com/role/ConvertiblePromissoryNotesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r58" ], "calculation": { "http://brickellbio.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CondensedConsolidatedStatementsOfOperations", "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r57" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General and Administrative Expense [Member]", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/StockBasedCompensationShareBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r129" ], "lang": { "en-US": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/StockBasedCompensationShareBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/StockBasedCompensationShareBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r73" ], "calculation": { "http://brickellbio.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r73" ], "calculation": { "http://brickellbio.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "Increase (Decrease) in Accrued Liabilities", "terseLabel": "Accrued liabilities" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "auth_ref": [ "r73" ], "calculation": { "http://brickellbio.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Increase (Decrease) in Contract with Customer, Liability", "terseLabel": "Deferred revenue" } } }, "localname": "IncreaseDecreaseInContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": { "auth_ref": [], "calculation": { "http://brickellbio.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other.", "label": "Increase (Decrease) in Other Noncurrent Liabilities", "terseLabel": "Research and development funding liability" } } }, "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r73" ], "calculation": { "http://brickellbio.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedTerseLabel": "Prepaid expenses and other current assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInTemporaryEquityRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Temporary Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Temporary Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInTemporaryEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r125", "r126" ], "calculation": { "http://brickellbio.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "terseLabel": "Intangible assets" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r55", "r114", "r215", "r218", "r240" ], "calculation": { "http://brickellbio.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedTerseLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseDebt": { "auth_ref": [ "r60", "r137" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.", "label": "Interest Expense, Debt", "terseLabel": "Interest expense" } } }, "localname": "InterestExpenseDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/ConvertiblePromissoryNotesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r69", "r71", "r77" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Interest paid" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeInterest": { "auth_ref": [ "r59", "r113" ], "calculation": { "http://brickellbio.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.", "label": "Investment Income, Interest", "terseLabel": "Investment and other income, net" } } }, "localname": "InvestmentIncomeInterest", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCost": { "auth_ref": [ "r228", "r229" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lease cost recognized by lessee for lease contract.", "label": "Lease, Cost", "terseLabel": "Lease expense" } } }, "localname": "LeaseCost", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r223" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Lessee, Leases [Policy Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseDiscountRate": { "auth_ref": [ "r225" ], "lang": { "en-US": { "role": { "documentation": "Discount rate used by lessee to determine present value of operating lease payments.", "label": "Lessee, Operating Lease, Discount Rate", "terseLabel": "Discount rate" } } }, "localname": "LesseeOperatingLeaseDiscountRate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "auth_ref": [ "r224" ], "lang": { "en-US": { "role": { "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Renewal Term", "terseLabel": "Renewal term" } } }, "localname": "LesseeOperatingLeaseRenewalTerm", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "auth_ref": [ "r224" ], "lang": { "en-US": { "role": { "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Term of Contract", "terseLabel": "Lease term" } } }, "localname": "LesseeOperatingLeaseTermOfContract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r26" ], "calculation": { "http://brickellbio.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r18", "r237", "r245" ], "calculation": { "http://brickellbio.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities, redeemable convertible preferred stock, and stockholders\u2019 equity (deficit)" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities, redeemable convertible preferred stock, and stockholders\u2019 equity (deficit)" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r28" ], "calculation": { "http://brickellbio.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesFairValueAdjustment": { "auth_ref": [], "calculation": { "http://brickellbio.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://brickellbio.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 4.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of addition (reduction) to the amount at which a liability could be incurred (settled) in a current transaction between willing parties.", "label": "Liabilities, Fair Value Adjustment", "negatedTerseLabel": "Change in fair value of derivative liability", "terseLabel": "Change in fair value of derivative liability" } } }, "localname": "LiabilitiesFairValueAdjustment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CondensedConsolidatedStatementsOfCashFlows", "http://brickellbio.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesFairValueDisclosure": { "auth_ref": [ "r200" ], "calculation": { "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesFairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value of financial and nonfinancial obligations.", "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure", "totalLabel": "Total" } } }, "localname": "LiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesFairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities, Fair Value Disclosure [Abstract]", "terseLabel": "Liabilities:" } } }, "localname": "LiabilitiesFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesFairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r30" ], "lang": { "en-US": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/NotePayableNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r30", "r133" ], "lang": { "en-US": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/NotePayableNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputDiscountRateMember": { "auth_ref": [ "r203" ], "lang": { "en-US": { "role": { "documentation": "Measurement input using interest rate to determine present value of future cash flows.", "label": "Measurement Input, Discount Rate [Member]", "terseLabel": "Discount rate" } } }, "localname": "MeasurementInputDiscountRateMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesFairValueMeasurementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputExpectedDividendRateMember": { "auth_ref": [ "r203" ], "lang": { "en-US": { "role": { "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year.", "label": "Measurement Input, Expected Dividend Rate [Member]", "terseLabel": "Expected dividend yield" } } }, "localname": "MeasurementInputExpectedDividendRateMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/NovaquestFundingArrangementNarrativeDetails", "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesFairValueMeasurementInputsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputExpectedTermMember": { "auth_ref": [ "r203" ], "lang": { "en-US": { "role": { "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.", "label": "Measurement Input, Expected Term [Member]", "terseLabel": "Expected term (in years)" } } }, "localname": "MeasurementInputExpectedTermMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/NovaquestFundingArrangementNarrativeDetails", "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesFairValueMeasurementInputsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputPriceVolatilityMember": { "auth_ref": [ "r203" ], "lang": { "en-US": { "role": { "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.", "label": "Measurement Input, Price Volatility [Member]", "terseLabel": "Expected volatility" } } }, "localname": "MeasurementInputPriceVolatilityMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/NovaquestFundingArrangementNarrativeDetails", "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesFairValueMeasurementInputsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputRiskFreeInterestRateMember": { "auth_ref": [ "r203" ], "lang": { "en-US": { "role": { "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.", "label": "Measurement Input, Risk Free Interest Rate [Member]", "terseLabel": "Risk free interest rate" } } }, "localname": "MeasurementInputRiskFreeInterestRateMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/NovaquestFundingArrangementNarrativeDetails", "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesFairValueMeasurementInputsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputTypeAxis": { "auth_ref": [ "r203" ], "lang": { "en-US": { "role": { "documentation": "Information by type of measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Axis]", "terseLabel": "Measurement Input Type [Axis]" } } }, "localname": "MeasurementInputTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/NovaquestFundingArrangementNarrativeDetails", "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesFairValueMeasurementInputsDetails", "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesFairValueMeasurementsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Domain]", "terseLabel": "Measurement Input Type [Domain]" } } }, "localname": "MeasurementInputTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/NovaquestFundingArrangementNarrativeDetails", "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesFairValueMeasurementInputsDetails", "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesFairValueMeasurementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r70" ], "calculation": { "http://brickellbio.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by (used in) financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r70" ], "calculation": { "http://brickellbio.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash provided by (used in) investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r70", "r72", "r75" ], "calculation": { "http://brickellbio.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "terseLabel": "Net cash used in operating activities", "totalLabel": "Net cash provided by (used in) operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CondensedConsolidatedStatementsOfCashFlows", "http://brickellbio.com/role/OrganizationAndNatureOfOperationsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r50", "r52", "r56", "r75", "r100", "r239", "r248" ], "calculation": { "http://brickellbio.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://brickellbio.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0 }, "http://brickellbio.com/role/CondensedConsolidatedStatmentsOfComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "netLabel": "Net income (loss)", "terseLabel": "Net loss", "totalLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CondensedConsolidatedStatementsOfCashFlows", "http://brickellbio.com/role/CondensedConsolidatedStatementsOfOperations", "http://brickellbio.com/role/CondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit", "http://brickellbio.com/role/CondensedConsolidatedStatmentsOfComprehensiveLoss", "http://brickellbio.com/role/OrganizationAndNatureOfOperationsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r94", "r97" ], "calculation": { "http://brickellbio.com/role/CondensedConsolidatedStatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "totalLabel": "Net loss attributable to common stockholders" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Sources of change to generally accepted accounting principles (GAAP) in the United States. The FASB released the FASB Accounting Standards Codification as the authoritative source of literature effective for interim and annual periods ending after September 15, 2009. As part of the Codification process, the FASB issues \"Accounting Standards Updates\" to amend the Codification but otherwise the Accounting Standards Updates are not authoritative in their own right. All previous accounting standards (such as FASB Statements of Financial Accounting Standards, FASB Interpretations, FASB Staff Positions, Emerging Issues Task Force Consensuses, other pronouncements of the FASB or other designated bodies, or other forms of GAAP are considered accounting pronouncements) were superseded upon the adoption of the Codification. For an interim period, references to the superseded standards are included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.", "label": "Adjustments for New Accounting Pronouncement [Member]", "terseLabel": "Impact of Adoption" } } }, "localname": "NewAccountingPronouncementMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/RecentAccountingPronouncementsEffectsOfTopic842Details" ], "xbrltype": "domainItemType" }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]", "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]" } } }, "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/RecentAccountingPronouncementsEffectsOfTopic842Details" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": { "auth_ref": [ "r93", "r95" ], "lang": { "en-US": { "role": { "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.", "label": "New Accounting Pronouncements or Change in Accounting Principle [Table]", "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Table]" } } }, "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/RecentAccountingPronouncementsEffectsOfTopic842Details" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "New Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NotesPayableCurrent": { "auth_ref": [ "r25" ], "calculation": { "http://brickellbio.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.", "label": "Notes Payable, Current", "terseLabel": "Note payable" } } }, "localname": "NotesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayableOtherPayablesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A written promise to pay a note to a third party.", "label": "Notes Payable, Other Payables [Member]", "terseLabel": "Note Payable" } } }, "localname": "NotesPayableOtherPayablesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/NotePayableNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://brickellbio.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [], "calculation": { "http://brickellbio.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r226", "r229" ], "calculation": { "http://brickellbio.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease, Cost", "terseLabel": "Amortization of operating lease right-of-use asset", "verboseLabel": "Amortization of operating lease right-of-use assets" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CommitmentsAndContingenciesNarrativeDetails", "http://brickellbio.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r222" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "terseLabel": "Operating lease liability" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/RecentAccountingPronouncementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r222" ], "calculation": { "http://brickellbio.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "negatedTerseLabel": "Lease liability, current portion", "terseLabel": "Lease liability, current portion" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CondensedConsolidatedBalanceSheets", "http://brickellbio.com/role/RecentAccountingPronouncementsEffectsOfTopic842Details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r222" ], "calculation": { "http://brickellbio.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "negatedTerseLabel": "Lease liability, net of current portion", "terseLabel": "Lease liability, net of current portion" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CondensedConsolidatedBalanceSheets", "http://brickellbio.com/role/RecentAccountingPronouncementsEffectsOfTopic842Details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r221" ], "calculation": { "http://brickellbio.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease right-of-use asset" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CondensedConsolidatedBalanceSheets", "http://brickellbio.com/role/RecentAccountingPronouncementsEffectsOfTopic842Details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r227", "r229" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Expected remaining term" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r0", "r199" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "ORGANIZATION AND NATURE OF OPERATIONS" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/OrganizationAndNatureOfOperations" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]", "terseLabel": "Other comprehensive loss:" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CondensedConsolidatedStatmentsOfComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "auth_ref": [ "r42", "r45" ], "calculation": { "http://brickellbio.com/role/CondensedConsolidatedStatmentsOfComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.", "label": "Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, after Tax", "terseLabel": "Unrealized loss on available-for-sale marketable securities arising during holding period, net of tax benefit of $0", "verboseLabel": "Unrealized loss on available-for-sale marketable securities" } } }, "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit", "http://brickellbio.com/role/CondensedConsolidatedStatmentsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax": { "auth_ref": [ "r43", "r46" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of tax expense (benefit) before reclassification adjustments of unrealized holding gain (loss) on available-for-sale securities.", "label": "Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, Tax", "negatedTerseLabel": "Unrealized loss arising during holding period, tax benefit (expense)" } } }, "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CondensedConsolidatedStatmentsOfComprehensiveLossParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r31" ], "calculation": { "http://brickellbio.com/role/CondensedConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Research and development funding liability" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaidInKindInterest": { "auth_ref": [ "r74" ], "calculation": { "http://brickellbio.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Paid-in-Kind Interest", "terseLabel": "Non-cash interest expense" } } }, "localname": "PaidInKindInterest", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PayablesAndAccrualsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Payables and Accruals [Abstract]" } } }, "localname": "PayablesAndAccrualsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "auth_ref": [ "r68" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.", "label": "Payments of Debt Issuance Costs", "terseLabel": "Facility fees" } } }, "localname": "PaymentsOfDebtIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/NotePayableNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireProductiveAssets": { "auth_ref": [ "r64" ], "calculation": { "http://brickellbio.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.", "label": "Payments to Acquire Productive Assets", "negatedTerseLabel": "Capital expenditures" } } }, "localname": "PaymentsToAcquireProductiveAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r171", "r179" ], "lang": { "en-US": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CapitalStockReservedAuthorizedSharesOfCommonStockDetails", "http://brickellbio.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CapitalStockReservedAuthorizedSharesOfCommonStockDetails", "http://brickellbio.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockAccretionOfRedemptionDiscount": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of accretion of the preferred stock redemption discount during the period.", "label": "Preferred Stock, Accretion of Redemption Discount", "negatedTerseLabel": "Accretion of redeemable convertible preferred stock to redemption value" } } }, "localname": "PreferredStockAccretionOfRedemptionDiscount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockRedemptionDiscount": { "auth_ref": [ "r102" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The excess of (1) the carrying amount of the preferred stock in the registrant's balance sheet over (2) the fair value of the consideration transferred to the holders of the preferred stock, during the accounting period, which will be added to net earnings to arrive at net earnings available to common shareholders in the calculation of earnings per share.", "label": "Preferred Stock Redemption Discount", "terseLabel": "Reduction of redeemable convertible preferred stock to redemption value" } } }, "localname": "PreferredStockRedemptionDiscount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r2", "r19", "r20" ], "calculation": { "http://brickellbio.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrimeRateMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Interest rate charged by financial institutions to their most creditworthy borrowers.", "label": "Prime Rate [Member]", "terseLabel": "Prime Rate" } } }, "localname": "PrimeRateMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/NotePayableNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromConvertibleDebt": { "auth_ref": [ "r66" ], "calculation": { "http://brickellbio.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.", "label": "Proceeds from Convertible Debt", "terseLabel": "Proceeds from issuance of convertible promissory notes" } } }, "localname": "ProceedsFromConvertibleDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CondensedConsolidatedStatementsOfCashFlows", "http://brickellbio.com/role/ConvertiblePromissoryNotesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": { "auth_ref": [ "r61", "r62", "r119" ], "calculation": { "http://brickellbio.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale", "terseLabel": "Maturities of marketable securities" } } }, "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r65", "r180" ], "calculation": { "http://brickellbio.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from the exercise of stock options" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r7", "r8", "r128", "r246" ], "calculation": { "http://brickellbio.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RedeemableConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Description of type or class of redeemable convertible preferred stock. Convertible redeemable preferred stock possess conversion and redemption features. The stock has redemption features that are outside the control of the issuer.", "label": "Redeemable Convertible Preferred Stock [Member]", "netLabel": "Redeemable convertible preferred stock (as converted into common stock)", "terseLabel": "Series A, B, C & C-1 Redeemable Convertible Preferred Stock", "verboseLabel": "Warrants to purchase common stock" } } }, "localname": "RedeemableConvertiblePreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CapitalStockNarrativeDetails", "http://brickellbio.com/role/CondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit", "http://brickellbio.com/role/OrganizationAndNatureOfOperationsNarrativeDetails", "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesRedeemableConvertiblePreferredStockNarrativeDetails", "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfCommonSharesExcludedFromEpsCalculationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RepaymentsOfNotesPayable": { "auth_ref": [ "r67" ], "calculation": { "http://brickellbio.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation.", "label": "Repayments of Notes Payable", "negatedTerseLabel": "Payments of principal of note payable" } } }, "localname": "RepaymentsOfNotesPayable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CondensedConsolidatedStatementsOfCashFlows", "http://brickellbio.com/role/NotePayableNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Research and Development [Abstract]" } } }, "localname": "ResearchAndDevelopmentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Research and Development Arrangement, Contract to Perform for Others [Line Items]", "terseLabel": "Research and Development Arrangement, Contract to Perform for Others [Line Items]" } } }, "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/NovaquestFundingArrangementNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r185", "r252" ], "calculation": { "http://brickellbio.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/StockBasedCompensationShareBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock": { "auth_ref": [ "r253" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.", "label": "Research, Development, and Computer Software Disclosure [Text Block]", "terseLabel": "NOVAQUEST FUNDING ARRANGEMENT" } } }, "localname": "ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/NovaquestFundingArrangement" ], "xbrltype": "textBlockItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r15", "r153", "r244" ], "calculation": { "http://brickellbio.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CondensedConsolidatedBalanceSheets", "http://brickellbio.com/role/OrganizationAndNatureOfOperationsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r159", "r160" ], "calculation": { "http://brickellbio.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Collaboration revenue", "verboseLabel": "Revenue recognized" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CondensedConsolidatedStatementsOfOperations", "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r83", "r164" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue from Contract with Customer [Policy Text Block]", "terseLabel": "Revenue Recognition" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule of Accrued Liabilities [Table Text Block]", "terseLabel": "Schedule of Accrued Liabilities" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/AccruedLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r99" ], "lang": { "en-US": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfCommonSharesExcludedFromEpsCalculationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r99" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "auth_ref": [ "r188", "r189" ], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/OrganizationAndNatureOfOperationsNarrativeDetails", "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesMergerNarrativeDetails", "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfNetAssetsAcquiredDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "auth_ref": [ "r197" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]" } } }, "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "auth_ref": [ "r170", "r177", "r181" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/StockBasedCompensationShareBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r170", "r177", "r181" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Share-based Compensation Expense" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": { "auth_ref": [ "r93", "r95", "r103", "r104", "r105" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.", "label": "Schedule of New Accounting Pronouncements and Changes in Accounting Principles [Table Text Block]", "terseLabel": "Schedule of New Accounting Pronouncements and Changes in Accounting Principles" } } }, "localname": "ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/RecentAccountingPronouncementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": { "auth_ref": [ "r192" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.", "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]", "terseLabel": "Summary of Net Assets Acquired" } } }, "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable": { "auth_ref": [ "r186", "r187" ], "lang": { "en-US": { "role": { "documentation": "A schedule reflecting the terms of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others (including royalty arrangements, purchase provisions, license agreements, and commitments to provide additional funding), aggregated by similar arrangements or individually if necessary to understand the effects on the financial statements.", "label": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]", "terseLabel": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]" } } }, "localname": "ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/NovaquestFundingArrangementNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r171", "r179" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShortTermDebtTable": { "auth_ref": [ "r24" ], "lang": { "en-US": { "role": { "documentation": "A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.", "label": "Schedule of Short-term Debt [Table]", "terseLabel": "Schedule of Short-term Debt [Table]" } } }, "localname": "ScheduleOfShortTermDebtTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/ConvertiblePromissoryNotesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r34", "r87", "r142", "r144", "r145", "r147", "r148", "r149", "r150", "r151", "r152", "r153" ], "lang": { "en-US": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]", "terseLabel": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CapitalStockNarrativeDetails", "http://brickellbio.com/role/CapitalStockReservedAuthorizedSharesOfCommonStockDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockByClassTextBlock": { "auth_ref": [ "r11", "r12", "r13", "r84", "r143", "r144", "r145", "r147", "r148", "r149", "r150", "r151", "r152", "r153" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.", "label": "Schedule of Stock by Class [Table Text Block]", "terseLabel": "Reserved Authorized Shares of Common Stock" } } }, "localname": "ScheduleOfStockByClassTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CapitalStockTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SeriesAPreferredStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Outstanding nonredeemable series A preferred stock or outstanding series A preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Series A Preferred Stock [Member]", "terseLabel": "Series A" } } }, "localname": "SeriesAPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CapitalStockSummaryOfPreferredStockDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SeriesBPreferredStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Outstanding nonredeemable series B preferred stock or outstanding series B preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Series B Preferred Stock [Member]", "terseLabel": "Series B" } } }, "localname": "SeriesBPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CapitalStockSummaryOfPreferredStockDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SeriesCPreferredStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Outstanding nonredeemable series C preferred stock or outstanding series C preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Series C Preferred Stock [Member]", "terseLabel": "Series C" } } }, "localname": "SeriesCPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CapitalStockSummaryOfPreferredStockDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r73" ], "calculation": { "http://brickellbio.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r173" ], "lang": { "en-US": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized", "terseLabel": "Shares authorized (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r179" ], "lang": { "en-US": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant", "terseLabel": "Shares available for grant (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r169", "r174" ], "lang": { "en-US": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CapitalStockReservedAuthorizedSharesOfCommonStockDetails", "http://brickellbio.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r172" ], "lang": { "en-US": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period", "terseLabel": "Expiration term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShortTermDebtLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Short-term Debt [Line Items]", "terseLabel": "Short-term Debt [Line Items]" } } }, "localname": "ShortTermDebtLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/ConvertiblePromissoryNotesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShortTermDebtTypeAxis": { "auth_ref": [ "r24" ], "lang": { "en-US": { "role": { "documentation": "Information by type of short-term debt arrangement.", "label": "Short-term Debt, Type [Axis]", "terseLabel": "Short-term Debt, Type [Axis]" } } }, "localname": "ShortTermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/ConvertiblePromissoryNotesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShortTermDebtTypeDomain": { "auth_ref": [ "r22" ], "lang": { "en-US": { "role": { "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing.", "label": "Short-term Debt, Type [Domain]", "terseLabel": "Short-term Debt, Type [Domain]" } } }, "localname": "ShortTermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/ConvertiblePromissoryNotesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r92" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/SummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r11", "r12", "r13", "r146" ], "lang": { "en-US": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CapitalStockNarrativeDetails", "http://brickellbio.com/role/CapitalStockSummaryOfPreferredStockDetails", "http://brickellbio.com/role/CondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit", "http://brickellbio.com/role/ConvertiblePromissoryNotesNarrativeDetails", "http://brickellbio.com/role/OrganizationAndNatureOfOperationsNarrativeDetails", "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesRedeemableConvertiblePreferredStockNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r37", "r146" ], "lang": { "en-US": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit", "http://brickellbio.com/role/OrganizationAndNatureOfOperationsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": { "auth_ref": [ "r12", "r13", "r153" ], "lang": { "en-US": { "role": { "documentation": "Number of shares of stock issued during the period pursuant to acquisitions.", "label": "Stock Issued During Period, Shares, Acquisitions", "terseLabel": "Common stock issued in recapitalization (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesAcquisitions", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit", "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesMergerNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "auth_ref": [ "r36", "r146", "r147", "r153" ], "lang": { "en-US": { "role": { "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.", "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities", "terseLabel": "Conversion of securities (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r12", "r13", "r146", "r153", "r175" ], "lang": { "en-US": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "terseLabel": "Issuance of common stock through exercise of stock option (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueAcquisitions": { "auth_ref": [ "r37", "r146", "r153" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value of stock issued pursuant to acquisitions during the period.", "label": "Stock Issued During Period, Value, Acquisitions", "terseLabel": "Common stock issued in recapitalization" } } }, "localname": "StockIssuedDuringPeriodValueAcquisitions", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net amount of stock issued during the period upon the conversion of convertible securities, net of adjustments (for example, to additional paid in capital) including the write-off of an equity component recognized to record the convertible debt instrument as two separate components - a debt component and an equity component. This item is meant to disclose the value of shares issued on conversion of convertible securities that were recorded as two separate (debt and equity) components.", "label": "Stock Issued During Period, Value, Conversion of Convertible Securities, Net of Adjustments", "verboseLabel": "Conversion of securities" } } }, "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r37", "r146", "r153" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Issuance of common stock through exercise of stock option" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r13", "r16", "r17", "r117" ], "calculation": { "http://brickellbio.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending Balance", "periodStartLabel": "Beginning Balance", "totalLabel": "Total stockholders\u2019 equity (deficit)" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CondensedConsolidatedBalanceSheets", "http://brickellbio.com/role/CondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders\u2019 equity (deficit):" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r156" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "CAPITAL STOCK" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CapitalStock" ], "xbrltype": "textBlockItemType" }, "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": { "auth_ref": [ "r154" ], "lang": { "en-US": { "role": { "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.", "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio", "terseLabel": "Reverse stock split ratio" } } }, "localname": "StockholdersEquityNoteStockSplitConversionRatio1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/OrganizationAndNatureOfOperationsNarrativeDetails" ], "xbrltype": "pureItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r230" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "SUBSEQUENT EVENTS" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplement Disclosure of Cash Flow Information:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TemporaryEquityAccretionToRedemptionValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value of accretion of temporary equity to its redemption value during the period.", "label": "Temporary Equity, Accretion to Redemption Value", "terseLabel": "Accretion of redeemable convertible preferred stock to redemption value" } } }, "localname": "TemporaryEquityAccretionToRedemptionValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment": { "auth_ref": [], "calculation": { "http://brickellbio.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of decrease to net income for accretion of temporary equity to its redemption value to derive net income apportioned to common stockholders.", "label": "Temporary Equity, Accretion to Redemption Value, Adjustment", "negatedTerseLabel": "Reduction (accretion) of redeemable convertible preferred stock to redemption value" } } }, "localname": "TemporaryEquityAccretionToRedemptionValueAdjustment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_TemporaryEquityByClassOfStockTable": { "auth_ref": [ "r6", "r143" ], "lang": { "en-US": { "role": { "documentation": "Table of capital stock that is classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer. This table may include a description by series, value, shares authorized, shares issued and outstanding, redemption price per share and subscription receivable.", "label": "Temporary Equity, by Class of Stock [Table]", "terseLabel": "Temporary Equity, by Class of Stock [Table]" } } }, "localname": "TemporaryEquityByClassOfStockTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CapitalStockSummaryOfPreferredStockDetails", "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesRedeemableConvertiblePreferredStockNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": { "auth_ref": [], "calculation": { "http://brickellbio.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, Carrying Amount, Attributable to Parent", "periodEndLabel": "Ending Balance", "periodStartLabel": "Beginning Balance", "terseLabel": "Redeemable convertible preferred stock (Series A, B, C and C-1), $0.01 par value, 5,000,000 and 4,182,943 shares authorized at September 30, 2019 and December 31, 2018, respectively; 0 and 1,256,466 shares issued and outstanding at September 30, 2019 and December 31, 2018, respectively; aggregate liquidation preference of $0 and $46,985 at September 30, 2019 and December 31, 2018, respectively", "verboseLabel": "Carrying Value" } } }, "localname": "TemporaryEquityCarryingAmountAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CapitalStockSummaryOfPreferredStockDetails", "http://brickellbio.com/role/CondensedConsolidatedBalanceSheets", "http://brickellbio.com/role/CondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_TemporaryEquityLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Temporary Equity [Line Items]", "terseLabel": "Temporary Equity [Line Items]" } } }, "localname": "TemporaryEquityLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CapitalStockSummaryOfPreferredStockDetails", "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesRedeemableConvertiblePreferredStockNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TemporaryEquityLiquidationPreference": { "auth_ref": [ "r33" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, Liquidation Preference", "verboseLabel": "Redeemable convertible preferred stock, liquidation preference (in usd)" } } }, "localname": "TemporaryEquityLiquidationPreference", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_TemporaryEquityParOrStatedValuePerShare": { "auth_ref": [ "r6", "r143" ], "lang": { "en-US": { "role": { "documentation": "Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.", "label": "Temporary Equity, Par or Stated Value Per Share", "terseLabel": "Redeemable convertible preferred stock, par value (in usd per share)" } } }, "localname": "TemporaryEquityParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_TemporaryEquitySharesAuthorized": { "auth_ref": [ "r10" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, Shares Authorized", "terseLabel": "Redeemable convertible preferred stock, shares authorized", "verboseLabel": "Preferred Shares Authorized (in shares)" } } }, "localname": "TemporaryEquitySharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CapitalStockSummaryOfPreferredStockDetails", "http://brickellbio.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_TemporaryEquitySharesIssued": { "auth_ref": [ "r10" ], "lang": { "en-US": { "role": { "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, Shares Issued", "terseLabel": "Redeemable convertible preferred stock, shares issued", "verboseLabel": "Preferred Shares Issued (in shares)" } } }, "localname": "TemporaryEquitySharesIssued", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CapitalStockSummaryOfPreferredStockDetails", "http://brickellbio.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_TemporaryEquitySharesOutstanding": { "auth_ref": [ "r10" ], "lang": { "en-US": { "role": { "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, Shares Outstanding", "periodEndLabel": "Ending Balance (in shares)", "periodStartLabel": "Beginning Balance (in shares)", "terseLabel": "Redeemable convertible preferred stock, shares outstanding", "verboseLabel": "Preferred Shares Outstanding (in shares)" } } }, "localname": "TemporaryEquitySharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CapitalStockSummaryOfPreferredStockDetails", "http://brickellbio.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://brickellbio.com/role/CondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_TemporaryEquityTableTextBlock": { "auth_ref": [ "r6", "r143" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary Equity [Table Text Block]", "terseLabel": "Summary of Preferred Stock" } } }, "localname": "TemporaryEquityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CapitalStockTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital": { "auth_ref": [ "r6", "r143" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying amount of the par value of temporary equity outstanding. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, Par Value", "terseLabel": "Par Value" } } }, "localname": "TemporaryEquityValueExcludingAdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CapitalStockSummaryOfPreferredStockDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TypeOfAdoptionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Adoption and early adoption of sources of change to generally accepted accounting principles (GAAP) in the United States. The FASB released the FASB Accounting Standards Codification as the authoritative source of literature effective for interim and annual periods ending after September 15, 2009. As part of the Codification process, the FASB issues Accounting Standards Updates to amend the Codification but otherwise the Accounting Standards Updates are not authoritative in their own right. All previous accounting standards (such as FASB Statements of Financial Accounting Standards, FASB Interpretations, FASB Staff Positions, Emerging Issues Task Force Consensuses, other pronouncements of the FASB or other designated bodies, or other forms of GAAP are considered accounting pronouncements) were superseded upon the adoption of the Codification. For an interim period, references to the superseded standards are included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.", "label": "Type of Adoption [Domain]", "terseLabel": "Type of Adoption [Domain]" } } }, "localname": "TypeOfAdoptionMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit", "http://brickellbio.com/role/RecentAccountingPronouncementsEffectsOfTopic842Details", "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r197" ], "lang": { "en-US": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r106", "r107", "r108", "r109", "r110", "r111", "r112" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]", "terseLabel": "Variable Rate [Axis]" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/NotePayableNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.", "label": "Variable Rate [Domain]", "terseLabel": "Variable Rate [Domain]" } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/NotePayableNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]", "terseLabel": "Warrants to purchase common stock" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfCommonSharesExcludedFromEpsCalculationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantsAndRightsOutstanding": { "auth_ref": [ "r91" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.", "label": "Warrants and Rights Outstanding", "terseLabel": "Warrant liability" } } }, "localname": "WarrantsAndRightsOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/NotePayableNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": { "auth_ref": [ "r205" ], "lang": { "en-US": { "role": { "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.", "label": "Warrants and Rights Outstanding, Measurement Input", "terseLabel": "Fair value measurement input", "verboseLabel": "Warrants, measurement input" } } }, "localname": "WarrantsAndRightsOutstandingMeasurementInput", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/NovaquestFundingArrangementNarrativeDetails", "http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesFairValueMeasurementInputsDetails" ], "xbrltype": "decimalItemType" }, "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).", "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted", "terseLabel": "Weighted-average shares used to compute net loss per share attributable to common stockholders, basic and diluted (in shares)" } } }, "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://brickellbio.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "sharesItemType" } }, "unitCount": 6 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=27010884&loc=d3e42851-122695" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e725-108305" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e765-108305" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.10-01.(b)(6))", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=27015980&loc=d3e46468-122699" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9031-108599" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26610-111562" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26853-111562" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26626-111562" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=118942338&loc=SL82898722-210454" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14326-108349" }, "r132": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109126253&loc=d3e4724-112606" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031898-161870" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6036836-161870" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6036836-161870" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12317-112629" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12355-112629" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 4.C)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775" }, "r156": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944033&loc=SL49130531-203044" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944033&loc=SL49130532-203044" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048" }, "r164": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116855982&loc=d3e4534-113899" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=SL79508275-113901" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11149-113907" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11178-113907" }, "r184": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "37", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116868840&loc=d3e2207-128464" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116869197&loc=d3e4845-128472" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116869197&loc=d3e4845-128472" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "b", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r199": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "2C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL7498348-110258" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13433-108611" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=119364159&loc=SL77916155-209984" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918666-209980" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "http://asc.fasb.org/topic&trid=2122774" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=6488278&loc=d3e603758-122996" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r253": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "730", "Topic": "985", "URI": "http://asc.fasb.org/subtopic&trid=2197926" }, "r254": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r255": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r256": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-13" }, "r257": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1-" }, "r258": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r259": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6801-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.28(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.28,29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6911-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e637-108580" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e640-108580" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e681-108580" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669686-108580" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "17B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL34724394-108580" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6935-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e557-108580" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(b))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(27)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3151-108585" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3367-108585" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4297-108586" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(i))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(d),(e))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(e),(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(i)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(i)(4))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(i))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r92": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794" }, "r96": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "250", "URI": "http://asc.fasb.org/topic&trid=2122394" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1377-109256" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" } }, "version": "2.1" } XML 34 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 35 R13.htm IDEA: XBRL DOCUMENT v3.19.3
ACCRUED LIABILITIES
9 Months Ended
Sep. 30, 2019
Payables and Accruals [Abstract]  
ACCRUED LIABILITIES ACCRUED LIABILITIES

Accrued liabilities consisted of the following (in thousands):
 
September 30,
2019
 
December 31,
2018
Accrued contracted research and development services
$
1,715

 
$
847

Accrued professional fees
992

 
1,269

Accrued compensation
768

 
569

Accrued note issuance costs

 
587

Total
$
3,475

 
$
3,272


XML 36 R17.htm IDEA: XBRL DOCUMENT v3.19.3
CAPITAL STOCK
9 Months Ended
Sep. 30, 2019
Equity [Abstract]  
CAPITAL STOCK CAPITAL STOCK

Common Stock

Each share of common stock is entitled to one vote, and the holders of common stock are entitled to receive dividends when and as declared or paid by its board of directors. At the effective date of the Merger, each outstanding share of the Company’s common stock was converted into the right to receive approximately 2.4165 shares of the Private Brickell’s common stock.

The Company has reserved authorized shares of common stock, on an as-converted basis, for future issuance at September 30, 2019 as follows:
 
September 30, 2019
Common stock options outstanding
1,802,895

Common stock warrants
1,632,495

Options available for grant under the Vical Plan
119,070

Options available for grant under the 2009 Plan
17,232

Total
3,571,692


Preferred Stock

In August 2019, in conjunction with the Merger, all outstanding shares of redeemable convertible preferred stock converted into shares of common stock at a ratio of 1:1 and were immediately exchanged for common stock at an Exchange Ratio of 2.4165 as a result of the Merger.  

Redeemable convertible preferred stock consisted of the following prior to the conversion on August 31, 2019 (in thousands, except share data):
 
Preferred
Shares
Authorized
 
Preferred
Shares
Issued and
Outstanding
 
Par
Value
 
Carrying
Value
 
Common
Stock Issued
Upon
Conversion
Series A
1,162,505

 
401,309

 
$
4

 
$
12,164

 
401,309

Series B
882,216

 
286,151

 
3

 
10,084

 
286,151

Series C
869,565

 
256,583

 
3

 
11,630

 
256,583

Series C-1
1,531,942

 
312,423

 
3

 
14,138

 
312,423

 
4,446,228

 
1,256,466

 
$
13

 
$
48,016

 
1,256,466


Redeemable convertible preferred stock consisted of the following as of December 31, 2018 (in thousands, except share data):
 
Preferred
Shares
Authorized
 
Preferred
Shares
Issued and
Outstanding
 
Par
Value
 
Carrying
Value
 
Common
Stock Issuable
Upon
Conversion
Series A
1,162,505

 
401,309

 
$
4

 
$
16,098

 
401,309

Series B
882,216

 
286,151

 
3

 
13,011

 
286,151

Series C
869,565

 
256,583

 
3

 
13,018

 
256,583

Series C-1
1,268,657

 
312,423

 
3

 
16,163

 
312,423

 
4,182,943

 
1,256,466

 
$
13

 
$
58,290

 
1,256,466



As of September 30, 2019, the Company had no outstanding shares of redeemable convertible preferred stock and had not designated the rights, preferences, or privileges of any class or series of preferred stock. Although, the Company’s board of directors has the authority, at its discretion, to issue preferred stock in one or more classes or series and to fix the designations, powers, preferences and rights, and the qualifications, limitations, or restrictions thereof, including dividend rights, conversion right, voting rights, terms of redemption, liquidation preferences, and the number of shares constituting any class or series of preferred stock, without further vote or action by the stockholders.
XML 37 R38.htm IDEA: XBRL DOCUMENT v3.19.3
NOVAQUEST FUNDING ARRANGEMENT - Narrative (Details)
9 Months Ended
Sep. 03, 2019
USD ($)
Sep. 30, 2019
USD ($)
$ / shares
shares
Dec. 31, 2018
Sep. 30, 2018
USD ($)
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Monthly distribution amount as percent of invoiced R&D   67.00%    
Potential milestone payments   $ 37,500,000    
Potential milestone payments due upon approval   20,000,000.0    
Termination amount   $ 25,000,000.0    
Commitment funding amount $ 5,600,000      
NovaQuest        
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Commitment amount       $ 25,000,000.0
Stock issuable upon warrants (in shares) | shares   241,225    
Exercise price (in usd per share) | $ / shares   $ 10.36    
Minimum        
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Termination amount, interest rate   8.00%    
Maximum        
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Termination amount, interest rate   12.00%    
Expected volatility        
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Warrants, measurement input   0.8556 0.3000  
Risk free interest rate        
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Warrants, measurement input   0.0150 0.0259  
Expected term (in years)        
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Warrants, measurement input   10 7.1  
Expected dividend yield        
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Warrants, measurement input   0.0000 0  
NovaQuest Warrants        
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Commitment funding amount $ 900,000      
XML 38 R34.htm IDEA: XBRL DOCUMENT v3.19.3
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition Narrative (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 9 Months Ended
May 31, 2018
Mar. 31, 2018
Dec. 31, 2017
Oct. 31, 2017
Mar. 31, 2015
Sep. 30, 2019
Sep. 30, 2018
Mar. 31, 2018
Sep. 30, 2019
Sep. 30, 2018
Dec. 31, 2018
Jan. 01, 2018
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                        
Revenue recognized           $ 1,183 $ 3,042   $ 7,248 $ 8,415    
Deferred revenue, current portion           2,464     2,464   $ 8,117  
General and administrative           3,901 $ 1,206   $ 7,290 $ 4,694    
Collaborative Arrangement                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                        
Non-refundable upfront fees $ 15,600       $ 11,000              
Development milestone payments         10,000              
Commercialization milestone payments         $ 30,000              
Expected performance period 1 year 5 months 12 days                      
Basis point reduction                 1.50%      
Revenue recognized     $ 5,000     1,200   $ 5,000 $ 7,200      
Deferred revenue, current portion           $ 2,500     $ 2,500      
Prepayment option percent       50.00%                
Prepayment amount     $ 5,000                  
Milestone payment received   $ 5,000                    
Accounting Standards Update 2014-09                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                        
Effect of adoption of Topic 606                       $ 2,734
Sublicensing Costs | Collaborative Arrangement                        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                        
General and administrative       $ 1,000       $ 1,000        
XML 39 R30.htm IDEA: XBRL DOCUMENT v3.19.3
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Fair Value Measurements Narrative (Details)
Sep. 30, 2019
USD ($)
Dec. 31, 2018
USD ($)
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Marketable securities, available-for-sale, amortized cost $ 18,500,000 $ 0
U.S. treasuries 18,500,000 0
Marketable securities, available-for-sale, accumulated unrealized gain $ 20,000 $ 0
Minimum | Individual cumulative achievement probabilities    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Contingent consideration, measurement input 0.021  
Minimum | Discount rate    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Contingent consideration, measurement input 0.155  
Maximum | Individual cumulative achievement probabilities    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Contingent consideration, measurement input 0.209  
Maximum | Discount rate    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Contingent consideration, measurement input 0.271  
XML 40 R23.htm IDEA: XBRL DOCUMENT v3.19.3
ACCRUED LIABILITIES (Tables)
9 Months Ended
Sep. 30, 2019
Payables and Accruals [Abstract]  
Schedule of Accrued Liabilities

Accrued liabilities consisted of the following (in thousands):
 
September 30,
2019
 
December 31,
2018
Accrued contracted research and development services
$
1,715

 
$
847

Accrued professional fees
992

 
1,269

Accrued compensation
768

 
569

Accrued note issuance costs

 
587

Total
$
3,475

 
$
3,272


XML 41 R27.htm IDEA: XBRL DOCUMENT v3.19.3
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Merger Narrative (Details) - USD ($)
$ / shares in Units, $ in Thousands
Aug. 31, 2019
Jun. 02, 2018
Vical Warrants [Member]    
Business Acquisition [Line Items]    
Warrants converted (in shares)   891,582
Exercise price (in usd per share)   $ 0.07
Vical    
Business Acquisition [Line Items]    
Common stock issued in recapitalization (in shares) 3,367,988  
Net acquired tangible assets $ 36,093  
XML 42 R4.htm IDEA: XBRL DOCUMENT v3.19.3
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2019
Sep. 30, 2018
Income Statement [Abstract]        
Collaboration revenue $ 1,183 $ 3,042 $ 7,248 $ 8,415
Operating expenses:        
Research and development 3,337 4,135 13,585 8,571
General and administrative 3,901 1,206 7,290 4,694
Total operating expenses 7,238 5,341 20,875 13,265
Loss from operations (6,055) (2,299) (13,627) (4,850)
Investment and other income, net 54 23 64 45
Gain on extinguishment 2,318 0 2,318 0
Interest expense (1,098) (267) (1,982) (769)
Change in fair value of derivative liability 0 0 (11) 0
Change in fair value of warrant liability 0 2 223 8
Net loss (4,781) (2,541) (13,015) (5,566)
Reduction (accretion) of redeemable convertible preferred stock to redemption value (82) (966) 10,274 (5,071)
Net loss attributable to common stockholders $ (4,863) $ (3,507) $ (2,741) $ (10,637)
Net loss per share attributable to common stockholders, basic and diluted (in usd per share) $ (1.65) $ (5.98) $ (1.98) $ (18.13)
Weighted-average shares used to compute net loss per share attributable to common stockholders, basic and diluted (in shares) 2,943,896 586,738 1,382,592 586,701
XML 43 R8.htm IDEA: XBRL DOCUMENT v3.19.3
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
9 Months Ended
Sep. 30, 2019
Sep. 30, 2018
CASH FLOWS FROM OPERATING ACTIVITIES:    
Net loss $ (13,015) $ (5,566)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:    
Depreciation 25 37
Accretion of discount on marketable securities (25) 0
Non-cash interest expense 666 0
Change in fair value of derivative liability 11 0
Change in fair value of warrant liability (223) (8)
Gain on extinguishment (2,318) 0
Amortization of operating lease right-of-use assets 50 50
Amortization of convertible promissory notes discount 828 0
Amortization of debt discounts and financing costs 215 310
Stock-based compensation 1,007 516
Changes in operating assets and liabilities:    
Prepaid expenses and other current assets (2,480) 14
Accounts payable (2,776) 473
Accrued liabilities (2,207) (343)
Lease liability (50)  
Research and development funding liability 5,600 0
Deferred revenue (7,248) 12,188
Net cash provided by (used in) operating activities (21,940) 7,621
CASH FLOWS FROM INVESTING ACTIVITIES:    
Cash and cash equivalents acquired in recapitalization 13,017 0
Maturities of marketable securities 5,500 0
Capital expenditures (8) (8)
Net cash provided by (used in) investing activities 18,509 (8)
CASH FLOWS FROM FINANCING ACTIVITIES:    
Payments of principal of note payable (4,808) (509)
Proceeds from issuance of convertible promissory notes 7,397 0
Proceeds from the exercise of stock options 0 27
Net cash provided by (used in) financing activities 2,589 (482)
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS (842) 7,131
CASH AND CASH EQUIVALENTS—BEGINNING 8,067 5,399
CASH AND CASH EQUIVALENTS—ENDING 7,225 12,530
Supplement Disclosure of Cash Flow Information:    
Interest paid 319 310
Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]    
Conversion of redeemable convertible preferred stock and preferred stock dividends to common stock 48,016 0
Accretion (reduction) of redeemable convertible preferred stock to redemption value (10,377) 5,041
Shares issued in recapitalization 23,076 0
Accretion of redeemable convertible preferred stock issuance costs 103 30
Derivative liability issued with convertible promissory notes 1,442 0
Warrants to purchase common stock issued with funding agreement 876 0
Warrants to purchase common stock issued with convertible promissory notes 1,492 0
Change in unrealized loss on available-for-sale marketable securities $ (11) $ 0
XML 44 R46.htm IDEA: XBRL DOCUMENT v3.19.3
STOCK-BASED COMPENSATION - Narrative (Details)
9 Months Ended
Sep. 30, 2019
shares
Vical Plan  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Expiration term 10 years
Maximum shares permitted to be granted in a single calendar year (in shares) 1,300,000
Options | 2009 Plan  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Shares authorized (in shares) 1,634,655
Shares available for grant (in shares) 17,232
Options | Vical Plan  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Shares authorized (in shares) 413,710
Shares available for grant (in shares) 119,070
XML 45 R42.htm IDEA: XBRL DOCUMENT v3.19.3
COMMITMENTS AND CONTINGENCIES - Narrative (Details)
3 Months Ended 9 Months Ended
Sep. 30, 2019
USD ($)
ft²
renewal_term
Sep. 30, 2018
USD ($)
Sep. 30, 2019
USD ($)
ft²
renewal_term
Sep. 30, 2018
USD ($)
Commitments and Contingencies Disclosure [Abstract]        
Lease term 5 years   5 years  
Renewal term 3 years   3 years  
Number of additional terms | renewal_term 2   2  
Area of leased property | ft² 3,038   3,038  
Monthly payment, initial year $ 4,430   $ 4,430  
Annual payment percentage increase 3.50%   3.50%  
Monthly fees $ 2,160   $ 2,160  
Discount rate 12.00%   12.00%  
Expected remaining term 2 years 9 months 18 days   2 years 9 months 18 days  
Amortization of operating lease right-of-use asset $ 17,000   $ 50,000 $ 50,000
Remaining lease term     2 years 1 month 6 days  
Lease expense $ 22,000 $ 22,000 $ 100,000 $ 100,000
XML 46 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 47 R36.htm IDEA: XBRL DOCUMENT v3.19.3
RECENT ACCOUNTING PRONOUNCEMENTS - Narrative (Details)
$ in Millions
Jan. 01, 2019
USD ($)
Accounting Policies [Abstract]  
Operating lease liability $ 0.2
XML 48 R32.htm IDEA: XBRL DOCUMENT v3.19.3
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Reconciliation of Level 3 Financial Instruments (Details)
$ in Thousands
9 Months Ended
Sep. 30, 2019
USD ($)
Derivative Liability  
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]  
Beginning Balance $ 0
Fair value of financial instruments issued 1,442
Change in fair value 11
Reclassification to equity (1,453)
Ending Balance 0
Common Stock Warrant Liability  
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]  
Beginning Balance 0
Fair value of financial instruments issued 1,492
Change in fair value 17
Reclassification to equity (1,509)
Ending Balance 0
Redeemable Convertible Preferred Stock Warrant Liability  
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]  
Beginning Balance 242
Fair value of financial instruments issued 0
Change in fair value (240)
Reclassification to equity (2)
Ending Balance 0
Contingent Consideration Liabilities  
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]  
Beginning Balance 145
Fair value of financial instruments issued 0
Change in fair value 0
Reclassification to equity 0
Ending Balance $ 145
EXCEL 49 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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htm IDEA: XBRL DOCUMENT v3.19.3
SUBSEQUENT EVENTS
9 Months Ended
Sep. 30, 2019
Subsequent Events [Abstract]  
SUBSEQUENT EVENTS SUBSEQUENT EVENTS

On October 23, 2019, Bodor Laboratories, Inc. (“Bodor”) notified the Company of its termination of the license agreement entered into between Bodor and the Company, dated December 15, 2012, as amended by Amendment No. 1 to License Agreement, effective as of October 21, 2013, and Amendment No. 2 to License Agreement, effective as of March 31, 2015 (the “License Agreement”). Bodor alleges that the Company materially breached the License Agreement resulting in its termination.

On October 23, 2019, Bodor and Nicholas S. Bodor (the “Plaintiffs”), filed a complaint (the “Bodor Complaint”) against the Company in the United States District Court for the Southern District of Florida. The complaint alleges damages incurred by the Plaintiffs in connection with the Company’s alleged breach of the License Agreement. The complaint seeks: (i) a declaratory judgment that the termination of the License Agreement by the Plaintiffs was valid and enforceable; (ii) an injunction requiring the Company to cease and desist use of the Plaintiffs’ intellectual property; and (iii) damages for breach of contract and breach of the covenant of good faith and fair dealing.

On October 25, 2019, NovaQuest provided written notice to the Company of its determination that a “Material Adverse Event” (as defined in Section 1.1 of the Funding Agreement) occurred as a result of the matters described above. As a result, NovaQuest exercised its right under Section 3.3(e) of the Funding Agreement to suspend further Development Payments (as defined in Section 3.1(a) of the Funding Agreement). Pursuant to the Funding Agreement, NovaQuest is obligated to resume Development Payments if the Material Adverse Event is resolved or cured by the Company to NovaQuest’s reasonable satisfaction by October 25, 2020. If the Material Adverse Event is not resolved or cured to NovaQuest’s reasonable satisfaction by such date, then NovaQuest may, in its sole discretion, terminate any future payment obligation under the Funding Agreement and Brickell may be obligated to make certain payments to NovaQuest.

On October 30, 2019, the Company initiated an arbitration proceeding pursuant to Article 9 of the License Agreement with the American Arbitration Association (“AAA”) in Florida against Bodor and Nicholas S. Bodor. This arbitration seeks a declaratory judgment that the purported termination of the License Agreement by Bodor and Nicholas S. Bodor was invalid and unenforceable and asserts (i) a claim for breach of the License Agreement against Bodor and Nicholas S. Bodor, in his individual capacity, and (ii) a claim against Bodor and Nicholas S. Bodor, in his individual capacity, for tortious interference with the Company’s business relations. The Company requested expedited treatment of the arbitration proceeding and concurrent mandatory mediation under the AAA rules. On October 30, 2019, the Company concurrently filed with the United States District Court for the Southern District of Florida a motion to dismiss the complaint brought against the Company by Bodor and Nicholas S. Bodor described above.

As a result of the matters described above, the timeline for the Company’s Phase 3 clinical trials in patients with primary axillary hyperhidrosis in the United States may be negatively impacted. Any potential impact to the financial statements with respect to loss contingencies for asserted legal and other claims is not estimable by the Company at this time.

XML 51 R11.htm IDEA: XBRL DOCUMENT v3.19.3
RECENT ACCOUNTING PRONOUNCEMENTS
9 Months Ended
Sep. 30, 2019
Accounting Policies [Abstract]  
RECENT ACCOUNTING PRONOUNCEMENTS RECENT ACCOUNTING PRONOUNCEMENTS

In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement (“ASU 2018-13”), which amends certain disclosure requirements over Level 1, Level 2, and Level 3 fair value measurements. ASU 2018-13 is effective for fiscal years beginning after December 15, 2019 and interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the impact of adopting ASU 2018-13, but does not anticipate it will have a material impact on its disclosures.

In February 2016, the FASB issued ASU No. 2016-02, “Leases (Topic 842)” (“ASU 2016-02”). ASU 2016-02 is aimed at making leasing activities more transparent and comparable and requires substantially all leases be recognized by lessees on their balance sheets as a right-of-use asset and corresponding lease liability, including leases currently accounted for as operating leases. The Company adopted ASU 2016-02 on January 1, 2019 using the modified retrospective approach. The adoption did not have a material impact on the Company’s condensed consolidated statements of operations. The new standard has required the Company to establish liabilities and corresponding right-of-use assets on its condensed balance sheet for operating leases of $0.2 million that existed as of the January 1, 2019 adoption date. The impact on the condensed consolidated balance sheets as of January 1, 2019 was as follows (in thousands):
Balance Sheet
 
Topic 840
January 1, 2019
 
Topic 842
January 1, 2019
 
Impact of
Adoption
Operating lease right-of-use asset
 
$

 
$
219

 
$
219

Lease liability, current portion
 

 
(68
)
 
(68
)
Lease liability, net of current portion
 

 
(151
)
 
(151
)

XML 52 R15.htm IDEA: XBRL DOCUMENT v3.19.3
NOTE PAYABLE
9 Months Ended
Sep. 30, 2019
Debt Disclosure [Abstract]  
NOTE PAYABLE CONVERTIBLE PROMISSORY NOTES

In March 2019, the Company initiated a convertible promissory notes offering pursuant to which the Company issued unsecured convertible promissory notes (the “Prom Notes”), bearing interest at 12.00% with a maturity of one year and convertible into shares of Series C-1 redeemable convertible preferred stock or the most senior preferred equity outstanding at the time of conversion at the option of the holder at a conversion price of $31.05 per share. In addition, the Prom Notes were automatically convertible upon closing of a qualified financing of at least $15.0 million before maturity at a conversion price equal to 80% of the effective price per share paid in the qualified financing, but not to exceed $38.82 per share. Through August 31, 2019, the Company had raised an aggregate principal amount of $7.4 million in Prom Notes. On August 31, 2019, prior to the Merger, the Prom Notes and related accrued interest converted into 1,069,740 shares of Private Brickell common stock at a conversion price of $7.54 per share (the “Conversion”).

The Prom Notes also provided for the issuance of warrants at 50% coverage, to acquire 490,683 shares of common stock. The warrants are exercisable for a term of five years at an exercise price of $10.36. Prior to the Merger, the warrants were exercisable at an exercise price of $42.70 or 10% premium to the effective price per share paid in a qualified financing. The Company evaluated the various financial instruments under ASC 480 and ASC 815 and determined the warrants required fair value accounting. The fair value of the warrants was recorded as a warrant liability upon issuance. The fair value of the warrants on the dates of issuance of $1.5 million was determined with the assistance of a third-party valuation firm. The fair value of the warrants was recorded as a debt discount upon issuance and was amortized to interest expense over the term of the Prom Notes based on the effective interest method.

At inception of the Prom Notes offering, the Company analyzed the conversion feature of the agreement for derivative accounting consideration under ASC 815 and determined that the embedded conversion features should be classified as a derivative because the exercise price of the Prom Notes are subject to a variable conversion rate. The Company determined that the variable conversion feature was a redemption feature that was not clearly and closely related to the Prom Notes and was therefore required to be bifurcated. In accordance with AC 815, the Company bifurcated the conversion feature of the Prom Notes and recorded a derivative liability.

The embedded derivative for the Prom Notes was carried on the Company’s condensed consolidated balance sheet at fair value. The derivative liability was marked-to-market each measurement period and any change in fair value was recorded as a component of the statements of operations. The fair value of the derivative liabilities on the date of issuance of $1.4 million was determined with the assistance of a third-party valuation firm. The fair value of the conversion feature was recorded as a debt discount upon issuance and was amortized to interest expense over the term of the Prom Notes based on the effective interest method.

The Company evaluated the conversion option to discern whether a beneficial conversion feature existed based upon comparing the effective exercise price of the convertible notes to the fair value of the shares they were convertible into. The Company concluded no beneficial conversion feature existed. During the three months ended September 30, 2019, the Company recognized $1.1 million of interest expense, including $0.4 million of accretion of discounts using an effective interest rate of 12.00%. During the nine months ended September 30, 2019, the Company recognized $2.0 million of interest expense, including $0.8 million of accretion of discounts using an effective interest rate of 12.00%.

As a result of the Conversion on August 31, 2019, the Prom Notes payable, warrant liability, and derivative liability balances were reclassified to equity in the condensed consolidated balance sheets. A gain of $2.3 million resulted from the Conversion of the Prom Notes, which is included in the gain on extinguishment line in the condensed consolidated statements of operations.
NOTE PAYABLE

On February 18, 2016, the Company entered into a loan and security agreement (the “Loan Agreement”) with Hercules Capital, Inc. (the “Lender”) under which the Company borrowed $7.5 million upon the execution of the Loan Agreement on February 18, 2016. The interest rate applicable to each tranche was variable based upon the greater of either (i) 9.2% and (ii) the sum of (a) the Prime Rate as reported in The Wall Street Journal minus 3.5%, plus (b) 9.2%; notwithstanding the above, such rate could not exceed the permissible rates of interest on commercial loans under the laws of the State of California. Payments under the Loan Agreement were interest only until June 1, 2017, followed by equal monthly payments of principal and interest through the maturity date of September 1, 2019. The Company was required to make an end of term payment of 4.5% of the sum of (i) term loan advances, plus (ii) 50% of the aggregate unfunded term loan commitments. The Loan Agreement was further amended in December 2017, March 2018, and July 2018 (as further amended, “Loan Agreement”) to provide for an additional combined interest-only period of eight months, and the outstanding loan balance continued to be paid in equal monthly installments of principal and interest. As a result of the amendments, the Company was required to increase the end-of-term payment by $0.1 million. At the inception of the loan and the following amendment dates, the Company paid the Lender aggregate facility fees of $0.2 million in connection with the Loan Agreement.

In connection with the Loan Agreement, the Company issued warrants to the Lender, which are exercisable for 9,005 shares of common stock at a per share exercise price of $33.31 (the “Hercules Capital Warrants”). The Hercules Capital Warrants will terminate, if not earlier exercised, on February 18, 2026. The fair value of the Hercules Capital Warrants was recorded at inception as a redeemable convertible preferred stock warrant liability upon issuance. The fair value of the Hercules Capital Warrants on the date of issuance of $0.3 million was determined using the Black-Scholes option-pricing model and was recorded as a debt discount upon issuance and was amortized to interest expense over the term of the loan based on the effective interest method.

On September 3, 2019, the Company repaid the remaining outstanding loan balance of $2.6 million and an associated accrued interest and aggregate end-of-term payment of $0.6 million, and the Loan Agreement was terminated. At the effective time of the Merger, the warrant liability was reclassified to equity in the condensed consolidated balance sheet. As of September 30, 2019, there were no remaining unaccreted debt discounts and issuance costs.
XML 53 FilingSummary.xml IDEA: XBRL DOCUMENT 3.19.3 html 211 313 1 false 58 0 false 6 false false R1.htm 0001000 - Document - COVER PAGE Sheet http://brickellbio.com/role/CoverPage COVER PAGE Cover 1 false false R2.htm 1001000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://brickellbio.com/role/CondensedConsolidatedBalanceSheets CONDENSED CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 1001501 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (PARENTHETICAL) Sheet http://brickellbio.com/role/CondensedConsolidatedBalanceSheetsParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (PARENTHETICAL) Statements 3 false false R4.htm 1002000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://brickellbio.com/role/CondensedConsolidatedStatementsOfOperations CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Statements 4 false false R5.htm 1003000 - Statement - CONDENSED CONSOLIDATED STATMENTS OF COMPREHENSIVE LOSS Sheet http://brickellbio.com/role/CondensedConsolidatedStatmentsOfComprehensiveLoss CONDENSED CONSOLIDATED STATMENTS OF COMPREHENSIVE LOSS Statements 5 false false R6.htm 1003001 - Statement - CONDENSED CONSOLIDATED STATMENTS OF COMPREHENSIVE LOSS (PARENTHETICAL) Sheet http://brickellbio.com/role/CondensedConsolidatedStatmentsOfComprehensiveLossParenthetical CONDENSED CONSOLIDATED STATMENTS OF COMPREHENSIVE LOSS (PARENTHETICAL) Statements 6 false false R7.htm 1004000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS??? EQUITY (DEFICIT) Sheet http://brickellbio.com/role/CondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit CONDENSED CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS??? EQUITY (DEFICIT) Statements 7 false false R8.htm 1005000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://brickellbio.com/role/CondensedConsolidatedStatementsOfCashFlows CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 8 false false R9.htm 2101100 - Disclosure - ORGANIZATION AND NATURE OF OPERATIONS Sheet http://brickellbio.com/role/OrganizationAndNatureOfOperations ORGANIZATION AND NATURE OF OPERATIONS Notes 9 false false R10.htm 2102100 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://brickellbio.com/role/SummaryOfSignificantAccountingPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 10 false false R11.htm 2103100 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS Sheet http://brickellbio.com/role/RecentAccountingPronouncements RECENT ACCOUNTING PRONOUNCEMENTS Notes 11 false false R12.htm 2104100 - Disclosure - NOVAQUEST FUNDING ARRANGEMENT Sheet http://brickellbio.com/role/NovaquestFundingArrangement NOVAQUEST FUNDING ARRANGEMENT Notes 12 false false R13.htm 2105100 - Disclosure - ACCRUED LIABILITIES Sheet http://brickellbio.com/role/AccruedLiabilities ACCRUED LIABILITIES Notes 13 false false R14.htm 2106100 - Disclosure - CONVERTIBLE PROMISSORY NOTES Notes http://brickellbio.com/role/ConvertiblePromissoryNotes CONVERTIBLE PROMISSORY NOTES Notes 14 false false R15.htm 2107100 - Disclosure - NOTE PAYABLE Sheet http://brickellbio.com/role/NotePayable NOTE PAYABLE Notes 15 false false R16.htm 2108100 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://brickellbio.com/role/CommitmentsAndContingencies COMMITMENTS AND CONTINGENCIES Notes 16 false false R17.htm 2109100 - Disclosure - CAPITAL STOCK Sheet http://brickellbio.com/role/CapitalStock CAPITAL STOCK Notes 17 false false R18.htm 2110100 - Disclosure - STOCK-BASED COMPENSATION Sheet http://brickellbio.com/role/StockBasedCompensation STOCK-BASED COMPENSATION Notes 18 false false R19.htm 2111100 - Disclosure - SUBSEQUENT EVENTS Sheet http://brickellbio.com/role/SubsequentEvents SUBSEQUENT EVENTS Notes 19 false false R20.htm 2202201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 20 false false R21.htm 2302302 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Sheet http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesTables SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Tables http://brickellbio.com/role/SummaryOfSignificantAccountingPolicies 21 false false R22.htm 2303301 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS (Tables) Sheet http://brickellbio.com/role/RecentAccountingPronouncementsTables RECENT ACCOUNTING PRONOUNCEMENTS (Tables) Tables http://brickellbio.com/role/RecentAccountingPronouncements 22 false false R23.htm 2305301 - Disclosure - ACCRUED LIABILITIES (Tables) Sheet http://brickellbio.com/role/AccruedLiabilitiesTables ACCRUED LIABILITIES (Tables) Tables http://brickellbio.com/role/AccruedLiabilities 23 false false R24.htm 2309301 - Disclosure - CAPITAL STOCK (Tables) Sheet http://brickellbio.com/role/CapitalStockTables CAPITAL STOCK (Tables) Tables http://brickellbio.com/role/CapitalStock 24 false false R25.htm 2310301 - Disclosure - STOCK-BASED COMPENSATION (Tables) Sheet http://brickellbio.com/role/StockBasedCompensationTables STOCK-BASED COMPENSATION (Tables) Tables http://brickellbio.com/role/StockBasedCompensation 25 false false R26.htm 2401401 - Disclosure - ORGANIZATION AND NATURE OF OPERATIONS - Narrative (Details) Sheet http://brickellbio.com/role/OrganizationAndNatureOfOperationsNarrativeDetails ORGANIZATION AND NATURE OF OPERATIONS - Narrative (Details) Details 26 false false R27.htm 2402403 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Merger Narrative (Details) Sheet http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesMergerNarrativeDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Merger Narrative (Details) Details 27 false false R28.htm 2402404 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Summary of Net Assets Acquired (Details) Sheet http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfNetAssetsAcquiredDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Summary of Net Assets Acquired (Details) Details 28 false false R29.htm 2402405 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Fair Value of Assets and Liabilities Measured on a Recurring Basis (Details) Sheet http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesFairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Fair Value of Assets and Liabilities Measured on a Recurring Basis (Details) Details 29 false false R30.htm 2402406 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Fair Value Measurements Narrative (Details) Sheet http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesFairValueMeasurementsNarrativeDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Fair Value Measurements Narrative (Details) Details 30 false false R31.htm 2402407 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Fair Value Measurement Inputs (Details) Sheet http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesFairValueMeasurementInputsDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Fair Value Measurement Inputs (Details) Details 31 false false R32.htm 2402408 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Reconciliation of Level 3 Financial Instruments (Details) Sheet http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesReconciliationOfLevel3FinancialInstrumentsDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Reconciliation of Level 3 Financial Instruments (Details) Details 32 false false R33.htm 2402409 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Redeemable Convertible Preferred Stock Narrative (Details) Sheet http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesRedeemableConvertiblePreferredStockNarrativeDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Redeemable Convertible Preferred Stock Narrative (Details) Details 33 false false R34.htm 2402410 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition Narrative (Details) Sheet http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionNarrativeDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition Narrative (Details) Details 34 false false R35.htm 2402411 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Summary of Common Shares Excluded from EPS Calculations (Details) Sheet http://brickellbio.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfCommonSharesExcludedFromEpsCalculationsDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Summary of Common Shares Excluded from EPS Calculations (Details) Details 35 false false R36.htm 2403402 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS - Narrative (Details) Sheet http://brickellbio.com/role/RecentAccountingPronouncementsNarrativeDetails RECENT ACCOUNTING PRONOUNCEMENTS - Narrative (Details) Details 36 false false R37.htm 2403403 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS - Effects of Topic 842 (Details) Sheet http://brickellbio.com/role/RecentAccountingPronouncementsEffectsOfTopic842Details RECENT ACCOUNTING PRONOUNCEMENTS - Effects of Topic 842 (Details) Details 37 false false R38.htm 2404401 - Disclosure - NOVAQUEST FUNDING ARRANGEMENT - Narrative (Details) Sheet http://brickellbio.com/role/NovaquestFundingArrangementNarrativeDetails NOVAQUEST FUNDING ARRANGEMENT - Narrative (Details) Details 38 false false R39.htm 2405402 - Disclosure - ACCRUED LIABILITIES - Summary of Accrued Liabilities (Details) Sheet http://brickellbio.com/role/AccruedLiabilitiesSummaryOfAccruedLiabilitiesDetails ACCRUED LIABILITIES - Summary of Accrued Liabilities (Details) Details 39 false false R40.htm 2406401 - Disclosure - CONVERTIBLE PROMISSORY NOTES - Narrative (Details) Notes http://brickellbio.com/role/ConvertiblePromissoryNotesNarrativeDetails CONVERTIBLE PROMISSORY NOTES - Narrative (Details) Details 40 false false R41.htm 2407401 - Disclosure - NOTE PAYABLE - Narrative (Details) Sheet http://brickellbio.com/role/NotePayableNarrativeDetails NOTE PAYABLE - Narrative (Details) Details 41 false false R42.htm 2408401 - Disclosure - COMMITMENTS AND CONTINGENCIES - Narrative (Details) Sheet http://brickellbio.com/role/CommitmentsAndContingenciesNarrativeDetails COMMITMENTS AND CONTINGENCIES - Narrative (Details) Details 42 false false R43.htm 2409402 - Disclosure - CAPITAL STOCK - Narrative (Details) Sheet http://brickellbio.com/role/CapitalStockNarrativeDetails CAPITAL STOCK - Narrative (Details) Details 43 false false R44.htm 2409403 - Disclosure - CAPITAL STOCK - Reserved Authorized Shares of Common Stock (Details) Sheet http://brickellbio.com/role/CapitalStockReservedAuthorizedSharesOfCommonStockDetails CAPITAL STOCK - Reserved Authorized Shares of Common Stock (Details) Details 44 false false R45.htm 2409404 - Disclosure - CAPITAL STOCK - Summary of Preferred Stock (Details) Sheet http://brickellbio.com/role/CapitalStockSummaryOfPreferredStockDetails CAPITAL STOCK - Summary of Preferred Stock (Details) Details 45 false false R46.htm 2410402 - Disclosure - STOCK-BASED COMPENSATION - Narrative (Details) Sheet http://brickellbio.com/role/StockBasedCompensationNarrativeDetails STOCK-BASED COMPENSATION - Narrative (Details) Details 46 false false R47.htm 2410404 - Disclosure - STOCK-BASED COMPENSATION - Share-based Compensation Expense (Details) Sheet http://brickellbio.com/role/StockBasedCompensationShareBasedCompensationExpenseDetails STOCK-BASED COMPENSATION - Share-based Compensation Expense (Details) Details 47 false false R9999.htm Uncategorized Items - a20190930-10q.htm Sheet http://xbrl.sec.gov/role/uncategorizedFacts Uncategorized Items - a20190930-10q.htm Cover 48 false false All Reports Book All Reports a20190930-10q.htm bbi-20190930.xsd bbi-20190930_cal.xml bbi-20190930_def.xml bbi-20190930_lab.xml bbi-20190930_pre.xml ex311.htm ex312.htm ex321.htm http://xbrl.sec.gov/dei/2019-01-31 http://fasb.org/srt/2019-01-31 http://fasb.org/us-gaap/2019-01-31 true true XML 54 R37.htm IDEA: XBRL DOCUMENT v3.19.3
RECENT ACCOUNTING PRONOUNCEMENTS - Effects of Topic 842 (Details) - USD ($)
$ in Thousands
Sep. 30, 2019
Jan. 01, 2019
New Accounting Pronouncements or Change in Accounting Principle [Line Items]    
Operating lease right-of-use asset $ 176  
Lease liability, current portion (75)  
Lease liability, net of current portion $ (94)  
Topic 842    
New Accounting Pronouncements or Change in Accounting Principle [Line Items]    
Operating lease right-of-use asset   $ 219
Lease liability, current portion   (68)
Lease liability, net of current portion   (151)
Impact of Adoption    
New Accounting Pronouncements or Change in Accounting Principle [Line Items]    
Operating lease right-of-use asset   219
Lease liability, current portion   (68)
Lease liability, net of current portion   $ (151)
XML 55 R33.htm IDEA: XBRL DOCUMENT v3.19.3
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Redeemable Convertible Preferred Stock Narrative (Details) - USD ($)
$ in Thousands
9 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Temporary Equity [Line Items]    
Amortization of debt discounts and financing costs $ 215 $ 310
Series A, B, C & C-1 Redeemable Convertible Preferred Stock    
Temporary Equity [Line Items]    
Amortization of debt discounts and financing costs $ 100 $ 30
XML 56 R10.htm IDEA: XBRL DOCUMENT v3.19.3
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
9 Months Ended
Sep. 30, 2019
Accounting Policies [Abstract]  
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The accompanying condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, Brickell Subsidiary, Inc., are presented in U.S. dollars and have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”) and applicable rules and regulations of the SEC for interim reporting. As permitted under those rules and regulations, certain footnotes or other financial information normally included in financial statements prepared in accordance with US GAAP have been condensed or omitted. These condensed consolidated financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments, consisting only of normal recurring adjustments, which are necessary for a fair presentation of the Company’s financial information. The results of operations for the three and nine months ended September 30, 2019 are not necessarily indicative of the results to be expected for the full year ending December 31, 2019, for any other interim period, or for any other future period. The condensed consolidated balance sheet as of December 31, 2018 has been derived from audited financial statements at that date but does not include all of the information required by US GAAP for complete financial statements. All intercompany balances and transactions have been eliminated in consolidation.

The Merger has been accounted for as a recapitalization. Prior to the Merger, Vical wound down its pre-merger business assets and liabilities. The owners and management of Private Brickell have actual and effective voting and operating control of the combined company. In the Merger transaction, Vical is the accounting acquiree and Private Brickell is the accounting acquirer. A recapitalization is equivalent to the issuance of stock by the private operating company for the net monetary assets of the accounting acquiree accompanied by a recapitalization with accounting similar to that resulting from a reverse acquisition, except that no goodwill or intangible assets are recorded. 

In connection with the Merger, 3,367,988 shares of common stock were transferred to the existing Vical stockholders and the Company assumed approximately $36.1 million in net tangible assets from Vical, which were recorded as charges against additional paid-in capital. The following table summarizes the net assets acquired based on their estimated fair values immediately prior to the Merger (in thousands):
Cash and cash equivalents
$
13,017

Marketable securities
23,959

Prepaid expenses and other current assets
1,474

Accrued liabilities
(2,357
)
Net acquired tangible assets
$
36,093



In connection with the Merger, the Company assumed warrants previously held by Vical, which provide the warrantholder the right to purchase 891,582 shares of common stock at an exercise price of $0.07 (the “Vical Warrants”). The Vical Warrants were classified as equity.

The combined company assumed all the outstanding options, under Vical’s equity incentive plan (the "Vical Plan") with such options representing the right to purchase a number of shares of Brickell common stock previously represented by such options, as adjusted for the recapitalization.
 
Use of Estimates

The Company’s condensed consolidated financial statements are prepared in accordance with US GAAP, which requires it to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Although these estimates are based on the Company’s knowledge of current events and actions it may take in the future, actual results may ultimately differ from these estimates and assumptions.

Risks and Uncertainties

The Company’s business is subject to significant risks common to early-stage companies in the pharmaceutical industry including, but not limited to, the ability to develop appropriate formulations, scale up and production of the compounds, dependence on collaborative parties, uncertainties associated with obtaining and enforcing patents and other intellectual property rights, clinical implementation and success, the lengthy and expensive regulatory approval process, compliance with regulatory and other legal requirements, competition from other products; uncertainty of broad adoption of its approved products, if any, by physicians and patients; significant competition; ability to manage third-party manufacturers, suppliers, contract research organizations, business partners and other alliance management, and obtaining additional financing to fund the Company’s efforts.

The product candidates developed by the Company require approvals from the U.S. Food and Drug Administration (“FDA”) and foreign regulatory agencies prior to commercial sales in the United States or foreign jurisdictions, respectively. There can be no assurance that the Company’s current and future product candidates will receive the necessary approvals. If the Company is denied approval or approval is delayed, it may have a material adverse impact on the Company’s business and its financial condition.

The Company expects to incur substantial operating losses for the next several years and will need to obtain additional financing in order to complete clinical studies and launch and commercialize any product candidates for which it receives regulatory approval. There can be no assurance that such financing will be available or will be at terms acceptable by the Company.

Fair Value Measurements

Fair value is the price that the Company would receive to sell an asset or pay to transfer a liability in a timely transaction with an independent counterparty in the principal market or in the absence of a principal market, the most advantageous market for the asset or liability. A three-tier hierarchy is established to distinguish between (1) inputs that reflect the assumptions market participants would use in pricing an asset or liability developed based on market data obtained from sources independent of the reporting entity (observable inputs) and (2) inputs that reflect the reporting entity’s own assumptions about the assumptions market participants would use in pricing an asset or liability developed based on the best information available in the circumstances (unobservable inputs), and establishes a classification of fair value measurements for disclosure purposes.

The hierarchy is summarized in the three broad levels listed below:
 
Level 1—quoted prices in active markets for identical assets and liabilities
Level 2—other significant observable inputs (including quoted prices for similar assets and liabilities, interest rates, credit risk, etc.)
Level 3—significant unobservable inputs (including the Company’s own assumptions in determining the fair value of assets and liabilities)

The following tables set forth the fair value of the Company’s financial assets and liabilities measured at fair value on a recurring basis based on the three-tier fair value hierarchy as of September 30, 2019 and December 31, 2018 (in thousands):
 
September 30, 2019
 
Level 1 
 
Level 2 
 
Level 3 
Assets:
 
 
 
 
 
Money market funds
$
7,225

 
$

 
$

U.S. treasuries
18,473

 

 

Total
$
25,698

 
$

 
$

Liabilities:
 
 
 
 
 
Contingent consideration
$

 
$

 
$
145

 
December 31, 2018
 
Level 1
 
Level 2
 
Level 3
Assets:
 
 
 
 
 
Money market funds
$
8,067

 
$

 
$

Liabilities:
 
 
 
 
 
Redeemable convertible preferred stock warrant liability
$

 
$

 
$
242

Contingent consideration

 

 
145

Total
$

 
$

 
$
387



Fair Value of Financial Instruments

The following methods and assumptions were used by the Company in estimating the fair values of each class of financial instrument disclosed herein:

Money Market Funds—The carrying amounts reported as cash and cash equivalents in the condensed consolidated balance sheets approximate their fair values due to their short-term nature and/or market rates of interest (Level 1 of the fair value hierarchy).

U.S. Treasuries—The Company has designated its investments in U.S. treasury securities as available-for-sale securities and accounts for them at their respective fair values. The securities are classified as short-term or long-term based on the nature of the securities and their availability to meet current operating requirements. Securities that are readily available for use in current operations are classified as short-term available-for-sale marketable securities and are reported as a component of current assets in the condensed consolidated balance sheets (Level 1 of the fair value hierarchy).

Securities that are classified as available-for-sale are measured at fair value, including accrued interest, with temporary unrealized gains and losses reported as a component of stockholders’ equity until their disposition. The Company reviews available-for-sale securities at the end of each period to determine whether they remain available-for-sale based on its then current intent. The cost of securities sold is based on the specific identification method. The securities are subject to a periodic impairment review. An impairment charge would occur when a decline in the fair value of the investments below the cost basis is judged to be other-than-temporary.

As of September 30, 2019, the Company’s available-for-sale securities had an amortized cost of $18.5 million, fair value of $18.5 million, and an unrealized gain of $20 thousand. Because the securities were acquired in August 2019 in connection to the Merger, there were no related balances as of December 31, 2018.

Contingent Consideration—These amounts represent future payments in conjunction with various business combinations related to the acquisition of certain early-stage pipeline assets. The ultimate amount of future payments is based on specified future criteria, such as the achievement of certain future development and regulatory milestones. The Company evaluates its estimates of the fair value of contingent consideration on a quarterly basis. The fair value of the contingent consideration was determined with the assistance of a third-party valuation firm applying the income approach. This approach estimates the fair value of the contingent consideration related to the achievement of future development and regulatory milestones by assigning an achievement probability and date of expected completion to each potential milestone and discounting the associated cash payment to its present value using a risk-adjusted rate of return. The probability of success of each milestone assumes that the prerequisite developmental milestones are successfully completed and is based on the asset’s current stage of development and anticipated regulatory requirements. The probability of success for each milestone is determined by multiplying the preceding probabilities of success. The unobservable inputs (Level 3 of the fair value hierarchy) to the valuation models that have the most significant effect on the fair value of the Company’s contingent consideration are the probabilities that certain in-process development projects will meet specified development milestones, including ultimate approval by the FDA, with individual cumulative probabilities ranging from 2.1% to 20.9%. Other unobservable inputs used in this approach include risk-adjusted discount rates ranging from 15.5% to 27.1% and estimates of the timing of the achievement of the various product development, regulatory approval, and sales milestones.

Redeemable Convertible Preferred Stock Warrant Liability—These amounts represented potential future obligations to transfer assets to the holders at a future date. The Company remeasured these warrants to current fair value at each balance sheet date, and any change in fair value was recognized as a change in fair value of warrant liability in the condensed consolidated statements of operations. The Company estimated the fair value of these warrants at December 31, 2018 using the Black-Scholes option-pricing model (Level 3 of the fair value hierarchy table). These warrants converted from warrants exercisable for redeemable convertible preferred stock to common stock in August 2019 in connection to the Merger (see further discussion in Note 7).

Inputs used to determine estimated fair value of the warrant liabilities included the estimated fair value of the underlying stock at the valuation date, the estimated term of the warrants, risk-free interest rates, expected dividends, and the expected volatility of the underlying stock. The most significant unobservable inputs used in the fair value measurement of the convertible preferred stock warrant liability were the fair value of the underlying stock at the valuation date and the estimated term of the warrants. Generally, increases (decreases) in the fair value of the underlying stock and estimated term resulted in a directionally similar impact to the fair value measurement.

The fair value of the outstanding warrants was remeasured as of each period end using the Black-Scholes option-pricing model with the following assumptions:
 
2018
Expected term (in years)
7.1

Expected volatility
30.00
%
Risk free interest rate
2.59
%
Expected dividend yield
%


The fair value of the shares of the convertible preferred stock underlying the preferred stock warrants was historically determined with the assistance of a third-party valuation firm. Because there had been no public market for the Company’s convertible preferred stock, the third-party valuation firm determined fair value of the convertible preferred stock at each balance sheet date by considering a number of objective and subjective factors, including valuation of comparable companies, sales of convertible preferred stock to unrelated third parties, operating and financial performance, the lack of liquidity of capital stock, and general and industry specific economic outlook, among other factors.

Remaining Term. The Company derived the expected term based on the time from the balance sheet date until the preferred stock warrant’s expiration date.

Expected Volatility. Since the Company was a private entity with no historical data regarding the volatility of its preferred stock, the expected volatility used was based on volatility of a group of similar entities. In evaluating similarity, the Company considered factors such as industry, stage of life cycle, and size.

Risk-free Interest Rate. The risk-free interest rate was based on U.S. Treasury zero-coupon issues with remaining terms similar to the expected term of the warrants.

Expected Dividend Rate. The Company has never paid any dividends and does not plan to pay dividends in the foreseeable future and, therefore, used an expected dividend rate of zero in the valuation model.

Derivative Liability—These amounts represented potential future obligations to transfer assets to the holders at a future date. The fair value of the derivative liability has historically been determined with the assistance of a third-party valuation firm (Level 3 of the fair value hierarchy table) (see further discussion in Note 6). At the inception of the liability, there was no public market for the Company’s common stock, and a third-party valuation firm determined fair value of the stock by considering a number of objective and subjective factors, including valuation of comparable companies, sales of common stock to unrelated third parties, operating and financial performance, the lack of liquidity of capital stock, and general and industry specific economic outlook, among other factors. The derivative liability was marked-to-market each measurement period and any change in fair value was recorded in the condensed consolidated statements of operations. In August 2019, in connection to the Merger, the derivative liability was reclassified to equity in the condensed consolidated balance sheet (see further discussion in Note 6).

Common Stock Warrant Liability—These amounts represented potential future obligations to transfer assets to the holders at a future date. The fair value of the warrants was historically determined with the assistance of a third-party valuation firm (Level 3 of the fair value hierarchy table) (see further discussion in Note 6). At the inception of the liability, there was no public market for the Company’s common stock, and a third-party valuation firm determined fair value of the stock by considering a number of objective and subjective factors, including valuation of comparable companies, sales of common stock to unrelated third parties, operating and financial performance, the lack of liquidity of capital stock, and general and industry specific economic outlook, among other factors. The warrant liability was remeasured to fair value at each balance sheet date, and any change in fair value was recognized as a change in fair value of warrant liability in the condensed consolidated statements of operations. The Company estimated the fair value of these warrants using the Black-Scholes option-pricing model. In August 2019, in connection to the Merger, the warrant liability was reclassified to equity in the condensed consolidated balance sheet (see further discussion in Note 6).

Inputs used to determine estimated fair value of the warrant liabilities included the estimated fair value of the underlying stock at the valuation date, the estimated term of the warrants, risk-free interest rates, expected dividends, and the expected volatility of the underlying stock. The most significant unobservable inputs used in the fair value measurement of the warrant liability were the fair value of the underlying stock at the valuation date and the estimated term of the warrants. Generally, increases (decreases) in the fair value of the underlying stock and estimated term resulted in a directionally similar impact to the fair value measurement.

The following table sets forth a summary of the changes in the fair value of the Company’s Level 3 financial instruments as follows (in thousands):
 
Derivative
Liability
 
Common
Stock
Warrant
Liability
 
Redeemable
Convertible
Preferred
Stock Warrant
Liability
 
Contingent
Consideration
Liabilities
Fair value as of December 31, 2018
$

 
$

 
$
242

 
$
145

Fair value of financial instruments issued
1,442

 
1,492

 

 

Change in fair value
11

 
17

 
(240
)
 

Reclassification to equity
(1,453
)
 
(1,509
)
 
(2
)
 

Fair value as of September 30, 2019
$

 
$

 
$

 
$
145



Leases

On January 1, 2019, the Company adopted Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 842, Leases (“ASC 842”), using the modified retrospective method for all lease arrangements at the beginning of the
period of adoption. Results for reporting periods beginning January 1, 2019 are presented under ASC 842, while prior period amounts were not adjusted and continue to be presented in accordance with the Company’s historical accounting under ASC Topic 840, Leases. ASC 842 had an impact on the Company’s condensed consolidated balance sheets but did not have a significant impact on the Company’s net loss.

Under ASC 842, the Company determines if an arrangement is a lease at inception. Leases with a term greater than one year are recognized on the balance sheet as right-of-use assets, lease liabilities and, if applicable, long-term lease liabilities. The Company has elected the practical expedient not to recognize on the balance sheet leases with terms of one-year or less and not to separate lease components and non-lease components for long-term real-estate leases. Lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company estimates the incremental borrowing rate based on industry peers in determining the present value of lease payments. The Company’s facility operating lease has one single component. The lease component results in a right-of-use asset being recorded on the balance sheet, which is amortized as lease expense on a straight-line basis in the Company’s condensed consolidated statements of operations.

Redeemable Convertible Preferred Stock

Redeemable convertible preferred stock was classified as a mezzanine instrument outside of the Company’s capital accounts. Accretion of redeemable convertible preferred stock included the greater of an adjustment to fair market value or the accrual of dividends on and accretion of issuance costs of the Company’s redeemable convertible preferred stock. The carrying values of the redeemable convertible preferred stock were increased or reduced by periodic accretion or reduction to their respective redemption values from the date of issuance to August 31, 2019, the date that all outstanding shares of redeemable convertible preferred stock converted into shares of common stock. The carrying value adjustments were recorded as charges against additional paid-in capital balance.

Preferred stock issuance costs represent costs related to the Company’s issuance of redeemable convertible preferred stock. These amounts were included as a reduction of redeemable convertible preferred stock and were amortized over the estimated redemption period until its conversion to common stock in August 2019. For the nine months ended September 30, 2019 and 2018, amortization of preferred stock issuance costs amounted to approximately $0.1 million and $30 thousand, respectively.
 
Redeemable Convertible Preferred Stock Warrants

The Company accounted for warrants to purchase shares of its redeemable convertible preferred stock as liabilities at their estimated fair value because the underlying shares were redeemable, which obligated the Company to transfer assets to the holders at a future date. The warrants were subject to remeasurement to fair value at each balance sheet date, and any fair value adjustments were recognized as change in fair value of redeemable convertible preferred stock warrant liability in the condensed consolidated statements of operations. The Company continued to adjust the liability for changes in fair value until the conversion of the redeemable convertible preferred stock into common stock in August 2019. At that time, the redeemable convertible preferred stock warrant liability was adjusted to fair value in the condensed consolidated statements of operations with the final fair value reclassified to equity.

Revenue Recognition

The Company recognizes revenue upon the transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies the performance obligations. At contract inception, the Company assesses the goods or services promised within each contract and assesses whether each promised good or service is distinct and determines those that are performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.

To date, the Company’s drug candidates have not been approved for sale by the FDA or any other country’s regulatory authority, and the Company has not generated or recognized any revenue from the sale of products.

In March 2015, the Company entered into a license and collaboration agreement with Kaken Pharmaceutical, Co., Ltd. (“Kaken”), which is referred to as the “Collaboration Agreement.” Under the Collaboration Agreement, the Company granted to Kaken an exclusive right to develop, manufacture, and commercialize the Company’s sofpironium bromide compound (formerly BBI-4000), a topical anticholinergic, in Japan and certain other Asian countries (the “Territory”). In exchange, Kaken paid the Company an upfront, non-refundable payment of $11.0 million (the “upfront fee”). In addition, the Company is entitled to receive aggregate payments of up to $10.0 million upon the achievement of specified development milestones, and $30.0 million upon the achievement of commercial milestones, as well as tiered royalties based on a percentage of net sales of licensed products in the Territory. The Collaboration Agreement further provides that Kaken will be responsible for funding all development and commercial costs for the program in the Territory and, until such time, if any, as Kaken elects to establish its own source of supply of drug product, Kaken can purchase product supply from the Company to perform all non-clinical studies, and Phase 1 and Phase 2 clinical trials in Japan at cost. Kaken is also required to enter into negotiations with the Company, to supply the Company, at cost, with clinical supplies to perform Phase 3 clinical trials in the United States.

Collaboration Arrangement Subsequent to Adoption of Topic 606

The Company evaluates collaboration arrangements to determine whether units of account within the collaboration arrangement exhibit the characteristics of a vendor and customer relationship. The Company determined that the licenses transferred to Kaken in exchange for the upfront fees were representative of this type of a relationship. If a license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from non-refundable, upfront fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other performance obligations, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition on a prospective basis.

Under Topic 606, the Company evaluated the terms of the Collaboration Agreement and the transfer of intellectual property and manufacturing rights (the “license”) was identified as the only performance obligation as of the inception of the agreement. The Company concluded that the license for the intellectual property was distinct from its ongoing supply obligations. The Company further determined that the transaction price under the arrangement was comprised of the $11.0 million upfront payment. The future potential milestone amounts were not included in the transaction price, as they were all determined to be fully constrained. As part of its evaluation of the development and regulatory milestones constraint, the Company determined that the achievement of such milestones is contingent upon success in future clinical trials and regulatory approvals, each of which is uncertain at this time. The Company will re-evaluate the transaction price each quarter and as uncertain events are resolved or other changes in circumstances occur. Future potential milestone amounts would be recognized as revenue from collaboration arrangements, if unconstrained. The remainder of the arrangement, which largely consisted of both parties incurring costs in their respective territories, provides for the reimbursement of the ongoing supply costs. These costs were representative of a collaboration arrangement outside of the scope of Topic 606 as it does not have the characteristics of a vendor and customer relationship. Reimbursable program costs are recognized proportionately with the delivery of drug substance and are accounted for as reductions to research and development expense and are excluded from the transaction price.

Under Topic 606, the entire transaction price of $11.0 million was allocated to the license performance obligation. The license was deemed to be delivered in 2015 in connection with the execution of the Collaboration Agreement and upon transfer of the underlying intellectual property the performance obligation was fully satisfied. As a result, a cumulative adjustment to reduce deferred revenue and the corresponding sublicensing costs of $2.7 million was recorded upon the adoption of Topic 606 on January 1, 2018. As of September 30, 2019, the Company does not have a deferred revenue or deferred sublicensing costs balance related to the upfront fee on the condensed consolidated balance sheet.

In May 2018, the Company entered into an amendment to the Collaboration Agreement (as further amended, “Collaboration Agreement”), pursuant to which, the Company received an upfront non-refundable fee of $15.6 million (the “Collaboration R&D Payment”), which was initially recorded as deferred revenue, to provide the Company with research and development funds for the sole purpose of conducting certain clinical trials and other such research and development activities required to support the submission of a NDA for sofpironium bromide. These clinical trials have a benefit to Kaken and have the characteristics of a vendor and customer relationship. The Company has accounted for these under the provisions of Topic 606. This Collaboration R&D Payment will be initially recognized using an input method over the average estimated performance period of 1.45 years in proportion to the cost incurred. Upon receipt of the Collaboration R&D Payment, on May 31, 2018, a milestone payment
originally due upon the first commercial sale in Japan was removed from the Collaboration Agreement and all future royalties to the Company under the Collaboration Agreement were reduced 150 basis points.

Consequently, during the three and nine months ended September 30, 2019, the Company recognized revenue of $1.2 million and $7.2 million, respectively related to the Collaboration R&D Payment. As of September 30, 2019, the Company has a deferred revenue balance related to the Collaboration R&D Payment of $2.5 million, which is recorded in deferred revenue, current portion on the accompanying condensed consolidated balance sheets.

Milestones

At the inception of each arrangement that includes milestone payments (variable consideration), the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company or the Company’s collaboration partner’s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such milestones and any related constraint, and if necessary, adjust the Company’s estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration or other revenues and earnings in the period of adjustment.

In October 2017, the Company entered into an amendment to the Collaboration Agreement, pursuant to which, the Company granted Kaken a prepayment option (the “Kaken Option”) on 50% of the Initiation of Phase 3 milestone (the “Phase 3 Milestone”). The Kaken Option was exercisable by Kaken within 25 business days of receipt of the BBI-4000-CL-203 study topline results. In December 2017, Kaken exercised the Kaken Option and paid the Company $5.0 million (the “Kaken Option Payment”). Upon receipt of the non-refundable Kaken Option Payment, the Company provided Kaken the right to negotiate an exclusive license to develop, manufacture and commercialize each of the Company’s other product candidates in Japan (“ROFN Agreement”). Under the ROFN Agreement, following the completion of any Initial Proof of Concept Clinical Trial (“Initial POC”) for the Company’s other product candidates, the Company must provide Kaken with certain information relating to the results of the clinical trial (“Initial POC Package”). The ROFN Agreement is exercisable by Kaken within 30 days of receipt of the Initial POC Package. In December 2017, the Company recognized collaboration revenue related to the Collaboration Agreement of $5.0 million, in connection with the Kaken Option. Additionally, the Company recognized sublicensing costs of $1.0 million, which are included in general and administrative expenses.

The Collaboration Agreement was further amended in March 2018 to accelerate payment of the Phase 3 Milestone. The Phase 3 Milestone was modified to be due upon the successful completion of the End of Phase 2 Meeting with the PMDA by Kaken on March 8, 2018, as determined by Kaken in its reasonable discretion (the “Third Milestone”). In March 2018, Kaken triggered the Third Milestone and paid the Company $5.0 million (the “Third Milestone Payment”). Upon receipt of the non-refundable Third Milestone Payment, the ROFN Agreement was amended (the “Amended ROFN Agreement”) to grant an additional option to exercise upon completion of a Subsequent Clinical Trial (first clinical trial after the Initial POC) for the Company’s other product candidates. The Company has determined that the ROFN Agreement is not a material right and has not allocated transaction price to this provision. As of September 30, 2019, Kaken has not exercised the Amended ROFN Agreement. In March 2018, the Company recognized collaboration revenue related to the Collaboration Agreement of $5.0 million in connection with the Third Milestone. Additionally, the Company recognized sublicensing costs of $1.0 million, which are included in general and administrative expenses.

Royalties

For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognized revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue from any collaborative arrangement.

Under collaborative arrangements, the Company has been reimbursed for a portion of the Company’s research and development expenses, including costs of drug supplies. When the research and development services are performed under a reimbursement
or cost sharing model with a collaboration partner, the Company records these reimbursements as a reduction of research and development expense in the Company’s condensed consolidated statements of operations.
 
Net Loss per Common Share

Basic and diluted net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares outstanding. When the effects are not anti-dilutive, diluted earnings per share is computed by dividing the Company’s net earnings by the weighted average number of common shares outstanding and the impact of all dilutive potential common shares.

Diluted earnings per share gives effect to all dilutive potential common shares outstanding during the period, including stock options and warrants, using the treasury stock method, and redeemable convertible preferred stock, using the if-converted method. In computing diluted earnings per share, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants. Potentially dilutive common share equivalents are excluded from the diluted earnings per share computation in net loss periods because their effect would be anti-dilutive.

The following table sets forth the potential common shares excluded from the calculation of net loss per common share, because their inclusion would be anti-dilutive:
 
Three and Nine Months Ended
September 30,
 
2019
 
2018
Warrants to purchase common stock
1,632,495

 
55,360

Options to purchase common stock
1,802,895

 
1,347,500

Redeemable convertible preferred stock (as converted into common stock)

 
1,256,466

Warrants to purchase redeemable convertible preferred stock (as converted into common stock)

 
9,005

Total
3,435,390

 
2,668,331


XML 57 R14.htm IDEA: XBRL DOCUMENT v3.19.3
CONVERTIBLE PROMISSORY NOTES
9 Months Ended
Sep. 30, 2019
Debt Disclosure [Abstract]  
CONVERTIBLE PROMISSORY NOTES CONVERTIBLE PROMISSORY NOTES

In March 2019, the Company initiated a convertible promissory notes offering pursuant to which the Company issued unsecured convertible promissory notes (the “Prom Notes”), bearing interest at 12.00% with a maturity of one year and convertible into shares of Series C-1 redeemable convertible preferred stock or the most senior preferred equity outstanding at the time of conversion at the option of the holder at a conversion price of $31.05 per share. In addition, the Prom Notes were automatically convertible upon closing of a qualified financing of at least $15.0 million before maturity at a conversion price equal to 80% of the effective price per share paid in the qualified financing, but not to exceed $38.82 per share. Through August 31, 2019, the Company had raised an aggregate principal amount of $7.4 million in Prom Notes. On August 31, 2019, prior to the Merger, the Prom Notes and related accrued interest converted into 1,069,740 shares of Private Brickell common stock at a conversion price of $7.54 per share (the “Conversion”).

The Prom Notes also provided for the issuance of warrants at 50% coverage, to acquire 490,683 shares of common stock. The warrants are exercisable for a term of five years at an exercise price of $10.36. Prior to the Merger, the warrants were exercisable at an exercise price of $42.70 or 10% premium to the effective price per share paid in a qualified financing. The Company evaluated the various financial instruments under ASC 480 and ASC 815 and determined the warrants required fair value accounting. The fair value of the warrants was recorded as a warrant liability upon issuance. The fair value of the warrants on the dates of issuance of $1.5 million was determined with the assistance of a third-party valuation firm. The fair value of the warrants was recorded as a debt discount upon issuance and was amortized to interest expense over the term of the Prom Notes based on the effective interest method.

At inception of the Prom Notes offering, the Company analyzed the conversion feature of the agreement for derivative accounting consideration under ASC 815 and determined that the embedded conversion features should be classified as a derivative because the exercise price of the Prom Notes are subject to a variable conversion rate. The Company determined that the variable conversion feature was a redemption feature that was not clearly and closely related to the Prom Notes and was therefore required to be bifurcated. In accordance with AC 815, the Company bifurcated the conversion feature of the Prom Notes and recorded a derivative liability.

The embedded derivative for the Prom Notes was carried on the Company’s condensed consolidated balance sheet at fair value. The derivative liability was marked-to-market each measurement period and any change in fair value was recorded as a component of the statements of operations. The fair value of the derivative liabilities on the date of issuance of $1.4 million was determined with the assistance of a third-party valuation firm. The fair value of the conversion feature was recorded as a debt discount upon issuance and was amortized to interest expense over the term of the Prom Notes based on the effective interest method.

The Company evaluated the conversion option to discern whether a beneficial conversion feature existed based upon comparing the effective exercise price of the convertible notes to the fair value of the shares they were convertible into. The Company concluded no beneficial conversion feature existed. During the three months ended September 30, 2019, the Company recognized $1.1 million of interest expense, including $0.4 million of accretion of discounts using an effective interest rate of 12.00%. During the nine months ended September 30, 2019, the Company recognized $2.0 million of interest expense, including $0.8 million of accretion of discounts using an effective interest rate of 12.00%.

As a result of the Conversion on August 31, 2019, the Prom Notes payable, warrant liability, and derivative liability balances were reclassified to equity in the condensed consolidated balance sheets. A gain of $2.3 million resulted from the Conversion of the Prom Notes, which is included in the gain on extinguishment line in the condensed consolidated statements of operations.
NOTE PAYABLE

On February 18, 2016, the Company entered into a loan and security agreement (the “Loan Agreement”) with Hercules Capital, Inc. (the “Lender”) under which the Company borrowed $7.5 million upon the execution of the Loan Agreement on February 18, 2016. The interest rate applicable to each tranche was variable based upon the greater of either (i) 9.2% and (ii) the sum of (a) the Prime Rate as reported in The Wall Street Journal minus 3.5%, plus (b) 9.2%; notwithstanding the above, such rate could not exceed the permissible rates of interest on commercial loans under the laws of the State of California. Payments under the Loan Agreement were interest only until June 1, 2017, followed by equal monthly payments of principal and interest through the maturity date of September 1, 2019. The Company was required to make an end of term payment of 4.5% of the sum of (i) term loan advances, plus (ii) 50% of the aggregate unfunded term loan commitments. The Loan Agreement was further amended in December 2017, March 2018, and July 2018 (as further amended, “Loan Agreement”) to provide for an additional combined interest-only period of eight months, and the outstanding loan balance continued to be paid in equal monthly installments of principal and interest. As a result of the amendments, the Company was required to increase the end-of-term payment by $0.1 million. At the inception of the loan and the following amendment dates, the Company paid the Lender aggregate facility fees of $0.2 million in connection with the Loan Agreement.

In connection with the Loan Agreement, the Company issued warrants to the Lender, which are exercisable for 9,005 shares of common stock at a per share exercise price of $33.31 (the “Hercules Capital Warrants”). The Hercules Capital Warrants will terminate, if not earlier exercised, on February 18, 2026. The fair value of the Hercules Capital Warrants was recorded at inception as a redeemable convertible preferred stock warrant liability upon issuance. The fair value of the Hercules Capital Warrants on the date of issuance of $0.3 million was determined using the Black-Scholes option-pricing model and was recorded as a debt discount upon issuance and was amortized to interest expense over the term of the loan based on the effective interest method.

On September 3, 2019, the Company repaid the remaining outstanding loan balance of $2.6 million and an associated accrued interest and aggregate end-of-term payment of $0.6 million, and the Loan Agreement was terminated. At the effective time of the Merger, the warrant liability was reclassified to equity in the condensed consolidated balance sheet. As of September 30, 2019, there were no remaining unaccreted debt discounts and issuance costs.
XML 58 R18.htm IDEA: XBRL DOCUMENT v3.19.3
STOCK-BASED COMPENSATION
9 Months Ended
Sep. 30, 2019
Share-based Payment Arrangement [Abstract]  
STOCK-BASED COMPENSATION STOCK-BASED COMPENSATION

Equity Incentive Plans

The Company’s 2009 Equity Incentive Plan, as amended and restated (the “2009 Plan”), provides for the Company to sell or issue common stock or restricted common stock, or to grant incentive stock options or nonqualified stock options for the purchase of common stock, to employees, members of the Board of Directors, and consultants of the Company. At September 30, 2019, the total shares authorized under the 2009 Plan were 1,634,655 shares. The Board of Directors or a designated Committee of the Board is responsible for the administration of the 2009 Plan and determines the term, exercise price, and vesting terms of each option. Options granted under the 2009 Plan have an exercise price equal to the market value of the common stock at the date of grant and expire ten years from the date of grant. At September 30, 2019, a total of 17,232 shares were available for grant under the 2009 Plan.

In connection with the Merger, the Company adopted Vical’s Equity Incentive Plan (the “Vical Plan”). At September 30, 2019, the total shares authorized under the Vical Plan were 413,710 shares The Vical Plan, as amended, provides for the Company to sell or issue common stock or restricted common stock, or to grant incentive stock options or nonqualified stock options for the purchase of common stock, to employees, members of the Board of Directors, and consultants of the Company. The plan provides for the grant of incentive and nonstatutory stock options and the direct award or sale of shares, including restricted stock. The exercise price of stock options must equal at least the fair market value of the underlying common stock on the date of grant. The maximum term of options granted under the plan is ten years. The Vical Plan also limits the number of options that may be granted to any plan participant in a single calendar year to 1,300,000 shares. At September 30, 2019, a total of 119,070 shares were available for grant under the Vical Plan.

Share-based Compensation Expense

Total stock-based compensation expense related to stock options granted under the 2009 Plan was allocated as follows (in thousands):
 
Three Months Ended
September 30,
 
Nine Months Ended
September 30,
 
2019
 
2018
 
2019
 
2018
Research and development
$
81

 
$
76

 
$
237

 
$
263

General and administrative
243

 
75

 
770

 
253

Total stock-based compensation expense
$
324

 
$
151

 
$
1,007

 
$
516


XML 59 R22.htm IDEA: XBRL DOCUMENT v3.19.3
RECENT ACCOUNTING PRONOUNCEMENTS (Tables)
9 Months Ended
Sep. 30, 2019
Accounting Policies [Abstract]  
Schedule of New Accounting Pronouncements and Changes in Accounting Principles The impact on the condensed consolidated balance sheets as of January 1, 2019 was as follows (in thousands):
Balance Sheet
 
Topic 840
January 1, 2019
 
Topic 842
January 1, 2019
 
Impact of
Adoption
Operating lease right-of-use asset
 
$

 
$
219

 
$
219

Lease liability, current portion
 

 
(68
)
 
(68
)
Lease liability, net of current portion
 

 
(151
)
 
(151
)

XML 60 R26.htm IDEA: XBRL DOCUMENT v3.19.3
ORGANIZATION AND NATURE OF OPERATIONS - Narrative (Details)
3 Months Ended 9 Months Ended
Aug. 31, 2019
$ / shares
shares
Sep. 30, 2019
USD ($)
$ / shares
shares
Jun. 30, 2019
USD ($)
shares
Mar. 31, 2019
USD ($)
shares
Sep. 30, 2018
USD ($)
shares
Jun. 30, 2018
USD ($)
shares
Mar. 31, 2018
USD ($)
shares
Sep. 30, 2019
USD ($)
$ / shares
shares
Sep. 30, 2018
USD ($)
shares
Dec. 31, 2018
USD ($)
$ / shares
shares
Dec. 31, 2017
shares
Business Acquisition [Line Items]                      
Common stock, par value (in usd per share) | $ / shares   $ 0.01           $ 0.01   $ 0.01  
Common stock, shares outstanding | shares 7,810,680 7,810,680           7,810,680   589,001  
Common stock, shares issued | shares 7,810,680 7,810,680           7,810,680   589,001  
Net loss   $ (4,781,000) $ (3,654,000) $ (4,580,000) $ (2,541,000) $ (3,552,000) $ 527,000 $ (13,015,000) $ (5,566,000)    
Net cash used in operating activities               (21,940,000) $ 7,621,000    
Cash, cash equivalents and marketable securities   25,700,000           25,700,000      
Accumulated deficit   $ (74,118,000)           $ (74,118,000)   $ (71,624,000)  
Common Stock                      
Business Acquisition [Line Items]                      
Common stock, shares outstanding | shares   7,810,680 589,001 589,001 587,563 586,700 586,700 7,810,680 587,563 589,001 585,262
Brickell Former Securityholders                      
Business Acquisition [Line Items]                      
Percent of shares owned 57.00%                    
Vical Former Securityholders                      
Business Acquisition [Line Items]                      
Percent of shares owned 43.00%                    
Vical                      
Business Acquisition [Line Items]                      
Common stock, par value (in usd per share) | $ / shares $ 0.01                    
Reverse stock split ratio 0.1429                    
Series A, B, C & C-1 Redeemable Convertible Preferred Stock                      
Business Acquisition [Line Items]                      
Conversion ratio 1 1           1      
NovaQuest                      
Business Acquisition [Line Items]                      
Commitment amount         $ 25,000,000.0       $ 25,000,000.0    
Stock issuable upon warrants (in shares) | shares   241,225           241,225      
XML 61 R9.htm IDEA: XBRL DOCUMENT v3.19.3
ORGANIZATION AND NATURE OF OPERATIONS
9 Months Ended
Sep. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
ORGANIZATION AND NATURE OF OPERATIONS ORGANIZATION AND NATURE OF OPERATIONS

Brickell Biotech, Inc. (the “Company” or “Brickell”) is a clinical-stage pharmaceutical company focused on the development of innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases. The Company’s pipeline consists of potential novel therapeutics for hyperhidrosis, cutaneous T-cell lymphoma, psoriasis, and other prevalent dermatological conditions. Its pivotal Phase 3-ready clinical-stage product candidate, sofpironium bromide, is a proprietary new molecular entity that belongs to a class of medications called anticholinergics. The Company is developing sofpironium bromide as a potential best-in-class, self-administered, once daily, topical therapy for the treatment of primary axillary hyperhidrosis. The Company’s operations to date have been limited to business planning, raising capital, developing its pipeline assets (in particular sofpironium bromide), identifying product candidates, and other research and development.

On August 31, 2019, the Company, then known as Vical Incorporated (“Vical”), and Brickell Biotech, Inc., a then privately-held Delaware corporation that began activities in September 2009 (“Private Brickell”), completed a recapitalization in accordance with the terms of the Agreement and Plan of Merger and Reorganization, dated June 2, 2019, as further amended on August 20, 2019 and on August 30, 2019 (the “Merger Agreement”), by and among Vical, Vical Subsidiary, Inc., a wholly owned subsidiary of Vical (“Merger Sub”), and Private Brickell. Pursuant to the Merger Agreement, Merger Sub merged with and into Private Brickell, with Private Brickell surviving as a wholly-owned subsidiary of Vical (the “Merger”). Additionally, on August 31, 2019, immediately after the completion of the Merger, the Company changed its name from “Vical Incorporated” to “Brickell Biotech, Inc.” and Private Brickell changed its name from "Brickell Biotech, Inc." to "Brickell Subsidiary, Inc."

The accompanying condensed consolidated financial statements and related notes reflect the historical results of Private Brickell prior to the Merger and of the combined company following the Merger, and do not include the historical results of Vical prior to the completion of the Merger. These financial statements and related notes should be read in conjunction with the audited financial statements of Private Brickell for the year ended December 31, 2018, included in the Company’s Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on September 3, 2019.

On August 31, 2019, in connection with, and prior to the consummation of the Merger, Vical effected a reverse stock split of its common stock, par value $0.01 per share, at a ratio of 1-for-7 (the “Reverse Stock Split”). Unless otherwise noted herein, references to share and per-share amounts give retroactive effect to the Reverse Stock Split.

On August 31, 2019, all shares of preferred stock of Private Brickell converted into shares of common stock of Private Brickell on a one-for-one basis.

At the effective date of the Merger, the Company issued shares of its common stock to Private Brickell stockholders, at an exchange rate of approximately 2.4165 shares of common stock in exchange for each share of Private Brickell common stock outstanding immediately prior to the Merger (the “Exchange Ratio”). The exchange rate was calculated by a formula that was determined through arms-length negotiations between the Vical and Private Brickell. Unless otherwise noted herein, references to share and per-share amounts give retroactive effect to the Reverse Stock Split and the Exchange Ratio, which was effected upon the Merger.

Immediately following the consummation of the Merger, there were 7,810,680 shares of common stock issued and outstanding, with Private Brickell’s former securityholders beneficially owning approximately 57% of the outstanding shares of common stock and Vical’s former securityholders beneficially owning approximately 43% of the outstanding shares of common stock.

Funding Agreement with NovaQuest

On August 31, 2019, concurrent with the Merger Agreement, the Company entered into a research and development arrangement with NovaQuest Capital Management, LLC (“NovaQuest”) pursuant to which NovaQuest committed up to $25.0 million in research and development funding to the Company following the closing of the Merger (the “Funding Agreement”). These proceeds will partially fund the Company's Phase 3 clinical trials in the United States for sofpironium bromide. The Company issued a warrant to NovaQuest to purchase 241,225 shares of common stock. Additional details of this agreement are described in Note 4. In October 2019, additional funding was temporarily suspended. Refer to Note 11 for additional details.

Liquidity and Capital Resources

The accompanying condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. The condensed consolidated financial statements do not reflect any adjustments relating to the recoverability and reclassification of assets and liabilities that might be necessary if the Company is unable to continue as a going concern. The Company has incurred significant operating losses and has an accumulated deficit as a result of ongoing efforts to develop product candidates, including conducting preclinical and clinical trials and providing general and administrative support for these operations. For the nine months ended September 30, 2019, the Company had a net loss of $13.0 million and net cash used in operating activities of $21.9 million. As of September 30, 2019, the Company had cash, cash equivalents, and marketable securities of $25.7 million, and an accumulated deficit of $74.1 million.

Pending resolution of the contentious matter discussed further in Note 11 and NovaQuest resuming additional funding, the Company intends to conserve its resources. The advancement of the Phase 3 clinical trials for sofpironium bromide may be negatively impacted by these developments. The Company may take actions to reduce its cash spend, including delaying the start of the clinical trials or staff reductions. Taking these measures into account, the Company believes that its cash, cash equivalents, and marketable securities as of September 30, 2019 would be sufficient to fund its operations for at least the next 12 months from the issuance of these condensed consolidated financial statements.

The Company expects to continue to incur additional substantial losses in the foreseeable future as a result of the Company’s research and development activities. Additional funding will be required in the future to maintain the Company’s current and proposed research activities. There can be no assurance that additional equity or debt financing will be available on acceptable terms, if at all. If the Company is unable to raise additional funding to meet its working capital needs in the future, it will be forced to delay or reduce the scope of its research programs and/or limit or cease its operations.
XML 62 R1.htm IDEA: XBRL DOCUMENT v3.19.3
COVER PAGE - shares
9 Months Ended
Sep. 30, 2019
Nov. 07, 2019
Cover page.    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Sep. 30, 2019  
Document Transition Report false  
Entity File Number 000-21088  
Entity Registrant Name BRICKELL BIOTECH, INC.  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 93-0948554  
Entity Address, Address Line One 5777 Central Avenue,  
Entity Address, City or Town  Boulder,  
Entity Address, State or Province CO  
Entity Address, Postal Zip Code 80301  
City Area Code 720  
Local Phone Number 505-4755  
Title of 12(b) Security Common stock, $0.01 par value per share  
Trading Symbol BBI  
Security Exchange Name NASDAQ  
Entity Interactive Data Current Yes  
Entity Current Reporting Status Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   7,810,680
Entity Central Index Key 0000819050  
Document Fiscal Period Focus Q3  
Amendment Flag false  
Document Fiscal Year Focus 2019  
Current Fiscal Year End Date --12-31  
XML 63 R5.htm IDEA: XBRL DOCUMENT v3.19.3
CONDENSED CONSOLIDATED STATMENTS OF COMPREHENSIVE LOSS - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2019
Sep. 30, 2018
Statement of Comprehensive Income [Abstract]        
Net loss $ (4,781) $ (2,541) $ (13,015) $ (5,566)
Other comprehensive loss:        
Unrealized loss on available-for-sale marketable securities arising during holding period, net of tax benefit of $0 (11) 0 (11) 0
Total comprehensive loss $ (4,792) $ (2,541) $ (13,026) $ (5,566)
XML 64 R9999.htm IDEA: XBRL DOCUMENT v3.19.3
Label Element Value
Accounting Standards Update 2014-09 [Member] | Retained Earnings [Member]  
Cumulative Effect of New Accounting Principle in Period of Adoption us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption $ 2,734,000
XML 65 R47.htm IDEA: XBRL DOCUMENT v3.19.3
STOCK-BASED COMPENSATION - Share-based Compensation Expense (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2019
Sep. 30, 2018
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]        
Share-based compensation expense $ 324 $ 151 $ 1,007 $ 516
Research and development        
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]        
Share-based compensation expense 81 76 237 263
General and administrative        
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]        
Share-based compensation expense $ 243 $ 75 $ 770 $ 253
XML 66 R43.htm IDEA: XBRL DOCUMENT v3.19.3
CAPITAL STOCK - Narrative (Details)
Sep. 30, 2019
Aug. 31, 2019
Warrants to purchase common stock    
Class of Stock [Line Items]    
Conversion ratio 1 1
Common Stock    
Class of Stock [Line Items]    
Conversion ratio 2.4165  

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